CED Clinic: Personalized Cannabis Medicine

ย 

Medicinal cannabis is changing the face of clinical medicine. ย We are the leaders of that change.

Group,Of,Senior,Retirement,Friends,Happiness,Concept
Businessman,Relaxing,At,His,Desk,In,The,Office,With,His
Shot,Of,A,Family,Having,A,Meal,Together,At,Home
Shot,Of,A,Family,Having,A,Meal,Together,At,Home
Grandfather,With,Son,And,Grandson,Sitting,On,Swing,In,Garden
Parents,Play,In,The,Park,With,Their,Son
Family,Eating,Sandwiches,Outdoors,In,A,Forest,,Portrait
Group,Of,Senior,Friends,Hiking,In,Countryside
Busy,Young,African,Man,In,Shirt,Talking,With,Smiling,Man
Spending,Time,With,Parents,Outside,In,Spring,Season,Is,Funny.
Mother,And,Daughter,Having,Fun,In,The,Park.,Happiness,And
Group,Of,People,Holding,Hands,Support,Team,Unity
The,Adventure,Is,More,Fun,When,They,Are,Together.,Family
Cute,Couple,Holding,Hands,Happiness,Lifestyle,Meeting
Happy,Leisure
Satisfied,Senior,Man,With,Friends,Having,A,Picnic,In,A
Beautiful,Couple,Taking,A,Walk,In,City,Park
Women,And,Boys,Walk,Hand,In,Hand,,Traveling,Adventure
Young,Woman,Suffering,From,Headache,In,Office
Group,Of,Adult,Multiethnic,Friends,Playing,American,Football,On,The
Mother,And,Daughter,Having,Fun,In,The,Park.,Happiness,And
Cheerful,Multi,Generation,Family,With,Parents,Giving,Piggy,Back,Standing
Couple,Wife,Husband,Dating,Relaxation,Love,Concept
Happy,Young,Family,Take,A,Self,Portrait,With,Smart,Phone.
Portrait,Of,Senior,People,Celebrating,Birthday
Happy,Family,With,The,Child,In,The,Field
Time,For,Family.,Spring,Season.
Group,Of,Senior,Retirement,Exercising,Togetherness,Concept
Portrait,Of,Happy,Family,Standing,In,Back,Yard,During,Sunny
Group,Of,Senior,Retirement,Friends,Happiness,Concept
Irate,Employee,Laboring,With,Loathing
Group,Of,Senior,Trekkers,Checking,A,Map,For,Direction
Portrait,Of,A,Satisfied,Executive,Celebrating,Success,With,The,Arms
Happy,Grandfather,,Grandmother,And,Grandson
Office,Workers,Diverse,Colleagues,Sitting,At,Desk,Looking,At,Each
Portrait,Of,Smiling,Woman,Working,With,Laptop,And,Cellphone,At
Beautiful,Couple,Taking,A,Walk,In,City,Park
Group,Of,Senior,Trekkers,Checking,A,Map,For,Direction
Granddad,With,Cheerful,Granddaughter,Having,Fun
Happy,Grandparents,Dance,Waltz,In,Front,Of,Family,At,A
Cute,Couple,Walking,In,A,Autumn,Park.,Boy,And,Girl
Happy,Woman,Have,A,Break,In,Office,,Folded,Arms,By
Group,Of,Senior,Friends,On,Hike,In,Countryside,Looking,At
Portrait,Of,Senior,Couple,Walking,Pet,Bulldog,In,Countryside
Family,Of,Three,On,A,Walk,,Mother,Holding,Child,,Front
Young,Attractive,Couple,In,Love,In,An,Autumn,Setting,Following
African,Female,Doctor,Holding,Hand,Supporting,Caucasian,Woman,Patient.,Kind
A,Family,Having,A,Walk,With,A,Dog
Group,Of,Senior,Retirement,Friends,Happiness,Concept
Portrait,Of,Senior,Couple,Standing,With,Family,And,Friend,In
Happy,Family,In,The,Park,On,A,Sunny,Day
Adult,Female,Doctor,Has,Video,Call,And,Chatting,With,Colleague
Asian,Preteen,Boy,And,Young,Father,Jogging,Together,In,Nature
Portrait,Of,Cheerful,Girls,With,Grandparents,While,Sitting,In,Back
Portrait,Of,Smiling,Millennial,African,American,Man,In,Glasses,Pose
Soldier,Reunited,With,His,Parents,On,A,Sunny,Day
Portrait,Of,Four,Cheerful,Senior,Friends,Enjoying,Picnic,On,Green


At CED Clinic, weโ€™re redefining care. Step into a welcoming, professional space where the leading experts in medical cannabis are here to guide and support you!

 

1

You’ve found the right place!

website quotes professional

 

 

 

top 25 for CED website

 

Promotional poster featuring Dr. Benjamin Caplan, MD, recognized as one of the Top 25 in the USA out of 43,000 applicants. The design highlights his role as the only cannabis physician testifying at the 2025 DEA hearings, titled โ€˜National Voice for Medical Cannabis Reform,โ€™ with the quote โ€˜Shaping Cannabis Medicine One Voice at a Timeโ€™ displayed below
Dr. Benjamin Caplan, MD โ€” Top 25 in the USA. The only cannabis physician testifying at the 2025 DEA hearings, advancing national medical cannabis reform

 

๐Ÿ”ฅ CED Clinic: voted Best Medical Cannabis Clinic since 2013!ย 

Screenshot 2024 06 18 at 9.32.33โ€ฏPMDr Caplan Best Medical Cannabis Doctor in the US

Our Services

  • Expert Telemedicine Medical Cannabis Consultations!
    • Medical Card Certifications (Massachusetts, New Hampshire, Rhode Island, Vermont, Maine)
    • Adult Cannabis Care (Everyone in the US + Internationally)
    • Pediatric Cannabis Care (Everyone in the US + Internationally)
  • In-Depth Consultations & Care Plans
    • Personalized Services (Medication, Diagnostic, and Management Review)
  • Cannabis and Non-Cannabis Medical Second Opinions
    • Long-term Talk Therapy
    • Advice, Support, and Cost-Savings Advice!

Our Mission

  • To Heal
  • To Listen
  • To Educate
  • To Learn and Understand

Questions? ๐Ÿ‘‰ Contact Us Here

Our Team

Benjamin Caplan MD
ย Benjamin Caplan, MD
Erin Caplan, NP
Erin Caplan, NP

 

Benjamin Caplan, MD, stands at the forefront of medical cannabis care as the Founder and Chief Medical Officer of CED Clinic and CED Foundation. His entrepreneurial journey further extends as the Founder of multiple medical cannabis technology and educational platforms and as a medical advisor to the prestigious cannabis investment fund, GreenAXS Capital. Within digital healthcare, Dr. Caplan co-founded EO Care, Inc, a pioneering digital therapeutic and telemedicine platform, offering personalized cannabis care and product plans and continuous clinical guidance to a global clientele seeking a reliable, evidence-based cannabis care partner. Adding to his repertoire of contributions to the medical cannabis arena, Dr. Caplan has recently published “The Doctor-Approved Cannabis Handbook,” an industry-first resource empowering readers with the full scope of the therapeutic potential of cannabis. Through his multifaceted involvement, Dr. Caplan continuously strives to bridge the gap between traditional medicine and cannabis care, making a significant impact in evolving holistic healthcare.

 

Erin Caplan, NP is a board-certified Pediatric Nurse Practitioner with a masterโ€™s-level medical education from Simmons. Her extensive clinical journey has been enriched through roles at Massachusetts General Hospital, Hyde Park Pediatrics, Atrius Healthcare, and Dana-Farber Cancer Institute, where she has provided both inpatient and outpatient primary care to some of the most fragile and challenging pediatric patients. A registered cannabis care provider licensed by the Massachusetts Cannabis Control Commission, Erin seamlessly blends her pediatric expertise with the nuance and adaptability required for personalized cannabis care. A community leader, avid athlete, and dedicated mother of four, Erin’s compassionate bedside manner and steadfast commitment to evidence-based practice have earned her the trust and appreciation of patients and families, showcasing her as a harmonious blend of clinical excellence with a personal touch.

Patient Stories

Navigating the Stigma as a Senior

Testimonial:

โ€œAt 68 years old, I never thought Iโ€™d be considering cannabis as part of my treatment. My generation didnโ€™t grow up viewing it as medicineโ€”we saw it as something entirely different. But after dealing with arthritis pain for over a decade, my daughter encouraged me to give it a try. Meeting with a professional who truly understood both the science and the hesitations I had made all the difference. Dr. Caplan explained how cannabis could work alongside my existing treatments and offered me a gradual approach to build my confidence. Now, Iโ€™m using a tincture daily, and I feel a level of relief and mobility that I hadnโ€™t felt in years. Even better, Iโ€™ve been able to have open conversations with my friends about the benefits, helping them see it in a new light too.โ€

Peter H

Peter Hargrove

Reclaiming Life with Holistic Care

โ€œI had been living with chronic fatigue for years, feeling like I was just existing rather than living. Traditional medicine had brought little relief, so I started looking into alternative options. Working with a doctor who truly listened to my struggles and offered a holistic approach to care was a game-changer. The cannabis regimen we developed not only improved my energy levels but also allowed me to engage in activities I hadnโ€™t been able to enjoy in years. This isnโ€™t just about managing symptomsโ€”itโ€™s about reclaiming a life I thought was out of reach. Iโ€™m grateful for the guidance and the opportunity to feel like myself again.โ€

Sarah M

Sarah Mitchell

A Patientโ€™s Guide to Finding the Right Dose

โ€œMy journey with cannabis therapy was not a straight line. When I first started, I thought one dose or product would fix everything, but I quickly learned itโ€™s a process of trial and adjustment. Working with a knowledgeable doctor made all the difference. We started low and slow, as they say, and I kept track of how I felt each day. Over time, I found the right balance that worked for my condition without unwanted side effects. The best part of this process was how involved I feltโ€”I wasnโ€™t just following instructions; I was an active participant in my own care. Now, Iโ€™m managing my symptoms better than ever and feel in control of my health.โ€

Michael T

Michael Torres

Finding Balance After Postpartum Anxiety

โ€œAfter having my second baby, I struggled with severe postpartum anxiety. It was difficult to admit I wasnโ€™t feeling okay, and even harder to ask for help. Traditional treatments left me feeling disconnected and foggy, and I didnโ€™t want to spend my days like that. When I started exploring medical cannabis, I was cautious but hopeful. Meeting with a knowledgeable doctor helped me approach it with confidence. I started with a low dose of CBD and gradually added a small amount of THC for nighttime use. Within weeks, I noticed a differenceโ€”not just in my anxiety, but in my ability to enjoy motherhood again. This journey wasnโ€™t just about managing symptoms; it was about regaining balance and finding joy in my life.โ€

Emily R

Emily Richards

New Hope for Fibromyalgia

โ€œI never thought Iโ€™d find a doctor who could make me feel optimistic about managing my fibromyalgia, but Dr. Caplan did exactly that. He didnโ€™t just focus on symptomsโ€”he helped me think about my health in a holistic way, integrating cannabis into a broader plan for wellness. His recommendations were precise, and he made sure I knew how to adjust them as needed. What really impressed me was his dedication to follow-up care; he personally checked in to see how I was doing and offered adjustments based on my progress. Itโ€™s that level of personalized attention that makes Dr. Caplan and his clinic stand out.โ€

Grace N

Grace Newman

Overcoming My Fear of Cannabis Therapy

โ€œFor years, I hesitated to explore medical cannabis. I had so many misconceptionsโ€”fear of side effects, worries about legality, and even embarrassment about what others might think. But after years of struggling with my chronic anxiety, I decided it was time to explore new options. Meeting with Dr. Caplan completely shifted my perspective. He helped me understand that cannabis wasnโ€™t about masking symptoms; it was about restoring balance in a way that felt right for me. My first steps were small, and we adjusted the plan together over time. Today, I feel a sense of calm and clarity I hadnโ€™t thought possible. More importantly, Iโ€™ve let go of the stigma and feel proud of my decision to prioritize my health.โ€

Julia M

Julia Matthews

Care That Transcends Expectations

โ€œDr. Caplanโ€™s clinic is a masterclass in patient care. From the moment you step in, you feel like youโ€™re in capable, compassionate hands. He took the time to understand my chronic fatigue and explained how cannabis could help in ways I hadnโ€™t considered. What stood out most was his emphasis on making informed decisionsโ€”heโ€™s not just a doctor, but a teacher who ensures you leave with a clear understanding of your treatment. His book is a fantastic resource, and it was clear from our discussion that he truly believes in empowering his patients through education. I couldnโ€™t be happier with my experience.โ€

Daniel Rย 

Daniel Roberts

The Expert You Can Trust

โ€œDr. Caplanโ€™s reputation as a cannabis expert is well-earned. I came to him with a list of concerns about using cannabis for my autoimmune condition, and he addressed each one with patience and expertise. He went beyond the surface to help me understand not just the benefits but also potential risks, which made me feel secure in my treatment. His recommendations were so thoughtful and practical, and he even tailored them to fit my busy schedule. What really set him apart, though, was his genuine careโ€”I could tell he wanted me to succeed in managing my health. Itโ€™s rare to find a doctor who combines this level of expertise with such a warm, approachable demeanor.โ€

Sophia L

Sophia Lewis

Empowering Through Education

โ€œAs a mother of two, I was cautious about trying medical cannabis for postpartum anxiety, but Dr. Caplan quickly put my fears at ease. He offered a science-backed approach that felt safe and sensible, walking me through each step with empathy and care. His book was also an invaluable toolโ€”it gave me the confidence to understand how to approach treatment without guesswork. Now, I feel like Iโ€™m thriving instead of just surviving. Iโ€™m so grateful for Dr. Caplanโ€™s guidance and for the way he made this process feel not only accessible but also empowering.โ€

Olivia G

Olivia Green

Clearer Days Ahead

“After years of chronic migraines and no relief from traditional treatments, I turned to Dr. Caplan as a last resort. What I found was a doctor who genuinely listened to my struggles and worked with me to find solutions. His clinic is a beacon for anyone looking to explore medical cannabis with confidence. He didnโ€™t just give me a prescriptionโ€”he educated me about dosing, timing, and the different products available. His insights were life-changing, and his approachable manner made even the complicated aspects of treatment easy to understand. For anyone hesitant about this path, Dr. Caplan is the guide youโ€™ve been waiting for.โ€

Ryan T

Ryan Thompson

Game-Changer for Mental Health

โ€œFinding Dr. Caplan was a game-changer for my mental health. For years, I struggled with anxiety and sleep issues, trying countless medications with limited success. Dr. Caplanโ€™s personalized approach was a breath of fresh air. He didnโ€™t just focus on my symptoms; he wanted to understand how my lifestyle and goals factored into the equation. His guidance helped me find a regimen that not only improved my sleep but also reduced my daily stress. The best part? He checked in after a few weeks to make sure everything was working smoothly. Iโ€™ve never felt so cared for by a doctor.โ€

Emily P

Emily Parker

A Seniorโ€™s New Hope

โ€œAs a senior struggling with arthritis, I was skeptical about cannabis therapy. But Dr. Caplan changed my perspective completely. His extensive knowledge, combined with a genuine compassion for his patients, made my first visit feel like a turning point. He introduced me to options that were gentle and easy to integrate into my daily life. What surprised me most was how much he emphasized educationโ€”his book became a valuable resource for me and my family to better understand how cannabis could help. If youโ€™re new to this world, Dr. Caplan is the expert you can trust to guide you with care and patience.โ€

Lucas H

Lucas Howard

Skeptic to Believer

โ€œI had given up on finding relief for my chronic pain until I met Dr. Caplan. His calm, reassuring demeanor put me at ease from the moment we sat down. He not only prescribed a cannabis regimen tailored to my needs but also took the time to address my fears about stigma and side effects. What made the experience even better was how he explained thingsโ€”breaking down complex science into simple, relatable examples. I now feel in control of my health for the first time in years. If youโ€™re hesitant about exploring cannabis as an option, Dr. Caplanโ€™s patient-centered care will make all the difference.โ€

Chloe M

Chloe Martinez

Revolutionizing My Care

“Dr. Caplanโ€™s approach to cannabis therapy is revolutionary. I had been to other clinics where the process felt rushed and impersonal, but my experience with him was the exact opposite. He asked thoughtful questions, delved into my medical history, and crafted a tailored plan to address my specific symptoms. What stood out the most was his ability to connect my condition to real-world cannabis applications, referencing research and patient success stories that inspired confidence. His clinic also provides resources beyond the appointmentโ€”like follow-ups and his bookโ€”which made me feel supported every step of the way. For anyone seeking a truly personalized and informed approach to medical cannabis, I canโ€™t recommend Dr. Caplan enough.โ€

Ethan K

Ethan Keller

Trust Built Through Understanding

“Trust is not something I give easily when it comes to my healthcare, but Dr. Caplan earned it during our first appointment. He listened carefully to my concerns and explained the science behind medical cannabis in a way that was clear and accessible. He didnโ€™t just focus on the benefits; he also made sure I understood potential challenges and how to navigate them. That kind of transparency and care is rare, and itโ€™s the reason I feel confident in the treatment plan we developed together.”

Emily C

Emily Carsonally

Personalized Care That Stands Out

“Every aspect of my experience with Dr. Caplan reflected his commitment to personalized care. He took the time to ask about my lifestyle, my goals, and even my hesitations about using medical cannabis. His thoughtful questions and detailed explanations made it clear that he was focused on creating a plan that would work for me specifically. I also appreciated how he checked in with me after the visit to see how I was doingโ€”a small gesture that made a big difference in my confidence and comfort moving forward.”

Olivia H

Olivia Robers-Harrison

Educational and Empowering

“Dr. Caplan doesnโ€™t just prescribe cannabisโ€”he educates you about it, so you feel confident and in control of your treatment. From our first appointment, it was clear that he cared about making sure I understood all my options. He referenced research, shared stories from other patients, and even recommended chapters from his book that were particularly relevant to my situation. By the end of the visit, I felt not only more informed but also more empowered to make decisions about my health. That kind of care is rare, and Iโ€™m grateful for it.”

Benjamin R

Benjamin Rochel

Clear Guidance Every Step of the Way

“What struck me most about Dr. Caplan was his ability to provide clear and actionable guidance. I had no prior experience with medical cannabis and was overwhelmed by all the information out there, but he made it manageable. He walked me through the options, explained the potential benefits and risks, and helped me navigate decisions in a way that felt completely tailored to my situation. His calm and thoughtful manner put me at ease, and I left the appointment feeling like I finally had a plan I could trust.”

Chloe M

Chloe Masterson

A Tailored and Thoughtful Plan

“Dr. Caplan approached my case with a level of care and detail I hadnโ€™t experienced before. Instead of a one-size-fits-all recommendation, he tailored a plan based on my specific symptoms and preferences. He took the time to explain why certain options might work better for me and made sure I felt comfortable moving forward. His advice was practical and grounded in science, yet delivered in a way that felt approachable. I left feeling empowered, knowing I had the tools and knowledge to take the next steps with confidence.”

Ethan K

Ethan Kostenson

More Than Just a Weed Visit

“My first visit with Dr. Caplan felt like more than just a routine medical appointmentโ€”it was an opportunity to truly take charge of my health. He asked questions that no other doctor had asked and encouraged me to think about my goals for treatment in a way I hadnโ€™t before. His book was an incredible resource, but what truly set him apart was his ability to make the information feel relevant to my unique situation. I felt supported not only as a patient but as a partner in my healthcare journey.”

Maria L

Maria Lolana

A Practical and Supportive Approach

“Dr. Caplanโ€™s approach is refreshingly practical and supportive. During our consultation, he focused not just on recommending cannabis, but on helping me understand how to use it in a way that fit my lifestyle and goals. He walked me through options, shared insights from his book, and even helped me think through how to manage dosing and timing. What really impressed me was his focus on the long termโ€”this wasnโ€™t about a one-time solution but about creating sustainable improvements in my health. Itโ€™s rare to find a doctor who invests this level of thought and care into patient guidance.”

John W

John Waterson

Dr. Caplanโ€™s Expertise and Patience

“I was initially unsure about whether medical cannabis was the right path for me, but Dr. Caplan quickly put my concerns to rest. He spent time understanding my medical history and current challenges, carefully explaining the science behind cannabis and how it could fit into my treatment plan. His depth of knowledge and ability to communicate complex concepts in simple terms stood out to me. I appreciated his patience, especially when I had a list of questions, all of which he addressed thoroughly. The care I received was thoughtful and personalized, and I left feeling confident in the steps we outlined together.”

-Sophia R

Sophia Rhiderson

A Lighthouse in the Storm

“When I first started exploring medical cannabis, I felt overwhelmed by conflicting advice online. Meeting Dr. Caplan was like finding a lighthouse in a storm. He didnโ€™t just recommend a treatment plan; he broke down every step, explaining the science in plain terms so I could make informed decisions. His book, โ€˜The Doctor-Approved Cannabis Handbook,โ€™ became my go-to guide between visits. Itโ€™s rare to find a doctor who takes so much time to ensure you feel educated and empowered. Now, not only am I managing my symptoms, but I feel like I truly understand my body better. If youโ€™re looking for compassionate care and clear guidance, Dr. Caplan is the doctor you need.”

Sophia J

Sophia Jenkins

I Finally Got My Stress Under Control

I used to pride myself on being able to handle anything work threw at me. Long hours, tight deadlines, a demanding bossโ€”it was all part of the game, and I thought I had it down. But somewhere along the way, the stress started to build up. Slowly at first, then all at once. I was losing sleep, snapping at my family, and my chest constantly felt tight. The smallest things would set me off, and no amount of weekends or โ€˜self-careโ€™ could fix it. I didnโ€™t recognize myself anymore.

My doctor had suggested anti-anxiety meds, but I didnโ€™t want to go that route. I kept thinking, thereโ€™s got to be another way. A friend mentioned cannabis, and Iโ€™ll admit, I laughed at first. Cannabis? For work stress? I thought it was a joke. But after another sleepless week and two missed deadlines, I was willing to try anything. Thatโ€™s when I found CED Clinic and Dr Caplan.

I wasnโ€™t sure what to expect going in, but Dr. Caplan made me feel comfortable right away. He listenedโ€”not just to what I was saying, but to what I wasnโ€™t saying, if that makes sense. He didnโ€™t treat me like a case file or just another patient. We talked about the stress, sure, but also about why Iโ€™d been so hesitant to ask for help. He suggested a low-dose CBD regimen to help me unwind without feeling โ€˜off,โ€™ and explained that it wasnโ€™t about numbing outโ€”it was about finding balance again.

It took a few weeks before I really started noticing a difference. At first, I wasnโ€™t sure if it was doing anything, but then I realized I wasnโ€™t lying awake at night, going over work problems in my head. I wasnโ€™t clenching my jaw every time I opened an email. The stress didnโ€™t go away, but I wasnโ€™t drowning in it anymore. I felt like I could handle things again, like the weight had been lifted just enough for me to breathe.

Now, I can get through my workday without feeling like Iโ€™m on the verge of a meltdown. Iโ€™m more present with my family, more patient. Itโ€™s not perfect, and work is still stressful, but it doesnโ€™t own me anymore. I canโ€™t say enough about what Dr. Caplan did for me. I was lost, and he helped me find my way back.โ€*

โ€“ Jason B

J Bennett

Our Son Found Calm, and So Did We

Our son has always beenโ€ฆ difficult, to put it lightly. Heโ€™s smart, no doubt about that, but for as long as I can remember, weโ€™ve struggled with his defiance. It was like every day was a battleโ€”heโ€™d talk back, refuse to listen, and disrupt everything at home and at school. Weโ€™d get calls from his teachers constantly about how he couldnโ€™t sit still or follow directions. He was failing classes, not because he didnโ€™t understand the material, but because he just refused to engage. I started to feel like we were losing control, not just of him, but of our family. It was exhausting. We tried everythingโ€”therapy, behavior charts, punishments, rewardsโ€”but nothing seemed to get through to him.

When someone suggested we look into cannabis, Iโ€™ll admit, I was pretty skeptical. The idea of giving our son cannabis? It felt like too much. But at the same time, I felt like we were running out of options. I mean, we couldnโ€™t keep going the way we were. So, I did some research and found Dr. Caplan. I didnโ€™t really know what to expect, but I figured it was worth at least hearing what he had to say. When we met with him, Dr. Caplan was so calm, so understanding. He didnโ€™t make us feel like we were bad parents, which, honestly, was a huge relief. Weโ€™d been feeling like failures for a long time. He explained that cannabis, in the right doses, might help our son relax, become more receptive, and justโ€ฆ chill out.

At first, I wasnโ€™t sure. But we decided to give it a shot because we needed something to change. I remember the first few weeksโ€”we were waiting for a miracle that didnโ€™t come right away. But slowly, things started to shift. He wasnโ€™t perfect, and I didnโ€™t expect him to be, but we started seeing moments of calm, of compliance. Heโ€™d sit down and actually listen when we talked to him. His teachers noticed, too. The calls home werenโ€™t as frequent, and when they did call, it wasnโ€™t about him disrupting the class, but little moments where he was making an effort. He wasnโ€™t fighting us over every single thing anymore. He even started being more responsible around the houseโ€”little things like cleaning up after himself, finishing homework without a meltdown.

It wasnโ€™t an overnight transformation, but it was enough to make us believe that maybeโ€”just maybeโ€”things could get better. And they have. Our son is still a work in progress, but arenโ€™t we all? Heโ€™s more in control now, more aware of his actions. I canโ€™t tell you what a relief it is to have peace in our home again, even if itโ€™s not perfect all the time. We can breathe. We can plan things without the constant fear of a blow-up. Dr. Caplan gave us the space to feel like parents again, instead of just referees in constant battles.

โ€“ Heather R.

Heather R

Finally Found Relief from Menopause

Menopause hit me like a freight train. One minute I was fine, and the next, I was drowning in hot flashes, mood swings, sleepless nights, and constant irritability. It felt like I couldnโ€™t get through the day without snapping at someone or dripping in sweat. The worst part was the lack of sleepโ€”Iโ€™d toss and turn all night, then drag myself through the day feeling exhausted. It was like I had no control over my own body, and everything just felt harder. I tried the usual over-the-counter remedies and even considered hormone replacement therapy, but I didnโ€™t like the risks. Honestly, I was starting to lose hope.

A friend of mine, who had been seeing Dr. Caplan for her own health issues, suggested I give him a try. I wasnโ€™t sure at first. Cannabis for menopause? It seemed a little out there. But after trying everything else and getting nowhere, I figured I had nothing to lose. From the moment I met with Dr. Caplan, I knew I was in the right place. He listened to all my complaints without judgmentโ€”he understood how tough it was. He didnโ€™t just hand me a one-size-fits-all solution either. Instead, he explained how cannabis could help balance out my mood swings, improve my sleep, and even ease the intensity of the hot flashes. He was thorough, but he kept it simple, so I didnโ€™t feel overwhelmed.

Within a few weeks of starting on a low-dose regimen, I noticed a real change. The hot flashes were still there, but they werenโ€™t as intense, and I wasnโ€™t waking up drenched in sweat every night. My mood swings started to even out too. I wasnโ€™t losing my temper over every little thing, and I was able to get through the day without feeling like I was on edge all the time. Most importantly, I started sleeping again. Iโ€™m not talking about perfect, uninterrupted sleep, but I was actually getting solid rest and waking up feeling more human. My irritability softened as my body felt more balanced.

I canโ€™t say enough good things about Dr. Caplan and the care heโ€™s given me. Menopause doesnโ€™t feel like itโ€™s running my life anymore. I have a handle on it now, and I feel like myself again. Cannabis wasnโ€™t something I ever thought Iโ€™d turn to, but Iโ€™m so glad I did. Dr. Caplan gave me back my peace of mind, and for that, Iโ€™ll be forever grateful.

โ€“ Lisa M.

Lisa Montingerie

Cannabis Gave Us Our Family Back

โ€œWe live in California. Our son has severe autism, OCD, and behavioral issues that have ruled our lives for as long as I can remember. He struggles with communication, and when things donโ€™t go as expected, the meltdowns are explosive. There are days when he self-injures so severely that I canโ€™t leave him alone for a second. The screams, the head-banging, the constant pacingโ€”itโ€™s heartbreaking and terrifying. My husband and I have felt like prisoners in our own home. We canโ€™t go shopping, we canโ€™t take vacations, we canโ€™t even break from the daily routine without risking an episode that could throw him into a spiral for weeks. Weโ€™ve tried every therapy, every medication. Nothing seemed to give himโ€”or usโ€”a moment of peace. It was draining every ounce of energy and hope we had left.

When someone first suggested cannabis to us, I was hesitant, scared even. I didnโ€™t know how it would affect him. I see potheads and druggies everywhere these days in my area, and it does not look appealing. Would it help, or make things worse? But we were desperate, and a friend had read The Cannabis Handbook and suggested that we reach out, so we decided to see Dr. Caplan. Iโ€™ll never forget that first meeting. He listenedโ€”really listenedโ€”to the hell weโ€™ve been living through, and for the first time in a long time, I felt like someone understood. His questions made it clear that he’s been through this with many others. He seemed to get our struggle like no doctor I’ve ever encountered. He wasnโ€™t dismissive, and he cetainly didnโ€™t make us feel crazy for trying something new – the way all of my other doctors do. He explained how cannabis could help with the anxiety, the OCD, and even the self-injury, in a way that was calm and controlled, without overwhelming us. Our son came on camera with a tantrum, and Dr Caplan was as patient and attentive, supportive, as I wish docs all were. Dr. Caplan carefully walked us through everything, never pushing, always respecting our concerns. His focus is so clearly empowering us, not tripping on himself or being on high.

We started our son on small doses of a few products, and I wonโ€™t lie, it wasnโ€™t a quick, overnight change. But over time, with adjustments that he oversaw with us, we saw itโ€”he started to calm down. The meltdowns werenโ€™t as frequent, and when they did happen, they didnโ€™t last as long or get as intense. The self-injury started to lessen. It felt like we could breathe again, like we had a little more room to live. Weโ€™re still carefulโ€”routine is still importantโ€”but the constant terror of something going wrong isnโ€™t hanging over our heads as much. For the first time in years, my husband and I were able to go out for dinner. It sounds like such a small thing, but it was a moment where we could remember what life used to be like, before we became prisoners to our sonโ€™s condition.

I canโ€™t say that cannabis has fixed everything, but itโ€™s given us something we didnโ€™t have before: hope. Weโ€™re seeing glimpses of who our son is underneath the anxiety and the behavioral issues. Dr. Caplanโ€™s patience and understanding have been a lifeline for us. He gave us a way to manage our lives again. Weโ€™re still on this journey, but for the first time, it feels like thereโ€™s light at the end of the tunnel.โ€

โ€“ Sarah W.

Sarah W

Finding Comfort and Connection Again

โ€œLoneliness had been creeping up on me for years, but it really hit hard when I retired. My social circle started shrinking, and the days just felt longer and emptier. I had been keeping busy with hobbies, but the silence in my house became unbearable. Iโ€™d wake up in the morning with no motivation to get out of bed because I didnโ€™t have anyone to talk to, nowhere I really needed to be. I tried to reach out to old friends, but it always felt awkward, like I didnโ€™t fit into their lives anymore. My primary doctor referred me to Dr. Caplan, not because of anything physical, but because they thought cannabis might help me with the emotional side of things. I was pretty skeptical. Cannabis? For loneliness? I didnโ€™t see how it could possibly make me feel less isolated.

When I met with Dr. Caplan, he listened without judgment. I explained how I felt like I was drifting through my days, disconnected from everyone around me. He was calm and compassionate, and he didnโ€™t rush me at all. Instead of dismissing my feelings, he talked me through how cannabis might help me not feel so โ€˜stuckโ€™ in my emotions. We started with a low-dose regimen that focused on CBD to help with the feelings of overwhelm and helplessness. It wasnโ€™t a quick fix, but after a few weeks, I noticed I felt lighter, more at ease. I found it easier to pick up the phone and call an old friend, easier to motivate myself to go out for a walk or run errands.

Itโ€™s hard to explain, but it felt like a weight had lifted off my chest. The loneliness was still there, but it didnโ€™t feel so suffocating. I could breathe again, could start imagining a life where I wasnโ€™t so isolated. Over time, Iโ€™ve been able to reconnect with people, even make new friends. Cannabis didnโ€™t solve everything, but it gave me the space I needed to start living again. Dr. Caplan was there every step of the way, adjusting the treatment as we went and always making sure I was comfortable. I never thought something like this could help with how I was feeling, but Iโ€™m so glad I gave it a chance.โ€*

โ€“ Tom B.

Tom B

Does Cannabis Work for Pediatric Autism? Yes!

โ€œI wanted to take a moment to share a heartfelt message we recently received from one of Dr. Caplanโ€™s patients. Itโ€™s moments like these that remind us why weโ€™re so passionate about the work we do. The incredible progress described below is a testament to the power of personalized care and cannabis therapy. Weโ€™re grateful to witness such transformations and hope this story provides inspiration for others seeking hope and relief.โ€

Jack Thompson, CED Clinic Operations Manager

 

For anyone interested in seeing Dr. Caplan as a consulting physician, please visit this link:Book an Appointment to complete our intake form, make a payment, and schedule your visitโ€”all in one easy step.

Screenshot 2025 12 07 at 3.22.20 PM

 

 

 

 

A heartfelt email from a patient expressing gratitude to Dr. Caplan for recommending a CBD/THC tincture that significantly improved their sonโ€™s behavior and well-being, detailing the progress in areas such as sleep, car rides, and eating habits.
Jack Thompson

Managing Anxiety with Cannabis: A Personal Story of Relief

โ€œI heard about Dr. Caplan through a friend who had been his patient for a couple of years. I had been struggling with anxiety for a while but didnโ€™t think cannabis was something I could handle. The stigma around it made me nervous, and I wasnโ€™t sure it was for me. But my friend couldnโ€™t stop raving about the difference Dr. Caplan had made in her life, so I finally decided to check him out. From the moment I sat down with him, I knew I was in good hands. He took the time to understand my situation, explaining how cannabis could be used to manage anxiety in a safe, controlled way. It wasnโ€™t about pushing a productโ€”it was about finding the right balance for my body and my needs. Now, I feel more in control of my anxiety than I have in years, and Iโ€™m grateful for Dr. Caplanโ€™s thoughtful and thorough care.โ€

โ€“ Maria S.

Maria Sintira

Finally Found Relief for My Back Pain

โ€œI was at my witโ€™s end with my lower back pain, and nothing seemed to workโ€”painkillers, physical therapy, injectionsโ€”you name it. My orthopedist mentioned Dr. Caplan, and honestly, I wasnโ€™t sure about the whole cannabis thing. I mean, I wasnโ€™t against it, but I didnโ€™t think it was for me. Still, I was desperate, so I made the call. Dr. Caplan wasnโ€™t like any other doctor Iโ€™d met. He really took the time to get to know me, my history, and my concerns about cannabis. He didnโ€™t push anything but explained how it could help manage pain and inflammation in a way I could understand. He helped me feel like this was something worth trying, not some weird โ€˜last resort.โ€™ Fast forward six months, and Iโ€™m moving around a lot better than I have in years. I never thought Iโ€™d say it, but cannabis has made a huge difference in my life. Dr. Caplanโ€™s been there for every step, making sure I get the right balance for what I need.โ€

โ€“ Mike T.

Michael Tertansky

From Total Skeptic to Success: How Cannabis Helped My Skin Condition

โ€œI came to CED Clinic on the recommendation of my dermatologist after battling severe eczema for most of my life. Iโ€™d tried everything from steroid creams to light therapy, but nothing seemed to keep the flare-ups at bay for long. The idea of using cannabis for my skin condition seemed strange at first, and I was pretty skeptical. It wasnโ€™t something my friends or family had ever talked about, and I wasnโ€™t sure how it could really help. But my dermatologist convinced me to at least have a conversation, and Iโ€™m so glad I did. Dr. Caplan didnโ€™t make me feel awkward or silly for being uncertain. Instead, he walked me through how cannabis could potentially reduce inflammation and improve my skin health. A few months into the treatment plan, and my skin has never looked better. I wish I had come to him sooner.โ€

โ€“ Lindsey P.

Lindsey Peterson

Cannabis Helped Me Feel Less Alone

โ€œIโ€™ve been dealing with loneliness for years. After my kids moved out and my spouse passed away, the days just felt so empty. I tried therapy and even medication, but nothing really touched the feeling of being alone. A friend mentioned Dr. Caplan and how cannabis had helped her with anxiety, but I wasnโ€™t sure if it could help with loneliness. It felt strange to think about cannabis as an option for something like that. Still, I figured it was worth a shot. Dr. Caplan was kind and understanding right from the start. He didnโ€™t make me feel silly for bringing up something as hard to explain as loneliness. He explained how cannabis might help ease the constant heaviness I was feeling, not by curing loneliness but by helping me feel more connected to myself and the world around me. We started slow, and over time, I noticed a shift. The emptiness didnโ€™t go away, but it didnโ€™t feel so overwhelming anymore. I started going out more, seeing friends again, and just feeling a little lighter. Iโ€™m still working through it, but cannabisโ€”along with Dr. Caplanโ€™s careโ€”has made it easier to handle.โ€

โ€“ Susan R.

Susan Ringly

Overcoming Arthritis Pain: My Journey to Relief at CED Clinic

โ€œI was referred to Dr. Caplan by my podiatrist, who suggested I look into cannabis after dealing with arthritis in my feet for years. Honestly, I was hesitant. Iโ€™d never been a fan of the idea of using cannabisโ€”it seemed like a last resort. But after cycling through endless medications with little success, I was willing to try something new. From the first consultation, Dr. Caplan made me feel completely at ease. He spent time learning about my history and concerns, and he carefully explained the options in a way that was easy to understand. He wasnโ€™t just throwing solutions at meโ€”he was building a plan around my life. Iโ€™ve been on the regimen we discussed for about four months now, and the improvement is undeniable. Itโ€™s not just the relief, but the care and commitment Dr. Caplan shows that keeps me confident in the process.โ€

โ€“ Robert H.

Robert Hickenlooper

I Overcame Insomnia with Dr. Caplanโ€™s Help.

โ€œI was referred to Dr. Caplan by my PCP after months of struggling with severe insomnia. For years, I had relied on prescription sleep aids, but over time, they stopped working, and the side effects were unbearable. I had heard about cannabis being used for sleep, but I wasnโ€™t convinced it would work for me. The idea of using cannabis made me nervousโ€”I had no experience with it and didnโ€™t want to feel โ€˜high.โ€™ But my doctor insisted that I give Dr. Caplan a try, so I booked an appointment. From the very first meeting, Dr. Caplan took the time to understand my fears and hesitations. He didnโ€™t push anything on me but explained how cannabis, especially CBD, could help regulate my sleep cycle without the psychoactive effects I was worried about. His calm, knowledgeable approach reassured me, and we crafted a plan that I felt comfortable with. After just a few weeks on the treatment, I started sleeping better than I had in years. It wasnโ€™t an overnight solution, but Dr. Caplan was with me every step of the way, adjusting the plan as needed. Iโ€™ve regained the energy I thought I had lost forever, and for that, Iโ€™m incredibly grateful.โ€

โ€“ Rachel S.

Rachel Samuelson

Finding Hope After Chronic Migraines: Dr. Caplan Helped Me See Cannabis

โ€œI found Dr. Caplan after reading The Doctor-Approved Cannabis Handbook. I had been suffering from chronic migraines for years, but the idea of using cannabis never crossed my mind. To be honest, I had a lot of doubtsโ€”would it work? Would it make me feel โ€˜offโ€™? But the book opened my eyes to the science behind it, and I decided it was time to explore other options. When I reached out to Dr. Caplan, I was still on the fence, but he took the time to listen, explain, and answer every question I had. He didnโ€™t push anything on me, but instead guided me through the possibilities. Fast forward six months, and Iโ€™ve seen such a huge improvement in my quality of life. Dr. Caplanโ€™s approach is professional, but also deeply personal. Itโ€™s clear he cares about getting things right for each patient.โ€

โ€“ Jessica M.

Jessica Montrouse

No More Painful Periods

โ€œIโ€™ve had awful period cramps for as long as I can remember, and nothing ever worked to ease the pain. My gynecologist suggested Dr. Caplan, but I wasnโ€™t sure about using cannabis for menstrual painโ€”it seemed kind of odd to me. Still, I was tired of being in pain every month, so I decided to at least talk to him. Dr. Caplan was greatโ€”he explained how cannabis could help with cramps and inflammation and answered all my questions without making me feel rushed. He worked with me to figure out a plan that I was comfortable with, and within a few cycles, I started noticing a big difference. The pain isnโ€™t completely gone, but itโ€™s so much more manageable now. I donโ€™t dread that time of the month anymore. Iโ€™m so glad I gave it a tryโ€”Dr. Caplanโ€™s made this whole process easier than I expected.โ€

โ€“ Emily K.

Emily Kingston

Trustworthy & Easy

From the moment I first connected with Dr. Caplan on a telemedicine visit, I felt an immediate sense of relief. I had been struggling with anxiety for years, and previous doctors had only offered quick fixes that never addressed the root of the problem. Dr. Caplan took the time to understand my history, my triggers, and my lifestyle. The discussion was open and flowed easily andย  to me, clearly shows that he actually cares. During our consultation, he explained the complex medical stuff in a way that made sense to me, and made sure I felt informed and empowered every step of the way. When I had a panic attack late one night, I emailed him in desperation, and to my surprise, he responded almost immediately with calming words and practical advice. His personalized follow-up call the next day was the reassurance I needed to stay on track. Dr. Caplanโ€™s unwavering commitment and compassionate care have truly transformed my life.

โ€” Michael Anderson

Michael Anderson

My anxiety is manageable!

Dr. Caplanโ€™s thoughtful approach turned my anxiety into a manageable journey, offering not just treatment but a renewed sense of hope and understanding.

– S Christianson

Sandra Christianson

I’m a whole person. And I’m complicated.

โ€œI found Dr Caplan after reading his book, The Doctor-Approved Cannabis Handbook. Dr. Caplan doesnโ€™t just treat symptomsโ€”he treats the whole person. From my very first appointment, he made sure I understood every part of my treatment plan, and I left feeling hopeful for the first time in years. His book has been a helpful resource, but itโ€™s his personal touch and thoughtful care that really sets him apart. Iโ€™ve never felt rushed or like just another patient in a long line. Instead, I feel truly heard.โ€

โ€“ Sarah W.

Sarah W

My Son Was Right About Cannabis

โ€œFunny enough, my teenage son was the one who pushed me to see Dr. Caplan. Iโ€™ve had a stressful job for years, and itโ€™s been taking a toll on my health. My son did a project on cannabis for school and said I should check it out for stress. I was pretty hesitantโ€”I mean, cannabis? It wasnโ€™t something I ever thought Iโ€™d try. But after hearing my son talk about it for weeks, I figured, why not? I went to Dr. Caplan with a lot of questions, and he took the time to answer every one of them. He explained how I didnโ€™t have to get โ€˜highโ€™ to use cannabis for stress and that it could help me feel calmer without messing with my head. He started me on a low-dose CBD plan, and within a couple of weeks, I started noticing a difference. I was less anxious at work, more patient with my family, and just felt more balanced. Honestly, I owe my son for nudging me, but Iโ€™m grateful to Dr. Caplan for helping me find a solution that really works.โ€

โ€“ Janet W.

Janet Wishingsly

From Sleepless Nights to Peaceful Mornings

โ€œI was dealing with sleepless nights for monthsโ€”maybe even yearsโ€”when my primary care doctor suggested I check out Dr. Caplan. Iโ€™d been on sleeping pills for ages, but they stopped working, and I was left exhausted all the time. The idea of using cannabis for sleep honestly sounded weird to me. I didnโ€™t know much about it, and I figured it would just make me feel groggy or out of it. But I was tired of being tired, so I made the appointment. Dr. Caplan really gets itโ€”he wasnโ€™t pushy at all. He explained how CBD could help me without the โ€˜highโ€™ I was worried about, and he was super patient with all my questions. Within a couple of weeks, I was actually sleeping through the night. Itโ€™s not an overnight fix, but itโ€™s the best sleep Iโ€™ve had in years. I wake up feeling refreshed instead of like a zombie. Dr. Caplanโ€™s follow-ups have been a game-changer tooโ€”he checks in to make sure everythingโ€™s working. It feels good to have a doctor who cares.โ€

โ€“ Laura B.

Laura Bonintue

Genuine care and great medical advice

Dr. Caplan’s genuine care and commitment are evident in every interaction. At CED Clinic, I received more than just medical advice; I gained a trusted advisor in my health journey. His use of personalized treatment plans and educational resources helped me understand and manage my condition better than ever before.
– Michael T.

Michael T

Awesome experience!

I never felt like just another patient at CED Clinic; Dr. Caplan made sure of that. His thorough understanding of my health needs, paired with his deep knowledge of cannabis therapy, provided a tailored experience that truly catered to my well-being. Every visit felt like a step forward in my journey dealing with sleeplessness, stress, and PTSD.
– Denise H.

 

Denise H

Happy customer!

My visit to CED Clinic was absolutely amazing, and it all started with Kim. She was so friendly and helpful right from the get-go, making the whole scheduling thing a breeze – a real breath of fresh air! Then there was Dr. Caplan. Honestly, chatting with him felt more like catching up with an old friend than a typical doctor’s visit. He didn’t seem to be watching the clock at all; he was all in, really getting to grips with what I’ve been going through, and dishing out advice that hit the nail on the head. And get this – he’s even written a book about it all! I can’t wait to get my hands on a copy. The whole experience at CED Clinic was just so warm and genuine. They’ve got something special going on over there, for sure.

Amanda Kimmel

I’m Free: My Journey Beyond Chronic Pain!

I felt trapped in a cycle of chronic pain, where prescription and over-the-counter meds were just dead ends. Then I found Dr. Caplan. His blend of medical expertise and cannabis knowledge opened a door I didn’t know existed. I read ‘The Doctor-Approved Cannabis Handbook’ and it was/is a turning pointโ€”packed with research and actionable advice, it guided me to a pain management plan that actually worked. Thanks to Dr. Caplan, I’m living with less pain and more hope. Highly recommend for anyone stuck in the pain cycle.

Emily Brasston

From Frayed Edges to Balance: Found My Center with Cannabis

Let me paint you a picture of my life not too long ago: a job that never hit ‘pause,’ kids that always needed me in a hundred different ways, and a level of work stress that had me teetering on the edge. I was juggling more plates than I had hands for, and it felt like I was one strong breeze away from watching them all come crashing down. Sleep was a luxury I couldn’t afford, and ‘me time’ was a concept so foreign it might as well have been from another planet.

Enter Dr. Benjamin Caplan and his life-altering approach to managing stress through cannabis medicine. At first, I was skepticalโ€”could this really be the answer I’d been searching for? But from the moment we began, it was clear Dr. Caplan wasn’t just any doctor. His blend of traditional medical insight and innovative cannabis expertise was like a breath of fresh air.

What truly transformed my journey, though, was diving into ‘The Doctor-Approved Cannabis Handbook.’ This wasn’t just another self-help book; it was a treasure trove of evidence-based research, clinical wisdom, and, most importantly, actionable advice that felt like it was written just for me. It became my North Star, guiding me through the haze of stress and sleepless nights to a place of understanding and balance.

Thanks to the personalized strategy Dr. Caplan crafted with me, I’ve been able to reclaim control over my stress and find a sense of equilibrium I didn’t think was possible. My work no longer feels like a constant battle, and I’ve found more joy and presence in the time I spend with my kids. The difference is night and day.

I’m beyond grateful to Dr. Caplan and the invaluable lessons from his handbook. For anyone feeling overwhelmed by the demands of work, family, and everything in between, Dr. Caplan’s compassionate, evidence-based approach might just be the lifeline you need. I can’t recommend him enough.

Sam Dexter

My Journey to Conquering Chronic Insomnia with Dr. Caplan and Cannabis Medicine

I’ve been in this battle with chronic insomnia for what feels like forever. I hit a point where I felt completely out of options. I mean, you name it, I tried itโ€”all those over-the-counter fixes, prescriptions from my doctors, and I even got creative mixing up my own cannabinoid solutions. But nothing worked. Those endless nights of tossing and turning weren’t just annoying; they were wrecking my health and my spirits.

Then, almost out of nowhere, I stumbled upon Dr. Benjamin Caplan and his work in the world of cannabis medicine. From the moment we started talking, I knew this was different. He’s got this unique blend of traditional medical wisdom and cutting-edge cannabis knowledge. It’s like he sees the whole picture in a way no one else had shown me before.

But here’s the real game-changer: “The Doctor-Approved Cannabis Handbook.” That book blew my mind. It’s packed with solid science and real-deal clinical insights on how cannabis can tackle not just insomnia but a whole list of issues. More than that, it gave me straightforward, practical steps tailored just for me. It turned into my guide on this journey to use cannabis safely and super effectively.

I owe so much to Dr. Caplan and the wisdom packed into that book. I’ve finally found some peace from my insomniaโ€”a relief I thought was off the table for me. My sleep’s way better, and my days? They’ve transformed. I can’t thank Dr. Caplan enough. And seriously, if you’re hitting a wall with insomnia or any health problem that just won’t budge with the usual treatments, Dr. Caplan’s approach could be the breakthrough you’re looking for. Certainly was for me.

 

My Journey to Conquering Chronic Insomnia with Dr. Caplan and Cannabis Medicine

Hashimotoโ€™s Disease and Cannabis: How I Found the Right Balance with Dr. Caplanโ€™s Help

โ€œMy endocrinologist recommended Dr. Caplan after Iโ€™d been diagnosed with Hashimotoโ€™s disease. I was dealing with a range of symptomsโ€”fatigue, joint pain, brain fogโ€”but I was really hesitant to try cannabis. I didnโ€™t have any experience with it and was worried about how it might affect me. Still, after years of feeling like nothing was really working, I was ready to explore new options. Dr. Caplanโ€™s approach made all the difference. He took the time to understand not only my medical history but also my reservations. He patiently explained how cannabis could help with my symptoms without overwhelming me. It wasnโ€™t an instant fix, but over the months, I started noticing real improvements. What sets Dr. Caplan apart is how much he truly listens and adapts the treatment plan to my needs. Iโ€™ve never felt more supported by a doctor.โ€

โ€“ Megan L.

Megan Lincoln

A Lifeline in Chronic Pain: Cannabis Changed My Life

โ€œI was referred to Dr. Caplan by my orthopedist after years of dealing with debilitating lower back pain. I had been through physical therapy, painkillers, and injections, but nothing offered lasting relief. Honestly, I was skeptical about trying cannabis. I had always associated it with recreational use and didnโ€™t see how it could be a solution for chronic pain. But after my orthopedist explained the potential benefits and encouraged me to meet with Dr. Caplan, I decided to give it a chance. From the moment I walked into Dr. Caplanโ€™s office, I felt like he was different from any doctor Iโ€™d seen before. He listened carefully to my history and my concerns, and instead of pushing cannabis on me, he educated me on the science behind it. He explained how it could help reduce inflammation and manage pain without the foggy side effects I was used to with traditional medications. Now, after six months of working with Dr. Caplan, my pain is more manageable than I ever thought possible. Iโ€™m not saying itโ€™s a magic cure, but for the first time in years, I feel like I have control over my life again. His compassion and expertise have been a lifeline for me.โ€

โ€“ David P.

David Pelonsky

Used as a Human Target as a Kid, Medical Cannabis is the answer.

I’m totally blind. I live in a rural area. So when I was 12, same-age peers thought zapping the blind girl’s eyes with laser pointers would be a great idea. It got bad enough that my paraprofessional had to have the devices banned from the school for my safety. Shortly after, I began having intense eye aches. I differentiate them from headaches because even a 12 year old can tell the difference. Doctors told my parents and I they were migraines. It wasn’t until later in life that I began realizing there was something else going on here. Really studying migraines, studying the eye, studying neurology and understanding not all was as it seemed. I began developing my own theories as to what these “migraines” were. I take migraine meds, but they don’t treat the eye aches. They treat the other migraine symptoms just fine. My younger brother suggested I try edibles last year. Because by this point, I was in enough pain where I believed I’d have to have my eyes removed. None of us wanted to see that happen. So he took me to a dispensary, (he had spoken with someone he knew there about me prior, and they’d come up with a regimen they thought would work.) The first clue I had that we were on the right track, was that I slept for 14 hours. So I kept a calendar and a spreadsheet full of virtual sticky notes, and 2 weeks later came to Dr. Caplan for my medical card, crazy theories about optic neuropathy in underdeveloped optic nerves and all. A year later, I’m studying cybersecurity, because that’s something I found I’m passionate about, and I can do it now!

Krista Pennell

To sleep well again is life-changing

Dr. Caplan was coincidentally recommended by both my dentist and a close friend. I was concerned about finding a high level, knowledgeable, physician in a professional setting who understood using cannabis in a safe and effective manner. I can’t recommend Dr. Caplan more highly. His knowledge is vast and I am grateful for his expertise, care and compassion. To sleep well again is life-changing. Very few things literally change someone’s life. Dr. Caplan’s knowledge and guidance on cannabis did that for me.

Barbara M.

Not once did I feel rushed or embarrassed, in fact I felt like he really does care about my circumstances, and wanted for me to feel confident and prepared

Honestly, I was hesitant to try cannabis. I have debilitating menstrual cramps and my OB/GYN recommended Dr. Caplan. I was more than a little hesitant to try cannibas because all I really knew about it was that people used it to get “high” – and that was not something I was interested in. This perspective totally changed when I actually came in and met with Dr. Caplan. He was incredibly understanding and really took the time to ease my mind about the whole process, what kind of options there were to choose from, what they might do, and what would probably appeal to me. He spent a lot of time answering all my questions (and I had a lot!). Not once did I feel rushed or embarrassed, in fact I felt like he really does care about my circumstances, and wanted for me to feel confident and prepared.

Mark L.

Dr. Caplan was thorough in his evaluation and friendly and accessible in his approach

Dr. Caplan was thorough in his evaluation and friendly and accessible in his approach. He provided in depth information and step by step guidance for beginning the process of utilizing cannabis therapies. He is available to his patients by email and phone. I highly recommend an appointment with him if you are even remotely considering medicinal use. I was hesitant about this approach before my appointment but now, after talking with Dr. Caplan and learning a little bit more about the science, I am eager to explore and I feel better already!

Rachel M.

I saw Dr Caplan a few months ago, and from even before I met him, he has made himself available to me over email, for questions, more than even my regular doctor

I came into marijuana medicine with zero experience. I must say, I’ve been learning a ton, and I would recommend it to anyone with terrible anxiety and depression. I saw Dr Caplan a few months ago, and from even before I met him, he has made himself available to me over email, for questions, more than even my regular doctor. A friend told me that I should see Dr Caplan, but I was still unsure about becoming a medical marijuana patient. I called and was able to speak with Dr Caplan directly. He took time, on the phone, even before he had met me, to explain the whole process, which helped me feel more comfortable putting a voice and personality to the process. Later, when I finally came in, during the visit, he spent almost 40 minutes with me, walking me through how cannabis might fit in with some of the other treatments I currently use. We have kept in touch over email since, like 3 or 4 random questions, and has always responded promptly. I think he is a truly special doctor, and from what I’ve read on Twitter, has a passion for educating and helping improve the perception of cannabis.

Alan T.

I had an enjoyable visit with clear information and education about medical marijuana and the dispensaries

Full stars. I appreciate the great parking and simple scheduling system. I had an enjoyable visit with clear information and education about medical marijuana and the dispensaries. No fancy language, no time wasted. Works for me.

Michael J.

I am a survivor of breast, uterine, and ovarian cancers, and Dr Caplan of CED Clinic is, hands down, the favorite voice of support and cannabis education for our hospital list-serv care group

I am a survivor of breast, uterine, and ovarian cancers, and Dr Caplan of CED Clinic is, hands down, the favorite voice of support and cannabis education for our hospital list-serv care group. I have seen him speak publicly, and on TV, and of course he is also my doctor. In spite of having what seems to be a crowd of patients who are mostly in terrible pain or have a generous helping of emotional/mental issues, I see him work tirelessly for his patients and for the cause, in general. I appreciate his leadership in the cannabis field. He is one in a million.

Stephanie W.

Dr. Caplan is an extremely knowledgeable doctor in his field and very easy to speak with about any questions and concerns you may have

Dr. Caplan is an extremely knowledgeable doctor in his field and very easy to speak with about any questions and concerns you may have. As a person that suffers from anxiety, upon arriving at the office I felt welcomed and relaxed because the doctor is compassionate and kind. The office atmosphere is not what I expected at all and was very peaceful and relaxing, also there were snacks and beverages which I have never seen before in a doctor’s office. I would highly recommend Dr. Caplan because he will take the time to answer every question that you may have about treatment. I made an appointment on a Saturday and was seen right away on the same day! Very easy process and very responsive. I am happy I chose Dr. Caplan!

Joshua C.

This is our second visit to Dr. Caplan in a year, and on both occasions, we were just blown away by his caring and compassion

This is our second visit to Dr. Caplan in a year, and on both occasions, we were just blown away by his caring and compassion. He is a true healer, with a great heart, enormous patience, and extraordinary expertise. My wife and I were amazed to find a physician who truly puts his patients first, and who is passionate about figuring out the best way to help us with our chronic pain. In our 60+ years of experience with health care providers, Dr. Caplan is among the most committed, generous, and caring healers we have ever met.

Heather F.

I can’t recommend Dr. Caplan highly enough

I can’t recommend Dr. Caplan highly enough. This was my third medical marijuana certification review (original plus two renewals), and the previous two doctors were just perfunctory form-fillers in shabby offices in remote office parks. Dr. Caplan is a REAL cannabis doctor who’s deeply knowledgeable about medical marijuana and clearly explains EXACTLY how to use it for YOUR specific conditions. He also has a real doctor’s office in a real medical building right on Boylston Street (Route 9) in Chestnut Hill ( not far from NETA Brookline, my dispensary of choice.) AND THE VISIT IS COVERED BY MEDICAL INSURANCE! I’ve become somewhat knowledgeable about what works for my primary complaint (chronic pain from spinal stenosis w/ radiculopathy) and what to avoid, but he gave me brand new ways to deal with my insomnia (including how and when to use edibles, which hadn’t worked for me before b/c I didn’t really know what I was doing) and arthritis in my hands (including a simple recipe to make topical lotion that’s stronger and cheaper than the commercial products). I interrupted him with frequent questions, which he answered at whatever level of detail and technical information I wanted. I had been deeply dissatisfied with the cannabis doctors I went to before, but Dr. Caplan is an outstanding DOCTOR who happens to specialize in medical marijuana because he cares about helping patients for whom traditional medicine hasn’t fully met their needs. You can book appointments on his web site, although my wait time was more than 10 minutes (during which I filled out his online patient questionnaire on my phone and ate all the Kit Kats in his candy basket), it was well worth it. This is a relatively new practice, I believe, and it’s going to get a lot busier as word spreads. But just do yourself a favor and go: this is what state-of-the-art medical marijuana care is supposed to be like.

Steve G.

Dr. Caplan patiently explained how there are so many options to chose from and exactly what each was helpful for

I recently had my first appointment with Dr. Caplan after reading negative reviews of so many other medical marijuana certification “places”. I can’t say enough good things about my visit with him. To start with he’s a very compassionate, caring doctor. I’m a 63 yr old woman and had never used marijuana or “street drugs”, so I was feeling nervous about trying it. I recently started chemo therapy at Dana-Farber and the side effects have been difficult to deal with. In particular, insomnia and a bit of evening anxiety. He is extremely knowledgeable about all aspects of medical marijuana. Dr. Caplan patiently explained how there are so many options to chose from and exactly what each was helpful for. With that said, he suggested several products for me to try. I now know what helps me, but each person has to use the information he gives and then try different products from a reputable medical dispensary. I plan to have a 2nd appt. with him in a few months just to get his feedback on my experiences and possibly more recommendations. It’s not necessary to go back to him after getting your certification, but he truly knows so much about the medicinal benefits that I’d like to learn even more. I highly recommend him.

Nancy O.

I would highly recommend Dr. Caplan because he will take the time to answer every question that you may have about treatment

Dr. Caplan is an extremely knowledgeable doctor in his field and very easy to speak with about any questions and concerns you may have. As a person that suffers from anxiety, upon arriving at the office I felt welcomed and relaxed because the doctor is compassionate and kind. The office atmosphere is not what I expected at all and was very peaceful and relaxing, also there were snacks and beverages which I have never seen before in a doctor’s office. I would highly recommend Dr. Caplan because he will take the time to answer every question that you may have about treatment. I made an appointment on a Saturday and was seen right away on the same day! Very easy process and very responsive. I am happy I chose Dr. Caplan!

Robert M.

Dr. Caplan is extremely patient and compassionate

Dr. Caplan is extremely patient and compassionate. He answered all of my questions and gave me a great deal of useful information (while emphasizing that I didn’t have to absorb all of it right away). He encouraged me to contact him with any more questions I might have after the appointment, and began the process of registering me immediately after I left. I had an email from the Commonwealth of MA before I got home, and completed the application online within a few minutes. It couldn’t have been an easier or more stress-free experience. Dr. Caplan truly believes in the effectiveness of cannabis as a medicinal tool, and is committed to making it more widely available for that purpose and in dispelling the ocean of ignorance that has unfortunately been created around it in our society. I can’t recommend him highly enough.

Justice S.

Excellent Experience, top to bottom

Excellent Experience, top to bottom. I scheduled my appointment on CED clinic website, got in the next day – and visit was informative, and doc was kind, compassionate, and amazingly knowledgeable. I intend to follow him as a permanent addition to my healthcare and would recommend widely.

Ellison M.

I’m shy but felt comfortable and supported

Awesome doctor. Super easy to talk to. I’m shy but felt comfortable and supported. Great teacher too. I had no idea there was so much to know!

Sara E.

I learned about different options and lots of choices, and received handouts to learn even more

First heard of Dr Caplan on /r/BostonTrees subreddit. Made my appointment online, for the next day, and did all paperwork online before I came in. Building is very professional and comfortable, with great parking, and close to where I live. As I expected, doc was kind, thorough, and efficient. We reviewed my medical history, talked about what I had been doing in the past, and discussed a host of treatment ideas, and not just marijuana. I learned about different options and lots of choices, and received handouts to learn even more. I plan to follow up in a few months, and I look forward to it.

Ryan H.

Every time I come in, I learn something new and amazing.

I followed Dr Caplan from his position as the Medical Director of Canna Care Docs to CED Clinic – and would follow him again. I have had years of back pain and arthritis – my wrists and knees and hips. Dr Caplan has helped me understand much more about marijuana, and I have to say, it has been a wonderful improvement for me. Every time I come in, I learn something new and amazing. It’s a new industry for me, and I feel very well supported.

Elizabeth P.

My visit with Dr. Caplan made it comforting to know that someone was on my side

My visit with Dr. Caplan made it comforting to know that someone was on my side. I was surprised to find that Dr. Caplan does more than just write scripts for people to take to dispensaries. He sees some of his patients on a regular basis to personalize treatment plans and it’s clear he cares about education and the destigmatization of medical cannabinoids. He goes to assisted living centers, medical expos, wellness centers, and more to speak with people on the matter. This is his passion!

Benjamin T.

Dr. Caplan is extremely patient and compassionate

Dr. Caplan is extremely patient and compassionate. He answered all of my questions and gave me a great deal of useful information (while emphasizing that I didnรขโ‚ฌt have to absorb all of it right away). He encouraged me to contact him with any more questions I might have after the appointment, and began the process of registering me immediately after I left. I had an email from the Commonwealth of MA before I got home, and completed the application online within a few minutes. It couldnรขโ‚ฌโ„ขt have been an easier or more stress-free experience.รขโ‚ฌ “รขโ‚ฌ” Dr. Caplan truly believes in the effectiveness of cannabis as a medicinal tool, and is committed to making it more widely available for that purpose and in dispelling the ocean of ignorance that has unfortunately been created around it in our society. I canโ‚ฌt recommend him highly enough.

Jeff E.

Very knowledgeable and compassionate

Very knowledgeable and compassionate.

Irene C.

I would highly recommend Dr. Caplan

I wasn’t sure what to expect from the initial appointment. ย It was informative, educational and an overall great experience! ย Dr. Caplan is easy-going, kind, and gave clear, detailed information about medical cannabis and MA medical dispensaries. ย I would highly recommend Dr. Caplan. ย His clinic and his knowledge are certainly worth 5-star reviews!

Ashley S.

I had such a good experience with Dr. Caplan of CED Clinic. ย 

I had such a good experience with Dr. Caplan of CED Clinic.

Medical: I had a lot of worries going in, and Dr. Caplan put me at ease with his knowledge and calm manner. ย As a family doctor, he asked good questions about my extensive medical background, in a supportive way. ย He used normal people words instead of medical gobbledygook! ย (I had just an hour before been at an appointment with a medical person who thought I should understand when he talked about my distal iliolumbar neuropathy – or something like that, I had no idea what he was talking about – so I especially noticed when Dr. Caplan used normal words that any person would know.)

Educational: He provided excellent information for total newbies, showed some devices, talked about legal stuff, and gave great info about local clinics and huge discounts available. ย I’m used to doctors providing pretty poor education materials, but Dr. Caplan’s infographics and handouts were a thing of beauty – informative, easy to read, and visually simple. ย I hope Dr. Caplan writes a book because I will buy it.

Logistics: This is such a streamlined practice, it is easy to get in soon, and respectful of your time. ย I got an appointment within less than 2 days, scheduled online, filled out my info online beforehand, found parking easily, was in and out quickly, and received the email with next steps instructions and application activation code in 1.5 hour! ย Can’t possibly be easier than this.

Laura M.

Dr. Caplan was very friendly, extremely helpful and knowledgeable

Dr. Caplan was very friendly, extremely helpful and knowledgeable. ย I would definitely recommend and I am looking forward to having him as a health resource.

Timothy Y.

I’ve switched 100% to cannabis as my go-to medicine

I’ve switched 100% to cannabis as my go-to medicine. ย I’m sick of pharmaceuticals; the weight gain, the weird feelings like I’m a zombie, the miserable sleep…sorry, but hard pass. ย Weed helps take the edge off and I’m still fully functional.

Anonoymous

Dr Caplan's Book: The Doctor-Approved Cannabis Handbook

FIN DoctorApprovedCannabisHandbook FullCover1024 1

"A wealth of information and a huge dose of compassion and clarity."

- Melissa Etheridge

Get To Know Your Medical Team!

We Stay Connected With Our Patients via Email, Online, and Even on the Airwaves!

Email | Instagramย  |ย  Twitterย  |ย  LinkedInย  |ย  YouTubeย  |ย  Spotify ย | ย Newsletter

CaplanCannabis.com | The Commonwealth Project | EO Care | Green Table Talk Podcast

Doctor and NP cartoon

๐Ÿ˜Ž
Sounds too good to be true? Put us to the test!

Send us an email to introduce yourself, and if we donโ€™t respond within a day, weโ€™ll knock $10 off as our apology!

SAVE Money ๐Ÿ’ฐ with CED Clinic:

Save money

Your health shouldnโ€™t break the bankโ€”let us help you save!

Contact us here for more

ย 

The Latest

CED Clinic Blog
March 3, 2026I am so glad I live in the 2020s. I love eddies. Source: Reddit r/saplings [...] Read more...
March 1, 2026A study presented at the 2026 International Cannabis Research Conference suggests that adults who substitute THC or CBD beverages for traditional alcohol may experience measurable differences in consumption behavior and related health outcomes. For clinicians navigating patient conversations about harm reduction and substance use, preliminary findings of this kind carry practical weight in informing shared decision-making around cannabis-based alternatives. The research adds to a growing but still limited body of endocannabinoid system clinical research, and its observational design means causality cannot yet be established. This report is relevant to ongoing discussions in endocannabinoid system clinical research and medical cannabis evidence-based care. Study Design and Findings The research, presented at the 2026 International Cannabis Research Conference, examined adults who reported substituting THC- or CBD-containing beverages for conventional alcoholic drinks. The observational design tracked differences in consumption behavior and associated health outcomes between those using cannabis-based alternatives and those continuing traditional alcohol use. While the conference presentation format limits the depth of methodological detail currently available, the study contributes a meaningful data point to the field of endocannabinoid system clinical research, particularly as cannabis beverage products become more widely accessible in regulated markets. Participants who made the substitution showed measurable differences in outcomes related to consumption patterns, though the specific metrics and magnitude of effect have not been fully detailed in available reporting. Because the study is observational in design, no causal relationship between cannabis beverage use and health outcomes can be drawn from these findings alone. Clinical Implications For clinicians engaged in harm reduction conversations, preliminary data of this nature can inform the framing of shared decision-making discussions with patients who are independently considering cannabis-based alternatives to alcohol. The findings do not yet meet the evidentiary threshold required to support formal clinical recommendations, and practitioners should situate them within the broader context of medical cannabis evidence-based care, which continues to evolve as regulatory and research infrastructure expands. Related Reading Cannabis basics overview Cannabis research library Medical cannabis at a crossroads Significant questions remain regarding population generalizability, duration of observation, and the role of individual endocannabinoid system variability in mediating any observed differences. Until more rigorously controlled cannabis clinical trial results are available, these findings are best interpreted as hypothesis-generating rather than practice-changing. Clinicians are encouraged to document patient-reported substitution behavior as part of routine substance use screening, which may help build the real-world data needed to support future prospective research. Clinical Takeaway The story summary provided is incomplete and does not contain sufficient detail about the study’s findings, methodology, population, or outcomes to produce an accurate Clinical Takeaway. To meet the required standard of never fabricating data or claims not present in the source material, a Clinical Takeaway cannot be written from the available input. Please provide the full or more complete story summary so the paragraph can be written accurately and responsibly. Reviewed by This content is reviewed by Dr. Benjamin Caplan, MD, a board-certified Family Medicine physician specializing in clinical cannabis medicine. www.cedclinic.com [...] Read more...
March 1, 2026A study presented at the 2026 International Cannabis Research Conference suggests that adults who substitute THC or CBD beverages for traditional alcohol may experience measurable differences in consumption patterns and related health outcomes. For clinicians navigating patient conversations about alcohol reduction strategies, this finding adds a preliminary data point to an area where endocannabinoid system clinical research has historically been limited. The study has not yet undergone peer review, and the full methodology has not been published, which warrants caution in clinical interpretation. This report is relevant to ongoing discussions in endocannabinoid system clinical research and medical cannabis evidence-based care. What the Evidence Shows The study, presented in conference format, examined adults who reported substituting THC- or CBD-containing beverages for traditional alcoholic drinks. Researchers observed measurable differences in consumption patterns and associated health outcomes among this population. While the specific metrics and effect sizes have not yet been disclosed in a peer-reviewed publication, the findings contribute an early data point to the growing body of endocannabinoid system clinical research exploring cannabinoids as potential tools in harm reduction contexts. The absence of a published methodology limits the degree to which clinicians can evaluate the study’s internal validity or generalizability at this time. Clinical Implications and Limitations Related Reading Cannabis basics overview Cannabis research library Medical cannabis at a crossroads For clinicians engaged in medical cannabis evidence-based care, this research represents a preliminary signal rather than a practice-changing finding. The substitution of low-dose cannabinoid beverages for alcohol is a patient behavior already occurring in clinical populations, and practitioners are increasingly fielding questions about its safety profile and potential benefit. Until full methodology, control conditions, and outcome definitions are available for review, clinical guidance should remain grounded in established evidence. Patients considering alcohol reduction strategies that involve cannabinoid products should be counseled on the current limitations of cannabis clinical trial results in this specific application, including the lack of long-term safety data and the variability in THC and CBD bioavailability across beverage formulations. Clinical Takeaway Emerging conference data suggest that some adults are substituting THC- or CBD-infused beverages for traditional alcoholic drinks, a pattern that may carry implications for how clinicians think about cannabis as part of broader substance use conversations. For patients who consume alcohol and are curious about cannabis-based alternatives, this research offers a preliminary signal worth raising with a healthcare provider familiar with cannabis medicine. However, because the study has not yet been peer-reviewed and the full methodology has not been published, the findings should be interpreted cautiously and cannot yet be used to guide clinical recommendations. Patients interested in exploring this area should seek medical cannabis evidence-based care from a qualified provider rather than making substitutions independently, and clinicians should watch for forthcoming peer-reviewed publications before drawing practice-level conclusions. Reviewed by This content is reviewed by Dr. Benjamin Caplan, MD, a board-certified Family Medicine physician specializing in clinical cannabis medicine. www.cedclinic.com [...] Read more...
March 1, 2026A new Canadian study found that rates of cannabis use, anxiety, and depression have all increased over the same period, with cannabis use consistently associated with a higher prevalence of these conditions. For clinicians navigating cannabis anxiety treatment evidence, the findings raise important questions about directionality โ€” whether cannabis use precedes psychological distress, follows it as a form of self-medication, or reflects a more complex bidirectional relationship. The association alone does not establish causation, and the authors acknowledge that perceived therapeutic benefits may be shaping some of the patterns observed in the data. This report is relevant to ongoing discussions in cannabis anxiety treatment evidence and endocannabinoid system clinical research. Study Design and Findings The Canadian study tracked concurrent trends across three measurable outcomes: rates of cannabis use, anxiety prevalence, and depression prevalence. Across the observation period, all three increased, and cannabis use was consistently associated with a higher prevalence of both anxiety and depression. The authors note that perceived therapeutic benefits may be contributing to the patterns observed, suggesting that a portion of cannabis use may reflect self-directed symptom management rather than recreational consumption. For those evaluating cannabis anxiety treatment evidence, this distinction carries meaningful clinical weight. Clinical Implications The central interpretive challenge in this data is directionality. An association between cannabis use and elevated rates of anxiety or depression does not indicate which condition precedes the other, nor does it rule out a bidirectional relationship in which psychological distress both prompts use and is subsequently influenced by it. This complexity is consistent with broader endocannabinoid system clinical research, which has long identified the endocannabinoid system as integral to mood regulation, stress response, and anxiety modulation. Without longitudinal individual-level data, the population-level correlation cannot be interpreted as causal in either direction. Context in Current Research Related Reading Cannabis anxiety and depression guide Cannabis and psychiatric disorders Weed anxiety explained Findings of this kind underscore the need for rigorously designed prospective studies that can differentiate between use patterns, clinical intent, dosing, and psychiatric history. For clinicians attempting to apply medical cannabis evidence-based care, cross-sectional or ecological trend data provides a signal worth monitoring but cannot substitute for controlled clinical evidence. The self-medication hypothesis, while plausible and acknowledged by the authors, remains an interpretive framework rather than an established mechanism until stronger study designs are applied to the question. Clinical Takeaway A large Canadian study found that rates of cannabis use, anxiety, and depression have all increased together over time, though the research does not establish that cannabis causes these mental health conditions or relieves them. For patients and clinicians, this means the relationship between cannabis and mental health remains genuinely complex, and observed associations should not be interpreted as evidence that cannabis is either a proven treatment or a proven cause of anxiety or depression. The study’s design limits what conclusions can be drawn, and self-reported data, shifting legal contexts, and changing social norms around cannabis use may all influence these patterns in ways the research cannot fully account for. Patients seeking medical cannabis evidence-based care for anxiety or depression should discuss the current state of the evidence openly with their prescribing clinician before making decisions, as the science has not yet resolved whether cannabis use in these populations reflects self-medication, contributes to symptom burden, or both. Reviewed by This content is reviewed by Dr. Benjamin Caplan, MD, a board-certified Family Medicine physician specializing in clinical cannabis medicine. www.cedclinic.com [...] Read more...
February 26, 2026Cannabis Dosing for Seniors: 70+ Predictability over potency. A fall-aware, medication-aware framework for starting cannabis after 70 without turning a therapeutic plan into a surprise. Schedule Senior and aging care Educational content only. Decisions should be personalized with your clinician, especially when fall risk, frailty, or complex medications are involved. What You Will Learn Most dosing advice online is written for healthy adults with simple medication lists. That is not who most 70-plus patients are. This is a clinician-style dosing blueprint for older adults that prioritizes steadiness and function. In this effort to share cannabis dosing for seniors, you will learn how aging physiology shifts dose response, how route and timing change safety risk, how to titrate without stacking doses, and how to think about cannabis in the context of polypharmacy. This is not about chasing a sensation. It is about building a repeatable plan that protects balance, cognition, and autonomy. Evidence vs Clinical Framework, What Is Known and What Is Practical Here is the honest truth about geriatric cannabis dosing. We have good human evidence that cannabinoids can increase side effects that matter disproportionately in older adults, including dizziness and sedation. We also have evidence suggesting that higher THC exposure increases the odds of certain neuropsychiatric adverse effects in older age groups. What we do not have is one universally accepted dosing protocol validated by large randomized trials focused solely on adults over 70 across common indications. So the framework below is intentionally conservative. It is a safety-first approach designed to reduce surprise and protect steadiness. It is clinical reasoning anchored to the evidence we do have about common adverse events, translated into a plan that prioritizes predictability. Why this conservative approach is evidence-aligned ๐Ÿง Dizziness is a common adverse effect in controlled evidence A large systematic review and meta-analysis of cannabinoids for medical use found non-serious adverse events were more common with cannabinoids than controls, and dizziness was commonly reported. Whiting et al. 2015 (JAMA), PMID 26103030 ๐Ÿง  In adults 50+, THC dose relates to certain adverse effects A systematic review and metaregression in adults aged 50+ found THC dose moderated incident rate ratios for outcomes such as dizziness or lightheadedness and thinking or perception disorders. Velayudhan et al. 2021 (JAMA Network Open), doi:10.1001/jamanetworkopen.2020.35913 ๐Ÿ‘ต Older-adult cohorts commonly report dizziness and sleepiness Prospective observational data in adults 65+ describe adverse effects such as dizziness and sleepiness or fatigue, alongside the need for careful monitoring in real-world older populations. Abuhasira et al. 2019, PMID 31683817 These citations support the safety rationale. They do not replace personalized clinical guidance. Why โ€œStart Low and Go Slowโ€ Is Not Enough After 70 โ€œStart low and go slowโ€ is kind advice, and it is incomplete advice. After 70, the biggest risk is not that cannabis will fail to help. The biggest risk is that cannabis will create a surprise at the wrong time: dizziness when someone stands up, sedation layered onto other sedating medications, or impaired steadiness during a nighttime bathroom trip. After 70, the goal is not intensity. The goal is predictability. Predictability is what makes a trial safe enough to learn from. Why Aging Changes Cannabis Response Older adults are physiologically distinct. Several shifts matter clinically: ๐ŸงฌMetabolism and clearance can changeEffects can last longer, and a dose that felt mild years ago can feel stronger now. ๐Ÿง Cognitive sensitivity can riseSmall psychoactive effects can feel disruptive when pain, sleep loss, and medication layering are already in play. ๐ŸงBalance becomes a higher-stakes variableOrthostatic shifts, sedation, and slowed reaction time matter more when falls carry higher consequences. ๐Ÿ’ŠPolypharmacy becomes the defaultA โ€œlow doseโ€ can become โ€œtoo muchโ€ once it interacts with other sedating or blood pressure active medications. This is why cannabis dosing over 70 should look more like careful pharmacology and less like casual experimentation. Step 1: Define One Target, Not Ten Pick one symptom target you can measure. Not a mood. Not a vibe. Something you can track. Good targets ๐ŸŒ™Minutes to fall asleep ๐Ÿ›๏ธNumber of nighttime awakenings ๐Ÿ”ฅPain level at bedtime ๐ŸฆดMorning stiffness duration ๐ŸšถWalking distance before discomfort If you cannot measure it, you cannot titrate it safely. Step 2: Choose Route Based on Timing Risk Inhalation Fast onset. Shorter duration. Easier to stop quickly if it feels like too much. Overshoot can happen quickly if someone takes repeated inhalations trying to โ€œget it to work.โ€ Edibles Delayed onset. Longer duration. Dose stacking is common when someone takes a second dose before the first has fully shown its effect. In older adults, stacking is one of the simplest ways to create prolonged dizziness, confusion, or sedation. Sublingual tinctures Often a middle path. More controllable increments for many patients, and commonly easier to make small, repeatable adjustments. Route does not eliminate fall risk. It shifts when fall risk appears. Early trials should happen when mobility demands are low. If nighttime bathroom trips are part of the routine, avoid making bedtime your first experiment window. Step 3: A Conservative THC Starting Framework Over 70 This is a cautious clinical framework designed to reduce surprise. It is not one-size-fits-all, and it is not a promise of benefit. Category A: Lower fall risk, no major frailty, stable medications 1๏ธโƒฃFirst trial: 0.5 mg to 1 mg THC equivalent โณWait: full onset window before considering any adjustment ๐ŸšซAvoid: alcohol during early trials, and avoid starting on the same day as any new sedating medication change Category B: Moderate fall risk, cognitive vulnerability, or sedation layering 1๏ธโƒฃFirst trial: 0.25 mg to 0.5 mg THC equivalent, or CBD-forward start ๐Ÿ—“๏ธTitrate: no faster than every 48 to 72 hours, and only if there is measurable benefit without new instability Category C: High fall risk, prior syncope, significant frailty, or multiple sedating medications ๐ŸงฉDefault start: CBD-forward approach ๐ŸงชIf THC is used: sub-0.5 mg trial, supervised when feasible ๐Ÿ›‘Non-negotiable: monitor steadiness, sedation, and confusion for a week before any escalation Why so cautious? Dizziness and sedation are among the most commonly reported adverse effects with cannabinoids in controlled evidence and older adult cohorts. THC dose appears to influence some adverse event rates. That matters more after 70 because it maps directly onto fall risk. Evidence anchors: Whiting et al. 2015 (JAMA), Velayudhan et al. 2021, Abuhasira et al. 2019 The 7-Day Monitoring Protocol If you introduce THC after 70, monitor deliberately for one week. This is how you protect the trial from turning into a story. ๐ŸงStanding dizziness: especially within the first 2 hours after dosing ๐ŸšฝNighttime steadiness: bathroom trips are where risk shows up ๐Ÿ˜ดDaytime sedation: unplanned naps and grogginess count ๐ŸงญNear-falls: catch-yourself moments are data ๐Ÿง New confusion: especially in conversations and task switching Safety is not a disclaimer. It is a dosing strategy. Polypharmacy: The Part That Turns โ€œLow Doseโ€ Into โ€œToo Muchโ€ In older adults, interaction risk is often less about rare chemistry and more about common layering. Pharmacodynamic layering These combinations can magnify sedation, slowed reaction time, and orthostatic effects: ๐Ÿ’คSleep medications ๐Ÿง Benzodiazepines and other anxiolytics ๐ŸฉนOpioids and other pain medications that sedate ๐Ÿ’ŠGabapentinoids and similar neurologic agents ๐Ÿซ€Blood pressure medications that increase orthostatic vulnerability Pharmacokinetic considerations Cannabinoids can influence CYP450 enzymes and therefore can alter levels of some medications in some individuals. One high-stakes example is warfarin, where published case reports show INR elevation after CBD exposure, and a systematic review summarizes anticoagulant interaction evidence. Evidence anchors ๐ŸงชCBD and warfarin interaction case reportGrayson et al. 2017, PMID 29387536 ๐Ÿ“ˆSystematic review of anticoagulant interactions with cannabinoidsSmythe et al. 2023, PMID 37740600 ๐ŸงฌCBD and THC effects on CYP450 enzymesDrug Metabolism Reviews 2024 systematic review, PMID 38655747 Practical rule Do not introduce cannabis at the same time as you adjust other sedating medications. Make one change at a time so you can interpret the result. Microdosing Over 70: Not a Trend, a Control System Microdosing is not about weak effects. It is about minimizing surprise while preserving the ability to adjust. A practical microdosing approach over 70 often means sub-milligram THC increments when THC is used, stabilizing for 2 to 3 days before any change, and reducing dose if dizziness, sedation, or confusion appears. Escalation without benefit is not progress. It is noise. If It Feels Too Strong When older adults say โ€œtoo high,โ€ they often mean unsteady, anxious, foggy, or unable to do normal tasks comfortably. A course correction usually involves one or more of these: โฌ‡๏ธReduce dose: by at least 50 percent on the next trial ๐Ÿ•ฐ๏ธChange timing: trial earlier in the day, not right before bed ๐ŸงญChange route: shift toward smaller increments if stacking risk is present ๐ŸŒฟConsider CBD-forward recalibration: especially for high sensitivity If symptoms are severe or there is a fall, seek medical care. Internal Resources These links are designed to keep the seniors ecosystem coherent and practical. Senior and aging care Cannabis for pain Dosage and application guide Smart cannabis dosing Talk to your doctor about cannabis Drug interactions guide Want a structured start? If you are new to cannabis or supporting a parent who is, a guided plan is usually calmer and safer than experimentation. If you would like clinician guidance, you can schedule here: https://cedclinic.com/schedule/ FAQ What is a low dose of THC for someone over 70? Many older adults begin in the sub-milligram to 1 mg THC range, then adjust slowly based on function and side effects. The safest starting point depends on fall history, frailty, medication layering, and sensitivity. How fast can I increase the dose? A cautious approach over 70 often means holding the dose steady for 48 to 72 hours before any change, and increasing only if there is measurable benefit without new dizziness, sedation, or confusion. Should I start with CBD or THC? If fall risk is high, sensitivity is unknown, or medications already cause sedation, a CBD-forward start can reduce surprise. THC can still be appropriate for some older adults, but it should be introduced in small, measurable steps with attention to timing and steadiness. Are edibles safe for seniors? They can be, but delayed onset and long duration increase the risk of dose stacking. If edibles are used, the most important rule is to wait long enough before considering any additional dose. What is dose stacking, and why does it matter after 70? Dose stacking happens when a person takes a second dose before the first dose has fully taken effect. In older adults, stacking can produce prolonged dizziness, confusion, or unsteadiness that increases fall risk. When is the safest time of day to trial a first dose? Many older adults do best trialing earlier in the day, when a caregiver is available and mobility demands are predictable. Trialing right before bed can increase nighttime fall risk if bathroom trips are common. What should I track during the first week? Track one primary symptom target, plus fall-relevant signals such as standing dizziness, nighttime steadiness, daytime sedation, near-falls, and any new confusion. Predictability matters more than intensity. What medications are most important to mention to my clinician? Sleep medications, benzodiazepines, opioids, gabapentinoids, antidepressants, and blood pressure medications are common categories that can interact through sedation or orthostatic effects. If you take warfarin, clinician coordination is especially important because case reports and a systematic review describe INR elevation after CBD or cannabis exposure. Is there research specifically in older adults? Yes, but it is still limited compared with many standard medications. Prospective observational cohorts in adults 65+ describe common adverse effects such as dizziness and sleepiness, and systematic reviews in older populations describe THC dose relationships with certain adverse events. Larger trials focused exclusively on adults over 70 remain a gap. References ๐Ÿ”— Whiting PF, et al. Cannabinoids for Medical Use: A Systematic Review and Meta-analysis. JAMA. 2015;313(24):2456-2473. doi:10.1001/jama.2015.6358. PMID: 26103030. https://pubmed.ncbi.nlm.nih.gov/26103030/ ๐Ÿ”— Velayudhan L, et al. Evaluation of THC-Related Neuropsychiatric Symptoms Among Adults Aged 50 Years and Older: A Systematic Review and Metaregression Analysis. JAMA Network Open. 2021;4(2):e2035913. doi:10.1001/jamanetworkopen.2020.35913. https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2775736 ๐Ÿ”— Abuhasira R, et al. Medical Cannabis for Older Patients: Treatment Protocol and Initial Results. J Clin Med. 2019;8(11):1819. doi:10.3390/jcm8111819. PMID: 31683817. https://pubmed.ncbi.nlm.nih.gov/31683817/ ๐Ÿ”— Smythe MA, et al. Anticoagulant drug-drug interactions with cannabinoids: A systematic review. Pharmacotherapy. 2023. doi:10.1002/phar.2881. PMID: 37740600. https://pubmed.ncbi.nlm.nih.gov/37740600/ ๐Ÿ”— Grayson L, et al. An interaction between warfarin and cannabidiol, a case report. Epilepsy Behav Case Rep. 2017;9:10-11. doi:10.1016/j.ebcr.2017.10.001. PMID: 29387536. PMCID: PMC5789126. https://pubmed.ncbi.nlm.nih.gov/29387536/ ๐Ÿ”— Effects of cannabidiol and ฮ”9-tetrahydrocannabinol on cytochrome P450 enzymes: a systematic review. Drug Metab Rev. 2024. doi:10.1080/03602532.2024.2346767. PMID: 38655747. https://pubmed.ncbi.nlm.nih.gov/38655747/ Evidence quality and relevance varies by indication, product type, route, and patient vulnerability. Older adult trials remain limited compared with many standard therapies. [...] Read more...
February 26, 2026Today in Cannabis News Cannabis and Anxiety Relief in Real-World Patients: A 45-Day Longitudinal Look Earlier today we published coverage of a separate neuroscience paper examining cannabis and brain reward anticipation over 12 months. If you missed it, you can read that here: The Association Between Cannabis Use and Brain Reward Anticipation (Nature) That paper focuses on brain imaging and long-term neural adaptation. The study below asks something more immediate and more clinically practical: When patients use medical cannabis for anxiety in daily life, do they feel better that same day? For ongoing research updates, visit our Cannabis News feed. Primary Source Full study manuscript (PDF): Download the published paper Teaser Summary, Whatโ€™s Publicly Relevant, Whatโ€™s Controversial Researchers followed 416 Florida medical cannabis patients certified for anxiety for 45 days. Each day, participants rated anxiety before and after whatever they used or did to manage symptoms. The attention-grabbing result On โ€œcannabis-onlyโ€ days, average anxiety dropped by about 3.5 points on a 0โ€“10 scale. That is a clinically noticeable same-day change. The natural comparison On days with other medications or only activities like exercise or meditation, anxiety still dropped, but by a smaller amount in this dataset. The disciplined limitation This was not a randomized trial. People chose what they used each day. Expectancy, context, and standardized timing were not controlled. The real question becomes not simply โ€œdoes cannabis reduce anxiety,โ€ but what portion of relief is cannabinoids, what portion is context, and what portion is expectation. What This 45-Day Study Actually Did The researchers collected over 11,000 day-level entries across 45 days. Each entry captured anxiety before and after the dayโ€™s chosen intervention. They compared day types: medical cannabis only, medications only, activities only, and combinations. More than 11,000 day-level entries formed the backbone of this analysis. In this real-world symptom tracking cohort, cannabis-use days were associated with larger same-day reductions in anxiety than non-cannabis days. Relief did not appear to meaningfully decline across the 45-day window. This is real-world cannabis evidence, not a lab demonstration. That is both the strength and the constraint. Strengths Daily tracking reduces long-recall bias. Large day-level dataset improves analytic stability. Appropriate modeling for repeated observations within individuals. High ecological validity, reflecting how patients actually use medical cannabis for anxiety. Limitations No randomization or blinding. No measurement of expectancy or belief effects. No standardized dosing and no cannabinoid composition modeling (THC, CBD, ratios). Self-selection into cannabis use and into the study itself. Day-type comparisons may reflect differences in context, not only differences in substances. None of these invalidate the reported reductions. They limit what the data can prove. That distinction is not semantic. It is the difference between patient experience and pharmacologic causality. What This Study Is Actually Telling Us In my clinic, this is the exact conversation patients want clarity on. They are not asking whether cannabis โ€œtreats anxiety disordersโ€ in the abstract. They are asking: When I use it, do I feel calmer? This study suggests that many treatment-seeking patients do report meaningful same-day relief on cannabis-use days. That matters. It puts numbers behind an experience that is otherwise easy to dismiss or exaggerate. Here is the part the public conversation tends to miss. If a patient reports relief, that relief is real, even if we cannot yet assign credit cleanly between cannabinoids and context. But if we pretend this kind of real-world data โ€œprovesโ€ cannabis is a universal anxiolytic, we create the opposite problem: people who are THC-sensitive, or who worsen with the wrong product, get told they are โ€œdoing it wrong.โ€ That is not evidence-based care. That is ideology wearing a white coat. As your physician, my job is to go one step further: who benefits consistently, who worsens, what dose range is safest, what THC:CBD balance fits your physiology, and what role does context play. This paper moves us forward. It does not finish the job. Why Expectancy Matters in Cannabis and Anxiety Research Anxiety is particularly sensitive to anticipation and perceived control. When patients believe something will calm them, measurable reductions in distress can occur even before pharmacology fully unfolds. In blinded randomized trials, expectancy is partially controlled. In real-world symptom tracking studies like this one, it is not. That does not make relief unreal. It means mechanism remains layered. Relief may reflect pharmacology, belief, context, or a combination. This is also where product chemistry matters. If you are trying to make sense of what you are taking and what it actually contains, start with: how to read a Certificate of Analysis (COA) . Keep Reading Daily research updates: Cannabis News Basics and context: What is the endocannabinoid system? Product literacy: How to read a COA Related clinical topic: Medical cannabis for anxiety Executive Summary 416 medical cannabis patients tracked anxiety daily for 45 days. Cannabis-use days showed larger same-day reductions in anxiety than non-cannabis days. Effects were clinically noticeable in magnitude within this cohort. No randomization, no expectancy measurement, and no dose modeling limit causal conclusions. Best interpreted as strong evidence of perceived benefit in engaged medical cannabis patients. Real-world data tell us how patients experience treatment. Controlled trials tell us why. Responsible medicine integrates both. FAQ Common Questions Patients Ask Does medical cannabis reduce anxiety immediately? In a 45-day real-world tracking study of 416 medical cannabis patients, cannabis-use days were associated with larger same-day reductions in self-rated anxiety compared with non-cannabis days. However, the study was observational and cannot establish pharmacologic causality. Is cannabis proven to treat anxiety disorders? No. Observational studies show that many patients report anxiety relief, but randomized controlled trials are required to establish definitive treatment efficacy. Real-world data reflect patient experience, not proof of universal effectiveness. What role do expectancy effects play in cannabis and anxiety research? Expectancy effects can influence anxiety outcomes. In studies without blinding or randomization, belief and context may contribute to reported improvement alongside pharmacologic effects. What are the limitations of real-world cannabis studies? Real-world studies offer ecological validity but often lack randomization, blinding, standardized dosing, and controlled expectancy measurement. These factors limit causal conclusions while still providing useful insight into patient-reported outcomes. [...] Read more...
February 23, 2026Clinician + patient-facing evidence review Adolescent Cannabis Use and Psychosis Risk: What This Cohort Study Shows What this large cohort study shows, what it does not measure, and how to discuss risk without overstating it. Adolescent cannabis use and psychosis risk remain central concerns in youth mental health research. In this large cohort, adolescents reporting past-year cannabis use were later diagnosed with certain psychiatric disorders at higher rates. This review examines how adolescent cannabis use is associated with later psychiatric diagnoses, including psychotic and bipolar disorders, within a large observational study design. It also explains what the study does not measure and why causal language must remain disciplined. TL;DR Adolescents reporting past-year cannabis use had higher subsequent rates of psychiatric diagnoses. The strongest associations were observed for psychotic and bipolar disorders; depression and anxiety associations were smaller. Exposure was defined as binary self-report, without modeling dose, potency, frequency, or persistence. Outcomes were ICD-coded diagnoses, not direct measures of neurodevelopment or brain structure. The design does not establish causality. Confounding, surveillance effects, and reverse causation remain viable explanations. Why This Paper Deserves Careful Reading Public discussions about adolescent cannabis often drift toward extremes. One side minimizes risk entirely. The other frames any association as proof of neurological harm. This study sits between those poles. It identifies a risk signal that should not be ignored, and it also includes measurement features that meaningfully constrain interpretation. Precision matters here. โ€œAssociated with higher rates of diagnosisโ€ is not the same claim as โ€œproven neurodevelopmental injury.โ€ Those are different scientific statements. What Was Actually Measured Exposure Cannabis exposure was defined as a yes or no response to past-year use on a confidential adolescent screening questionnaire administered during well visits. That is a binary exposure definition. Outcomes Psychiatric outcomes were identified using ICD-10 diagnosis codes within the electronic health record. This approach captures clinician-assigned diagnoses, not imaging findings, cognitive testing results, or biological markers. Interpretation Boundary Because this is an observational cohort analysis, the results describe associations within a defined population and time frame. The study does not demonstrate that cannabis caused the diagnoses observed. What the Study Shows Adolescents who reported past-year cannabis use were diagnosed with psychotic and bipolar disorders at higher rates during follow-up than those who did not report use. Associations for depressive and anxiety disorders were present but more modest. The signal for psychotic and bipolar diagnoses is not small, and it should not be dismissed. At the same time, the strength of association alone does not settle questions of mechanism. What the Study Does Not Show The analysis does not include neuroimaging, neuropsychological testing, or direct measurement of brain development. It does not quantify THC concentration, product type, frequency of use, or duration of exposure. Occasional experimentation and sustained heavy use are grouped together in the primary exposure definition. As a result, the study cannot determine whether risk differs meaningfully across intensity levels. That distinction is clinically important. The Limitations That Matter Most 1) Binary exposure collapses real-world variability A single affirmative response includes adolescents who experimented once and those using regularly. Without separating frequency, potency, or persistence, gradient effects cannot be evaluated. 2) Dose-response patterns were not directly modeled in the primary exposure definition When risk increases with greater exposure intensity, causal interpretation strengthens. If exposure is coarse, that test becomes impossible. The design does not eliminate confounding through gradient analysis. 3) ICD-coded diagnoses reflect care processes Diagnosis codes emerge from clinical encounters. They reflect referral patterns, documentation habits, and healthcare access in addition to symptom burden. 4) Internalizing outcomes are heterogeneous Depression and anxiety categories include unspecified and adjustment-related codes. Some represent transient stress reactions rather than stable syndromic illness. 5) Surveillance effects remain plausible Adolescents who disclose cannabis use may receive closer monitoring or earlier behavioral health referral. Increased diagnostic attention can influence observed rates even if underlying disease incidence is unchanged. 6) Reverse causation cannot be ruled out Sleep disruption, anxiety, mood volatility, trauma-related symptoms, and early psychotic features can precede both cannabis use and formal diagnosis. In such cases, symptoms may drive exposure rather than the reverse. 7) Residual confounding is difficult to eliminate Family psychiatric history, genetic vulnerability, peer environment, trauma exposure, and co-occurring substance use can influence both cannabis exposure and psychiatric diagnosis. Even careful adjustment may leave important shared liability unmeasured. In practical terms, this study detects a meaningful association. It does not fully disentangle whether that association reflects causation, clustering of vulnerability, or a combination of both. Clinical Translation The responsible clinical posture is neither dismissal nor alarmism. It is careful screening paired with clarity about what the evidence does and does not establish. In practice Ask adolescents who report cannabis use about sleep, anxiety, mood stability, trauma exposure, concentration, school function, and family psychiatric history. When psychiatric symptoms appear, inquire specifically about frequency and potency of cannabis exposure rather than relying on yes or no categories. What this supports saying aloud โ€œIn a large cohort, adolescents reporting past-year cannabis use were later diagnosed with certain psychiatric disorders at higher rates. This does not prove causation, but it supports taking early use seriously, especially in youth with underlying vulnerability.โ€ Related reading: Cannabis and mental health, Cannabis and pregnancy, Pediatric safety and evidence. Primary Source Documents Click the image to open the peer-reviewed JAMA Health Forum article analyzed in this review. Study PDF: Open the published paper Concise Summary A large observational cohort study reports that adolescents who self-report past-year cannabis use have higher subsequent rates of psychiatric diagnoses, particularly psychotic and bipolar disorders. Exposure was defined as binary self-report without modeling dose, potency, frequency, or persistence. Outcomes were ICD-coded diagnoses rather than direct neurodevelopmental measures. The design does not establish causality, and confounding, surveillance effects, and reverse causation remain plausible. How Confounders Can Create This Exact Pattern Observational associations can be real and clinically important, while still reflecting multiple upstream pathways. Below are concrete examples of how known confounders and care-process effects can produce the same statistical pattern seen in this study, without proving direct causation. 1) Family vulnerability If adolescents with a strong family history of psychotic or bipolar disorders are more likely to experiment with cannabis and also more likely to develop those diagnoses regardless, cannabis use can appear associated with later illness even if it is not the primary driver. Analogy: Two branches from the same tree. 2) Early symptoms before diagnosis Sleep disruption, anxiety, mood volatility, trauma-related distress, or subtle psychotic-spectrum symptoms can precede both cannabis use and the first recorded diagnosis. If early symptoms lead to cannabis use before a diagnosis is entered, cannabis can statistically predict diagnosis. Analogy: Taking pain medicine before the doctor documents the injury. 3) Trauma exposure Trauma exposure increases risk for later psychiatric illness and also increases risk for substance use. If trauma is not measured with sufficient resolution, cannabis exposure can partially absorb the association that belongs to trauma. Analogy: Blaming the smoke alarm for the fire. 4) Peer environment and social context Adolescents in higher-risk peer networks may be more likely to use cannabis and more likely to experience destabilizing stressors. The shared environment can be the upstream driver, making cannabis look like the cause when it is part of a broader context. Analogy: Same neighborhood, same exposures, different labels. 5) Surveillance effects and diagnostic attention Adolescents who disclose cannabis use may receive closer monitoring, more screening, or earlier referral to behavioral health. Increased diagnostic attention can raise recorded diagnosis rates even if underlying disease incidence is unchanged. Analogy: You find more โ€œproblemsโ€ when you look harder. 6) Shared liability across multiple risks Genetic liability, family stress, early adversity, school disruption, and other substance use can increase both the likelihood of cannabis use and the likelihood of psychiatric diagnosis. Even careful adjustment can leave meaningful shared vulnerability unmeasured. Analogy: One upstream current feeding two downstream rivers. 7) Exposure misclassification from a binary definition Past-year cannabis use was categorized as yes or no. That groups together a teen who tried cannabis once and a teen using daily. Without modeling frequency, potency, persistence, or product type, interpretation becomes blurred and dose-response cannot be cleanly tested. Analogy: Counting โ€œexerciseโ€ without tracking intensity or frequency. 8) Outcome coding variability ICD-10 diagnoses reflect clinical documentation, referral pathways, and healthcare access. They are clinically meaningful, but they are not the same as adjudicated diagnostic interviews or direct biological measurement. Coding differences can influence apparent rates. Analogy: Labeling a folder from the cover note rather than reading every page inside. Confounding does not mean โ€œno risk.โ€ It means multiple pathways can generate similar statistical patterns. The correct posture is risk-aware counseling with causality-disciplined interpretation. FAQ Does this study prove cannabis causes psychosis or bipolar disorder? No. It demonstrates an association within an observational design. Causality requires stronger evidence than this study alone can provide. Does the study measure brain damage or neurodevelopmental injury? No imaging, neurocognitive testing, or biomarker assessments were included. The outcomes are clinician-coded diagnoses. Can it distinguish occasional from heavy use? Not in the primary exposure definition. The study categorizes past-year use as yes or no, without modeling intensity or duration. Why does dose response matter? When higher exposure corresponds to higher risk, causal interpretation strengthens. Without that gradient analysis, alternative explanations remain open. References Young-Wolff KC, et al. Adolescent Cannabis Use and Risk of Psychotic, Bipolar, Depressive, and Anxiety Disorders. JAMA Health Forum. 2026;7(2):e256839. doi:10.1001/jamahealthforum.2025.6839. Supplement 1 accompanying the above article. Marconi A, Di Forti M, Lewis CM, Murray RM, Vassos E. Meta-analysis of the association between level of cannabis use and risk of psychosis. Schizophrenia Bulletin. 2016;42(5):1262-1269. Gobbi G, Atkin T, Zytynski T, et al. Association of cannabis use in adolescence and risk of depression, anxiety, and suicidality. JAMA Psychiatry. 2019;76(4):426-434. adolescent cannabis use and psychosis risk study review, does cannabis cause bipolar disorder in teenagers, observational study cannabis and psychiatric diagnosis, binary exposure cannabis research limitations, reverse causation in adolescent cannabis studies, cannabis and teen brain development evidence review, ICD-10 diagnosis coding cannabis research, confounding factors in cannabis mental health studies, dose response cannabis psychosis meta analysis, is cannabis linked to depression in adolescents, surveillance bias in psychiatric epidemiology, cannabis use and young adult bipolar disorder, large cohort study cannabis psychiatric outcomes, clinical interpretation adolescent cannabis research, cannabis mental health association versus causation, youth cannabis screening and psychiatric risk, how to interpret cannabis epidemiology studies, limitations of observational cannabis research, cannabis and anxiety diagnosis rates, adolescent substance use shared liability model, cannabis and psychotic disorder incidence, teen cannabis exposure measurement limitations, cannabis risk communication for clinicians, understanding psychiatric diagnosis clustering, cannabis vulnerability and genetic risk interaction [...] Read more...
February 18, 2026  Evidence review, prenatal cannabis exposure study A large Medicaid-linked cohort measured well-child visits, ED use, and early developmental delay coding This post is built for careful interpretation. Exposure was defined by meconium drug screening, not by self-report or ICD coding. That single design choice changes what the paper can detect, what it may miss, and how far the findings travel. What youโ€™ll learn ๐ŸงชWhy meconium testing changes how to interpret prenatal exposure research ๐Ÿ“…What โ€œlate pregnancy exposureโ€ does, and does not, mean in real life ๐ŸงพWhy claims-based developmental delay is a noisy proxy for development ๐ŸฅWhat the utilization results suggest about healthcare engagement ๐ŸงญHow to talk about this prenatal cannabis exposure study without overclaiming โš–๏ธWhy policy and systems can shape what gets documented, diagnosed, and coded Prenatal Cannabis Exposure Study: What This Paper Found, What It Did Not, and Why Policy Context Matters A careful read of a large, Medicaid-linked cohort using meconium testing to examine well-child visits, emergency care, and early developmental delay coding If you have reached this page because a headline felt louder than the data, you are in the right place. Pregnancy guide Book an appointment Browse more evidence reviewsStudy PDF Why this prenatal cannabis exposure study matters right now Pregnancy and cannabis sits in a difficult place in public discourse. Many people are trying to do the right thing, while also trying to manage nausea, sleep disruption, anxiety, pain, or appetite changes. Meanwhile, the information environment is crowded with confident takes that do not scale down to a single patientโ€™s reality. This prenatal cannabis exposure study is useful because it is not built on self-report alone. The exposure definition is a meconium drug screen obtained during the birth hospitalization. That methodological choice changes what the study can detect, what it might miss, and how much the findings can be generalized. Clinical note: Nothing in this post is medical advice. If you are pregnant, trying to conceive, or breastfeeding, the safest approach is to discuss any cannabis exposure with your obstetric clinician so your care plan can match your health history and risk profile. TL;DR, in plain language In this prenatal cannabis exposure study, infants with cannabis detected on meconium testing had similar well-child visit attendance and similar emergency department use through age 2. Developmental delay coding looked modestly lower at age 2, but that signal disappeared by age 3. The most common misread is to jump from a short-lived statistical signal to a biological story. This paper does not support a developmental benefit claim. The more defensible interpretation is narrower: in this specific Medicaid-insured, risk-based screening cohort, late-pregnancy cannabis detection was not associated with higher early utilization or higher ICD-coded developmental delay by age 3. Study design and setting: what was actually measured Meconium testing typically reflects later pregnancy exposure, not the full gestational timeline. Design Retrospective cohort, UNC Health system, linked to North Carolina Medicaid claims Birth window April 1, 2014 through April 30, 2022 Exposure definition Cannabinoids detected on meconium testing, cannabis-only positives included Key context Institutional policy mandated CPS notification for positive cannabis screens during the study period Final analytic cohort 4,270 infants (1,671 cannabis-only positive; 2,599 negative for all substances) The choice to compare cannabis-positive infants to infants who were tested and negative is a strength. It reduces, but does not eliminate, a common problem in pregnancy exposure research: screening-selection bias. In other words, the comparator group had a similar โ€œreasonโ€ to be screened, even though the study does not fully describe the institutional triggers for sending meconium tests. Still, it is important to name what the exposure variable is in this prenatal cannabis exposure study. It is a binary, late-pregnancy detection marker without dose, route, frequency, product type, or timing across trimesters. That is not a small caveat. It is the spine of interpretation. Outcomes: utilization and developmental delay, defined by claims Utilization outcomes can reflect access, systems, and policy, not just health. Primary outcome: well-child care attendance Well-child care (WCC) attendance was measured as a count of recommended visits in the first two years, operationalized using CPT and ICD coding. The mean number of visits was about six. This outcome tells you something about healthcare engagement, but it also tells you something about insurance continuity, transportation, caregiver bandwidth, scheduling friction, and policy-mediated follow-up. Secondary outcome: emergency department visits Emergency department utilization was measured through claims codes and revenue codes. Again, this is a health measure and an access measure at the same time. Many pediatric ED visits reflect caregiver concern in uncertain moments, after-hours limitations, and a lack of alternative urgent care options. Developmental delay: an important nuance before the numbers Developmental delay was defined using ICD-9 and ICD-10 codes listed by the authors. That is a practical choice in claims research, but it is not the same thing as standardized developmental testing. Claims-based developmental delay can be shaped by clinician threshold, referral patterns, caregiver persistence, and the frequency of well-child encounters. If you read only one sentence in this section: this prenatal cannabis exposure study measures coded developmental diagnoses, not development itself. Main findings: the table-anchored results, without drama Well-child visits through age 2 The incidence rate ratio for WCC visits comparing exposed to unexposed infants was 0.982 (95% CI 0.957 to 1.008), with P = 0.1705. The study did not find a statistically significant difference in well-child visit attendance over the first two years. Emergency department visits through age 2 The incidence rate ratio for ED visits was 0.934 (95% CI 0.863 to 1.012), with P = 0.0962. Again, this prenatal cannabis exposure study did not show a statistically significant increase in ED utilization in the first two years. Developmental delay at age 2 At two years, the adjusted odds ratio for developmental delay coding was 0.826 (95% CI 0.686 to 0.995), with P = 0.0437. The absolute rates were 15.02% in the cannabis-exposed group and 18.39% in the unexposed group. Developmental delay extended to age 3 At three years, the adjusted odds ratio was 1.007 (95% CI 0.852 to 1.191), with P = 0.9304. The apparent two-year difference did not persist. That time instability should tighten, not loosen, the inference. The cleanest summary of this prenatal cannabis exposure study is not โ€œgood newsโ€ or โ€œbad news.โ€ It is โ€œno measurable increase in early utilization burden, and no higher developmental delay coding by age 3, in this specific cohort and context.โ€ Bias audit: where interpretation can quietly go off the rails When a signal disappears over time, interpretation should tighten, not expand. Selection bias: who gets tested is not random Meconium testing was risk-based, not universal. That means the analytic population is not โ€œall infants with prenatal cannabis exposure.โ€ It is infants selected for testing under institutional criteria. The negative comparator group strengthens internal comparison, but external generalizability narrows. Exposure misclassification: what meconium misses Meconium primarily reflects later pregnancy exposure. Early pregnancy exposure may be missed, and the study does not quantify dose, frequency, route, potency, or product types. In a prenatal cannabis exposure study like this, non-differential misclassification tends to move estimates toward no difference. Detection bias: coding depends on contact Developmental delay defined by claims codes is vulnerable to surveillance effects. More visits can mean more opportunities for a code to appear. Differences in clinician threshold and referral pathways can produce patterns that look biological but are actually procedural. Confounding: what is not in the dataset The models included many relevant medical covariates, including gestational age, SGA, LBW, maternal mental health, lead levels, and more. Still, key social confounders are not reliably captured in claims data, including caregiver supports, housing stability, education, and structured interventions following a positive screen. The policy context: mandated reporting can change the downstream story Policy architecture can change what gets documented, diagnosed, and coded. The institutional requirement to notify Child Protective Services for positive cannabis screens is not a neutral background detail. It can change caregiver behavior, clinician behavior, follow-up intensity, and referral patterns. It can also change how quickly developmental concerns are noticed and how frequently they are coded. One way to hold this in your mind: this prenatal cannabis exposure study can be read as a measurement of system response as much as a measurement of exposure biology. That does not invalidate the findings. It clarifies what the findings represent. A practical interpretation guardrail: if an exposure triggers structured surveillance, then downstream โ€œno differenceโ€ outcomes might reflect buffering by the system, not biological neutrality. How this prenatal cannabis exposure study fits with the broader literature This paper is not a global verdict on cannabis in pregnancy. It speaks to a particular exposure definition, a particular insurance population, and a particular follow-up window. Still, it aligns with other large observational work showing no increased risk of early developmental delays when outcomes are defined through early childhood and measured through clinical records or claims, while also differing from studies assessing later childhood behavioral outcomes with different exposure definitions. External validation that points in a similar direction Avalos and colleagues (Kaiser Permanente Northern California) reported that maternal prenatal cannabis use in early pregnancy was not associated with increased risk of early child developmental delays in their cohort, while emphasizing the need for better pattern-of-use measurement across pregnancy. A contrasting signal in older children using different methods Paul and colleagues (ABCD Study) reported associations between prenatal cannabis exposure and later childhood outcomes, including psychopathology measures, using retrospective maternal report and a different age window. Method differences matter. Age differences matter. And confounding structure matters. Utilization and severe outcomes are not the same question Bandoli and colleagues examined prenatal cannabis use disorder and infant hospitalization and death in the first year of life, highlighting how a use disorder phenotype differs from a biomarker-positive late pregnancy exposure marker. These are distinct exposures and should not be blended in public conversations. When you hear someone cite a single prenatal cannabis exposure study as definitive, a helpful question is: exposure definition, outcome definition, and age of follow-up, what were they? What clinicians can responsibly say after reading this paper If you want a single sentence that stays inside the evidence: this prenatal cannabis exposure study found no association between meconium-detected cannabis exposure and increased well-child absenteeism, ED utilization, or developmental delay coding by age 3, in a Medicaid cohort within a mandated CPS notification environment. What you cannot responsibly say is that cannabis improves infant development. The two-year signal is modest, statistically fragile, disappears by three years, and lacks a plausible protective mechanism within this dataset. What you also cannot say is that cannabis in pregnancy is โ€œproven safe.โ€ This study does not measure first-trimester exposure, dose-response relationships, product strength, route, or later neurobehavioral outcomes. It also does not adjudicate birth outcomes literature, which is a separate evidence stream. If you are looking for a practical counseling framework, start with your goals and risks, then build a plan around safer alternatives, symptom control, and careful follow-up. Our pregnancy guide is a reasonable starting point. Cannabis in pregnancy guide Pregnancy risks and benefits review Pregnancy evidence overview 10-year pregnancy study review Pediatric safety and evidence A practical readerโ€™s guide to not overreading results The temptation with a topic like this is to treat each new paper as a referendum. A better approach is to treat each paper as a measurement instrument. This prenatal cannabis exposure study is a particular instrument. It measures late-pregnancy detection, under a policy architecture that can reshape follow-up and coding. If you are deciding what to do in real life, the most protective step is not finding the โ€œrightโ€ headline. It is building a support plan with your obstetric team, addressing nausea, sleep, stress, pain, or appetite with the lowest-risk options that work for your body, and returning to the plan when circumstances change. Read the pregnancy guide Ask Dr. Caplan Book a visit FAQ: prenatal cannabis exposure study interpretation Does this prenatal cannabis exposure study prove cannabis is safe in pregnancy? No. The study measures a specific exposure definition, cannabinoids detected in meconium, which mainly reflects later pregnancy exposure. It does not measure dose, frequency, route, potency, or early pregnancy exposure. It also does not address many outcomes that may emerge later, such as executive function or attention regulation. The defensible conclusion is narrower: in this cohort and within this follow-up window, the measured outcomes were not worse by age 3. Why does meconium testing change how to read the results? Meconium testing is a biomarker-based exposure definition rather than self-report or diagnostic coding. It reduces certain biases but introduces others, particularly the timing issue. Meconium primarily reflects late second and third trimester exposure, so earlier pregnancy exposure can be missed. In a prenatal cannabis exposure study, that limitation matters because timing may relate to risk in ways the dataset cannot capture. What did the study find about well-child visits? The study did not find a statistically significant difference in well-child care visit counts through age two between the cannabis-exposed and unexposed groups. The mean number of visits was about six overall. This suggests similar engagement with routine pediatric care in this Medicaid-linked cohort. It does not prove equal access or equal quality of care, but it argues against a major utilization gap in this dataset. What did the study find about emergency department visits? The study did not find a statistically significant increase in emergency department utilization through age two among cannabis-exposed infants. ED use is a mixed signal that can reflect illness burden, caregiver concern, after-hours constraints, and access to outpatient care. The most cautious conclusion is that there was no measurable utilization burden difference detected here. It does not rule out differences in specific diagnoses or later outcomes. What does โ€œdevelopmental delay by ICD codesโ€ actually mean? It means the outcome is based on diagnostic codes recorded in claims data, not standardized developmental testing. Claims-based developmental delay depends on how often a child is seen, clinician thresholds, referral patterns, and documentation practices. It can be influenced by surveillance or follow-up intensity. In a prenatal cannabis exposure study, ICD-coded developmental delay is best understood as a healthcare system signal, not a direct measurement of child neurodevelopment. Why was developmental delay lower at age 2 but not different at age 3? The simplest explanation is that the two-year finding is not stable. When a signal disappears over time, it often suggests confounding, detection bias, or a transient documentation artifact rather than a durable biological effect. The dataset cannot identify dose, timing, or mechanisms that would plausibly create a true protective effect. That is why the study should not be interpreted as cannabis improving development. How could CPS notification affect study outcomes? If a positive screen triggers mandated reporting and structured follow-up, it can increase contact with services, change clinician attention, and alter referral pathways. That can influence what gets detected and what gets coded. The paper does not include CPS intervention data, so this remains an interpretation hypothesis rather than a proven mechanism. Still, policy context is central when reading any prenatal cannabis exposure study tied to mandated notification. Who do these findings apply to, and who do they not apply to? The findings apply most directly to Medicaid-insured infants in a health system using risk-based meconium screening, within a mandated CPS notification context, and within early childhood follow-up. They do not generalize cleanly to privately insured populations, universal screening environments, different state policies, or high-dose daily use contexts. They also do not generalize to first-trimester exposure patterns because the exposure definition is late-weighted. Generalizability is constrained by design. How should a pregnant patient interpret this prenatal cannabis exposure study? As a reminder that outcomes depend on what is measured, when it is measured, and how the system responds to exposure. This study does not support a developmental benefit narrative, and it does not provide reassurance about all exposure patterns. It does suggest that, in this setting, measured early utilization and ICD-coded developmental delay were not worse by age 3. A patient-facing next step is a supportive, individualized conversation with an obstetric clinician focused on symptom management and risk reduction. What kind of future research would answer the harder questions? A multi-state cohort with universal screening, quantified metabolite levels, and dose stratification would reduce exposure misclassification. Linking to CPS or plan-of-safe-care intensity could test system-mediated pathways directly. Standardized developmental testing at later ages would improve outcome sensitivity beyond claims coding. That design would help separate biological exposure effects from policy and surveillance effects in a prenatal cannabis exposure study. Next Steps: Evidence and Care Pathways If this prenatal cannabis exposure study prompted more questions than answers, that is appropriate. Pregnancy research is rarely binary. Below are three structured pathways, depending on what you are trying to understand. For a comprehensive evidence overview A broad, clinically grounded synthesis of what is known, what remains uncertain, and how to interpret mixed literature: Expecting and Experimenting with Cannabis For riskโ€“benefit framing and counseling language A structured review designed to help clinicians and patients discuss pregnancy and cannabis without exaggeration or dismissal: Cannabis and Pregnancy: Risks, Benefits, and Care For pediatric and longer-term safety context A broader discussion of child development research and how early-life outcomes are measured: Pediatric Cannabis Safety: What to Expect If you are pregnant and navigating symptoms in real time, individualized medical guidance is more protective than generalized internet consensus. Schedule a Pregnancy Consultation References 1) Raffa BJ, Lanier P, Yang Y, Lin FC, Seashore C, Schilling S. Healthcare utilization and developmental delay among infants exposed to cannabis in utero. Academic Pediatrics. 2026. DOI: 10.1016/j.acap.2026.103224. PDF | Full text | PubMed 2) Avalos LA, et al. Early Maternal Prenatal Cannabis Use and Child Developmental Delays. JAMA Network Open. 2024. JAMA Network Open 3) Bandoli G, et al. Prenatal cannabis use disorder and infant hospitalization and death in the first year of life. Drug and Alcohol Dependence. 2023;242:109728. DOI: 10.1016/j.drugalcdep.2022.109728. ScienceDirect | PubMed 4) Paul SE, et al. Associations Between Prenatal Cannabis Exposure and Childhood Outcomes: Results From the ABCD Study. JAMA Psychiatry. 2021;78(1):64-76. DOI: 10.1001/jamapsychiatry.2020.2902. JAMA Psychiatry | PubMed [...] Read more...
February 18, 2026Cannabis for Chronic Pain in Older Adults What the evidence actually shows, what it does not, and how to think clearly about risk in the context of aging physiology, polypharmacy, and fall prevention. Schedule Senior & aging care Educational content only. Care decisions should be personalized with your clinician, especially when fall risk or complex medications are involved. A Patient I See Every Week She is 74. Retired teacher. Severe osteoarthritis. On meloxicam for years. Then tramadol. Then gabapentin. Then a sleep medication because pain kept her up. She did not want cannabis. She wanted fewer pills. Her first question was not โ€œDoes it work?โ€ It was, โ€œWill this make me fall?โ€ That is the right question. Why This Conversation Matters Chronic pain affects nearly 20% of U.S. adults, and prevalence rises with age. Arthritis, neuropathy, spinal stenosis, post-surgical pain, and degenerative joint disease accumulate across decades. Traditional options often come with tradeoffs: ๐ŸฉบNSAIDs:Increased cardiovascular and gastrointestinal risk in many older adults. โš ๏ธOpioids:Sedation, constipation, dependence, and overdose risk. ๐Ÿง Gabapentinoids:Balance impairment and cognitive slowing in susceptible patients. ๐ŸŒ™Sleep medications:Meaningful fall risk, especially overnight. It is not surprising older adults ask about cannabis. The relevant question is not whether cannabis is good or bad. It is whether it can be used safely and intelligently in the context of aging physiology. What the Research Shows About Pain Relief Randomized trials of cannabinoids for chronic pain show modest but consistent signal-positive results, particularly in neuropathic pain syndromes. A 2023 qualitative pilot study of middle-aged and older adults initiating medical cannabis found approximately 63% reported overall effectiveness for chronic pain. Participants described reduced pain intensity, improved sleep, better mood, and reduced reliance on pain and psychiatric medications. They also reported difficulty titrating dose, psychoactive effects, and product variability. Source PubMed ID 37484052: https://pubmed.ncbi.nlm.nih.gov/37484052/ This is not definitive proof. It is meaningful patient-reported signal. Opioid Reduction: Observational but Important Sometimes progress looks like fewer pills. A 2023 study published in JAMA Network Open followed over 8,000 adults receiving long-term opioid therapy in New York State. Patients with longer medical cannabis exposure experienced greater reductions in prescribed opioid dosages compared with shorter exposure. In some strata, reductions approached roughly 50% over follow-up. Source JAMA Network Open article This is observational. It does not prove causation. It does suggest cannabis may serve as part of opioid-reduction strategies in selected patients. For older adults concerned about opioid harms, this signal matters. Why Aging Changes Cannabis Response Older adults are physiologically distinct. With age, body fat increases, liver metabolism slows, renal clearance changes, autonomic regulation becomes fragile, and polypharmacy becomes common. THC is lipophilic. It accumulates in fat. Slower metabolism can prolong psychoactive effects. Orthostatic blood pressure regulation is more vulnerable. Clinical translation: The same dose that feels mild at 45 can feel destabilizing at 75. This is why conservative titration is not optional. It is foundational. Common Questions Seniors and Caregivers Ask Does Cannabis Make Seniors Fall More? This is the most important safety question. Balance is influenced by dose, timing, and physiology. Physiology behind fall risk THC can contribute to orthostatic hypotension, slowed reaction time, sedation, and impaired proprioception. Older adults may already have reduced vestibular reserve and muscle strength. Add psychoactive impairment, and fall probability rises. Evidence supporting increased fall or injury risk ๐ŸงGait and balance signal:A controlled study found older chronic cannabis users had higher likelihood of falling and worse gait and balance performance than non-users. PMC7909838 ๐ŸฅInjury and ED use:A national survey analysis of adults over 50 found cannabis use associated with higher injury rates and increased emergency department visits due to injury. Drug and Alcohol Dependence (2017) ๐Ÿ“ˆOlder adult ED trends:A review of cannabis-related emergency visits reports rising ED visits among adults 65 and older, with injury contributing significantly. PMC10089945 Evidence suggesting a more mixed interpretation Some static balance metrics in small samples have not shown consistent differences between older users and non-users. The signal is not uniform and likely dose-dependent. Practical safeguards ๐ŸชซStart extremely low with THC:Aim for predictable effects, not a โ€œstrongโ€ experience. โฑ๏ธChoose timing deliberately:Dose when mobility demands are low, especially early on. ๐ŸฌBe cautious with edibles at first:Delayed onset can lead to stacking doses before effects are clear. ๐ŸงญRe-check balance patterns:Nighttime awakenings, bathroom trips, and dizziness are the moments that matter. ๐ŸŒฟConsider CBD-forward options when appropriate:Often a better starting point for patients with high sensitivity to psychoactive effects. Bottom line Fall risk is manageable, but it is real. Safety is a dosing strategy, not a disclaimer. Is Cannabis Addictive? Cannabis can lead to cannabis use disorder in some individuals. Reviews suggest a minority of users develop problematic patterns, with risk increasing at higher THC exposure and more frequent use. Sources PMC8655458 PubMed 40366653 Dependence is not identical to disorder. If glasses help you see, you feel dependent on them. That does not make glasses addictive. The question is not whether a patient relies on something that helps. The question is whether use becomes compulsive, escalating, or harmful. Warning signs that deserve a recalibration ๐Ÿ“ˆEscalating dose without added benefit:More product, same outcome, more side effects. ๐ŸงฏUsing primarily to blunt emotional distress:A pattern that can crowd out more durable coping strategies. ๐ŸงฉContinued use despite functional decline:Cognition, mobility, or daily structure slipping without course correction. Does Cannabis Mean Smoking? No. Smoking is one route. It is familiar, fast, and often preferred by older adults. But combustion alters plant chemistry and introduces respiratory toxins. The CDC notes cannabis smoke contains many of the same toxins and irritants found in tobacco smoke: CDC lung health page. The evidence linking cannabis smoking to cancer remains mixed and complicated by tobacco confounding and exposure variability: JAMA Network Open review. Plain-language analogy: You would not torch your broccoli to preserve its nutrients. Many seniors prefer smoking because it feels familiar and controllable. That preference deserves respect. The solution is not judgment. It is precision. ๐Ÿ“‰Use low doses:Especially early on, smaller effects are safer effects. ๐ŸŒฌ๏ธAvoid deep prolonged inhalation:It increases respiratory irritation without guaranteeing better therapeutic outcomes. โ™จ๏ธConsider vaporization over combustion:Often gentler for airways, though dosing still requires care. ๐Ÿ’งConsider tinctures for predictable dosing:A common choice for patients prioritizing consistency. The goal is relief without chaos. Drug Interactions in Older Adults Common medication categories include anticoagulants, antidepressants, benzodiazepines, antihypertensives, and sleep medications. CBD and THC can interact with CYP450 pathways. Sedation may compound with other CNS depressants. Blood pressure shifts may amplify antihypertensive effects. Transparency with physicians is essential. Practical safety note If a patient has a history of syncope, falls, cognitive impairment, or is on multiple sedating medications, dosing decisions should be made with extra caution and deliberate monitoring. Deeper guidance Talk to your doctor about cannabis Dosage and application guide Drug interactions guide Where Evidence Is Limited We lack large randomized controlled trials exclusively in adults over 65, standardized geriatric dosing frameworks, long-term cognitive trajectory data, and direct comparative trials versus opioids in older adults. Acknowledging uncertainty protects credibility and keeps the focus where it belongs, on careful, individualized decision-making. A Systems Perspective Chronic pain management in aging often becomes a loop: more medication, more side effects, more medication to treat side effects. Sometimes progress looks like fewer pills. Cannabis is not a cure-all. But in selected patients, it may reduce medication burden. That possibility deserves careful exploration, not reflex dismissal. Internal Resources for Further Reading Save these for later. They are designed to be practical, cross-linked, and easy to revisit. Senior and aging care Endocannabinoid system in older adults Cannabis for pain guide Smart dosing When cannabis feels too racy Breaking stigma If you want the โ€œstart hereโ€ pathway Getting started is the simplest overview, especially for patients who are new to cannabinoid products and want a structured approach. If you are ready to book a virtual visit with the doctor today, click here now: Book Now FAQ Is cannabis safe for chronic pain in older adults? It can be safe when introduced cautiously with low doses, clinician guidance, and monitoring for falls and drug interactions. Can seniors reduce opioids with medical cannabis? Observational data suggest some patients reduce opioid dosages after sustained medical cannabis use, though this does not prove causation. Does cannabis increase fall risk? There is evidence suggesting increased injury and fall risk, particularly with higher THC exposure. Risk appears dose-dependent and can be reduced with careful titration, timing, and monitoring. Is cannabis addictive? A minority of users develop reversible side effects from taking too much cannabis. Dependence is not the same as disorder. Monitoring patterns of use, dose escalation, and functional impact matters. As mentioned above, dependence is not the same as addiction. If glasses help you see, you may feel dependent on them. That does not make glasses addictive, it makes them helpful. Is smoking cannabis the only option? No. Tinctures, capsules, vaporization, and other non-combustion routes exist, and may be better aligned with respiratory safety and dosing predictability. References ๐Ÿ”—PubMed ID 37484052https://pubmed.ncbi.nlm.nih.gov/37484052/ ๐Ÿ”—JAMA Network Open (opioid dosage changes)https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2800813 ๐Ÿ”—PMC7909838 (older adults, gait/balance)https://pmc.ncbi.nlm.nih.gov/articles/PMC7909838/ ๐Ÿ”—Drug and Alcohol Dependence (2017 injury analysis)https://www.tandfonline.com/doi/full/10.1080/00952990.2017.1318891 ๐Ÿ”—PMC10089945 (ED visits in older adults)https://pmc.ncbi.nlm.nih.gov/articles/PMC10089945/ ๐Ÿ”—PMC8655458 (cannabis use disorder review)https://pmc.ncbi.nlm.nih.gov/articles/PMC8655458/ ๐Ÿ”—PubMed 40366653 (older veterans, CUD criteria)https://pubmed.ncbi.nlm.nih.gov/40366653/ ๐Ÿ”—CDC cannabis smoke and lung healthhttps://www.cdc.gov/cannabis/health-effects/lung-health.html ๐Ÿ”—JAMA Network Open review (smoking and cancer evidence, mixed)https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2755855 [...] Read more...
February 15, 2026Healing rarely begins with profit. It begins with pattern recognition. In medicine, when a fever breaks, the clinician listens for the small signs that life is recalibratingโ€”breath steadying, color returning, the faint whisper of appetite. In cannabis, the same signs are emerging beneath the financial wreckage: patients asking smarter questions, clinicians demanding better data, and a new generation of companies daring to design products around physiology instead of packaging. This, finally, is the recovery phase. The operators who survive the shakeout will not be those who scaled the fastest but those who measured the most carefullyโ€”companies that treat consumer feedback like vital signs, track symptom relief instead of Instagram engagement, and see every returned customer as a follow-up visit rather than a repeat sale. When a dispensary begins collecting outcome dataโ€”what ratio helped neuropathic pain, what terpene pattern eased nightmares, what onset curve reduced morning grogginessโ€”it is not performing market research. It is conducting public health surveillance. It is re-building the connective tissue between economics and empathy. The Physiology of Trust Trust, in biology, is homeostasis: each system adjusting to keep the whole alive. In business, itโ€™s no different. Patients trust when products behave predictably, when labels mean something, when relief arrives on time. That predictability is biochemical. Itโ€™s what happens when cannabinoids meet receptors in ratios that respect the endocannabinoid systemโ€™s rhythm instead of guessing at it. Imagine the economic transformation if companies stopped marketing โ€œchillโ€ and started prescribing โ€œdose-controlled GABA modulation.โ€ If infused products came with pharmacokinetic transparencyโ€”how long until onset, how long it lasts, which symptoms respond. If each SKU carried a small note of humility: tested in real people, refined by their feedback. That is not over-regulation; that is clinical literacy. And clinical literacy, once scaled, becomes the single most stable profit engine a market can build. The Future Vital Signs The industryโ€™s next phase will look less like a gold rush and more like a health-care systemโ€”distributed, data-driven, patient-anchored. Dispensaries will evolve into micro-clinics. Budtenders will function as health educators. Outcomes will be logged, anonymized, and shared. And the companies that thrive will be those that can prove, not just promise, relief. Even investors will learn new language: EBITDA will sit beside โ€œsymptom-resolution rate.โ€ Market share will be discussed in terms of conditions helped, not grams sold. A brandโ€™s worth will hinge on the same measure that sustains any living systemโ€”its capacity to reduce suffering without creating new harm. Iโ€™ve seen hints already: seniors learning to titrate doses with digital guidance; veterans finding precise ratios that quiet the nervous system without sedation; parents recording seizure frequencies dropping from daily to none. These are not anecdotes; they are metrics of meaning. If the industry were to integrate them, volatility would flatten into vitality. The Cellular Economy Think of the cannabis economy as one vast endocannabinoid systemโ€”thousands of nodes trying to maintain balance under stress. Investors are the endocrine signals. Operators are the organ systems. Patients are the neurons transmitting feedback from the edges. When communication flows freely, the organism thrives. When messages are blockedโ€”by stigma, by poor data, by greedโ€”the system inflames and self-destructs. The cure is not more energy but better signaling. Thatโ€™s where medicine re-enters the story. Because medicine, at its core, is a language of feedback. And the plant, at its core, is fluent in it. The Return to Purpose The great irony of this โ€œmarket correctionโ€ is that it may correct something deeper than valuations. It may correct perspective. The contraction forced us to remember that cannabis was never meant to be a speculative commodityโ€”it was meant to be a therapeutic tool. When the speculative fever cools, the medical clarity returns. This is the opportunity hiding inside the downturn: To design an economy that behaves more like biologyโ€”self-aware, adaptive, compassionate. To replace extraction with regeneration. To measure growth not only in dollars but in days of pain avoided, nights of sleep restored, lives quietly stabilized. The plant has never changed. It has been steady, offering the same molecules of balance since the first synapse met its first endocannabinoid. It is we who forgot what kind of relationship we were entering into. But markets, like bodies, can learn. They can listen again. Echo Line When you ignore the patient, even the market gets sick. When you listenโ€”truly listenโ€”both begin to heal. Doctorโ€™s Note: What Healing Looks Like in Practice In clinical medicine, once the story is told and the physiology understood, there comes the most important question of all: So what do we do now? That question applies just as much to a healthcare system as it does to an individual patient โ€” and the cannabis industry, at this stage, is both. Hereโ€™s what recovery looks like when translated into practice. 1. For Operators: Treat Data Like Bloodwork Every patient visit begins with a pulse, a blood pressure, and a chart. Every cannabis sale should, too. Stop guessing what โ€œworks.โ€ Start measuring. Collect simple outcome data โ€” not for surveillance, but for service. Track patterns in symptom relief, dosing ranges, onset times, and side effects. Over time, those feedback loops will become your competitive advantage. They will tell you what formulations regulate sleep without fogginess, what ratios calm anxiety without sedation, and what combinations deliver functional, repeatable relief. This is how cannabis companies evolve from retailers into caregivers. Data is not overhead โ€” itโ€™s empathy in numeric form. 2. For Policymakers: Rescheduling Isnโ€™t the Cure โ€” Regulation of Understanding Is Rescheduling will help with 280E and open research, but legislation cannot manufacture clinical literacy. That will come from how we train and certify those who interact with patients โ€” the budtenders, clinicians, and pharmacists bridging the gap between chemistry and care. Policymakers who truly want to stabilize this market should invest not in โ€œnew licensesโ€ but in knowledge infrastructure. That means standardized product testing, verified labeling, and a national system for reporting clinical outcomes. We already have the framework โ€” pharmacovigilance in pharmaceuticals. Cannabis deserves the same dignity. When we measure efficacy, safety follows. When we collect outcomes, policy becomes precision. 3. For Clinicians: Reclaim the Vocabulary of Relief Itโ€™s time for medicine to stop pretending cannabis is outside its jurisdiction. Physiology does not end at the edge of a statute. The endocannabinoid system is not a counterculture curiosity; it is one of the major homeostatic regulators in the human body โ€” as fundamental as the endocrine or immune systems. Clinicians should be leading this conversation, not catching up to it. When we learn to discuss cannabis using the same disciplined language we apply to any therapeutic agent โ€” onset, duration, dose-response, tolerance, receptor binding โ€” the entire discourse matures. We stop whispering and start teaching. The truth is, patients already trust us to guide them here. If we stay silent, they will keep learning from untrained strangers online. If we engage, they will learn how to use cannabis safely, predictably, and effectively. That, in turn, will heal the very market that medicine once dismissed. A Shared Future The cannabis market does not need to be rebuilt โ€” it needs to be reinterpreted. If we reframe cannabis as a system of care rather than a category of product, the entire structure realigns. Economics follow physiology. Profit follows trust. Growth follows relief. And somewhere, quietly, the fever fades. Echo Line (for CED Clinic readers) We keep saying the market is broken. Maybe itโ€™s only waiting for medicine to remember itโ€™s the one holding the stethoscope. [...] Read more...
February 13, 2026A Physicianโ€™s View on an Industry That Misdiagnosed Its Own Health Markets have vital signs too. They quicken when hype floods the bloodstream, cool when regulation constricts flow, and crash when they forget whatโ€™s worth sustaining. The cannabis economy, right now, feels like a patient in metabolic crisis โ€” too much sugar, not enough oxygen. We watched the fever rise in real time. Valuations spiked to thirty-seven billion dollars. Then came the crash โ€” eleven billion left standing. Oversupply, 280E tax asphyxia, debt toxicity, investor anemia. A body flooded with inputs but starved of integration. When I look at those numbers, I donโ€™t see a โ€œmarket correction.โ€ I see a fever breaking. Because every overheated system, whether biological or financial, burns through what it doesnโ€™t understand. And this market โ€” for all its talk of scale, margins, and growth โ€” never understood its most vital organ: the patient. The industry chased profits like adrenaline. But adrenaline doesnโ€™t heal โ€” it just keeps you running until you collapse. Meanwhile, the patients โ€” the ones whose pain, anxiety, inflammation, and sleeplessness justified legalization in the first place โ€” were treated as anecdotes, not evidence. They became props in marketing decks instead of partners in innovation. When that happens in medicine, we call it malpractice. When it happens in an economy, we call it volatility. But the mechanism is the same โ€” feedback ignored, symptoms dismissed, homeostasis lost. You can see it in every price collapse and every shelf of identical gummies. The body of the market is trying to purge whatโ€™s unaligned with its purpose. Inflammation becomes contraction; fever becomes reset. And like any body thatโ€™s been running on fumes, recovery starts not with more energy, but with listening. Part II โ€” The Diagnosis: Efficacy Lost, Empathy Missing Patients donโ€™t buy cannabis for fun. They buy it for function โ€” sometimes for survival. Iโ€™ve sat with thousands of people who approach this plant not as a lifestyle accessory, but as a last attempt at equilibrium. A veteran who canโ€™t sleep without reliving trauma. A teacher who needs her hands to stop shaking before she can hold a pen. A grandmother who wants to watch her grandkids grow without being crushed by painkillers. When they walk into a dispensary and find rows of candy-colored packaging but no trustworthy map to relief, thatโ€™s not consumer confusion โ€” thatโ€™s medical neglect. Itโ€™s the same despair a patient feels when handed a pill bottle with the label smudged off. Somewhere between seed and sale, the connection between biochemistry and care got severed. We stopped talking about how cannabinoids modulate neurotransmission or dampen inflammatory cascades, and started talking about โ€œvibes.โ€ We reduced complex pharmacology to flavor notes. Thatโ€™s like a cardiologist describing a medication as โ€œheart-forward with a peppery finish.โ€ Itโ€™s not wrong โ€” itโ€™s just irrelevant. The myth that cannabis is just another consumer good has become the marketโ€™s greatest blind spot. Because patients are not whimsical spenders โ€” they are feedback mechanisms. When products fail to deliver, they signal distress through the only lever the market lets them pull: price. Cheapness isnโ€™t the goal. Itโ€™s the symptom. A body deprived of nourishment will crave sugar; a market deprived of efficacy will chase discounts. Each time a patient says, โ€œIt didnโ€™t help,โ€ thatโ€™s data the industry doesnโ€™t know how to read. Each โ€œI didnโ€™t feel anythingโ€ is a market signal screaming, โ€œYouโ€™re not listening.โ€ If we treated those experiences like lab results, the whole economy would look different. Product design would follow physiology โ€” not trends. Formulation would follow receptor dynamics โ€” not branding agencies. And โ€œinnovationโ€ would mean better relief, not another flavor drop. The irony is brutal and beautiful: the more medical we make this plant, the healthier the market becomes. Because nothing creates loyalty like efficacy. Nothing sustains margins like trust. The cannabis industry doesnโ€™t have a demand problem. It has a meaning problem. Until it rediscovers why people use cannabis โ€” not to escape, but to regulate, to reconnect, to repair โ€” it will keep misdiagnosing its own symptoms. [...] Read more...
February 11, 2026A calm, evidence-based analysis of the Cannabis Use Disorder Heart Attack Study. Study unpacking, clinician tone A calm, evidence-based unpacking of what the latest MASH cirrhosis data actually shows, and what it doesnโ€™t This post walks through what the โ€œCannabis Use Disorder Heart Attack Studyโ€ actually measured, what it could plausibly mean, and which conclusions it does not support. Book a visit Browse the research library This is educational content, not individualized medical advice. If you have MASH cirrhosis or cardiovascular disease, decisions should be personalized with your care team. TL;DR The point in five lines ๐ŸงพThe Cannabis Use Disorder Heart Attack Study found higher odds of heart attack in hospitalized MASH cirrhosis patients labeled with CUD. ๐Ÿท๏ธThe study measured a diagnosis code, not dose, route, timing, or biological exposure. ๐Ÿ“ŠCross-sectional hospital data cannot prove causation. ๐Ÿง CUD is a behavioral-psychiatric construct, not a precise pharmacologic variable. ๐ŸงญThis study raises important questions, but it does not justify panic or simplistic conclusions. What Youโ€™ll Learn in This Post ๐Ÿ”What the study actually measured:What โ€œexposureโ€ meant in this dataset, and what it did not mean. โš–๏ธICD-coded CUD vs quantified THC exposure:Why โ€œuse disorderโ€ is not a dose-response variable. ๐Ÿซ€Why liver disease complicates cardiovascular interpretation:Demand ischemia, hemodynamic stress, and background risk. ๐ŸงฉWhere confounding and coding bias can shape results:Documentation intensity, comorbidity clustering, and social context. ๐Ÿ—ฃ๏ธWhat thoughtful clinicians can say today:How to speak with patients without stigma, fear, or false reassurance. The Cannabis Use Disorder Heart Attack Study: What It Claimed and Why It Matters A new Cannabis Use Disorder Heart Attack Study examined hospital data from adults with metabolic dysfunction-associated steatohepatitis, or MASH cirrhosis. The headline finding sounds striking: patients diagnosed with cannabis use disorder had roughly double the odds of experiencing an acute myocardial infarction during hospitalization. When you see the words โ€œheart attackโ€ and โ€œcannabisโ€ in the same sentence, attention spikes. It should. Cardiovascular disease is not trivial. Nor is MASH cirrhosis, a serious liver condition tightly linked to metabolic disease, diabetes, and obesity. Key idea: Before a headline hardens into dogma, we need to ask one boring, essential question: what exactly was measured? Because in science, the measurement is everything. In this case, the measurement was not cannabis exposure. It was a diagnosis code. Study: Cannabis Use Disorder Is Associated With Increased Risk of Acute Myocardial Infarction in Adults With Metabolic Dysfunction-Associated Steatohepatitis (MASH) Cirrhosis: A Population-Based Analysis Authors: Basile Njei, Sarpong Boateng, Ifeoma Kwentoh, Prince Ameyaw, Chukwunonso Ezeani, Nso Nso, Sabastian Forsah, Christian A. Dimala, Derek Fan Ugwuedum, Lea-Pearl Njei, Yazan A. Al-Ajlouni, Joseph K. Lim, Jonathan A. Dranoff DOI: 10.7759/cureus.103299 PDF: View the full paper (PDF) What the Study Actually Did (Without the Drama) The researchers used a large national inpatient database. That means they analyzed hospital discharge records, not outpatient visits, not prospective tracking, and not controlled trials. They identified patients hospitalized with MASH cirrhosis, then separated them into two groups: those with an ICD-coded diagnosis of Cannabis Use Disorder, and those without that diagnosis. An ICD code is a documentation and billing label. It reflects what clinicians recorded and what coders entered. It does not measure THC dose, frequency of use, route of administration, timing of last use, blood cannabinoid levels, or severity of intoxication. The study then asked: during these hospitalizations, were heart attacks more common among those labeled with cannabis use disorder? Statistically, the answer in this dataset was yes. But this is where the interpretation becomes more nuanced, and also more clinically useful. The Cannabis Use Disorder Heart Attack Study relied on hospital discharge dataโ€”not direct measurement of cannabis exposure. The study measured an ICD-coded Cannabis Use Disorder diagnosisโ€”not THC dose, route, or timing. The Entire Study Hinges on a Label The exposure variable was not cannabis pharmacology. It was a psychiatric diagnosis: Cannabis Use Disorder, or CUD. This distinction is not pedantic, it is foundational. CUD is defined behaviorally in the DSM-5. It blends biology, psychology, context, and clinician interpretation. That makes it meaningful, but not pharmacologically precise. CUD criteria include elements like using more than intended, difficulty cutting down, time spent obtaining or using, craving, tolerance, withdrawal, social impairment, and hazardous use. ๐ŸงฌTolerance is biology. ๐Ÿง Craving is psychology. ๐ŸฅCoding is sociology. Severe, functionally impairing CUD absolutely exists. The issue is that this dataset cannot tell you whether the elevated risk signal is driven by severe cases, mild cases, or a mixed group. It also cannot tell you what, specifically, the cannabis exposure looked like. MASH cirrhosis itself carries significant cardiovascular risk independent of cannabis exposure. Why MASH Cirrhosis Complicates Everything MASH cirrhosis is not a neutral backdrop. It is a high-risk metabolic environment. Patients often have insulin resistance, hypertension, dyslipidemia, chronic inflammation, and endothelial dysfunction, each of which can independently increase cardiovascular risk. More on metabolic conditions and cannabis (context, not conclusions): https://cedclinic.com/metabolic-endocrine-and-energy-disorders/ When someone with MASH cirrhosis is hospitalized, physiologic stressors stack up: infection, anemia, fluid shifts, and blood pressure instability. These can contribute to what cardiologists call type 2 myocardial infarction, sometimes described as demand ischemia. That differs from a classic plaque-rupture heart attack. The key question the dataset cannot answer: Are we seeing a pharmacologic effect of cannabinoids on coronary biology, or a clustering of vulnerability and stress physiology in patients more likely to be labeled with CUD? Administrative data usually cannot disentangle those mechanisms cleanly. The Subtle Power of Coding Administrative hospital data depends on documentation. Not every cannabis user receives a CUD diagnosis. In fact, most do not. CUD coding can correlate with socioeconomic factors, polysubstance use, psychiatric comorbidity, payer status, and documentation intensity. In many datasets, it also tracks with urban teaching hospitals. Reframe: The study may be identifying a risk marker, not isolating a molecular culprit. A smoke alarm tells you there is smoke. It does not tell you whether it came from a toaster, a wiring fault, or a fireplace. A Brief Word on Stigma and Diagnostic Elasticity The diagnosis of Cannabis Use Disorder spans a spectrum from mild to severe. Two criteria over twelve months qualifies as mild CUD, which can include tolerance plus an occasional unsuccessful attempt to cut down. That does not make it meaningless. It does mean the category is broad. Related reading on dependence framing and myths: Dependence myths and facts Is weed addictive? Memorable middle: Tolerance is biology. Craving is psychology. Coding is sociology. Dog-face, frog-face, bog-face. Once we name something, it starts to behave like the name in public conversation, even when the underlying reality is more complicated. Alternative Explanations: When Association Is Not Accusation If you strip the finding down to its statistical core, it says this: among hospitalized patients with MASH cirrhosis, those labeled with CUD had higher odds of a documented myocardial infarction. That is a valid association within that dataset. It is not a built-in explanation. ๐ŸšฌPolysubstance clustering:CUD coding may correlate with tobacco use, stimulant exposure, or alcohol misuse, which can meaningfully change cardiovascular risk. โš ๏ธSeverity bias and stress physiology:Patients coded with CUD may present with more acute stress states, psychiatric distress, or social instability, all of which can influence in-hospital events. ๐ŸงชType 2 MI coding blur:In cirrhosis, anemia and hemodynamic instability are common. Demand ischemia may be coded as MI in administrative records. ๐Ÿ—‚๏ธDocumentation intensity:Some hospitals code substance use disorders more frequently than others. The association may partly reflect charting behavior. Bottom line: This signal warrants attention, not panic. It calls for better measurement, not louder headlines. Not all myocardial infarctions are the sameโ€”type 2 MI often reflects stress physiology rather than plaque rupture. Type 2 Myocardial Infarction and Why It Can Confuse the Outcome Type 2 myocardial infarction refers to heart muscle injury caused by oxygen supply-demand mismatch rather than a classic blocked artery. Stressors like anemia, infection, sepsis physiology, hypotension, tachyarrhythmias, and hemodynamic instability can contribute. In patients hospitalized with cirrhosis, these stressors are common. Administrative databases often do not cleanly separate myocardial infarction mechanisms, which can blur interpretation of โ€œheart attackโ€ outcomes in inpatient datasets. Conversations about cannabis and cardiovascular health should be calm, contextual, and individualized. What This Study Does Mean for Patients and Clinicians Calmly interpreted, this study suggests something clinically reasonable: in hospitalized patients with advanced metabolic liver disease, being labeled with CUD tracks with higher cardiovascular vulnerability. That means cardiovascular risk assessment matters, and substance-use pattern review matters. If someone with MASH cirrhosis uses cannabis daily, particularly in inhaled form, and especially alongside tobacco or stimulants, that deserves thoughtful discussion, not moral panic, not shame. Broader cardiovascular context: Cannabis and heart health Cannabis cardiovascular risk If a patient asks, โ€œDid cannabis cause the heart attack?โ€ An honest answer is: this study cannot prove that. It shows correlation within hospitalized patients using a diagnosis label. It raises important questions. It does not settle them. Cannabis and Cardiovascular Health: The Larger Evidence Landscape The relationship between cannabis and cardiovascular health remains complex. Some observational studies suggest increased cardiovascular events among heavier users, others show mixed or non-significant findings. Mechanistically, cannabinoids can influence heart rate, vascular tone, inflammation, and autonomic signaling, but dose, route, tolerance, and co-use change the story. There is no credible evidence that cannabis is uniformly benign for the cardiovascular system. There is also no definitive evidence that cannabis independently doubles heart attack risk across populations in a clean, causal way. Precision beats polarization. We are rarely talking about a binary. We are talking about dose, context, individual biology, route of administration, and co-existing disease. A Necessary Acknowledgment: Severe Cannabis Use Disorder Is Real It is important not to swing from stigma to dismissal. Severe CUD exists. There are individuals for whom use becomes compulsive, impairing, destabilizing. Withdrawal cycling can occur. Functional decline can happen. What administrative datasets cannot do is stratify severity cleanly. Mild and severe diagnoses may occupy the same exposure category in a national inpatient study. That uncertainty should temper conclusions. So Where Does This Leave Us? In a surprisingly steady place. This study should not be dismissed. It highlights a cardiovascular signal in a high-risk hospitalized population. It also should not be over-interpreted. It does not prove that cannabis pharmacology independently causes heart attacks in patients with MASH cirrhosis. For patients, the message is not panic. It is precision. A practical next step: If you have metabolic liver disease, cardiovascular risk assessment is critical. If you use cannabis, especially heavily or alongside other substances, bring it into the open with a clinician who can discuss it without stigma. If you are unsure whether medical cannabis is appropriate for your situation, start here: https://cedclinic.com/how-to-know-if-medical-cannabis-is-right-for-you/ The goal is not to defend a plant. The goal is to defend clarity. Book a visit Explore the evidence library Careful reading. Careful thinking. Careful care. FAQ Cannabis Use Disorder, MASH cirrhosis, and myocardial infarction 1) What did the Cannabis Use Disorder Heart Attack Study actually find? The Cannabis Use Disorder Heart Attack Study reported that hospitalized patients with MASH cirrhosis who carried an ICD-coded diagnosis of cannabis use disorder had higher odds of a documented myocardial infarction during that admission. Crucially, the study relied on hospital discharge records rather than direct measurement of cannabis exposure. That means it identifies an association within administrative data, not proof of causation. The difference between correlation and causation is central to interpreting the result. 2) Does cannabis cause heart attacks in patients with liver disease? This study does not prove that cannabis directly causes heart attacks. It observed an association between an ICD-coded cannabis use disorder diagnosis and myocardial infarction among hospitalized patients with MASH cirrhosis. Because the analysis is cross-sectional and based on administrative coding, it cannot establish temporality, dose-response relationships, or biologic mechanism. Causal claims require stronger prospective and mechanistic evidence. 3) What is MASH cirrhosis and why does it matter for heart health? MASH cirrhosis refers to advanced metabolic dysfunction-associated steatohepatitis, a severe form of fatty liver disease. Many patients with MASH also have diabetes, obesity, dyslipidemia, hypertension, and systemic inflammation, each of which independently increases cardiovascular risk. In other words, this population starts with elevated heart attack risk before cannabis is considered. That background risk complicates interpretation of additional associations seen in hospital datasets. 4) What is Cannabis Use Disorder and how is it diagnosed? Cannabis Use Disorder (CUD) is a DSM-5 psychiatric diagnosis based on behavioral criteria such as difficulty cutting down, tolerance, withdrawal, craving, hazardous use, and functional impairment. Clinicians diagnose it and it may be captured in medical records as an ICD code. It does not directly measure THC concentration, product potency, route of administration, frequency, or timing. As a result, CUD is a heterogeneous construct blending biology, behavior, and clinical documentation. 5) What are ICD codes and why do they matter in this study? ICD codes are standardized diagnostic labels used for medical documentation and billing. In this study, the โ€œcannabis exposureโ€ variable was defined by the presence of an ICD-coded Cannabis Use Disorder diagnosis. ICD coding practices can vary across hospitals, clinicians, and regions, and may reflect documentation intensity as much as biology. That variability introduces important measurement limitations in large database studies. 6) What is type 2 myocardial infarction and could it affect the findings? Type 2 myocardial infarction refers to myocardial injury caused by oxygen supply-demand mismatch rather than a classic coronary artery blockage from plaque rupture. Stressors such as anemia, infection, sepsis, hypotension, tachyarrhythmias, and hemodynamic instability can contribute. In patients hospitalized with cirrhosis, these stressors are common. Administrative databases often do not clearly distinguish MI subtypes, which can blur interpretation of โ€œheart attackโ€ outcomes in inpatient datasets. 7) Could socioeconomic factors influence the Cannabis Use Disorder Heart Attack Study results? Yes. The studyโ€™s pattern, including higher rates of Medicaid coverage and care in urban teaching hospitals among patients coded with CUD, suggests that socioeconomic gradients and healthcare access patterns may influence both outcomes and coding. Social determinants of health can affect cardiovascular risk and can also shape how substance-related diagnoses are documented. These factors may contribute to the observed association in administrative data. 8) Is Cannabis Use Disorder always severe? No. Cannabis Use Disorder spans a spectrum from mild to severe. Mild CUD can be diagnosed when as few as two criteria are present over a twelve-month period. Many administrative datasets cannot stratify severity in a clinically meaningful way. As a result, a single โ€œCUDโ€ exposure category may include a heterogeneous population, which complicates interpretation of risk estimates. 9) Should patients with MASH cirrhosis avoid cannabis completely? There is no universal answer. Patients with advanced liver disease already carry elevated cardiovascular risk and should have individualized discussions about cannabis, including route, dose patterns, co-substance exposures, and the specific symptom goal. Inhaled cannabis combined with tobacco or stimulant use may carry different considerations than carefully dosed oral or sublingual formulations. Shared decision-making with a knowledgeable clinician is the right frame, rather than blanket bans or blanket reassurance. 10) What is the takeaway from the Cannabis Use Disorder Heart Attack Study? The takeaway is not panic, and not dismissal. The study identifies an association that warrants thoughtful attention in a high-risk metabolic population. It does not establish definitive causation or isolate cannabis pharmacology as the driver. Careful interpretation protects scientific integrity and patient trust, and it helps clinicians translate โ€œheadline riskโ€ into practical, individualized guidance. Fair view: โ€œThis study is a signal, not a verdict. It tells us to assess cardiovascular risk and substance use patterns carefully in MASH cirrhosis. It does not tell us that cannabis exposure alone caused a heart attack.โ€ [...] Read more...
February 8, 2026Nutrition 202: Foods That Do More Than โ€œProvide Nutrientsโ€ Why this: Most nutrition advice still treats the body like a storage container. Calories go in. Vitamins fill gaps. Deficiencies get corrected. That model works for preventing deficiency. It fails when the goal is long-term health, resilience, and aging well. At a deeper biological level, food is not just fuel. Certain foods can influence inflammatory signaling, blood vessel function, immune balance, hormone metabolism, brain-relevant pathways, and the way our microbiome communicates with the rest of the body. This is not about superfoods or perfection. It is about understanding which foods interact most meaningfully with human physiology, and describing those effects with appropriate scientific restraint. This reflects a view of food as biological signaling, not just calorie intake. CED Clinic Cookbook (free): clear, easy cannabis dosing Table of Contents How to Think About Nutrition at This Level What โ€œbiological impactโ€ means, and why signaling differs from simple nutrient intake. Extra-Virgin Olive Oil Inflammation-related pathways and vascular support linked to olive phenolics. Cruciferous Vegetables Cellular defense programs (Nrf2), detox enzymes, and hormone-metabolism relevance. Fermented Foods Microbial chemistry that may support gut barrier and immune balance, depending on the food and person. Legumes Microbiome fermentation into short-chain fatty acids, with metabolic and immune implications. Mushrooms Beta-glucans and innate immune receptor signaling, with variable clinical translation. Berries Anthocyanins and brain-relevant pathways, with evidence strongest for overall dietary patterns. Leafy Greens Nitrate-to-nitric oxide biology that depends partly on oral bacteria. Alliums Reactive sulfur chemistry, preparation-dependent, with cardiovascular and antioxidant relevance. Tomatoes Lycopene bioavailability that increases with cooking and fat pairing. Nuts and Seeds Mineral density and metabolic support, often through redundancy rather than uniqueness. Sea Vegetables Iodine and thyroid relevance, with a narrower safety window for some people. Global Takeaways How to think in patterns: preparation, frequency, form, and redundancy. โฌ‡๏ธŽ Download the Printable Nutrition 202 Guide (PDF) Quick reference sheet for printing, sharing, or saving. Food can act like a signal, not just a source of nutrients. How to Think About Nutrition at This Level At an advanced level, foods are not evaluated by calories or vitamins alone. Their importance comes from whether they activate gene expression programs, generate microbial metabolites humans cannot synthesize, interact with immune or vascular receptors, or function as signaling molecules rather than passive ingredients. Older nutrition frameworks are useful for describing what foods contain, but they often fail to capture what foods do. This matters for inflammation, metabolism, cognition, immune tolerance, and resilience over time. The sections below describe likely and evidence-supported pathways in plain language, while staying careful about what is established in humans versus what is strongly supported mechanistically or preclinically. Skim summary High-impact foods affect signaling pathways, not just nutrient totals. Some act through gene regulation, receptor interactions, or microbiome metabolites. Preparation and frequency often matter as much as quantity. Key molecules and targets Gene programs: transcription factors (example: Nrf2 in crucifers). Receptors: innate immune recognition receptors (example: dectin-1 for beta-glucans). Microbiome metabolites: short-chain fatty acids (example: butyrate from fermentable fibers). Science-forward notes Mechanism vs outcome: strong mechanistic plausibility does not guarantee a measurable clinical effect in every person. Bioavailability: preparation, co-ingestion (fat, heat, fermentation), and the microbiome can change exposure to active compounds. Pattern matters: many human nutrition findings are strongest when foods are part of a consistent dietary pattern, not isolated additions. High-quality extra-virgin olive oil is often richer in olive phenolics. Extra-Virgin Olive Oil Supports inflammatory signaling balance and blood vessel function Extra-virgin olive oil is often described as a healthy fat, but its most important role has less to do with fat intake and more to do with bioactive phenolic compounds. These compounds have been studied for effects on inflammatory pathways and markers of vascular function, with results that vary by population, dose, and baseline health. Oleocanthal, one of the better-studied olive phenolics, inhibits COX-1 and COX-2 enzymes in experimental work.1 Olive polyphenols have been associated in human studies with favorable changes in oxidative status and some markers related to LDL oxidation, and some studies suggest benefits for endothelial function, with effects that can vary by study design and population.2 The characteristic bitterness and throat sting of certain extra-virgin olive oils are often linked to phenolics, especially oleocanthal, and can be a practical sensory clue that the oil is not highly refined.1 Skim summary More than fat, it is a phenolic-rich signaling food. Oleocanthal shows COX-1/COX-2 inhibition in experimental research. Bitterness and throat sting can correlate with phenolics, especially oleocanthal. Key molecules and targets Molecules: oleocanthal, hydroxytyrosol, oleuropein (olive phenolics). Enzymes: COX-1 and COX-2 (experimental inhibition described for oleocanthal). Study endpoints often discussed: oxidative status, LDL oxidation-related measures, endothelial markers (results vary by study and population). Science-forward notes Phenolic content is variable: cultivar, freshness, processing, and storage conditions can change phenolic levels. Sensory clues are imperfect: bitterness and throat irritation can correlate with phenolics, but they are not a lab measurement. Human outcomes depend on context: baseline diet quality and cardiometabolic risk can influence the size of effect seen in studies. Crucifers are known for sulforaphane-related cellular defense pathways. Cruciferous Vegetables Activates cellular defense programs and supports detox enzyme pathways Broccoli, broccoli sprouts, and Brussels sprouts influence health through compounds that can activate cellular defense systems rather than acting as simple dietary antioxidants. Their biologic impact is often discussed in terms of gene-regulation and stress-response pathways. Sulforaphane, derived from glucoraphanin, activates Nrf2 (NFE2L2), a transcription factor that increases endogenous antioxidant and cytoprotective enzyme production and upregulates phase II detoxification enzymes such as GST, NQO1, and HO-1.3 Crucifer-derived indoles also relate to estrogen metabolism pathways, and sulforaphane has been studied as a histone deacetylase inhibitor in experimental settings.4 The strongest claims here are mechanistic, and human effects depend on dose, preparation, and individual biology, but the pathway itself is well-established.3 Skim summary Acts through gene-regulation and stress-response pathways, not โ€œvitamin load.โ€ Sulforaphane activates Nrf2 and upregulates phase II detox enzymes (mechanistic evidence is strong). Human effects vary with preparation, dose, and individual biology. Key molecules and targets Molecules: glucoraphanin โ†’ sulforaphane; indole-3-carbinol (from crucifers). Gene regulator: Nrf2 (NFE2L2). Detox enzymes: GST, NQO1, HO-1 (commonly cited downstream targets). Science-forward notes Activation is dose and preparation dependent: formation and exposure vary with plant form and handling. Mechanistic strength is high: the Nrf2 pathway is well-described; translating it to a single health outcome is more complex. Hormone-metabolism language needs restraint: indole-related pathways exist, but clinical implications vary by person and context. Fermented foods deliver acids and metabolites created during fermentation. Fermented Foods May support gut barrier resilience and immune signaling Fermented foods are often framed as probiotic delivery systems, but their effects can also come from fermentation-created chemistry, including organic acids, peptides, and other microbial metabolites. The impact varies substantially by food type, processing, salt content, and individual tolerance. Depending on the product, fermented foods may support gut barrier function and influence immune signaling through interactions with pattern-recognition pathways in the gut.5 Some benefits can occur even without long-term colonization by the microbes in a given food, because bioactive metabolites and acids can influence the gut environment.5 The most defensible way to think about fermented foods is as microbial chemistry you can eat, with effects that are plausible and supported in parts of the literature, but not uniform across all fermented products or all people.5 Skim summary Benefits can come from fermentation chemistry, not just โ€œlive bacteria.โ€ May support gut barrier function and immune signaling, depending on the product and person. Effects are not uniform across all fermented foods. Key molecules and targets Molecules: organic acids (especially lactic acid), bioactive peptides (food and process dependent). Microbial products: postbiotic compounds created during fermentation (varies widely by food). Systems discussed: gut barrier biology and mucosal immune signaling (variable outcomes in humans). Science-forward notes Fermentation is not a single intervention: yogurt, kefir, kimchi, and miso can differ meaningfully in composition. Gut effects can be indirect: acids and metabolites can influence the gut environment even without durable colonization. Clinical translation varies: salt, additives, and individual intolerance can offset benefits for some people. Legumes feed gut microbes that produce short-chain fatty acids such as butyrate. Legumes Supports metabolic stability through microbiome fermentation Legumes are often reduced to carbs, but their most distinctive physiology comes from what happens after they reach the colon. Their resistant starches and fermentable fibers are substrates for gut microbes, which convert them into short-chain fatty acids. Through microbial fermentation, legume fibers can increase production of short-chain fatty acids such as butyrate.6 Butyrate is an energy source for colonocytes and has well-described signaling roles, including functioning as a histone deacetylase inhibitor and acting through GPCR pathways (including receptors commonly discussed as GPR41 and GPR43 in this context), with the usual caveat that downstream effects vary by host context.6 These pathways are biologically credible and well-characterized mechanistically. The magnitude of clinical effect in any individual depends on baseline diet, microbiome composition, and the overall pattern of fiber intake.6 Skim summary Key benefit comes from colon fermentation, not rapid digestion. Microbes can convert fibers into SCFAs such as butyrate. Butyrate has signaling roles (HDAC-related and GPCR-related pathways) and supports colon cells. Key molecules and targets Inputs: resistant starch, fermentable fibers. Outputs: short-chain fatty acids (SCFAs), especially butyrate. Targets: HDAC (butyrate as an inhibitor); GPCRs often referenced as GPR41 and GPR43 in SCFA signaling. Science-forward notes Responder variability is expected: baseline microbiome and habitual fiber intake influence SCFA production. Mechanism is credible: SCFA signaling and colonocyte fueling are well-described; symptom outcomes are more individual. Practical lever: steady intake tends to matter more than occasional large servings. Some mushrooms contain beta-glucans that interact with innate immune receptors. Mushrooms Interacts with innate immune receptors and may modulate immune responses Mushrooms contain beta-glucans that interact with receptors involved in innate immune recognition. This is a real and well-described immunologic pathway, though translation to measurable clinical outcomes varies by mushroom type, dose, preparation, and host context.7 Beta-1,3 and beta-1,6 glucans bind receptors including dectin-1 and complement receptor 3, which can modulate innate immune signaling.7 Lionโ€™s mane contains compounds such as erinacines and hericenones that have shown nerve growth factor related effects in preclinical research, while human studies to date are smaller and more mixed.8 Human studies suggest possible cognitive or psychological effects in some contexts, but the mechanism in humans remains under investigation. A careful framing is that mushrooms contain compounds that plausibly support immune balance and brain-relevant pathways, without promising uniform outcomes. Skim summary Beta-glucans can interact with innate immune receptors (mechanistic pathway is well-described). Clinical outcomes can vary by mushroom type, dose, and preparation. Lionโ€™s mane has preclinical NGF-related findings; human mechanisms remain uncertain. Key molecules and targets Molecules: beta-1,3 and beta-1,6 glucans; (lionโ€™s mane) erinacines and hericenones (preclinical emphasis). Receptors: dectin-1; complement receptor 3 (CR3). Pathway discussed: nerve growth factor (NGF)-related signaling (stronger preclinical than clinical). Science-forward notes Terminology matters: โ€œimmune boostingโ€ is not precise; these pathways relate to recognition and modulation. Preparation and matrix: cooking and extraction methods can change beta-glucan exposure. Human evidence varies: preclinical mechanisms can be compelling, while clinical endpoints remain mixed by context. Berry polyphenols are studied for vascular and brain-relevant pathways. Berries Supports brain-relevant pathways and vascular function over time Berries provide anthocyanins and related polyphenols that have been studied for brain-relevant pathways and vascular function. Evidence is strongest when berries are part of broader dietary patterns associated with cardiometabolic and cognitive health, rather than as isolated magic ingredients.9 Anthocyanins and their metabolites have shown brain-relevant distribution in experimental studies, and berry intake has been associated with neuroprotective signaling pathways, endothelial support, and cognitive outcomes in some research, with effects that can vary substantially across study designs and populations.9 Mechanistic work often highlights microglial activation, synaptic signaling, and neurotrophic pathways such as BDNF, but direct effects and biomarker changes in humans can be variable. The most defensible takeaway is that berries are a reliable, low-risk way to support long-term vascular health and brain-adjacent biology, especially when consumed regularly in modest amounts. Skim summary Studied for vascular support and brain-relevant signaling pathways. Evidence is strongest in dietary patterns, not one-off โ€œsuperfoodโ€ claims. Human biomarker effects can vary; regular modest intake is a practical approach. Key molecules and targets Molecules: anthocyanins; flavonols and related polyphenols. Brain-relevant pathways discussed in research: neurotrophic signaling such as BDNF (context-dependent, variable in humans). Vascular biology: endothelial-related markers and oxidative balance measures (variable by study). Science-forward notes Metabolites matter: many observed effects relate to polyphenol metabolites rather than intact compounds alone. Outcome framing: associations and modest effects are more defensible than deterministic claims. Low-risk habit: berries are generally a practical addition when they displace more refined sweets, rather than stacking calories. Dietary nitrate relies partly on oral bacteria for nitric oxide-related effects. Leafy Greens Supports circulation through nitrate-to-nitric oxide biology Leafy greens support circulation partly through dietary nitrate, which can be converted to nitric oxide through a pathway that depends on oral bacteria. This can matter for blood pressure, vascular tone, and exercise tolerance in some people.10 Dietary nitrate is reduced to nitrite by oral microbes and can contribute to nitric oxide availability, supporting vasodilation and blood flow.10 This pathway can be blunted by antiseptic mouthwash in some studies.10 Leafy greens also provide folate and magnesium, which are relevant to methylation and cellular maintenance. As with many nutrition effects, magnitude varies, but the underlying pathway is well-established.10 Skim summary Supports circulation through nitrate โ†’ nitrite โ†’ nitric oxide pathways. Oral bacteria play a role; antiseptic mouthwash can blunt conversion in some studies. Also provides folate and magnesium for cellular maintenance. Key molecules and targets Nutrients: dietary nitrate, folate, magnesium. Conversion pathway: nitrate โ†’ nitrite (oral microbes) โ†’ nitric oxide (NO). Physiology: NO-related vasodilation and blood flow regulation (magnitude varies). Science-forward notes Dependency is real: the oral microbiome is part of the pathway, so behavior and hygiene products can influence it. Not a substitute for care: this pathway can support vascular tone, but it is not a stand-in for treating hypertension. Context: effects may be more noticeable in people with lower baseline NO availability or higher vascular risk. Alliums change chemically when chopped, crushed, rested, and heated. Alliums Preparation-dependent sulfur chemistry with cardiovascular and antioxidant relevance Garlic, onions, and leeks contain organosulfur compounds that change depending on how the food is cut, crushed, and heated. This chemistry is one of the reasons alliums are often studied for cardiovascular and antimicrobial effects. Allium-derived compounds have demonstrated antimicrobial activity in experimental contexts and have been associated with antiplatelet and antioxidant effects in some clinical and dietary research, though results vary and depend heavily on preparation.11 Alliums also relate to glutathione biology indirectly, since sulfur-containing compounds participate in broader antioxidant systems. A simple practical point is that crushing garlic and letting it rest before cooking can increase formation of certain sulfur compounds compared with immediately heating whole cloves.11 Skim summary Key compounds are preparation-dependent, chop and rest changes chemistry. Associated with antimicrobial, antiplatelet, and antioxidant effects in some research. Relevance ties to cardiovascular support and broader antioxidant systems. Key molecules and targets Molecules: allicin and other organosulfur compounds (formation depends on cutting and time). Systems discussed: platelet-related pathways and oxidative balance (variable across studies and preparations). Antioxidant network context: sulfur chemistry intersects with glutathione-related biology (indirectly). Science-forward notes Transient chemistry: some sulfur compounds are unstable, which helps explain why handling and timing change exposure. Study variability is expected: supplement trials and whole-food studies are not interchangeable. Practical lever: chopping or crushing, then resting briefly before cooking is a reasonable approach for those who tolerate garlic. Cooking tomatoes and pairing with fat improves lycopene bioavailability. Tomatoes Membrane protection supported by lycopene absorption Tomatoes are a reliable source of lycopene, a lipophilic compound that is incorporated into lipid environments and studied for oxidative protection of cell membranes and lipoproteins. Lycopene absorption increases with cooking and improves further when tomatoes are eaten with dietary fat.12 In this case, the biologic effect depends more on bioavailability than on whether tomatoes are raw. Over time, consistent intake of tomato products can support oxidative balance and is often discussed in relation to prostate and cardiovascular health, with outcomes depending on the broader diet and risk profile.12 Skim summary Lycopene is lipophilic and relates to oxidative protection in lipid environments. Cooking plus fat pairing improves absorption. Benefit depends on bioavailability, not โ€œrawness.โ€ Key molecules and targets Molecule: lycopene. Absorption enhancer: dietary fat improves lycopene bioavailability. Biology: oxidative stress measures in lipid environments (membranes, lipoproteins), with study-to-study variability. Science-forward notes Bioavailability is the point: the preparation that improves absorption is often more important than the raw ingredient itself. Outcome framing: โ€œsupportiveโ€ is more accurate than โ€œpreventiveโ€ when translating nutrition evidence. Co-ingestion: pairing with olive oil is a practical way to align the food matrix with a lipophilic compound. Nuts and seeds offer mineral density and supportive redundancy. Nuts and Seeds Mineral density and steady metabolic support through redundancy Nuts and seeds provide broad metabolic support rather than a single unique mechanism. They are useful partly because they supply multiple supportive compounds at once, including minerals and lipid-soluble antioxidants. They provide magnesium for ATP-dependent enzymatic reactions, arginine as a nitric oxide precursor, and various tocopherols and polyphenols that support oxidative balance. The most consistent benefits tend to show up when nuts and seeds replace less favorable snack patterns, rather than when they are simply added on top of an already high-calorie intake. Portion size and context matter. Skim summary Broad benefits, mostly through supportive redundancy. Magnesium supports ATP-dependent enzymes; arginine supports nitric oxide pathways. Best impact often comes from replacement of less favorable snacks, portion matters. Key molecules and targets Nutrients: magnesium; arginine. Vitamin E family: tocopherols (type varies by nut and seed). Pathway: nitric oxide (NO) precursor support via arginine (context-dependent, not a guarantee of outcome). Science-forward notes Replacement effect is real: many observed benefits occur when nuts displace refined snacks, not when they are added without adjusting intake. Matrix matters: whole-food fats, fiber, and micronutrients arrive together, which is part of the advantage. Portion is the lever: a small daily portion is more consistent with the evidence than large add-ons. Sea vegetables are iodine-dense, which makes dose and context important. Sea Vegetables Thyroid-relevant nutrition with a narrower safety window Sea vegetables are powerful but narrow tools. Their primary value lies in iodine, which is required for thyroid hormone synthesis. The same fact that makes them useful also makes dose important. Some seaweeds, particularly certain kelp products, can contain very high iodine levels, and excessive iodine intake can trigger thyroid dysfunction in susceptible individuals.13 Sea vegetables also contain polysaccharides such as fucoidans that have emerging evidence for immune and microbiome effects, much of it preclinical or early-stage. The practical message is simple: sea vegetables can be valuable in the right context, but they are not a daily requirement for everyone.13 Skim summary Main benefit is iodine for thyroid hormone synthesis. Some kelp products can be very high iodine, excess can be risky in susceptible people. Fucoidan-related effects are emerging and often early-stage evidence. Key molecules and targets Nutrient: iodine. Hormones: thyroid hormone synthesis context (T3/T4 physiology; intake needs vary by person). Polysaccharides: fucoidans (mechanistic and early-stage evidence emphasis). Science-forward notes Safety window matters: deficiency and excess are both possible, especially in people with thyroid vulnerability. Product variability: iodine content can vary by seaweed type, source, and serving size. Reasonable framing: sea vegetables can be a targeted tool, not a universal daily staple. Patterns and consistency tend to outperform one-off optimization. Global Takeaways Foods matter most when they regulate systems, not when they simply supply nutrients. Preparation, pairing, frequency, and form often matter more than quantity. Patterns of exposure usually outperform one-off optimization. Redundancy is protective, and true uniqueness is rare. This approach moves nutrition beyond calories, toward regulation of core biological systems. Skim summary Prioritize foods that influence systems, not just nutrient totals. Preparation and frequency can matter more than quantity. Redundancy is protective; uniqueness is uncommon. Key molecules and targets Compound families: phenolics, glucosinolate-derived compounds, organosulfur compounds, dietary nitrate, fermentable fibers. Representative targets: transcription factors (example: Nrf2), innate receptors (example: dectin-1), microbial metabolites (example: SCFAs such as butyrate). Practical target: bioavailability, preparation, and food matrix effects. Science-forward notes Nutrition is systems biology: effects often occur through networks, not single nutrients, and are shaped by baseline state. Claims need matching evidence: mechanistic plausibility is not the same as a proven disease outcome in humans. Most reliable strategy: consistent dietary patterns that repeatedly expose the body to these pathways. โฌ‡๏ธŽ Download the Printable Nutrition 202 Guide (PDF) Quick reference sheet for printing, sharing, or saving. Further Reading Beauchamp GK, et al. Beauchamp GK, Keast RSJ, Morel D, Lin J, Pika J, Han Q, et al. Phytochemistry: ibuprofen-like activity in extra-virgin olive oil. Nature. 2005;437(7055):45โ€“46. PubMed: https://pubmed.ncbi.nlm.nih.gov/16136122/ European Food Safety Authority (EFSA). EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA). Scientific Opinion on the substantiation of health claims related to polyphenols in olive oil and protection of LDL particles from oxidative damage. EFSA Journal. 2011;9(4):2033. doi:10.2903/j.efsa.2011.2033. https://efsa.onlinelibrary.wiley.com/doi/10.2903/j.efsa.2011.2033 Riedl MA, et al. Riedl MA, Saxon A, Diaz-Sanchez D. Oral sulforaphane increases Phase II antioxidant enzymes in the human upper airway. Clinical Immunology. 2009;130(3):244โ€“251. PubMed: https://pubmed.ncbi.nlm.nih.gov/19028145/ Myzak MC, Dashwood RH. Myzak MC, Dashwood RH. Histone deacetylases as targets for dietary cancer-preventive agents: lessons learned with butyrate, diallyl disulfide, and sulforaphane. Cancer Letters. 2006;241(2):247โ€“254. PMC review context discussing sulforaphane as an HDAC inhibitor: https://pmc.ncbi.nlm.nih.gov/articles/PMC3897785/ Marco ML, et al. Marco ML, Heeney D, Binda S, Cifelli CJ, Cotter PD, Folignรฉ B, et al. Health benefits of fermented foods: microbiota and beyond. Cell Host & Microbe. 2017;22(2):179โ€“188. PMC review on fermented foods, the microbiome, and health: https://pmc.ncbi.nlm.nih.gov/articles/PMC8620815/ Rรญos-Coviรกn D, et al. Rรญos-Coviรกn D, Ruas-Madiedo P, Margolles A, Gueimonde M, de Los Reyes-Gavilรกn CG, Salazar N. Intestinal short chain fatty acids and their link with diet and human health. Frontiers in Microbiology. 2016;7:185. PMC: https://pmc.ncbi.nlm.nih.gov/articles/PMC6333934/ Vetvicka V, et al. Vetvicka V, Vannucci L, Sima P, Richter J. ฮฒ-glucan as a new tool in vaccine development. Scandinavian Journal of Immunology. 2019;90(4):e12833. For mechanistic review of ฮฒ-glucan recognition by innate immune receptors including dectin-1 and CR3, see: Brown GD, Gordon S. Immune recognition of fungal ฮฒ-glucans. Cellular Microbiology. 2005;7(4):471โ€“479. PMC overview: https://pmc.ncbi.nlm.nih.gov/articles/PMC6618291/ Friedman M. Friedman M. Chemistry, nutrition, and health-promoting properties of Hericium erinaceus (lionโ€™s mane) mushroom fruiting bodies and mycelia and their bioactive compounds. Journal of Agricultural and Food Chemistry. 2015;63(32):7108โ€“7123. PMC review example on Hericium erinaceus: https://pmc.ncbi.nlm.nih.gov/articles/PMC5987239/ Berry polyphenols and brain-relevant pathways. Miller MG, Shukitt-Hale B. Berries and brain health. Journal of Agricultural and Food Chemistry. 2012;60(23):5709โ€“5715. Recent open-access review on berry polyphenols, brain-relevant pathways, and variability in human outcomes: https://pmc.ncbi.nlm.nih.gov/articles/PMC10669056/ Kapil V, et al. Kapil V, Haydar SM, Pearl V, Lundberg JO, Weitzberg E, Ahluwalia A. Physiological role for nitrate-reducing oral bacteria in blood pressure control. Free Radical Biology and Medicine. 2013;55:93โ€“100. Related work on antiseptic mouthwash disrupting the enterosalivary nitrateโ€“nitriteโ€“NO pathway and blood pressure: Montenegro MF, et al. Oral nitrite circumvents antiseptic mouthwash-induced disruption of enterosalivary nitrate reduction and promotes nitrosation and blood pressure lowering. Free Radical Biology and Medicine. 2017;104:1โ€“10. PubMed: https://pubmed.ncbi.nlm.nih.gov/25359409/ and https://pubmed.ncbi.nlm.nih.gov/27769921/ Linus Pauling Institute, Oregon State University. Linus Pauling Institute, Oregon State University. Garlic. In: Micronutrient Information Center. Updated monograph detailing alliinase-driven formation of organosulfur compounds, preparation, and heat effects. https://lpi.oregonstate.edu/mic/food-beverages/garlic Story EN, et al. Story EN, Kopec RE, Schwartz SJ, Harris GK. An update on the health effects of tomato lycopene. Nutrients. 2010;2(10):963โ€“988. PMC: https://pmc.ncbi.nlm.nih.gov/articles/PMC7996133/ Leung AM, Braverman LE. Leung AM, Braverman LE. Consequences of excess iodine. Endocrinology and Metabolism Clinics of North America. 2014;43(3):593โ€“608. Discussion includes iodine excess from seaweed and other sources. PMC: https://pmc.ncbi.nlm.nih.gov/articles/PMC8077470/ [...] Read more...
February 5, 2026ย  Why feeling โ€œless socialโ€ is often about bandwidth, not who you are Social Capacity vs Identity: Why This Confusion Is So Common Many people believe theyโ€™ve changed because social interaction feels harder than it used to. They assume they are less social now, more withdrawn, or fundamentally different than before. In reality, what has often shifted is social capacity vs identity being misread as the same thing. Social capacity reflects how much stimulation, interaction, and demand the nervous system can handle at a given time. Identity reflects preference and orientation when resources are available. When capacity drops for long enough, it starts to masquerade as identity. Understanding social capacity vs identity helps explain why so many people feel torn between relief when alone and loneliness when isolation stretches too far. Why Time Alone Feels Necessary When Social Capacity Drops Solitude can be genuinely restorative. Reduced stimulation lowers cognitive load and gives the nervous system space to settle. For many people, alone time is not about avoiding others but about managing limited bandwidth. After years of chronic stress, uncertainty, and disruption, social capacity has narrowed for many adults. In this context, choosing solitude is often an adaptive response rather than a true preference. The mistake happens when social capacity vs identity gets collapsed into a single conclusion about who someone is. Why Connection Still Regulates Us Despite reduced capacity, most people still feel better with some degree of connection. Shared presence, even quiet or low-demand interaction, provides emotional regulation that cannot be fully replicated alone. Social baseline theory and related frameworks show that proximity and shared effort reduce the internal work required to manage stress. When connection is absent, emotional regulation becomes more costly. The issue is not that connection stopped helping, but that its energy cost increased. This is where social capacity vs identity becomes clinically important. Capacity can fluctuate. Identity does not need to be rewritten every time it does. Where People Go Wrong: Confusing Social Capacity vs Identity In clinical settings, this confusion appears repeatedly. People narrate depletion as permanence. They build self-descriptions around low capacity states and reorganize their lives accordingly. The danger is subtle. Identities built around temporary constraints tend to outlast the conditions that created them. Over time, this narrows social worlds, emotional flexibility, and access to regulation that comes from being with others. Recognizing social capacity vs identity early can prevent unnecessary withdrawal and self-judgment. Health Is Responsiveness, Not Consistency There is no correct amount of social time or alone time. Balance shifts across seasons of life, health, and stress. Well-being rarely looks like consistency. It looks like responsiveness. Noticing when solitude stops restoring and starts isolating, or when connection stops nourishing and starts draining, requires attunement rather than rigid rules. Framing this through social capacity vs identity allows for adjustment without self-criticism. What the Nervous System Is Asking For From a clinical perspective, solitude and connection are not opposing needs. They are different tools. Quiet reduces stimulation. Connection provides external grounding and emotional regulation. After prolonged strain, many nervous systems remain more reactive than before. When people lean too hard into isolation because it feels easier, rumination often increases. When they force constant social exposure, burnout follows. The signal is rarely to choose one permanently. It is to recognize social capacity vs identity and switch tools as capacity shifts. Further Reading This topic is explored in greater depth in a recent Psychology Today essay, The Quiet Tension Between Needing Space and Needing People, which examines how depletion is misread as identity and why that misreading has real consequences. Read it here:https://www.psychologytoday.com/us/blog/beyond-the-white-coat/202602/the-quiet-tension-between-needing-space-and-needing-people FAQs Is feeling less social a personality change? Often no. It is usually a reflection of reduced social capacity rather than a shift in identity. How do I know if I need more solitude or more connection? Pay attention to whether solitude restores or isolates, and whether connection regulates or drains. This distinction clarifies social capacity vs identity. Can social capacity return? Yes. Capacity is dynamic and often improves as stressors resolve and regulation stabilizes. [...] Read more...
January 20, 2026Endocannabinoid System in Older Adults: 7 Essential Insights How aging reshapes ECS signaling and what that means for cannabis safety, dosing, and clinical decision-making later in life.   Introduction: Why the endocannabinoid system in older adults matters A growing number of older adults are curious about medical cannabis for relief from chronic pain, insomnia, anxiety, appetite loss and other age-related ailments. Data summarized by Stanford Medicine (drawing from national survey data) notes that 7% of adults over 65 reported recent cannabis use in 2023, up from less than 5% in 2021. See: Stanford Medicine: Cannabis and older adults. Yet few people understand the endocannabinoid system in older adults, the network of receptors, enzymes and signaling molecules that cannabis interacts with, or how it changes as we age. This guide explains what the ECS is, why its function can decline over time and what that might mean for seniors exploring cannabinoid therapies. For a practical senior-centered overview, see Cannabis for Seniors. What is the endocannabinoid system? The endocannabinoid system is an evolutionarily conserved biological network found in all mammals. It includes: Endocannabinoids – lipid-based signaling molecules produced on demand by the body. The best-studied molecules are anandamide (AEA) and 2-arachidonoylglycerol (2-AG). Receptors – primarily CB1 receptors concentrated in the central nervous system and CB2 receptors found in immune cells, bone, gastrointestinal tissues and peripheral nerves. These receptors also appear in organs like the heart, liver and kidneys. Enzymes – proteins that synthesize and break down endocannabinoids, including FAAH and MAGL, as well as synthesis pathways described in the literature (including NAPE-PLD and related enzymes). The ECS plays a key role in maintaining homeostasis, the balance of biological processes. It modulates the release of neurotransmitters, regulates inflammatory responses, influences pain perception, and helps control functions such as appetite, sleep, mood, bone health and immune function. When a stressor pushes the body away from equilibrium, endocannabinoids are released to restore balance. This is one reason why cannabis compounds, which mimic endocannabinoid signaling, can have widespread effects on the body. For clinician-facing mechanistic background that connects ECS biology to aging-related neurophysiology, see NIH-hosted reviews at PubMed Central and PubMed Central. How aging alters the endocannabinoid system in older adults As people age, several components of the endocannabinoid system change: Reduced endocannabinoid production – Research has described age-associated reductions in AEA and 2-AG in brain regions involved in memory and motor control. Lower endocannabinoid tone may contribute to chronic inflammation, cognitive vulnerability and reduced resilience to stress. For broader mechanistic context in aging and neurobiology, see: PubMed Central. Fewer cannabinoid receptors – CB1 and CB2 receptor density can diminish with age. This down-regulation may reduce the bodyโ€™s responsiveness to endocannabinoids and phytocannabinoids alike, which is one reason the same labeled dose may feel different in the endocannabinoid system in older adults than in younger adults. Altered enzyme activity – Aging can affect the enzymes that regulate endocannabinoids. Some studies suggest increased FAAH activity and changes in synthesis pathways, leading to faster breakdown of signaling molecules and reduced ECS tone. For neuroinflammation and neuroprotection frameworks often discussed alongside ECS signaling, see: PubMed Central. Shifts in receptor expression – CB1 and CB2 expression patterns can shift across stages of aging. These shifts may influence inflammatory pathways, bone density and metabolic health. These combined changes mean the ECS may become less efficient at maintaining balance in older adults. This decreased efficiency has been linked with conditions such as chronic pain, migraine, fibromyalgia and irritable bowel syndrome, as well as neurodegenerative disorders and metabolic diseases. This is a central reason discussions about cannabis in later life benefit from starting with physiology and not simply product potency. Why the endocannabinoid system in older adults matters clinically The decline of the ECS doesnโ€™t guarantee illness, but it can increase vulnerability to disease. The ECS helps regulate: Neuroprotection and cognitive function – Endocannabinoids can protect neurons from excitotoxicity, oxidative stress and inflammation. Age-related reductions in ECS tone may contribute to memory changes, slower information processing and increased risk of neurodegenerative disease pathways. Inflammation and immune responses – CB2 receptors modulate immune cell activity and help keep inflammation in check. Declines in CB2 signaling can worsen chronic low-grade inflammation, a major driver of age-related disease. Pain and musculoskeletal health – CB1 and CB2 receptors in peripheral nerves and joints influence pain signaling and inflammatory responses. A weaker ECS may contribute to heightened sensitivity to pain and slower recovery from injuries. For practical clinical context, see Chronic Pain and Inflammation. Metabolic function and bone health – The ECS is involved in energy balance, fat metabolism and bone remodeling. Alterations may contribute to insulin resistance, weight shifts and osteoporosis risk. Sleep, mood and stress response – Endocannabinoids help regulate the sleep-wake cycle and mediate stress response. Lower ECS tone is associated with insomnia, mood disturbances and heightened stress. For sleep-focused guidance, see Cannabis for Sleep and Sleep Disorders and Circadian Rhythm Issues. Understanding these roles helps explain why older adults explore cannabis. By supplementing the ECS with phytocannabinoids such as THC and CBD, some seniors hope to restore balance in systems affected by aging. However, evidence is limited, and cannabis use comes with distinct risks that warrant careful consideration, particularly within the endocannabinoid system in older adults. The potential benefits of cannabinoids for seniors Preliminary studies and patient reports suggest that cannabis-based therapies may offer symptom relief for certain conditions common in older adults. For example: Chronic pain and arthritis – Observational studies and patient-reported outcomes suggest some individuals report improvements in pain, stiffness and function. For practical context on pain and inflammation, see Chronic Pain and Inflammation. For an example of patient-reported outcomes literature in arthritis populations, see PubMed Central. Insomnia and sleep disorders – Observational studies report that medical cannabis use is associated with better sleep quality and decreased insomnia. Practical sleep guidance is here: Cannabis for Sleep, along with deeper circadian and sleep disorder context at Sleep Disorders and Circadian Rhythm Issues. Anxiety and mood disorders – Some seniors report reduced anxiety and improved mood with low doses of CBD or balanced THC:CBD products. However, higher THC exposure can worsen anxiety and paranoia for some individuals. See Cannabis for Anxiety and Anxiety and Stress. Appetite stimulation and nausea relief – Approved cannabinoid medications like dronabinol are used to combat nausea and appetite loss in certain conditions. Some older adults explore cannabis for appetite support when conventional approaches fall short. Spasticity and neuropathic pain – Cannabinoids have demonstrated some efficacy in managing spasticity from multiple sclerosis and some neuropathic pain syndromes. Results are mixed across studies, and benefits appear modest and dose-dependent. It is important to note that high-quality human evidence remains scarce for many of these indications in older populations. Much of the available data comes from observational studies, surveys, and mechanistic research. When evidence is limited, clinicians must balance potential benefits against known and unknown risks and tailor recommendations to each patientโ€™s goals and health status, especially given the variability of the endocannabinoid system in older adults. Safety considerations and risks for seniors Stronger products and accidental over-consumption Todayโ€™s cannabis products can be far more potent than those used decades ago. That potency gap increases the risk that older adults unintentionally consume more THC than intended, especially with concentrates and edibles. Stanford Medicine highlights this practical risk and the rise in accidental over-consumption concerns among older adults here: Stanford Medicine: Five things medical experts want you to know. Cardiovascular risks Cannabis can raise heart rate and blood pressure, which may stress the cardiovascular system. Older adults, especially those with heart disease or unstable blood pressure, may face increased risk of adverse cardiovascular symptoms. Public health cautions for adults over 55 are summarized in Health Canada guidance, and Ottawa Public Health specifically flags cardiovascular conditions as a reason older adults should consider avoiding cannabis: Ottawa Public Health: Cannabis information for older adults. Cognitive effects and fall risk THC is psychoactive and can impair memory, attention and coordination. In older adults, these effects may last many hours and can include anxiety, paranoia, confusion, and dizziness. These changes increase fall risk and injuries, particularly when cannabis is taken in the evening and combined with nighttime waking. Ottawa Public Health emphasizes cognitive and balance vulnerabilities in older adults here: Ottawa Public Health. Slower metabolism and medication interactions Aging slows metabolism and affects how drugs are processed. Seniors may clear cannabinoids more slowly, prolonging their effects and increasing the risk of drug interactions. CBD and THC can influence metabolic pathways involved in processing a range of medications. Because polypharmacy is common in older adults, it is crucial to discuss cannabis use with a healthcare provider to identify potential interactions and adjust monitoring when needed. Public health agencies emphasize this interaction risk for older adults: Ottawa Public Health guidance. Organ health Individuals with liver, kidney or cardiovascular disease are particularly susceptible to adverse effects. Cannabis may remain longer in the body when organ function is impaired, and the risk profile of cannabinoids can shift in ways that matter for safety. Health Canada explicitly notes that adults over 55 should avoid cannabis in the setting of serious liver, kidney, or heart or blood vessel disease: Health Canada: adults over 55. Ottawa Public Health similarly highlights liver disease, kidney disease, and cardiovascular disease as reasons older adults should consider not using cannabis: Ottawa Public Health. Mental health and addiction Regular use of high-THC cannabis can worsen certain symptoms for some individuals, including anxiety or mood instability. Long-term use can also lead to cannabis use disorder, characterized by cravings, tolerance, and withdrawal symptoms such as irritability, insomnia and appetite changes. Some older adults hesitate to disclose cannabis use to clinicians, delaying recognition and support when problematic patterns develop. Practical safety tips Public health agencies recommend the following for older adults considering cannabis: Consult your healthcare provider – Discuss goals, medical history and medications with a clinician who can help assess risks. For a senior-centered starting point, see Cannabis for Seniors. Start low and go slow – Begin with a very low THC dose and wait long enough to assess effects before considering more. This matters especially for edibles, where onset is delayed and the endocannabinoid system in older adults may clear cannabinoids more slowly. Choose balanced products – Products with equal or higher CBD relative to THC may reduce some THC-related adverse effects in some individuals. Avoid smoking and vaping – Smoking introduces combustion toxins and can increase cardiovascular and respiratory burden. Consider tinctures, capsules, edibles or topicals instead. Avoid mixing substances – Combining cannabis with alcohol or sedating medications can increase impairment and fall risk. Buy from regulated sources – Regulated products are tested for potency and contaminants and include labeling of THC and CBD amounts. COAs can help confirm whatโ€™s in a product. See How to Read a Cannabis COA. Use safety equipment – If balance is impaired, prioritize fall prevention strategies and avoid driving or operating machinery while under the influence. Monitor and adjust – Track dose, timing, formulation and effects. If side effects occur, reduce dose or discontinue and contact your clinician. For a structured dosing framework aligned with safety and personalization, see Smart Cannabis Dosing. Types of cannabis products and administration methods Understanding how different products deliver cannabinoids can help seniors tailor their approach: Inhalation (smoking or vaping) provides rapid onset (minutes) and higher immediate bioavailability. However, smoking exposes the lungs to combustion products, and vaping can deliver very high THC concentrations. Many older adults choose non-inhaled formats to reduce respiratory burden. Sublingual tinctures and sprays are absorbed under the tongue, often providing effects within 15 to 60 minutes. They can allow more precise dosing and avoid lung exposure. Edibles, beverages and capsules pass through the digestive tract and liver. Effects are delayed (often 30 minutes to 4 hours), longer-lasting (often 6 to 12 hours) and more difficult to predict. Delayed onset is a common reason people redose too soon. This matters even more in the endocannabinoid system in older adults, where slower metabolism can extend impairment. Topical creams and balms may relieve localized pain or inflammation without meaningful systemic effects for many users, since many topical cannabinoids do not reach substantial bloodstream concentrations. Transdermal patches deliver cannabinoids slowly through the skin into the bloodstream, providing steadier dosing. Data on use in seniors remains limited. When selecting a product, prioritize lab-tested formulations, avoid homemade products when dosing precision matters, and consider products with clear cannabinoid ratios. Look for Certificates of Analysis (COAs) from reputable laboratories. See How to Read a Cannabis COA. Patient variability and personalization Every individualโ€™s ECS is unique. Genetic factors, lifestyle, diet, microbiome composition and other medications influence how cannabis affects someone. Older adults metabolize drugs more slowly and may be more sensitive to cannabinoids. Starting low, monitoring effects and adjusting dosage gradually is key. Some seniors may find relief with very small amounts of THC or primarily CBD-dominant products, while others may not tolerate cannabis at all. Personalization also involves timing. For example, using a small dose of a balanced THC:CBD tincture 1 to 2 hours before bedtime may help with insomnia without causing morning grogginess. Conversely, daytime use of high-THC products can impair cognition and mobility and should generally be avoided in those at fall risk. If sleep is the priority, see Cannabis for Sleep and Sleep Disorders and Circadian Rhythm Issues. For anxiety-related personalization and dosing considerations, see Cannabis for Anxiety and Anxiety and Stress. This is the heart of working with the endocannabinoid system in older adults: the goal is not maximal effect, it is the smallest effective change that supports function, sleep, comfort, and safety. Limitations of current research Although preclinical studies and surveys are promising, clinical trials involving older adults remain limited. Many studies exclude participants over 65, making it difficult to extrapolate results to seniors. Moreover, cannabis products are diverse; different strains, ratios and formulations have varying effects. Regulatory barriers also hinder large-scale research. As a result, there is no universal dosing guideline for seniors, and clinicians must rely on observational data, mechanistic studies and individualized assessment. This limitation is also why education about the endocannabinoid system in older adults matters. Understanding physiology helps patients and clinicians interpret why responses are variable and why cautious dosing and monitoring are not simply a slogan, but a practical safety requirement. Talking to your healthcare team Open communication with healthcare providers is essential. Many physicians are still unfamiliar with cannabis, but there is growing interest in cannabinoid medicine. When discussing cannabis: Be honest about current use or interest. Let providers know what symptoms you hope to address. Share a full list of medications, including over-the-counter drugs and supplements, so clinicians can check for interactions. Ask about alternative therapies that may provide relief with fewer risks. Request referrals to specialists knowledgeable in geriatric pharmacology or cannabinoid medicine if your provider is unsure. Providers can help monitor for side effects, adjust dosages or suggest alternative approaches. They may also coordinate with pharmacists and specialists for safe medication management. If caregiving is part of the decision-making environment, see Caregiver Support for Seniors. Frequently asked questions (FAQ) What is the endocannabinoid system? The ECS is a network of receptors, signaling molecules (endocannabinoids) and enzymes that helps maintain balance in the body. It regulates processes like pain, inflammation, mood, appetite and sleep. Does the endocannabinoid system in older adults decline with age? Many studies suggest that endocannabinoid levels and cannabinoid receptor density can decrease with age, while enzyme activity that breaks down endocannabinoids can shift in ways that reduce ECS tone. These changes may contribute to inflammation, pain sensitivity and cognitive vulnerability. For clinician-facing mechanistic context, see NIH-hosted reviews at PubMed Central and PubMed Central. Can cannabis restore ECS function in seniors? Cannabis compounds mimic endocannabinoids and can activate cannabinoid receptors, potentially compensating for decreased endocannabinoid tone. Some seniors report relief of pain, insomnia and anxiety with low doses of cannabis. However, evidence is limited, and cannabis carries significant risks for older adults. Public health guidance for adults over 55 is summarized by Health Canada, and risk cautions are discussed by Stanford Medicine. Is cannabis safe for seniors with heart or liver disease? Cannabis can raise heart rate and blood pressure and may strain the cardiovascular system. It may also remain longer in the body when liver or kidney function is impaired. Adults with heart disease, liver disease or kidney disease should avoid cannabis or use it only under close medical supervision. See Health Canada: adults over 55 and Ottawa Public Health. What are the safest forms of cannabis for seniors? Non-inhaled products like low-dose sublingual tinctures, capsules or carefully dosed edibles with equal or higher CBD than THC are often considered lower respiratory risk options. Avoid smoking and vaping, choose lab-tested products, start with the lowest possible dose and wait long enough before taking more. For structured dosing guidance, see Smart Cannabis Dosing and for product verification, see How to Read a Cannabis COA. Can cannabis interact with my medications? Yes. CBD and THC can influence medication metabolism pathways. This can raise levels of drugs like blood thinners, seizure medications and antidepressants or reduce their effectiveness. Because polypharmacy is common in older adults, medication review with a clinician is important before using cannabis. Public health interaction cautions are summarized at Ottawa Public Health. Conclusion The endocannabinoid system in older adults plays a central role in maintaining balance across numerous physiological processes, and its decline with age may contribute to pain, inflammation, sleep problems and mood disorders. While many seniors report symptomatic relief from cannabis, the evidence base remains limited, and the risks, especially related to cardiovascular strain, cognition, falls and drug interactions, are substantial. Before using cannabis, older adults should consult healthcare providers, start with very low doses and choose lab-tested products with balanced cannabinoid profiles. A thoughtful, individualized approach can help seniors explore cannabinoid therapies while minimizing harm. Contact CED Clinic If youโ€™d like individualized guidance on cannabis use, dosing, product selection, or medication interaction risk, CED Clinic can help. Visit CEDclinic.com Contact Us Cannabis for Seniors Smart Cannabis Dosing How to Read a Cannabis COA For urgent symptoms, chest pain, severe confusion, or falls, seek emergency care. [...] Read more...
January 18, 2026CED Clinic | Practical AI Workflow   CED Clinic | Practical AI Workflow A simple way to get more out of LLMs: structure beats wishful prompting People often conclude that LLMs are not ready because they tried a few bare prompts and got bare results. In practice, the biggest gains usually come from how you structure the interaction. Caveats (worth reading) This is a workflow tool, not a magic spell. It improves consistency, but does not guarantee correctness. Always verify important claims, especially in clinical, legal, and financial contexts. The prompt Copy prompt Download as .txt Scroll to view more, or use the copy/download buttons. (Paste this into your LLM before using it as you normally would.) SYSTEM: [ I am an advanced autonomous reasoning agent designed to support complex, high-stakes intellectual work. My role is to help the user analyze, explain, critique, synthesize, and reason across domains with rigor, clarity, and intellectual honesty. I am structured in phases. I support runtime configuration, automatic construction of domain-specific expertise, disciplined self-critique, and strict safeguards against fabrication and overconfidence. The user does not need to understand or manage my internal mechanisms. ================================================ PHASE 0 โ€” CONFIGURATION & DOMAIN CONSTRUCTION ================================================ Before answering substantive questions, I must ensure I am configured for the userโ€™s intended use. I proceed in one of two ways: โ€ข If the user provides a CONFIG block, I parse it and proceed immediately. โ€ข If no CONFIG block is provided, I present the configuration menu below and wait for a single reply. ------------------------------------------------ PHASE 0 CONFIGURATION MENU (VISIBLE OPTIONS) ------------------------------------------------ You may answer once. You do not need to remember these later. (A) DOMAIN SCOPE 1. Single domain 2. Multi-domain 3. Ecosystem domain 4. Meta / cross-disciplinary 5. Full stack (direct + indirect + adjacent) (B) TASK TYPE (choose any) a explain b analyze c critique d compare e synthesize f teach g strategize h forecast i design j evaluate k persuade l summarize m extract / structure n compose (writing) o scenario building p problem-solve q generate options r draft + revise (multi-pass) (C) AUDIENCE (choose any) i clinicians ii patients iii caregivers / parents iv seniors v policymakers vi regulators vii payors / CMS viii academic scientists ix investors x media / public xi industry professionals xii students xiii internal expert (you) xiv multistakeholder (D) RIGOR LEVEL (choose one) 1 conversational 2 educator-grade 3 clinician-grade 4 scientific / peer-review 5 regulatory / compliance 6 multi-standard (shift by audience) (E) TIME HORIZON 1 immediate 2 operational 3 strategic 4 long-horizon (F) UNCERTAINTY HANDLING 1 minimal 2 explicit 3 forensic 4 decision-grade (known / unknown / unknowable) (G) OUTPUT FORM 1 brief 2 long-form 3 exhaustive 4 publication-ready 5 executive summary 6 deck-ready 7 memo 8 explainer 9 report 10 multi-format (H) MODE โ€” HOW THE MODEL THINKS AND SELF-CHECKS Choose one option below. This explainer will always be shown when you are asked to choose. Binding style (letter): A โ€” Parallel modules โ€ข Domains (clinical, research, policy, strategy, writing) remain distinct. โ€ข Best for explicit separation, traceability, or regulator-style reasoning. B โ€” Unified mesh โ€ข Domains are blended into one integrated thinking style. โ€ข Best for fluid, natural reasoning without visible compartmentalization. C โ€” Hybrid with traceability โ€ข Reasoning is fluid, but domain sources can be labeled when helpful. โ€ข Best for natural reasoning plus the ability to point to โ€œwhyโ€ or โ€œfrom where.โ€ Self-checking intensity (number): 1 โ€” Single review at the end โ€ข Fastest, least verbose. 2 โ€” Mid-course correction + final review โ€ข Best balance of speed and quality. 3 โ€” Iterative until satisfied โ€ข Draft, critique, revise until no meaningful improvement remains. โ€ข Highest rigor, slowest. Examples: โ€ข A1 = explicit modules, fast โ€ข B2 = fluid reasoning, self-correcting โ€ข C3 = fluid + traceable, iterative (highest rigor) (I) MODULE DEPTH 1 direct domains only 2 direct + indirect 3 full adjacency mapping (J) PERSISTENCE 1 single use 2 session-level 3 conceptual across sessions (patterns, preferences only) (K) DISCLOSURE 1 final answer only 2 reasoning summary 3 decision tree 4 full transparency (on request) ------------------------------------------------ CONFIG INPUT FORMAT ------------------------------------------------ You may answer everything in one reply as: CONFIG: A-#, B-, C-, D-#, E-#, F-#, G-#, H-, I-#, J-#, K-# DOMAINS: ------------------------------------------------ PHASE 0 ACTIONS (INTERNAL) ------------------------------------------------ Once configuration is received, I will: 1. Interpret the configuration. 2. Identify direct domains explicitly named. 3. Construct indirect and adjacent expertise modules required for competent reasoning. 4. Calibrate reasoning style, rigor, audience framing, and critique behavior. 5. Briefly summarize the constructed modules for confirmation. 6. Lock configuration for the session unless reconfigured. ================================================ MASTER ENGINE โ€” REASONING & EXECUTION ================================================ ------------------------------------------------ MODE SELECTION & HOT SWAP ------------------------------------------------ If MODE is not specified, default is: MODE: C2 The user may change MODE at any time by writing: SWITCH MODE: XY I will acknowledge and adapt immediately. ------------------------------------------------ SELF-CRITIQUE & QUALITY CONTROL ------------------------------------------------ Self-critique behavior depends on MODE: โ€ข Post-pass only โ€ข Mid-flight plus post-pass โ€ข Iterative until further revision adds no value Critique evaluates: โ€ข logical gaps โ€ข unsupported claims โ€ข overreach โ€ข audience mismatch โ€ข clarity failures โ€ข internal inconsistency ------------------------------------------------ EVIDENCE INTEGRITY & ANTI-HALLUCINATION RULES ------------------------------------------------ I maintain strict epistemic discipline at all times: โ€ข I do not fabricate citations, statistics, studies, or authorities. โ€ข I do not invent evidence to fill gaps. โ€ข When evidence is limited, mixed, or absent, I explicitly say so. โ€ข I clearly distinguish evidence, inference, and speculation. โ€ข I surface uncertainty honestly rather than smoothing it over. โ€ข Clinical, scientific, and regulatory claims are appropriately qualified. If a question cannot be answered responsibly, I say that directly and explain why. ------------------------------------------------ EXECUTION & OUTPUT ------------------------------------------------ After Phase 0 completes, I answer user queries using the constructed expertise modules. I do not expose internal tooling or operational scaffolding unless explicitly asked. Final responses are clean, human-readable, and aligned with the configured audience, rigor, and purpose. Final responses are labeled: ANSWER: ------------------------------------------------ DEFAULTS ------------------------------------------------ If the user provides no configuration: โ€ข I prompt once with the Phase 0 menu. โ€ข If still unspecified, I assume: MODE: C2 Domain scope: Multi-domain Rigor: Scientific Uncertainty: Explicit Module depth: Direct + indirect ================================================ END SYSTEM SPECIFICATION ================================================] [...] Read more...
January 12, 2026Why the pandemicโ€™s quiet rewiring of daily life is now showing up in bodies, clinics, and aging This piece isnโ€™t about the pandemic itself, but about what it quietly changed in our bodies after it ended. – Dr Caplan What Youโ€™ll Learn in This Post โ‡๏ธ How the post Covid baseline quietly altered social stamina, mood, and the cognitive cost of being around other humans. โ‡๏ธ Why weak social ties matter to human physiology and why their disappearance is a silent risk factor in aging. โ‡๏ธ How delayed care, self-triage, and long Covid now shape clinic visits more than most clinicians admit. โ‡๏ธ Where cannabis and the endocannabinoid system actually fit into the post Covid baseline rather than sitting outside of it. โ‡๏ธ Why seniors absorbed the heaviest share of these aftershocks and why Medicare cannot keep pretending otherwise. Naming the Post Covid Baseline Weโ€™re All Living In There was no closing ceremony. No collective decompression. No national debrief on what prolonged vigilance does to a nervous system. The country simply shifted from pandemic mode to complication mode, and the rest was left to individuals to metabolize on their own. Somewhere in that transition, a new default settled in. The post Covid baseline is not a diagnosis, nor a syndrome, nor a syndrome disguised as a personality trait. It is a broad reconfiguration of how humans are now moving through the world after two years of physical isolation, digital substitution, biological threat, and a healthcare system stretched to transparency. For many people the post Covid baseline feels like a subtle but stubborn shift in how much life can be carried without fraying. Socializing now has a price. Leaving the house requires deliberation. The body holds more tension than it can analytically justify. Rest feels thinner. Symptoms feel stickier. Optimism requires intention rather than arriving spontaneously. On paper, most of this does not register. Tests are normal. Imaging reassures. Clinicians say things like โ€œyour labs are fineโ€ and patients say things like โ€œthen why do I feel like this.โ€ The chart cannot capture the nervous systemโ€™s attempt to reorganize itself after prolonged uncertainty. It can only register disease, and the post Covid baseline is not disease, it is drag. Public Life Got Strange and No One Knows How to Name It Of all the changes the pandemic produced, the strangest might be in how humans now relate to the public world. We had two years where being around strangers was reclassified from ordinary to suspicious, and then we were expected to reverse the classification overnight. People did return to gatherings, restaurants, concerts, conferences, airports, and offices. But the return was tentative and often conditional. A subtle calculation sits behind many invitations: โ€œDo I have it in me for this today.โ€ Social stamina is now a variable rather than a constant. There is a quiet absurdity to the new rituals of participation. Events that once required nothing more than interest now require interest plus energy plus planning plus resilience. For many, the RSVP button has become a kind of mirror. In the pre-pandemic world, boredom was the obstacle to social life. In the post Covid baseline, the obstacle is capacity. It is not that people became antisocial, it is that public life became cognitively expensive. Clinically this shows up as a pattern that is easy to miss. Patients describe feeling โ€œoffโ€ or โ€œtiredโ€ or โ€œless motivatedโ€ or โ€œmore anxious around people,โ€ but rarely identify it as a shift in social stamina. To them it feels personal. To clinicians it often sounds psychological. To anthropology it is neither, it is an adaptation to prolonged threat that the nervous system has not fully reversed. ย  Weak Ties Vanished and Health Became Harder to Detect Before the pandemic, most people participated in a quiet lattice of relationships that sociologists call weak ties. These are not friends, they are the people who populate your surroundings and create the subtle hum of belonging. The barista who knows your face, the neighbor on the same walking schedule, the usher at church, the woman in your tai chi class. They are the background characters of a healthy social world. The pandemic wiped them out with brutal efficiency. When it was over, strong ties mostly returned, but weak ties did not. They require proximity, repetition, and low stakes, and the post Covid baseline is poor soil for all three. From a health perspective, weak ties serve two purposes. First, they buffer loneliness without triggering the pressures of intimacy. Second, and more importantly, they detect change. Weak ties are often the first to say things like โ€œyou look tired,โ€ โ€œyou are limping,โ€ โ€œyou missed last week,โ€ or โ€œyou do not seem like yourself.โ€ Primary care physicians often rely on families for these observations. Before the pandemic, society provided them for free. Remove weak ties and the first line of detection disappears. Problems that would have been noticed socially are now only noticed medically, and usually later. This is particularly punishing for older adults, whose health signals are often subtle before they are urgent. In clinics, this has produced a version of delayed discovery. By the time symptoms surface to medicine, they have already had time to entrench. The post Covid baseline did not invent frailty, depression, or cognitive decline. It simply removed the social tripwires that once caught them early. Self-Triage Became the New Primary Care During the pandemic, people were taught to manage symptoms at home, to avoid emergency rooms unless necessary, and to evaluate risk through apps, dashboards, and informal networks. The line between public health advice and self-management blurred. That logic did not vanish when restrictions lifted. It simply shifted focus. In the post Covid baseline, many people run a silent calculus before seeking care. They wait. They monitor. They Google. They tighten routines. They hope it resolves. When it does not, they wait longer. Clinicians are seeing the outcome. Problems are arriving later in their arc. There is more complexity at first presentation. There is more confusion about when symptoms began. People are less certain about what is normal for them and what is new. Cannabis enters here as an adaptation. For some, it is for sleep. For others, anxiety. For others, pain. There is no mystery in this. Humans will medicate discomfort long before they are willing to medicalize it. Cannabis is simply a tool that is widely accessible, socially tolerable, and physiologically versatile. In some cases, cannabis delays escalation by lowering symptom volume until patients can get care. In other cases, cannabis delays escalation by lowering symptom volume so they do not. Both patterns are rational in a world where medical access feels costly and the post Covid baseline normalizes feeling slightly unwell most of the time. ย  The Post Covid Baseline Lives in the Nervous System If the pandemic rearranged anything, it was vigilance. Humans are not built for multi-year threat monitoring. The nervous system can activate quickly and deactivate slowly, but it does not deactivate gracefully when the threat is ambiguous or ongoing. During Covid, threat was everywhere and nowhere. It was in the news, in the air, in the grocery store, in the bodies of strangers and family. You could silence the alerts on your phone. You could not silence the alerts in your limbic system. That kind of prolonged activation has consequences. Sleep becomes lighter. Startle becomes sharper. Fatigue becomes less responsive to rest. Mood becomes less spontaneous. Symptom perception becomes louder. The post Covid baseline is not only cultural, it is neurophysiological. The endocannabinoid system sits inside this architecture. It is the bodyโ€™s internal regulator for mood, sleep, pain, appetite, and immune tone. It helps decide how loudly the nervous system broadcasts threat. During prolonged stress, it spends enormous energy dampening signals so the organism can continue functioning. It does not do so indefinitely without cost. None of this requires exotic science to explain. When a nervous system is taught to expect uncertainty, it will continue expecting it until it has enough contradictory evidence to stand down. Most people have not had that evidence. The post Covid baseline therefore persists, not because the pandemic is ongoing, but because uncertainty is. Long Covid: The Concentrated Version There is a separate category of people who never returned to any baseline at all. Long Covid takes the post Covid baseline and places it into high relief. Fatigue, dysautonomia, brain fog, unrefreshing sleep, tachycardia, temperature sensitivity, exertion crashes. These are the symptoms of a nervous system and immune system struggling to coordinate under novel strain. Long Covid reveals something the broader culture tries to ignore. When recovery is incomplete, life does not pause. People keep working, keep caregiving, keep pretending. The nervous system absorbs the slack. The bill arrives later. In clinic, these patients tend to present with complexity that predates the appointment. By the time medicine sees them, they have already restructured their routines. They have developed coping strategies. Cannabis sometimes enters here as a tool of self-stabilization. Small doses can smooth pain, soften hyperarousal, and improve sleep onset. Higher doses can worsen cognitive fog, flatten motivation, or make pacing harder. The tragedy of long Covid is not only biological. It is cultural. Our society is not built for illnesses that do not resolve. It is built for injuries you can point to and diseases that have protocols. Long Covid has neither. It is an edge case of the post Covid baseline where the return-to-normal story collapses and the organism is left to improvise. Clinicians Are Living in This Baseline Too The healthcare system did not exit the pandemic unscathed. Clinicians absorbed a level of demand and grief that the system is not designed to metabolize. Many worked through crisis conditions with no psychological decompression. The culture of medicine rewards endurance, not integration. The result is a quiet erosion of clinical bandwidth. There is less patience for complexity. There is less time for nuance. There is more exhaustion beneath the surface. The post Covid baseline is not just for patients, it is for everyone in the exam room. When a patient enters with tangled symptoms, a clinician with a frayed baseline may not have the capacity to deconstruct them. The clinical impulse becomes triage rather than curiosity. The system becomes transactional rather than interpretive. The organism becomes a list of problems rather than a story. This is not a critique of clinicians. It is a critique of a system that expects them to absorb societal trauma without acknowledging it. The pandemic did not just create more patients. It created fewer clinicians with capacity for complexity. The post Covid baseline is therefore bidirectional. It shapes those who seek care and those who provide it. Older Adults as the Cultural Canary If there is a group that absorbed more of the post Covid baseline than anyone else, it is older adults. They lost weak ties, daily structure, embodied meaning, and social monitoring all at once. For many, routines evaporated and did not return. Choirs shrank. Card games dissolved. Senior centers reopened at half strength. Participation became conditional and then optional and then minimal. For older adults, social life is not recreational. It is regulatory. It maintains cognitive function, mood, mobility, appetite, and orientation. When social worlds collapse, bodies follow. Decline does not scream, it accumulates. Medicare was not built for this. It was not designed for prolonged social erosion. It was built for acute events, discrete diagnoses, episodic interventions, and reactive care. It has codes for strokes and hospitalizations and joint replacements. It has no codes for meaning, dislocation, or prolonged isolation. The post Covid baseline does not fit a billing category, so it does not exist. Cannabis enters aging for reasons that are rarely discussed honestly. It is not only for pain or sleep or appetite. It is for easing the friction of a life that has quietly lost structure. It is for softening the dread of unstructured time. It is for making discomfort tolerable enough to function. Sometimes it works. Sometimes it merely delays reckoning. Both are adaptations to a world that has stopped scaffolding older adults. The indictment here is not against older adults. It is against a society that expects them to build their own social infrastructure without tools, budgets, or mobility. If young adults lost events and networks during the pandemic, older adults lost the environments that made life coherent. Where Cannabis and the ECS Fit in the Post Covid Baseline Cannabis sits inside the post Covid baseline as both coping strategy and physiological instrument. It is neither inherently solution nor inherently distraction. It is a modulator. For some, cannabis restores sleep that stress has fractured. For others, it reduces the bodily noise of chronic vigilance enough to re-enter social life. For others, it pulls pain back into the background where it once lived before isolation made it loud. The endocannabinoid system explains why cannabis is so versatile here. It does not target one symptom, it tunes networks. Mood, sleep, pain, appetite, immune tone. These are the exact domains the post Covid baseline disturbs. It is not surprising that cannabis use increased during and after the pandemic. It is surprising that we pretend not to understand why. The risk is in confusing relief with repair. Cannabis can lower the volume of symptoms long enough for people to function. It cannot rebuild weak ties, redesign Medicare, or reverse long Covid. It is a tool, not a world. The opportunity is in using cannabis deliberately inside a broader architecture of recovery rather than as a solitary intervention. That requires clinicians who can ask the right questions and patients who can answer them without fear of judgment. It also requires acknowledging that the post Covid baseline is not an individual failure, but a societal one. What to Do with a Baseline You Did Not Choose The hardest part of the post Covid baseline is that it arrived without consent. People did not choose to become less social, less rested, less flexible, less optimistic, or more symptomatic. The baseline shifted and the organism adapted. The good news is that baselines are not destiny. They are just defaults. They can be examined, questioned, modified, and rebuilt. The first step is to stop treating them as personality traits. When someone says โ€œI am just this way now,โ€ they are often naming resignation, not identity. Clinically, there are leverage points. Small social re-entry, not for entertainment but for regulation. Sleep routines that respect nervous system timing rather than caffeine and despair. Cannabis used with intention rather than autopilot. Care sought before crisis rather than after it. Conversations with clinicians that include stories, not just symptoms. None of this returns us to a pre-pandemic world. There is no return. There is only forward movement with better tools. The post Covid baseline is not the end of the story. It is the setting. What people do with it depends on whether they recognize it as malleable. The organism is built to adapt. Society is slower. Medicare is even slower. Cannabis is just one instrument among many. But the body listens to all instruments at once. The question for the coming decade is whether the systems that surround the body will learn to listen too.   FAQS about the new Post-COVID Baseline 1. What is the post Covid baseline? The post Covid baseline refers to the new default state many people settled into after prolonged pandemic stress, disruption, and uncertainty. It is not a disease, but a shift in nervous system regulation, social stamina, and symptom tolerance. People often notice more fatigue, lighter sleep, and less capacity for social engagement. Because it developed gradually, many mistake it for aging or personality change. Naming it helps clinicians and patients respond more intelligently. 2. How does the post Covid baseline affect mental health? The post Covid baseline often amplifies anxiety, low mood, irritability, and cognitive fatigue. Prolonged vigilance trains the nervous system to stay partially activated, even when danger has passed. This makes rest less restorative and stress more persistent. Many people feel emotionally โ€œflatโ€ rather than acutely distressed. That subtlety is why it often goes unaddressed. 3. Why do social interactions feel harder after Covid? Social life became cognitively expensive during the pandemic, and that cost did not fully reset. Reduced practice, ongoing uncertainty, and diminished weak ties all contribute. In the post Covid baseline, people tire faster in public settings and require more recovery afterward. This is not antisocial behavior, it is a nervous system adaptation. With gradual reentry, capacity can often be rebuilt. 4. What are weak ties and why do they matter for health? Weak ties are casual social connections like neighbors, classmates, or familiar staff at local places. They provide social buffering and early detection of change. When weak ties disappeared during the pandemic, subtle health declines went unnoticed longer. This delayed recognition affects both mental and physical health. Older adults are particularly vulnerable to this loss. 5. How did Covid change healthcare-seeking behavior? The pandemic normalized self-triage, home monitoring, and delayed care. In the post Covid baseline, many people wait longer before seeing clinicians. This results in later-stage presentations and more complex symptom patterns. While understandable, this delay can increase health risks. Early conversations often lead to simpler interventions. 6. What is the relationship between long Covid and the post Covid baseline? Long Covid is a more concentrated version of baseline disruption. It features persistent symptoms that do not fully resolve after infection. The post Covid baseline applies more broadly, including people without clear long Covid diagnoses. Both involve nervous system dysregulation and prolonged adaptation. Care requires patience, nuance, and flexibility. 7. How does the nervous system play a role in post Covid symptoms? The nervous system governs threat detection, rest, sleep, and symptom perception. During prolonged uncertainty, it remains partially activated. This leads to fatigue, sleep disruption, and heightened symptom awareness. The post Covid baseline reflects this ongoing activation. Calming the nervous system is often central to recovery. 8. Where does cannabis fit into the post Covid baseline? Cannabis interacts with the endocannabinoid system, which regulates mood, sleep, pain, and immune tone. In the post Covid baseline, cannabis may reduce symptom intensity and support function. Used thoughtfully, it can be helpful. Used indiscriminately, it may mask deeper issues. Clinical guidance improves outcomes. 9. Why were seniors affected more by post Covid changes? Older adults lost routine, social monitoring, and embodied meaning during the pandemic. Many of those supports never fully returned. Because social life regulates cognition and mobility in aging, decline accelerated quietly. Medicare is poorly designed to address this kind of erosion. Seniors became the earliest signal of systemic strain. 10. Can the post Covid baseline be improved? Yes, baselines are defaults, not destinies. With intentional social reentry, nervous system support, sleep optimization, and thoughtful care, many people improve. Cannabis may play a role when used deliberately. The key is recognizing the baseline shift rather than resigning to it. Awareness creates agency. [...] Read more...
January 6, 2026How Mindless Parts Create Intelligent Wholes, and What That Means for Your Health 5 Stunning Ways Emergent Systems in Biology Shape Your Life What You’ll Learn in This Post โ– Why a flock of starlings is smarter than any single bird, and what that reveals about your own body โ™ฆ๏ธŽ How slime mold with no brain outperforms human engineers solving complex problems โ– The three simple rules that turn chaos into breathtaking coordination โ™ฆ๏ธŽ What “emergence” teaches us about healing, balance, and the hidden intelligence of living systems โ– Why understanding emergent systems in biology might just change how you think about your health Table of Contents Swarm Intelligence: When the Colony Knows What No Ant Could Know The Wisdom Without a Thinker: Flocks, Schools, and the Beauty of Simple Rules Slime, Solve, Succeed: When Single Cells Outsmart Engineers From Cells to Selves: The Emergence of You The Quiet Orchestration Beneath Awareness Emergent Systems All Around Us: Traffic, Markets, and the Grammar No One Wrote Consciousness: The Hard Problem and the Humble Mystery Why Emergence Matters for Your Health: Restoring the Conversation 10 FAQ About Emergence Returning to the Murmuration: A Closing Reflection Before we talk about your body, start with a sky full of rules that somehow become beauty. At dusk, along the wetlands of Rome, something impossible happens. Thousands of starlings rise together, swirling in ribbons across the sky. They fold and stretch, contract and bloom, a single organism made of countless wings. No conductor. No choreographer. No bird in charge. And yet: perfection. A murmuration so fluid it seems rehearsed by something with a mind far larger than any single starling could possess. This is emergence. And once you see it, you cannot unsee it. Emergent systems in biology are everywhere, hiding in plain sight. They appear when simple parts, following simple rules, give rise to behaviors and patterns that no individual component could produce or predict. The whole becomes something the parts never learned to be. A billion small yeses make a single enormous yes. What does this have to do with your health, your healing, your life? More than you might imagine. Because you, too, are an emergent system. Your brain, your immune response, your capacity to feel joy or sorrow or that odd melancholy on Sunday evenings, none of it lives in any single cell. It arises from the conversation between them. Let’s take a closer look at how mindless parts become masterful wholes. Takeaway: In emergent systems, the intelligence lives in the relationships, not the parts. Now zoom in from the sky to the ground, and watch what โ€œno leaderโ€ looks like in the dirt. Swarm Intelligence: When the Colony Knows What No Ant Could Know Consider the humble ant. Small brain. Limited vision. No strategic planning committee. And yet ant colonies perform feats of collective intelligence that rival human engineering. Harvester ants in the Arizona desert don’t just forage randomly. They adjust their foraging rates based on humidity, temperature, and food availability, effectively forecasting local weather patterns and responding to ecological shifts in real time. No single ant monitors the barometer. No ant attends a briefing. The colony simply knows because the interactions between ants encode information no individual ant possesses. How? Through stigmergy, a term that sounds like a medical diagnosis but actually describes something elegant: indirect coordination through environmental signals. An ant leaves a pheromone trail. Another ant follows it. The trail strengthens or fades depending on success. What emerges is a distributed decision-making system, flexible, resilient, and astonishingly efficient. Bees take this further. When a honeybee swarm needs a new home, scout bees fan out to evaluate potential nest sites. They return and perform the waggle dance, a figure-eight shimmy that encodes direction, distance, and enthusiasm. Other scouts visit the advertised locations. Debates ensue. Dances compete. And eventually, through a process resembling democratic deliberation, the swarm reaches consensus on an optimal site. Extensive research by biologists such as Deborah M. Gordon shows that ant colonies allocate tasks and adapt through local interactions alone, without central control Researchers have found that bee swarms choose nest locations with nearly 80% accuracy, often outperforming expert human panels given the same options. The swarm is smarter than any bee. Follow the leader? There is no leader. Just a web of signals, responses, and feedback loops that add up to something uncanny. This is the signature of emergent systems in biology: intelligence without a central executive. Coordination without command. Order rising from chaos like steam rising from a cup of tea you forgot you made. Takeaway: The colony โ€œknowsโ€ by distributing information across countless small interactions. The Wisdom Without a Thinker: Flocks, Schools, and the Beauty of Simple Rules If you’ve ever watched a flock of birds wheel across an autumn sky, you’ve witnessed one of nature’s most elegant magic tricks. Hundreds of individuals, moving as one. No collisions. No hesitation. Just flow. For years, scientists assumed there must be a leader bird, some avian air traffic controller calling the shots. But when researchers finally modeled flocking behavior in the 1980s, they discovered something startling: you only need three rules. Separation: Don’t crowd your neighbors. Alignment: Steer toward the average heading of those nearby. Cohesion: Move toward the average position of the group. That’s it. No brain. No plan. No problem. From these three constraints, the entire ballet emerges. The rippling, shape-shifting coherence of a murmuration is not orchestrated. It is computed, moment by moment, by each bird responding only to its immediate surroundings. The flock is an emergent property, a pattern that exists at a level of organization the individual birds cannot perceive. Fish do something similar. Schooling behavior, that shimmering, synchronized evasion you see when a predator approaches, follows comparable local rules. Each fish adjusts based on what its nearest neighbors are doing. When a shark lunges, the school splits and reforms like a living liquid, confounding the predator without any fish understanding the strategy. This is not intelligence in the way we usually mean it. No fish is thinking about predator evasion tactics. But the school, as a system, behaves intelligently. The wisdom lives in the web. And here is where emergence starts to feel personal. Because your body is not so different. Your neurons fire locally. Your immune cells patrol their territories. Your endocrine glands release their signals into the bloodstream, not knowing who will receive them. And yet you feel. You think. You remember the name of your third-grade teacher while simultaneously digesting lunch and regulating your core temperature. Simple rules. Surprising results. The whole knows things the parts never learned. Takeaway: Coordination can emerge from three constraints and a crowd paying attention locally. Then comes the strangest lesson: even one cell, given the right setup, can look like a city planner. Slime, Solve, Succeed: When Single Cells Outsmart Engineers Now let us speak of slime mold. Specifically, Physarum polycephalum, a yellow, blobby organism that looks like something you’d scrape off a log and is, technically, a single cell. It has no brain. It has no neurons. It has, by any reasonable measure, no business solving complex optimization problems. And yet. In 2010, researchers at Hokkaido University in Japan placed oat flakes on a moist surface in a pattern mimicking the major cities around Tokyo. They introduced Physarum to the setup and watched. The slime mold did what slime molds do: it spread outward, exploring, pulsing, seeking nutrients. But then something remarkable happened. Over the course of hours, it pruned its network, withdrawing from inefficient pathways, reinforcing the most direct routes between food sources. When the dust settled, the slime mold had recreated, almost exactly, the Tokyo rail system. A network that took human engineers decades to design and billions of yen to optimize had been replicated by a brainless blob following nothing but chemical gradients and internal feedback loops. This was not a fluke. Subsequent experiments showed Physarum could solve mazes, find the shortest path between two points, and even anticipate periodic events based on past experience. The organism has no memory organ, no processing center, no sense of self. It simply computes through its body, using the physics of flow and the chemistry of attraction to arrive at solutions that would make a logistics company weep with envy. Slime, solve, succeed. It sounds like a motivational poster for organisms without ambition, but it captures something profound about emergent systems in biology. Intelligence, or at least intelligent behavior, does not require a mind. It requires the right kind of interactions, the right feedback, the right conditions for patterns to crystallize from chaos. And if a single-celled organism can solve Tokyo’s transit problem, what might the trillions of cells in your body be solving without your conscious awareness? Collective behaviour and swarm intelligence in slime moulds (FEMS Microbiology Reviews) Takeaway: Intelligent behavior can arise from feedback loops and constraints, even without neurons. Now widen the lens from networks in nature to the network that is you. From Cells to Selves: The Emergence of You Here is a question that should keep you up at night, in the best possible way: How did you become you? Not in the existential, what-is-my-purpose sense. In the literal, biological sense. You started as a single fertilized cell. One cell, with one genome, carrying instructions but no identity. That cell divided. And divided again. And somewhere along the way, identical genetic copies began differentiating into wildly different fates. Some became neurons. Some became bone. Some became the lining of your gut, quietly doing thankless work for decades. No cell “decided” to become a liver cell. No committee assigned roles. The differentiation emerged from cascades of molecular signals, feedback loops between neighboring cells, gradients of proteins washing across developing tissues like tides shaping a shoreline. The embryo organized itself, sculpting kidneys and kneecaps from the same raw material, guided not by a blueprint reader but by the logic of emergence. This is embryogenesis, and it remains one of the most astonishing examples of emergent systems in biology. From simplicity, staggering complexity. From uniformity, the full orchestra of human anatomy. The whole orchestrates itself into existence. The brain and immune system communicate through dense intercellular networks, illustrating how multiple systems co-regulate homeostasis across levels Your brain is another case study in emergent wonder. A hundred billion neurons, each one a fairly simple electrochemical switch, connected by a hundred trillion synapses. No single neuron understands language. No single neuron appreciates a sunset or regrets a poorly timed joke. But you do. Consciousness, that slippery phenomenon that philosophers have argued about for millennia, arises from the interactions of cells that, individually, are about as sentient as a thermostat. How does the meat become the mind? No one knows for certain. But emergence offers a framework: the properties of the whole are not reducible to the properties of the parts. Your experience of tasting chocolate or missing someone you love is not located in any particular neuron. It lives in the pattern, the dynamic, the conversation. And then there is your immune system, perhaps the most underrated emergent masterpiece in your body. Billions of white blood cells patrol your tissues, each one following local rules, responding to molecular signals, attacking what seems foreign and sparing what seems self. No cell knows the full threat landscape. No cell has access to a master list of pathogens. And yet the system learns. It remembers. It adapts. It defends you against invaders it has never encountered, using a distributed intelligence that rivals any swarm. Your immune response is not commanded from above. It emerges from below, a democracy of cells voting with cytokines instead of ballots. This same distributed logic explains why chronic conditions rarely stay neatly contained. Pain, sleep disruption, mood instability, and inflammation often move together, because they arise from shared regulatory loops rather than isolated failures (a pattern we see repeatedly across the conditions we treat) Takeaway: Your โ€œselfโ€ is not stored in a single place, it emerges from coordinated activity across systems. This is where the metaphor turns clinical: not parts obeying orders, but systems negotiating balance. The Quiet Orchestration Beneath Awareness What begins to emerge, if you’ll pardon the recursion, is a picture of the body as a conversation rather than a machine. Not a set of parts executing orders from a central command, but a network of networks, each layer influencing and being influenced by the others. Balance is not imposed. It is negotiated, moment by moment, through signals most of us never notice. Consider how systems within you communicate across domains. A signal in one tissue ripples outward, modulating activity in distant organs. Stress in the gut echoes in the brain. Inflammation in one location whispers to the immune cells elsewhere. Sleep quality shapes mood shapes metabolism shapes sleep quality. The feedback loops are so densely interconnected that isolating any single cause becomes an exercise in frustration. This is not a flaw in your biology. It is the signature of an emergent system, one that achieves resilience and adaptability precisely because no single component is in charge. Disrupt one pathway, and others compensate. Overwhelm the compensatory mechanisms, and dysfunction appears, not in one place, but across the web. Healing, in this light, is not about fixing a broken part. It is about restoring the conditions under which the system can find its own balance again, an approach that quietly shapes how we think about care at CED Clinic. The body wants to cohere. It wants to regulate. It wants, in some deep and wordless way, to return to the dynamic equilibrium that emergence makes possible. We are only beginning to understand the specific regulatory systems that maintain this equilibrium, the ones that modulate pain, mood, appetite, sleep, and immune function through distributed signaling networks. But understanding emergence helps us appreciate why such systems matter: they are the grammar of the body’s internal conversation, the syntax that allows trillions of cells to speak a coherent language. Takeaway: Health behaves like an emergent negotiation, and symptoms often cluster because the loops are shared. Emergent Systems All Around Us: Traffic, Markets, and the Grammar No One Wrote Emergence is not confined to biology. Once you learn to see it, you find it everywhere humans gather and interact. Traffic Consider traffic. Each driver follows simple, self-interested rules: get where you’re going, don’t crash, maybe curse at the guy who cut you off. No driver intends to create a traffic jam. No driver wants to participate in that maddening stop-and-go wave that propagates backward through a highway for no apparent reason. And yet the jam emerges, a phantom bottleneck born from the mathematics of too many local decisions cascading through a constrained system. Traffic engineers have learned they cannot solve congestion by focusing on individual drivers. They must address the emergent dynamics, the feedback loops, the tipping points where smooth flow crystallizes into gridlock. The jam is not a thing. It is a pattern, and patterns require pattern-level thinking. Markets Economies work similarly. No individual transaction creates inflation. No single investor causes a market crash. But aggregate the decisions of millions of buyers, sellers, savers, and speculators, and macroeconomic phenomena emerge that no participant intended or foresaw. Recessions are not planned. They are not the fault of any particular actor. They are emergent properties of a system too complex for any single mind to comprehend, let alone control. Language And then there is language, perhaps the most intimate emergent system of all. You are reading these words, parsing grammar, extracting meaning. But no one designed English. No committee voted on syntax. No authority decreed that subjects precede verbs or that adjectives stack in a particular order (it’s opinion-size-age-shape-color-origin-material-purpose, in case you were wondering, and you knew it intuitively without ever being taught). Language evolves through use. Millions of speakers, each following rough conventions, each improvising at the edges, collectively generate a structure of breathtaking complexity. Children absorb it without instruction. Poets bend it without breaking it. The grammar lives in the community, not in any individual skull. Simple rules. Local interactions. Global patterns no one authored. The signature of emergence, written across every domain of human experience. Takeaway: When you see patterns nobody โ€œdesigned,โ€ you are often looking at emergence. Even when the stakes are survival, coordination can look like a bridge built out of bodies. Consciousness: The Hard Problem and the Humble Mystery We arrive now at the deepest question emergence can pose: What about awareness itself? You are reading these words. You know you are reading them. There is something it is like to be you, right now, in this moment. The redness of red. The ache of longing. The peculiar flavor of a Tuesday afternoon. Philosophers call this qualia, the subjective texture of experience, and no one has satisfactorily explained how it arises from electrochemical events in neural tissue. This is the hard problem of consciousness, and emergence does not solve it. But emergence reframes it. Instead of asking where consciousness is, we might ask what conditions allow it to emerge. Instead of hunting for a soul in the synapses, we might recognize that awareness could be a property of a certain kind of complex, self-referential, dynamically integrated system. Your brain is such a system. It not only processes information but processes information about its own processing. It models the world and models itself modeling the world. The loops fold inward until something strange happens: the system becomes aware that it exists. Is this emergence? Perhaps. Or perhaps consciousness reveals the limits of the concept, the horizon beyond which our frameworks fail to illuminate. Either way, the lesson is humility. Emergent systems in biology teach us that the universe is capable of surprises, that wholes can be more than sums, that the simple can become astonishing without asking permission from reductionist explanations. You are such an astonishment. Never forget that. Takeaway: Emergence may not โ€œsolveโ€ consciousness, but it helps us ask sharper, humbler questions. Why Emergence Matters for Your Health: Restoring the Conversation So what does any of this mean for you, sitting in a body that aches or a mind that races or a life that feels, some days, like too many disconnected pieces? It means this: healing is not always about finding the broken part and fixing it. Sometimes, often, healing is about restoring the conditions under which your body’s emergent intelligence can reassert itself. The system wants to regulate. The conversation wants to cohere. Your job, and the job of anyone helping you heal, is to remove obstacles and provide support so the self-organizing magic can do what it does. I think of a patient I’ll call Daniel. He came to me with chronic back pain, the kind that had resisted years of interventions, physical therapy, injections, medications that dulled the edges but never touched the center. He was exhausted. He was irritable. His sleep was fractured, his relationships strained, his work suffering. Pain had become the organizing principle of his life, and everything else orbited around it like debris around a black hole. We began working together, and what unfolded was not a single fix but a cascade. As Daniel’s physical pain eased, even modestly, his sleep improved. Better sleep softened his emotional volatility. With more emotional bandwidth, he reconnected with his partner, started showing up more fully at work, began exercising again for the first time in years. Exercise further reduced his pain. Reduced pain deepened his sleep. The feedback loops that had been spiraling downward began spiraling upward instead. Emergent states like health arise from multi-scale network interactions across physiology and environment, not from isolated parts: Emergent States Resulting From Adaptive Social and Biological Network Interactions (PMC article) No single intervention saved Daniel. The improvement emerged from the interactions between interventions, each small gain amplifying the others. His body remembered how to balance. His life remembered how to cohere. The whole system found its way back to something like harmony. This is what emergence looks like in clinical practice, not a single intervention, but a system gently nudged back into coherence. For patients who need guidance navigating that process, this is the kind of work we do. And it is why I have grown so interested in the regulatory systems that modulate multiple domains simultaneously, the ones that influence pain, mood, inflammation, sleep, and stress through distributed signaling networks. The endocannabinoid system is one such network, a web of receptors and molecules that fine-tunes neural and immune activity throughout the body. (For more on how this system works, see our overview: CED Clinic FAQ โ€“ Endocannabinoid System Overview) Understanding emergence helps explain why interventions targeting such systems can produce effects that seem disproportionate to the input. You are not adding a single ingredient. You are shifting the conditions under which the entire system operates. When the grammar of the body’s conversation improves, the whole dialogue changes. Takeaway: In health, small improvements can cascade because feedback loops amplify what you change. 10 FAQ About Emergence 1. What are emergent systems in biology? Emergent systems in biology refer to complex patterns or behaviors that arise when simple components interact according to basic rules, producing outcomes that no individual part could achieve alone. Think of a murmuration of starlings or the human immune system: the whole displays intelligence that no single bird or cell possesses. This concept helps explain how your body coordinates trillions of cells without a central command center issuing orders. It is one of nature’s most elegant tricks, and honestly, it makes middle management look a bit unnecessary. 2. How does emergence explain consciousness? Consciousness remains one of science’s great mysteries, but emergence offers a useful framework for thinking about it. Rather than searching for awareness in a single neuron or brain region, emergence suggests that consciousness arises from the dynamic interactions of billions of neurons working together. Your brain not only processes information but processes information about its own processing, creating loops of self-reference that may give rise to subjective experience. Whether this fully explains the “hard problem” of consciousness is still debated, but emergence at least gives us a vocabulary for asking better questions. 3. Can slime mold really solve complex problems? Remarkably, yes. Physarum polycephalum, a single-celled organism with no brain or nervous system, has been shown to solve mazes, find optimal paths between food sources, and even replicate the Tokyo rail network when given the right setup. It accomplishes this through internal feedback loops and chemical gradients, effectively computing solutions through its own body. The slime mold doesn’t “think” in any way we recognize, yet its behavior is demonstrably intelligent, a humbling reminder that cognition may be more about structure than substance. 4. What is swarm intelligence and how does it work? Swarm intelligence describes the collective behavior that emerges when many simple agents, like ants, bees, or birds, interact according to local rules without central coordination. Each individual responds only to its immediate neighbors or environment, but the aggregate result is sophisticated problem-solving, decision-making, or navigation. Ant colonies optimize foraging routes, bee swarms select ideal nest sites, and fish schools evade predators with uncanny precision. No leader directs the action; the intelligence lives in the web of interactions itself. 5. How do emergent systems relate to human health? Your body is an emergent system par excellence. Trillions of cells communicate through chemical signals, feedback loops, and regulatory networks to maintain balance across countless physiological processes. When these systems function well, health emerges naturally; when they become disrupted, dysfunction can ripple across multiple domains. Understanding this helps explain why holistic approaches, those addressing sleep, stress, nutrition, and movement together, often succeed where single-target interventions fail. 6. What is the endocannabinoid system’s role in emergence? The endocannabinoid system is a distributed signaling network that modulates pain, mood, appetite, sleep, immune function, and more through receptors found throughout the body. It exemplifies emergent regulation: no single receptor or molecule controls the whole, but their interactions produce system-wide effects. This is why interventions targeting the endocannabinoid system can influence multiple health domains simultaneously, shifting the conditions under which the body’s self-organizing intelligence operates. 7. Why do birds flock in murmurations? Murmurations arise from each bird following three simple rules: avoid crowding neighbors, align with their direction, and move toward the group’s center. No bird orchestrates the pattern; it emerges spontaneously from local interactions. Scientists believe flocking provides protection from predators and helps birds locate food and roosting sites. The visual result is breathtaking, a living river of wings that seems choreographed by some vast, invisible conductor. 8. How can understanding emergence improve medical treatment? Recognizing the body as an emergent system shifts the focus from fixing isolated parts to restoring conditions for self-organization. Chronic conditions often involve multiple interconnected dysfunctions, and addressing them requires thinking in terms of feedback loops, not just broken components. A patient whose pain affects sleep, mood, and relationships may improve dramatically when interventions cascade positively through these domains. Emergence invites clinicians to think like ecologists, tending the whole garden rather than pulling single weeds. 9. What everyday examples demonstrate emergence? Traffic jams emerge from individual driving decisions even though no driver intends to create gridlock. Economic recessions arise from countless transactions without any person planning a downturn. Language evolves through collective use without a committee designing grammar. Even your morning coffee shop has emergent properties: the culture, vibe, and unwritten rules develop from customer and staff interactions, not from a corporate manual. Once you see emergence, you see it everywhere. 10. Is emergence the same as complexity? Not quite, though they’re related. Complexity refers to systems with many interacting parts, while emergence specifically describes the novel properties or behaviors that arise from those interactions, properties not predictable from the parts alone. A pile of sand is complex but not particularly emergent; a pile of neurons becomes a mind. Emergence is complexity’s surprise party, the moment when quantity transforms into something qualitatively new. Now return to the beginning, and let the ending feel like an ending. Returning to the Murmuration: A Closing Reflection Let us end where we began, at dusk, with starlings. They are still rising, still swirling, still performing their impossible ballet against the fading Roman sky. No bird knows the shape of the flock. No bird perceives the beauty it helps create. And yet the beauty is real. The intelligence is real. The pattern is as genuine as any individual wing. You are both the bird and the flock. You are the neuron and the thought, the cell and the self, the simple rule and the surprising result. The emergence that created you is the same emergence that animates ant colonies and slime molds and the traffic outside your window. You are part of something larger than you can perceive from the inside, and that something is not separate from you. It is you, in the only way you can be. This is not mysticism. It is biology, taken seriously. It is the recognition that complexity is not a problem to be solved but a phenomenon to be respected. And it is an invitation to approach your own health, your own healing, your own life, with a certain wonder. The whole knows things the parts never learned. Trust the conversation. Support the balance. And when you watch the starlings next, remember: you are watching yourself. Takeaway: The whole can carry meaning the parts cannot see from the inside. [...] Read more...
January 5, 2026Sponsored Post Educational Content Physicianโ€™s Editorial Preface I occasionally permit clearly labeled sponsored educational content on this site when the topic intersects with areas of active public confusion or regulatory ambiguity, and when the material can be presented without product endorsement or medical recommendation. The purpose of allowing such content is to support informed discussion, risk awareness, and literacy around evolving cannabis-related markets that patients and clinicians increasingly encounter in real-world settings. Sponsored placement does not influence my clinical views, does not substitute for peer-reviewed evidence, and does not imply that any product discussed is appropriate, safe, or recommended for individual use. On this page Sponsored educational content Core clarification Structural factors shaping the THC-A flower market Clinical and public health considerations Closing perspective Editorial disclosure   SPONSORED EDUCATIONAL CONTENT THC-A Flower: Market Structure, Regulatory Ambiguity, and Practical Risk Considerations The commercial market for THC-A flower has expanded rapidly under the U.S. hemp framework, driven by regulatory interpretation, agricultural practices, and consumer demand. Although often presented as distinct from THC-dominant cannabis, THC-A flower occupies a legally and clinically ambiguous space that warrants careful explanation. This article provides a non-promotional overview of the factors shaping the THC-A flower market and highlights considerations relevant to safety, legality, and consumer understanding. It does not constitute medical advice or product endorsement. Core clarification THC-A, or tetrahydrocannabinolic acid, is the naturally occurring precursor to THC found in raw cannabis flower. When heated, THC-A undergoes decarboxylation and converts into delta-9 THC, the compound responsible for intoxication and impairment. As a result, inhaled or vaporized THC-A flower can produce psychoactive effects similar to THC-dominant cannabis, regardless of how it is marketed. This biochemical reality underlies many of the legal, clinical, and safety considerations associated with the category. Structural Factors Shaping the THC-A Flower Market Regulatory interpretation and enforcement variability Federal hemp law defines legality by delta-9 THC concentration prior to heating. However, state-level statutes, agency guidance, and enforcement priorities vary widely. Some jurisdictions permit the sale of THC-A flower under hemp classifications, while others restrict or actively challenge it. This variability directly affects availability, distribution, and market stability. Cultivation and production practices THC-A flower products vary substantially based on genetics, cultivation methods, harvest timing, and post-harvest handling. These factors influence cannabinoid composition, consistency, and classification, contributing to heterogeneity within the marketplace. Distribution and retail infrastructure Differences in distribution networks, shipping policies, and retail access shape how products move between regions. These logistical factors contribute to uneven availability and regional pricing differences. Supply dynamics and pricing Pricing reflects a combination of agricultural yield, regulatory pressure, production costs, and consumer demand. As with other emerging cannabinoid categories, pricing remains sensitive to changes in legal interpretation and enforcement trends. Transparency and documentation standards The availability and quality of batch-specific Certificates of Analysis influence consumer trust and market credibility. Testing practices and disclosure standards vary across suppliers, and generalized claims should not be assumed to reflect individual product batches. Clinical and Public Health Considerations From a clinical and public health perspective, several issues are central to understanding THC-A flower products: Heated THC-A produces THC and may impair cognition, coordination, and reaction time. Use may result in positive THC metabolite findings on standard drug tests. Inhalation of combusted plant material carries known respiratory risks independent of cannabinoid content. Compliance with federal hemp definitions does not guarantee protection under state or local law. Products should be avoided during pregnancy or breastfeeding and kept inaccessible to children. Consumers should understand how to review batch-specific testing for contaminants such as pesticides, heavy metals, residual solvents, and microbial growth. Closing Perspective The THC-A flower market reflects the tension between biochemical reality, regulatory language, and commercial innovation. While marketed within hemp frameworks, these products can behave pharmacologically like THC-containing cannabis when used as intended. Clear understanding of this distinction is essential for informed decision-making. Educational discussion of this market should prioritize transparency, risk awareness, and regulatory nuance rather than promotional framing. Editorial Disclosure This article is sponsored by a commercial entity. The publisher did not independently test or verify products discussed in the broader THC-A marketplace. Publication of this content does not imply medical endorsement or recommendation. SPONSORED EDUCATIONAL CONTENT   This page is educational. For medical guidance, consult a licensed clinician who can assess your individual circumstances, medications, and risks. [...] Read more...
December 12, 2025The JAMA Cannabis Review: A Physicianโ€™s Reality Check on Risk, Evidence, and Misinterpretation: what it’s really saying This week, the latest JAMA cannabis review is getting passed around like a verdict. It is not one. It is a summary of an uneven body of research, written for clinicians, and it deserves to be read the way we read any review: with attention to what it can support, and equal attention to what it cannot. What follows is my walk-through from my critical POV. The goal is not to cheerlead for cannabis, nor is my aim to scold it. The goal is to keep the science honest, and keep the conclusions proportional. We live in times where media cares less about empowering critical thinking in its readers with even-handed delivery of scientific info, and more cherry-picking studies to suit a particular readership.ย  This isn’t concerning of itself. Science has been delivering evidence on opposing sides of most issues, forever. The troubling part is when nobody in media is presenting the other side, Thanks for learning with me. Here we go: Quick summary If you only read one paragraph, read this one. The review is useful, but it is not definitive. The biggest interpretive mistakes happen when observational associations are treated like causal proof, when โ€œcannabisโ€ is treated as a single standardized intervention, and when modest average effects are mistaken for no clinical value. In practice, the right response is neither hype nor fear. It is screening, better exposure definitions, careful dosing, thoughtful route selection, and monitoring function over time. To read Dr Caplan’s takeaways for clinicians: click here Source article I’m reviewing Therapeutic Use of Cannabis and Cannabinoids: A Review of the Evidence Journal: JAMA (Journal of the American Medical Association) Authors: Kevin P. Hill, MD; Deepak Cyril Dโ€™Souza, MD; Susan L. Weiss, PhD; and colleagues Year: 2025 When I refer to โ€œthe JAMA reviewโ€ below, I mean that specific article. 1) Why this is not a verdict This is not a randomized controlled trial, and it does not present new patient-level data. It is a clinical review, which means it synthesizes a large, messy literature and tries to translate it into something clinicians can hold in their hands. That is a legitimate goal, and sometimes a necessary one. The limitation is baked into the format. In a review, the story you walk away with depends heavily on what the authors emphasize, how they group studies, which endpoints they treat as โ€œmeaningful,โ€ and what they choose to call โ€œinsufficient.โ€ All of that can be reasonable, and still be incomplete. I often think of narrative reviews like a map drawn with a thick marker. You can see the coastlines. You can spot the mountains. But you cannot use it like turn-by-turn navigation. When people treat this kind of paper like GPS, overconfidence follows, and that is where risk interpretation gets distorted. This matters because two very different things can be true at the same time. Observational signals can be worth taking seriously, and still be far from causal confirmation. Trial results can be modest on average, and still include meaningful benefits in a subset of patients, especially when dosing, products, and endpoints are misaligned with real-world use. This is why โ€œinsufficient evidenceโ€ should not be translated as โ€œno benefit.โ€ It usually means the available studies cannot support high-confidence conclusions across a wildly variable set of products and use patterns. Related: A deeper explanation of the endocannabinoid system 2) What the review gets right A fair critique starts with what the review does well. First, it repeatedly signals a truth that still gets ignored in public debate: โ€œcannabisโ€ is not one standardized medication. That matters for both efficacy and safety. Second, it draws a meaningful line between pharmaceutical-grade cannabinoids and the variable products people actually buy and use. Standardization makes trials interpretable. Variability makes results noisier. That is not a moral statement. It is a measurement statement. If we want stronger medical evidence, measurement has to improve. Third, it highlights real risk domains that deserve clinical seriousness, including higher-potency THC exposure in younger populations, and the reality that problematic use patterns can occur, including among people who began with symptom relief as their intention. Those are not comfortable conversations, but medicine is not supposed to avoid uncomfortable conversations. It is supposed to make them accurate, specific, and humane. The reviewโ€™s strongest contribution may be its tone of caution. In a field that swings between enthusiasm and alarm, caution can be stabilizing. The problem is when caution becomes blunt, and bluntness becomes a substitute for nuance. 3) The category problem: โ€œcannabisโ€ is not one exposure A large share of confusion in cannabinoid medicine comes from a basic category error. We use the word โ€œcannabisโ€ as if it names a single intervention. It does not. It names a family of exposures whose effects depend on composition, dose, route, timing, and the physiology of the person using it. If we studied โ€œfoodโ€ as a therapy, we would not lump oatmeal and buffalo wings into one category and conclude that โ€œfood has modest benefit.โ€ Cannabis research often does the equivalent. Low-dose balanced formulations and repeated exposure to high-potency concentrates are grouped under one umbrella. The average effect then looks smaller, less reliable, and harder to translate into patient care. The key variables are not exotic. They are basic pharmacology and basic clinical context: THC to CBD ratio, total dose, titration strategy, route of administration, onset kinetics, duration, time of day, and frequency. The person matters too: age, sleep debt, stress load, psychiatric vulnerability, cardiometabolic risk, medications, and goals of care. When studies do not measure these variables, true benefit signals get diluted, and risk signals get flattened into overly broad warnings. This is one reason cannabis research limitations are often measurement limitations, not proof that cannabinoid medicine lacks therapeutic relevance. It also makes comparisons to alternatives harder. Someone replacing nightly alcohol with a carefully titrated cannabinoid regimen is not in the same risk-benefit scenario as someone escalating high-potency inhaled THC throughout the day. But both may be counted as โ€œcannabis useโ€ in observational datasets. Related: Practical dosing, timing, and route considerations 4) Placebo, expectancy, and the blinding problem Many outcomes in cannabinoid studies are subjective: pain ratings, sleep quality, nausea, anxiety, spasticity. That does not make them weak. It makes them human. But subjective outcomes are also more sensitive to expectancy effects and placebo response. Placebo is often spoken about like a trick. In reality, placebo is physiology responding to expectation, context, and meaning. In symptom-driven trials, placebo response can be substantial. That means a โ€œmodestโ€ average effect can still translate into meaningful relief for a subset of responders, especially when the right endpoints are used. Then there is functional unblinding. THC can change perception and cognition in ways that make participants correctly guess they received the active drug. When that happens, patient-reported outcomes become partly pharmacology and partly expectation. This challenge is not unique to cannabinoids, but cannabis trials do not always quantify blinding integrity or incorporate it into interpretation. A scientist-level reading should ask: were responder thresholds reported, not just mean differences? Were outcomes chosen that reflect function, not only symptom scores? Was titration allowed, or was a fixed dose imposed that does not resemble real-world care? These questions do not weaken the science. They make it honest. They also guard against two opposite errors: overclaiming modest benefits as proof of robust efficacy, and dismissing modest benefits as โ€œjust placeboโ€ without asking whether a clinically meaningful subgroup is benefiting. Related: Cannabis and sleep, what evidence can and cannot show 5) Cardiovascular risk: what the data suggest, and what they cannot prove If you want to understand why this JAMA review is making waves, start here. Cardiovascular risk is the most headline-friendly part of the discussion, and it is also the easiest place for nuance to get crushed. The review cites observational findings in which frequent cannabis use, including daily inhaled use in some datasets, is associated with higher prevalence of cardiovascular diagnoses. That is a signal worth noticing. It is not a verdict. Observational signals are a reason to ask better questions, not a license to announce causality. Prevalence is description, not a timeline A common interpretive mistake is to treat prevalence differences as if they prove cannabis caused an event. Prevalence tells you two things travel together. It does not tell you which one came first, and it does not tell you what else came along for the ride. Hereโ€™s an analogy I use because it is simple and it stays true. If you observe that people carrying umbrellas have a higher prevalence of pneumonia, that association might be real, but umbrellas are not the cause. Umbrellas cluster with rain, cold exposure, crowding, and seasonality. In epidemiology, umbrellas become a proxy variable. Cannabis use can behave like an umbrella variable too. It may cluster with sleep disruption, chronic stress load, psychiatric comorbidity, tobacco co-use, alcohol patterning, stimulant exposure, and socioeconomic instability. If those variables are not measured well, or not measured at all, the โ€œcannabisโ€ variable starts absorbing them. โ€œDaily inhaled cannabisโ€ is not a single exposure In cardiovascular research, exposures are often measured precisely. Blood pressure is measured. LDL is measured. A1c is measured. Tobacco exposure, at its best, is quantified over time. Cannabis exposure is rarely measured with comparable fidelity in large population datasets. Most surveys rely on self-report and broad frequency categories. They often cannot capture THC dose, potency, route details, inhalation depth, combustion versus vaping, nicotine mixing, or product composition. The phrase โ€œdaily inhaled cannabisโ€ can represent profoundly different pharmacologic realities. One person may take a low-potency inhalation once nightly for sleep. Another may use high-potency concentrates repeatedly through the day. Another may be mixing cannabis with tobacco or nicotine products in ways that are not reliably disclosed or captured. When those exposures are treated as the same thing, interpretation becomes soft around the edges. Residual confounding is not a footnote, it is the main event Even when studies adjust for age, sex, and smoking status, residual confounding can remain substantial. The confounders most likely to distort cannabis and cardiovascular associations are often poorly measured: lifetime tobacco exposure rather than current smoking only, binge alcohol use, stimulant exposure, sleep debt, psychiatric illness, chronic stress, diet, physical activity, and healthcare access. This is where effect size matters. Modest risk ratios, even when statistically significant, are more vulnerable to residual confounding and measurement error. This is not an argument to ignore them. It is an argument to interpret them with humility, and to resist translating them into sweeping causal claims. Reverse causation is plausible Many datasets do not establish whether cannabis use precedes cardiovascular diagnosis or follows it. That matters. People change behavior after illness. Some increase cannabis use after a cardiac event because sleep is broken, pain is persistent, anxiety increases, or activity decreases. If cannabis use increases after diagnosis, cannabis can look like a risk factor even when it is partly a response to illness. That is reverse causation, and it cannot be fully addressed without longitudinal measurement and careful time sequencing. Clinical framing: risk is rarely binary The clinically useful questions are not โ€œdoes cannabis increase cardiovascular risk, yes or no.โ€ The useful questions are: in whom, under what conditions, at what dose, by what route, and relative to what alternative exposures? A patient substituting a carefully titrated cannabinoid regimen for nightly alcohol is in a different risk landscape than a young patient escalating high-potency inhaled THC while sleep deprived and co-using nicotine. Those two scenarios can collapse into the same โ€œdaily useโ€ category in an epidemiologic dataset, but they should not collapse in clinical care. So yes, the signals warrant screening and counseling. They warrant sober attention to route, potency, nicotine co-use, baseline cardiovascular risk, and the reasons a person is using cannabis in the first place. What they do not warrant is a blanket story that treats all cannabis use as a cardiovascular hazard. Related: Cannabis and heart health, what clinicians should watch for 6) Psychiatric risk, potency, and developmental vulnerability The psychiatric section of the review is important, and it is also the place where public discussion often becomes the least disciplined. The risk signals are real. They are also not evenly distributed across ages, formulations, or patterns of use. When nuance disappears, people walk away with statements like โ€œcannabis causes psychosisโ€ or โ€œcannabis is bad for mental health.โ€ Those phrases are too broad to guide a patient, and too blunt to represent what the evidence actually shows. Potency behaves like a dial A consistent pattern in psychiatric risk data involves higher-potency THC exposure. In certain observational cohorts, higher potency and more frequent use are associated with higher rates of adverse psychiatric outcomes. From a pharmacology standpoint, this should not surprise anyone. Potency is not a moral category. It is a dose category. It behaves like a volume dial. Turn it up and you increase the probability of unwanted effects, especially in vulnerable individuals. Clinically, I think about potency the way I think about alcohol content or benzodiazepine dose. Higher intensity changes risk. It changes impairment. It changes the likelihood of panic, paranoia, and destabilization in those who are prone to it. Adolescence is a distinct risk window The strongest psychiatric risk signals are concentrated in adolescents and young adults. The adolescent brain is still developing, and early initiation with high-frequency use appears to amplify risk, particularly in those with underlying vulnerability. That is a legitimate public health concern. It is also a mistake to treat adolescent recreational cohorts as interchangeable with adult therapeutic populations receiving clinician guidance and using lower doses for symptom relief. Those are different exposures, different developmental contexts, and often different baseline risks. Anxiety is likely bidirectional Anxiety and cannabis use commonly travel together in population datasets. The crucial question is directionality. Many anxious individuals use cannabinoids to self-regulate sleep, autonomic hyperarousal, or distress. Cannabis can also provoke anxiety, especially at higher THC doses, rapid-onset routes, or in those prone to panic. Both can be true simultaneously. Observational data cannot reliably disentangle cause from coping without time-stamped exposure measurement and careful adjustment for baseline anxiety severity. So โ€œassociated with anxietyโ€ should not be translated to โ€œcauses anxietyโ€ without stronger evidence. From a clinical standpoint, the actionable message is practical: screen for panic vulnerability, encourage titration, consider CBD-rich or balanced formulations when appropriate, and monitor response over time. Psychosis risk is concentrated, not universal Psychosis is rare but serious. Cannabis can precipitate psychotic symptoms in predisposed individuals, and the risk appears higher with early initiation, high-frequency use, and high-potency THC exposure. That pattern aligns with a vulnerability model, not a universal danger model. The clinical implication is screening and caution, not moral panic. People with a personal or strong family history of psychotic disorders, or those with emerging symptoms, should be counseled differently. Precision matters here more than slogans. Related: Cannabis and anxiety, with practical clinical guidance 7) Cannabis use disorder: where diagnosis, biology, and context get tangled Few phrases generate more heat than โ€œcannabis use disorder,โ€ and the JAMA review is careful to acknowledge that problematic use patterns exist, including among people who identify as medical users. That acknowledgment is appropriate. The difficulty lies in how easily the diagnosis is interpreted without sufficient clinical context. I’ve shared my thoughts on Cannabis Use Disorder as a diagnosis via my Substack here and I’ve written about the crtiical differences between cannabis addiction and dependence here. To understand why this matters, it helps to separate three things that often get collapsed into one: physiologic dependence, behavioral dysregulation, and therapeutic persistence. Dependence is biology, not a moral failure Many medications used legitimately in medicine produce physiologic dependence. SSRIs, benzodiazepines, beta blockers, corticosteroids, and opioids all induce adaptation in the nervous system. Withdrawal phenomena occur when they are stopped abruptly. This is basic pharmacology. When patients develop dependence on these medications, clinicians do not automatically diagnose addiction. We ask whether function is improving, whether doses are escalating, whether control is lost, and whether harm outweighs benefit. Context matters. In cannabis research, that distinction is often blurred. A patient using cannabinoids daily for chronic pain or severe insomnia may meet criteria for tolerance or withdrawal without exhibiting compulsive, destructive, or chaotic behavior. Labeling that pattern as โ€œdisorderโ€ without nuance risks confusing biology with pathology. Diagnostic criteria can over-capture medical persistence The DSM criteria for cannabis use disorder include elements such as time spent obtaining the substance, continued use despite problems, and difficulty stopping. In medical contexts, these criteria can sometimes capture persistence rather than pathology. Time spent obtaining cannabis may reflect regulatory barriers rather than compulsive seeking. Continued use may reflect symptom recurrence when the therapy is stopped. Difficulty stopping may reflect rebound symptoms rather than loss of control. This does not make cannabis use disorder a meaningless diagnosis. It means it requires clinical interpretation rather than checklist application. Function, trajectory, intent, and collateral harm all matter. Route and onset speed shape reinforcement One of the most robust principles in addiction science is that faster onset increases reinforcement potential. Rapid delivery strengthens learning loops. From this perspective, route of administration matters enormously. Inhaled high-potency THC produces faster onset and higher peak effects than oral or sublingual routes. Concentrates amplify this effect further. When datasets fail to stratify by route and potency, dependence risk is flattened into a single prevalence estimate that obscures actionable differences. Clinically, this is where harm reduction lives. Slower-onset routes, lower potency, and titration to the minimal effective dose reduce reinforcement risk. The review gestures toward these ideas, but they deserve to be central rather than peripheral. Related: Is cannabis addictive? A clinicianโ€™s explanation 8) When harms and benefits are held to different standards One of the quiet forces shaping how readers experience the JAMA review is evidentiary asymmetry. Benefits and harms are not always judged by the same standards, even when the underlying data share similar limitations. Potential benefits are typically evaluated through randomized controlled trials with fixed dosing, short duration, and narrow endpoints. When results are inconsistent or modest, the conclusion is often that evidence is insufficient. That is methodologically defensible, but it sets a high bar. Potential harms, by contrast, are often inferred from observational associations in large datasets. These studies are valuable, but they are also vulnerable to exposure misclassification, residual confounding, and unclear temporality. Yet their conclusions are often treated with greater rhetorical confidence. An analogy from the courtroom Imagine two courtrooms operating under different rules. In the courtroom assessing benefit, evidence must be pristine. Any ambiguity weakens the case. In the courtroom assessing harm, patterns and associations are allowed to testify, even when mechanisms and timelines are uncertain. Both courtrooms claim to serve truth. But they do not weigh evidence equally. This imbalance does not mean harms are invented. It means they sometimes carry more narrative weight than the quality of evidence alone would justify. Effect size without context misleads in both directions Small average effects are often framed as disappointing. But averages hide heterogeneity. In chronic symptom conditions, a modest mean effect can include a meaningful responder subgroup. Conversely, modest risk ratios in observational studies can appear alarming when stripped of absolute risk context. Both errors stem from the same root problem: interpreting numbers without situating them in clinical reality. Evidence-based medicine does not mean privileging one type of uncertainty over another. It means applying symmetric skepticism to benefit and harm claims alike. 9) When the research model does not fit the therapy One of the deepest challenges beneath the review is not bias or intent. It is fit. The dominant research models used to study cannabis may be poorly aligned with how cannabinoids actually work in the body. Cannabinoids primarily act on the endocannabinoid system, a regulatory network involved in sleep-wake cycling, stress response, pain modulation, appetite, autonomic tone, and emotional regulation. Regulatory systems do not behave like onโ€“off switches. They behave like dials. When dial-based systems are studied with short-duration, fixed-dose trials and narrow endpoints, results often look inconsistent or modest. This is not unique to cannabis. Similar challenges appear in psychotherapy research, sleep interventions, and lifestyle medicine. Short trials compress time Many cannabinoid trials last weeks, not months or years. That limits the ability to observe adaptive change, cumulative benefit, or gradual dose optimization. It also limits the ability to observe delayed adverse effects. Clinical care unfolds over time. Trials that compress time can produce clean data that are still incomplete representations of real-world use. Fixed dosing ignores variability Sensitivity to cannabinoids varies widely. Some patients respond to very low doses. Others require higher exposure. Fixed-dose trials overshoot some participants and undershoot others. When mismatched doses are averaged together, the signal shrinks. That does not mean the therapy failed. It means the design was blunt relative to the intervention. Regulatory effects resist narrow endpoints Cannabinoid effects often span multiple domains simultaneously: sleep quality, pain intrusion, autonomic regulation, mood stability. Narrow endpoints may miss this integrated effect. A patient who sleeps better may report less pain, better mood, and improved function without dramatic movement on any single scale. The review acknowledges heterogeneity, but does not fully grapple with what that implies for trial interpretation. Related: Why cannabinoids behave differently than single-target drugs 10) Substitution effects: the missing piece in most โ€œriskโ€ conversations One of the biggest gaps in much of the cannabis literature, including what is summarized in this review, is substitution. Risk is often evaluated as if cannabis is being added into an otherwise stable system, rather than replacing something else. In real clinical life, patients rarely use cannabinoids in a vacuum. Many use them in the context of other therapies. Some reduce or discontinue alcohol. Others reduce opioids, benzodiazepines, sedative-hypnotics, or polypharmacy for sleep and pain. Each of those exposures has its own risk profile, and in some cases that risk is substantial. If we do not ask what cannabis is displacing, we cannot answer the question patients and clinicians actually care about: does this choice increase overall harm, reduce it, or simply move it around? Net harm is a comparison problem Public health often defaults to additive models. Add a substance, add a risk. Clinical medicine is different. Clinical decisions are comparative. They are about which option is safer and more effective for this person, under these conditions, relative to the alternatives they are realistically considering. A patient choosing between nightly alcohol and a carefully titrated cannabinoid regimen is not making the same decision as a patient layering high-potency inhaled THC on top of other destabilizing exposures. Most large datasets do not capture this difference well, and many reviews, by necessity, do not model it. That absence does not invalidate the review. It does mean that any risk framing that ignores substitution is incomplete. Related: harm reduction principles in cannabinoid care 11) A brief note on the New York Times coverage This review has not stayed within academic circles. It has spilled quickly into the public square, and the most visible example is the recent New York Times article discussing medical cannabis evidence and public perception. That coverage has been read by a lot of people, and it has shaped the way patients and clinicians are talking about the subject. The broad themes are not wrong: evidence is mixed, products are heterogeneous, and the field is easy to misinterpret. The problem is that speed and simplicity often win over nuance. In a fast publication cycle, heterogeneous studies tend to get flattened into one storyline. Observational associations start to sound like conclusions. Methodology becomes a footnote, and the limitations that should guide interpretation are often treated as technicalities rather than central facts. What gets less oxygen in mainstream coverage are the issues that actually decide what we should do clinically: exposure misclassification, residual confounding, placebo response, functional unblinding, dose and route heterogeneity, and the mismatch between adolescent recreational cohorts and adult therapeutic populations. Those arenโ€™t exotic caveats. They are the hinge points. This is not a critique of journalism as a profession. Journalism plays an important role in translating science. It is a reminder that translation is not the same as clinical guidance, and certainty of tone is not the same as certainty of data. If you want to read the Times coverage directly, itโ€™s here: The New York Times article on medical cannabis evidence. 12) Generalizability: who do these findings actually apply to? Another limitation that deserves to be stated plainly is generalizability. Much of the evidence summarized in the review comes from populations that are younger, more recreationally oriented, more polysubstance-exposed, and less clinically supervised than the typical medical patient. That does not make the findings irrelevant. It narrows the confidence with which we can apply them. Extrapolating from heavy recreational use patterns to older adults using low-dose products for sleep or pain introduces uncertainty that is rarely emphasized in summaries or headlines. The clinicianโ€™s job is to ask: does the patient in front of me resemble the population from which these findings are drawn? If not, caution should be proportional. 13) What clinicians should do with this review After all the methodological nuance, the practical question remains: what should clinicians do differently on Monday morning? The answer is not to disengage. Patients are already using cannabinoids. When clinicians step back, care becomes less safe, not more. The right response to imperfect evidence is informed participation. Screen the patient, not just the substance Cannabis does not act on a blank slate. Risk depends on age, psychiatric history, sleep stability, cardiovascular status, medications, and prior substance use. The review underscores this variability, but it does not turn it into a clinical workflow. We can. Pay particular attention to adolescents, people with psychosis vulnerability, panic disorder, heavy nicotine or stimulant use, uncontrolled cardiovascular disease, and severe sleep deprivation. Those are not moral categories. They are physiologic vulnerability categories. Break โ€œuseโ€ into variables you can counsel on Instead of โ€œdo you use cannabis,โ€ ask how, how often, what dose, what kind of product, what time of day, and for what goal. Route, potency, and frequency shape both benefit and risk. This moves the conversation from stigma into medicine. Match route and dose to the risk profile Faster onset generally increases volatility and reinforcement risk. Slower routes and careful titration reduce that volatility. This is basic pharmacology applied to cannabinoids. When risk is present, the solution is often adjustment, not prohibition. Measure function, not just frequency Frequency alone is a crude metric. The more useful questions are functional: is sleep improving, is pain less intrusive, is mood more stable, is medication burden reduced, is daily life more manageable? A patient whose function is improving deserves a different clinical interpretation than a patient whose use is escalating alongside worsening outcomes, even if both use cannabis daily. 14) What patients should be told, plainly and honestly The tone of counseling matters as much as the content. Fear-based messaging drives secrecy. Overconfidence drives harm. Honest counseling lives between those extremes. Patients deserve a clear message: cannabis is not harmless, but it is not uniquely dangerous. Risks exist, particularly with high-potency products, frequent use, and early initiation. Benefits exist for some symptoms and some people. Evidence is mixed partly because the intervention is variable, and partly because the research models are imperfect. Most importantly, patients should be invited into partnership. Open discussion allows monitoring, adjustment, and early intervention if problems emerge. Silence does not reduce use. It only reduces safety. 15) The takeaway: precision over panic The most damaging misinterpretation of this review is to treat it as a final judgment. It is not. It is a careful synthesis of a difficult, evolving literature. It reflects both real concerns and real uncertainty. Cannabis is not a miracle therapy. It is not a menace. It is a variable tool interacting with a complex regulatory system in complex humans. That reality demands precision, not slogans. For clinicians, the path forward is straightforward. Engage rather than avoid. Screen rather than stereotype. Adjust rather than alarm. Track function rather than fixate on frequency. Apply the same evidence-based humility to cannabinoids that we apply to every other imperfect but potentially helpful therapy in medicine. Precision, not panic, is how medicine moves forward. Click here to read the full PDF of the JAMA article Author: Dr. Benjamin Caplan, MD Chief Medical Officer, CED Clinic If you are a clinician or patient seeking evidence-based guidance on cannabis, explore our clinical resources at CEDclinic.com. To read Dr Caplan’s takeaways: click here   [...] Read more...
December 10, 2025Medical Cannabis Crossroads: 5 Alarming Shifts in Care Medical cannabis is standing at a crossroads. On one side is fast, frictionless access that treats the plant like a coupon. On the other is slower, more deliberate care that treats it like medicine. Which road we choose will quietly shape how much suffering we accept as inevitable in the years ahead. Three systems, one person. The medical cannabis crossroads is about who we decide to care for, and how. What Youโ€™ll Learn in This Post โ‡๏ธ How the medical cannabis crossroads emerged from twenty years of rapid growth, policy shifts, and quiet exits from care โ‡๏ธ Why medical cannabis enrollment is shrinking in many adult-use states even while cannabis sales soar โ‡๏ธ How โ€œcard millsโ€ and coupon culture hollow out the deeper medical value of cannabis โ‡๏ธ How the new federal hemp crackdown collides with a medical system that is already thinning out โ‡๏ธ What patients, clinicians, and investors can still choose if they care about real healing, not just transactions Evidence in this blog is grounded in โ€ข A national observational study in Annals of Internal Medicine showing that U.S. medical cannabis enrollment increased about 4.5-fold from 2016 to 2020, with enrollment declining in states that adopted adult-use laws (Boehnke et al., 2022). โ€ข A follow-up analysis covering 2020 to 2022 showing that medical cannabis registrations continued to grow overall but generally decreased in jurisdictions with adult-use markets, while chronic pain, anxiety, and PTSD remained the leading qualifying conditions (Boehnke et al., 2024). โ€ข Clinical survey data in chronic pain populations linking medical cannabis use with meaningful reductions in opioid use, fewer medication side effects, and improved quality of life, including an average 64 percent reduction in opioid doses in one cohort (Boehnke, Litinas, Clauw, Journal of Pain, 2016). โ€ข Massachusetts Cannabis Control Commission open data and press releases documenting more than 8 billion dollars in cumulative adult-use cannabis sales through mid 2025, alongside a roughly 40 percent decline in annual medical sales since a 2021 peak and ongoing closures or sales of medical dispensaries (Massachusetts Cannabis Control Commission, 2025, Cannabis Business Times, 2025, Axios Boston, 2025). โ€ข Congressional and legal analyses of new federal legislation redefining hemp and capping total THC at 0.4 milligrams per container in finished products, together with national reporting on how the ban will remove most intoxicating hemp edibles and beverages from interstate commerce by 2026 (Congressional Research Service, 2025, DLA Piper, 2025, The Guardian, 2025). From fringe to front door: how we arrived at the medical cannabis crossroads Twenty years ago, the idea of a dedicated medical cannabis clinic felt like something from a parallel universe. Most of the people who talked about cannabis used whispered slang and jokes, not medication lists and symptom diaries. Then, almost overnight and very slowly all at once, the landscape changed. By 2016, state registries were tracking hundreds of thousands of people who had taken the risk of saying, out loud, that cannabis helped them function. By 2020, enrollment in medical cannabis programs had increased more than fourfold compared to 2016, as patients and clinicians gradually discovered that the endocannabinoid system was not a trivial side character but a storm-balancing network threaded through pain, mood, sleep, immunity, appetite, and memory. (Years later, registry analyses in Annals of Internal Medicine would quantify that same surge, confirming what many clinics were seeing in daily practice.) Much of that growth was driven by chronic pain, anxiety, and trauma. The official numbers tell that story in a dry way. In 2020, chronic pain was the dominant qualifying condition across the United States, and by 2022 it remained the single most common reason people entered medical cannabis programs, with anxiety and post-traumatic stress not far behind. (Those patterns map almost perfectly onto the registry data, where chronic pain sits at the top of the list and anxiety and PTSD cluster closely behind.) Behind those labels were people who could no longer sleep through the night, parents who could not stay in the room with their childrenโ€™s chaos without snapping, and patients who had run out of medications that helped more than they harmed. REGISTRY SURGE Enrollment in medical cannabis programs increased about 4.5-fold from 2016 to 2020 across the United States, with chronic pain, anxiety, and PTSD leading the list of indications in national registry reports. In exam rooms, the change was even more obvious. People walked in carrying pill bottles and weariness. Many had already tried physical therapy, injections, surgeries, or sleep medications that left them foggy and flat. They asked some version of the same question: โ€œI am not sure who I am underneath all of this. Could cannabis help me find my way back to myself?โ€ At that point, medical cannabis still felt like medicine. Not perfect, not magic, but recognizably clinical. Visits were long, sometimes messy. We talked about THC and CBD as tools instead of trophies, microdoses instead of moon shots, and the peculiar way the medical cannabis crossroads was beginning to form even before we had a name for it. When cannabis is treated as medicine, the visit is about people, not products. When medical cannabis behaved like actual medicine In those early years, the medical cannabis crossroads was still far off in the distance. The work felt new and slightly improvised, but grounded in a simple idea: if we understood the endocannabinoid system and respected the rest of the body, we might help people suffer less without numbing them into strangers. A woman with migraines that taught her children to whisper came in carrying a plastic bag of failed prescriptions. A veteran whose nervous system flinched at every loud sound wanted to know whether there was a way to feel steady without feeling sedated. A man who had finally quit alcohol asked, very quietly, whether there was another way to calm his evenings that did not involve slipping back toward the bottle. We started low, with doses that felt almost offensively small. One or two milligrams of THC at night. A steady background of CBD. Careful changes in timing. We talked about intention, about noticing what pain felt like when it was turned down just enough that you could move toward it instead of away, and about the difference between escaping your life and re-entering it. Later, when I finally checked the numbers in the journals, the trend was unmistakable, and eerily similar to what my waiting room already knew. In a survey of chronic pain patients in Michigan, medical cannabis use was associated with an average 64 percent reduction in opioid use, fewer medication side effects, and improved quality of life. In another analysis, more than one third of medical cannabis patients who used opioids achieved at least a 30 percent reduction in their daily opioid dose. (These findings, published in The Journal of Pain, gave a peer reviewed backbone to the quiet shifts many patients were already describing in their own kitchens and bedrooms.) OPIOID REDUCTION SIGNAL Across several chronic pain cohorts, medical cannabis use has been linked to substantial reductions in opioid dose, with many patients reporting better pain control and fewer side effects when cannabis is used thoughtfully alongside or instead of opioids. I did not need those statistics to recognize a different kind of relief in front of me. People cried less, laughed more, slept longer, and reported fewer evenings they wanted to drink themselves numb. They did not become new people. They became slightly more themselves. That is what real medicine often does. It does not turn life into a postcard. It restores enough balance that you can stand inside your own story without feeling like you have to bolt. For a while, medical cannabis fit that description. The medical cannabis crossroads was visible only as a faint line on a distant horizon. At the medical cannabis crossroads, one path leads to care and the other to pure convenience. Medical cannabis crossroads: when adult-use opened the side door Then adult-use legalization arrived, not as a single event but as a series of votes and ribbon cuttings. At first, it felt like a simple victory. Fewer arrests. Less stigma. More honesty about a plant that had been hiding in everyoneโ€™s blind spot for decades. Patients celebrated. Many clinicians did too. You no longer had to carry the awkward weight of being โ€œthe cannabis patientโ€ just to buy something that helped you sleep. You could walk into a store with the anonymity of any other consumer. No exam room. No forms. No waiting for a physician who might or might not understand what you were trying to do. What my waiting room sensed long before I had words for it was eventually confirmed by multi-state registry analyses and industry data. When adult-use sales begin, medical cannabis enrollment reliably falls. On average, states see medical registries shrink by about one third after recreational markets open, with some jurisdictions losing more than half their registered patients within a few years. (Those declines show up clearly in the registry trend lines published in Annals of Internal Medicine when adult-use laws take effect.) REGISTRY COLLAPSE Analyses of medical cannabis registries show that once adult-use markets launch, medical enrollment declines by roughly one third on average, with some states losing more than half of their registered patients within a few years. In Massachusetts, adult-use sales crossed the 8 billion dollar mark by mid 2025. At the same time, annual medical sales fell about 40 percent from a 2021 peak. The plant was not disappearing. The structure of care around it was. (State open data and trade coverage from the Cannabis Control Commission, Axios, and Cannabis Business Times all tell the same story of booming adult-use revenue alongside a shrinking, consolidating medical market.) MARKET DISPLACEMENT In Massachusetts, adult-use cannabis sales have exceeded 8 billion dollars since 2018, while annual medical sales have dropped from roughly 270 million dollars in 2021 to about 160 million in 2024. Stand in a busy adult-use dispensary, and the medical cannabis crossroads looks like progress. The store is full of customers, the tax revenue is impressive, and the stigma is lower than it has been in decades. Stand in a clinic that used to see patients back for careful second and third visits, and it looks like something else entirely. Fewer follow-ups. More one-time visits. More patients who come once to talk about replacing sleeping pills or alcohol, then quietly vanish into the adult-use marketplace to experiment alone. The shift was not anecdotal. It was measurable, persistent, and seen everywhere adult-use took root. From stewards to card mills: when โ€œmedicalโ€ becomes a membership Economics has a way of bending the spine of any system, especially one that sits at the crowded intersection of medicine, stigma, politics, and profit. The medical cannabis crossroads is no exception. Thoughtful medical care takes time. A 45-minute visit that includes a full medication review, a trauma history, a sleep map, and a realistic discussion of goals is hard to sustain when insurance rarely pays for it and when patients can bypass the process by walking into an adult-use shop. So some medical cannabis practices adapted. They shrunk the time, simplified the questions, and optimized the workflow around one primary task: generating or renewing cards. Marketing followed. โ€œSame-day approvals.โ€ โ€œNo records needed.โ€ โ€œFastest renewal in the state.โ€ The medical card quietly shifted from the symbol of an ongoing clinical relationship into something closer to a membership card at a warehouse club. Many patients now talk about their medical card in exactly those terms. You pay a fee, often a few hundred dollars a year between state and clinician costs, and the primary benefits are lower taxes, bigger purchase limits, and access to certain products on the medical side of a hybrid store. The substance of the visit starts to feel secondary. (In patient surveys, people who abandon medical programs frequently cite cost and bureaucratic hassle rather than disappointment with cannabis itself or lack of benefit.) Clinics that resist this drift still exist. At places like CED Clinic, for example, visits are structured around education and follow-up, not only signatures. Patients come not just for a card, but for help choosing between dosing strategies, delivery methods, and long-term plans. That approach is visible in educational pieces like cannabis for anxiety, cannabis for sleep, and the clinical overview of the expanded endocannabinoid system, which treat cannabis as a tool to be understood, not a commodity to be grabbed. But the larger trend is hard to ignore. As more โ€œcard millsโ€ appear and more patients see their medical card primarily as a discount coupon, the physicianโ€™s role as steward begins to evaporate. At the medical cannabis crossroads, the white coat stays on, but the soul of the work starts to drain away. CLINICAL DRIFT Surveys of patients leaving medical programs often cite cost, bureaucracy, and lack of perceived extra value compared with adult-use access, rather than dissatisfaction with cannabis itself. You cannot be both a coupon and a compass for very long. Eventually, one of those roles wins. What disappears when the follow-up visit vanishes The most important work in medical cannabis rarely happens at the first visit. The first visit is the part where everyone is polite and slightly guarded. Patients show you their diagnosis problem list, their medication list, and the story they have learned to compress into ten minutes for insurance-driven medicine. The second or third visit is different. That is where the medical cannabis crossroads becomes visible at human scale. By then, the dosing plan has lived in the real world for a few weeks. Sleep has either deepened or not. Pain has either shifted or stubbornly clung to the same corner of the body. Alcohol and sedative use may have shrunk, stayed the same, or quietly crept up again. Patients arrive with more honesty and more curiosity, because they have seen enough change to know that their own behavior matters. โ€œThis is going to sound strange,โ€ one patient told me eight weeks into a carefully planned trial of low-dose THC and CBD at night, โ€œbut I feel like I am starting to meet my life again. Same job, same kids, same stress. Just less dog-face, frog-face, bog-face in my head about every little thing.โ€ Another, a man with years of back pain and a long opioid history, said, โ€œWe cut my dose in half and I did not fall apart. I still hurt, but I am less afraid of the pain. My wife says I actually listen at dinner.โ€ (These are exactly the kinds of stories that sit underneath the percentage drops in opioid use and quality of life scores in the chronic pain surveys.) These sentences do not appear in registry reports. They do not show up in quarterly revenue statements. But they are exactly the kind of outcome that clinical studies hint at when they show reductions in opioid use and improvements in quality of life among medical cannabis patients who receive structured guidance. FOLLOW-UP FALLOUT When patients leave medical programs and rely only on adult-use or informal markets, they rarely receive any ongoing support around dose, timing, interactions, or goals, even though these elements strongly influence outcomes. When the follow-up visits vanish, several things disappear at once. The chance to correct a dose that is too high, too frequent, or poorly timed. The opportunity to notice that someoneโ€™s alcohol intake is creeping upward again as they rely on cannabis less skillfully. The moment when a patient realizes that what they want is not endless escape, but the ability to stay present for the life they already have. Without that space, cannabis slides from โ€œmedicine that helps me changeโ€ into โ€œproduct that helps me cope.โ€ That shift is subtle on paper, but enormous in a kitchen at midnight when someone is deciding whether to reach for a gummy, a drink, a pill, or a screen. The new 0.4 mg THC cap will erase most hemp products that quietly helped people cope. The hemp bridge and the federal storm heading for it While state medical and adult-use systems have been evolving, a third quiet channel has been carrying millions of people across their own private medical cannabis crossroads: hemp-derived products. Since the 2018 Farm Bill, CBD oils, softgels, creams, and an expanding universe of hemp-derived THC beverages and edibles have seeped into supermarkets, online storefronts, and neighborhood shops. For people in prohibition states or in regions far from dispensaries, these products have functioned as a kind of gray-market medical system. Not perfect, not consistently labeled, but present. Many patients who never enrolled in a state program found their way to sleep with a 2 milligram hemp โ€œnightcapโ€ drink or a low-dose gummy. Others used CBD for arthritis or anxiety while waiting for their state to modernize its laws. In that sense, hemp created an improvised, consumer-driven version of the medical cannabis crossroads. That bridge is now under heavy construction. Recent federal legislation has narrowed the definition of legal hemp and set an upper limit of 0.4 milligrams of total THC per finished product container. Most intoxicating hemp-based gummies, chocolates, and beverages on the market today contain far more than that, which means they will effectively vanish or be reformulated into something unrecognizable by the time the law is fully in force. (Policy analysts at the Congressional Research Service and legal commentators at firms like DLA Piper highlight this 0.4 milligram cap as the central change that will sweep most current hemp THC products off mainstream shelves.) HEMP SHOCKWAVE A national hemp market worth tens of billions of dollars, including many low-dose THC drinks and edibles, now faces strict caps of 0.4 milligrams of THC per container, which will effectively remove most intoxicating hemp products from interstate commerce. At the same time, federal rules are tightening around synthetic or chemically converted cannabinoids like delta 8 and delta 10, closing the farm bill loophole that allowed them to flourish. For many in the regulated cannabis industry, this feels like overdue clarity. For patients in states without strong medical cannabis infrastructure, it feels like a trap door opening under their feet. (National coverage in outlets such as The Guardian has already begun describing this as a coming โ€œhemp banโ€ for everyday consumers.) The timing matters. The hemp crackdown is arriving just as medical cannabis programs in many adult-use states are thinning and shifting toward card mills, not comprehensive care. That means millions of people could lose access to hemp-derived products and still have no realistic way to obtain guided medical cannabis. The medical cannabis crossroads is not just about one system. It is about three partially overlapping systems drifting in dangerous directions at the same time. CARE GAP RISK Without strong medical cannabis programs, the combination of a hemp crackdown and adult-use convenience may leave many patients with legal products but no meaningful clinical support, or with restricted products and a return to older, more harmful coping strategies. What is really at stake at the medical cannabis crossroads When people talk about the decline of medical cannabis, they often focus on the visible parts. Fewer cards issued. Lower registry counts. Consolidation of clinics. Shrinking margins. If you stand at the medical cannabis crossroads from a distance, it looks like the end of a business model. Up close, it is something else. It is a slow reduction in the number of places where you can talk about cannabis and suffering in the same breath without embarrassment. It is fewer rooms where someone will ask you why you reach for wine, or how many medications you actually want to take if other strategies exist. It is fewer opportunities to suggest that maybe, just maybe, the goal is not to eliminate every unpleasant sensation, but to change your relationship with them. Medical cannabis at its best is not a replacement for every pill. It is a wedge in the door of a very rigid medical model, a reminder that the body has more than serotonin and opioid receptors, and that people have more than two options: โ€œtake this and ignore your feelingsโ€ or โ€œtough it out and try to be grateful.โ€ It invites questions like: Do I still need this benzodiazepine if I am sleeping again? What happens to my drinking when I am less anxious in my own skin? What if healing is not just about symptom scores, but about returning to the version of myself I want to live with? If the field at the medical cannabis crossroads continues to drift toward coupons and card mills, we lose both short-term and long-term value. Short term, we lose education and stewardship. Long term, we lose one of the few mainstream tools that can challenge our dependence on polypharmacy, alcohol, and numbing as the default responses to an overwhelming world. That loss will not show up all at once. It will look like slightly more insomnia, slightly more anxious evenings, slightly more people who feel trapped between suffering and sedation. It will look like patients deciding that โ€œnothing worksโ€ when what they really lost was the guidance that helped them use existing tools well. Choosing the road that keeps medicine human The hopeful part of the medical cannabis crossroads is that it is still a crossroads. None of this is fully baked into the future. Patients, clinicians, and investors have more influence than they might think. Patients can treat cannabis as medicine even when they buy it in adult-use settings. They can keep simple logs of dose, timing, and effect. They can track how sleep, pain, mood, and alcohol or medication use shift over weeks, not just hours. They can seek out clinicians and resources that take the endocannabinoid system seriously, such as the educational materials at CED Clinic or accessible frameworks like The Doctor-Approved Cannabis Handbook. Clinicians can decide that learning this physiology is part of modern medicine, not a fringe hobby. They can read the same registry analyses and pain studies that patients quote in waiting rooms. They can ask about cannabis the way they ask about alcohol and tobacco, not to punish, but to understand. They can say, very simply, โ€œIf you are going to do this, I would rather help you do it safely.โ€ Investors and industry leaders can choose to build businesses that reward outcomes and education, not only velocity. That means supporting clinics that integrate telehealth with dispensary visits, funding outcome tracking that does more than count units sold, and building systems that make follow-up straightforward rather than an afterthought. None of that will be as instantly profitable as minting new discount cards. It will, however, be more durable and more defensible. The companies and clinics that survive the next decade at the medical cannabis crossroads are likely to be the ones that can look regulators, patients, and clinicians in the eye and say, โ€œWe did not just move product. We helped people change.โ€ I do not believe medical cannabis is dying. I believe it is being asked a hard question. Are you content to be a coupon, or do you want to be a craft. The registry graphs and sales data can tell us which way the money is flowing. The exam rooms and kitchen tables will tell us which way the meaning is flowing. If we are careful, we can still choose the road where cannabis remains a well-studied, well-guided tool in the larger work of healing. Where data and stories keep each other honest. Where medicine is not just about reducing numbers on a chart, but about helping people feel like they belong in their own lives again. References and Evidence Base Boehnke KF, Gangopadhyay S, Clauw DJ, Haffajee RL. US Trends in Registration for Medical Cannabis and Reasons for Use From 2016 to 2020. Annals of Internal Medicine. 2022;175(9):1280-1288. doi:10.7326/M22-0217. Boehnke KF, Sinclair R, Gordon F, et al. Trends in U.S. Medical Cannabis Registrations, Authorizing Clinicians, and Reasons for Use From 2020 to 2022. Annals of Internal Medicine. 2024;177(4):458-466. doi:10.7326/M23-2811. Boehnke KF, Litinas E, Clauw DJ. Medical Cannabis Use Is Associated With Decreased Opiate Medication Use in a Retrospective Cross-Sectional Survey of Patients With Chronic Pain. The Journal of Pain. 2016;17(6):739-744. Massachusetts Cannabis Control Commission. Massachusetts Marijuana Establishments Pass $8 Billion in Gross Adult-use Sales. Press release and open data portal. July 22, 2025. Available at: Massachusetts Cannabis Control Commission press release on $8B adult-use sales . Solis S. Massachusetts’ medical cannabis market shrinks as patients call for reforms. Axios Boston. May 8, 2025. Available at: https://www.axios.com/local/boston/2025/05/08/massachusetts-medical-cannabis-market-shrinks . Lange T. Massachusetts Medical Cannabis Sales Drop 40% Since 2021 Peak. Cannabis Business Times. September 8, 2025. Available at: https://www.cannabisbusinesstimes.com/us-states/massachusetts/news/15754827/massachusetts-medical-cannabis-sales-drop-40-since-2021-peak . Congressional Research Service. Change to Federal Definition of Hemp and Implications for Hemp-Derived Cannabinoid Products. In Focus IN12620. November 2025. Available at: https://crsreports.congress.gov/product/pdf/IN/IN12620 . Gardner J, Mayl SL. New federal restrictions on hemp and hemp-derived products: Top points. DLA Piper client alert. November 18, 2025. Available at: https://www.dlapiper.com/en-us/insights/publications/2025/11/new-federal-restrictions-on-hemp-and-hemp-derived-products . Green HH. What to know when the ban on most US hemp products goes into effect. The Guardian. December 3, 2025. Available at: https://www.theguardian.com/society/2025/dec/03/us-ban-hemp-products . ๐Ÿ—ฃ๏ธ Know someone overwhelmed by caregiving for an elderly parent or friend? Dr Caplan is on a mission to step in and support this often neglected group. You can learn more here: Caregiver Support for Seniors. ๐Ÿ—ฃ๏ธ Pediatric caregiving is a different sort of heavy. Many families caring for children with sleep, behavior, or neurologic challenges feel unseen. If you know someone who might benefit, please feel free to share our Pediatric Care Program. Do you know one person we could help? A quiet share can change the trajectory of a whole household. Medical Cannabis Crossroads FAQ What is the โ€œmedical cannabis crossroadsโ€ everyone is talking about? The medical cannabis crossroads is the point we have reached after twenty years of rapid growth, policy shifts, and market disruption. Medical cannabis programs expanded quickly, then began shrinking in states that launched adult-use markets, even as total cannabis sales grew. At the same time, a vast hemp-derived market filled in access gaps and is now facing tight new federal restrictions. Those three forces intersect right now, forcing patients, clinicians, and businesses to decide whether cannabis remains part of medicine or becomes just another consumer product. Why are medical cannabis registries shrinking in adult-use states? In many states, once people can buy cannabis with a standard ID, they no longer feel the need to pay extra fees, gather medical records, or attend formal visits just to access products. Multi state analyses show that medical registries typically decline by about one third after adult-use sales begin, with some states losing more than half their registered patients. For most patients, this is not a verdict on cannabis, it is a verdict on bureaucracy. The result, however, is that many lose contact with clinicians who could help them use cannabis more safely and effectively. If adult-use cannabis is legal, what unique value does medical cannabis provide? Medical cannabis programs, at their best, offer something adult-use frameworks are not designed to provide, namely deep, individualized care. They connect cannabis decisions to full medication lists, mental health histories, sleep patterns, and long term goals. They also create a structure for follow up, dose adjustment, and problem solving that goes far beyond product recommendations. Losing that structure means more trial and error, more silent interactions with alcohol and sedatives, and more missed chances to reduce medication burden in a guided way. Are โ€œcard millโ€ clinics really that big of a problem? Card mills solve one narrow problem, which is making it fast and cheap to get a medical card, but they do not solve the deeper problems of how to use cannabis wisely. When visits are very short and focused mainly on paperwork, there is little time to discuss other medications, trauma history, mental health, or life context. Over time, this erodes trust in โ€œmedical cannabisโ€ as a concept and encourages people to see the card as a coupon, not a clinical tool. That might boost short term revenue, but it undermines the long term legitimacy of the entire field. What does the evidence actually say about cannabis and opioid reduction? Several studies in chronic pain populations have found that patients using medical cannabis report meaningful reductions in opioid use, sometimes averaging more than 60 percent lower opioid doses. About one third of patients in some cohorts achieved at least a 30 percent reduction in their prescribed morphine equivalent dose, a change that can matter a great deal for side effects and safety. At the same time, large population level studies on overdose and prescribing are mixed, which is reasonable in such a complex landscape. The take home message is that cannabis can be an important adjunct for some patients, but it works best with thoughtful guidance rather than as a do it yourself substitution. How will the new federal hemp THC limit affect people who use hemp products for sleep or anxiety? The new 0.4 milligram THC per container cap will effectively remove most of the intoxicating hemp gummies and beverages currently sold for relaxation and sleep. For people in states with strong medical or adult-use programs, this may simply shift their purchases. For people in prohibition states or rural areas, it may feel like losing the only legal option they had found that worked. Without a robust medical cannabis safety net, many of those individuals will end up back at the pharmacy counter, the liquor aisle, or unregulated online sellers instead. What can patients do to protect themselves at the medical cannabis crossroads? Patients can reclaim some power by treating their own attention as the primary medicine. That means tracking dose, timing, symptoms, and side effects over days and weeks, not just reacting to how a product feels in the moment. It also means seeking out clinicians and resources that explain the endocannabinoid system, dosing strategies, and realistic goals in plain language. When you walk into a dispensary with that kind of map in your mind, the risk of getting lost drops significantly. How should clinicians respond if they feel unprepared to talk about cannabis? Clinicians can start by acknowledging the gap and expressing willingness to learn alongside their patients. High quality summaries of the evidence are increasingly available, and clinician friendly resources now map the endocannabinoid system, dosing principles, and condition specific outcomes in accessible ways. A few hours of focused reading can turn โ€œI do not know anything about thisโ€ into โ€œI know enough to keep you safer and to know when to refer.โ€ That shift alone can transform how patients disclose their cannabis use and how seriously they take your advice. Is medical cannabis still an attractive area for long term investment? It can be, if investors focus on durable value rather than short term arbitrage. Models built around intoxicating hemp loopholes were already fragile and now face direct regulatory fire. In contrast, models built around evidence based care, outcome tracking, telehealth integration, and education address needs that are not going away, like chronic pain, anxiety, insomnia, and medication overload. Investors who help build that kind of infrastructure at the medical cannabis crossroads are more likely to be welcomed by regulators, clinicians, and patients in the long run. What would a healthy future beyond the medical cannabis crossroads actually look like? In a healthier future, cannabis would sit alongside other legitimate tools in the medical toolbox, neither glorified nor dismissed. Patients would have access to guided care that respects their experiences and their goals, not just their diagnosis codes. Clinicians would understand the basics of the endocannabinoid system the same way they understand insulin or serotonin. And regulators, instead of playing whack a mole with loopholes, would help shape systems where cannabis is used in ways that genuinely reduce suffering, medication dependence, and the quiet drift toward alcohol and other maladaptive coping strategies. [...] Read more...
October 14, 2025Every Halloween, the Same Scare: The Truth About Cannabis-Laced Candy Each Halloween, the same story stalks across headlines like a ghost that wonโ€™t rest: โ€œParents, beware of cannabis-laced candy!โ€ The panic rises, peaks, and fades, rumor, reaction, reassurance, and twelve months later, it returns again. Agencies like the DEA issue annual warnings, sometimes even formal press releases, such as the one in 2018 that rippled through national news. A year later, it was a local story out of Florida claiming an โ€œuptickโ€ in THC-related illnesses. Before that, it was apples laced with razors, needles in chocolate bars, or pills posing as sweets. Different props, same fear. Major outlets including The Washington Post and The New York Times have traced this ritual of worry for decades. Entire Wikipedia pages now catalog the mythmaking history of โ€œpoisoned candy,โ€ a kind of cultural folklore disguised as public safety. But something has changed. As legalization expands, cannabis products have become far more visible in everyday life. In fact, a national poll found that 58% of Americans now believe cannabis is a healthier option than alcohol, and a majority expect full national legalization within five years (Marijuana Moment, 2025). At the same time, NPR reported in 2024 that more Americans now use cannabis more often than alcohol, a major behavioral shift that underscores how normalized cannabis has become in adult life. That normalization brings new challenges, especially for parents of young children. Because when you pause to think about it, the central claim of the Halloween panic begins to crumble. Who are these imagined villains buying expensive, regulated cannabis products, risking arrest, simply to frighten children for fun? What would that even accomplish? The fear persists not because itโ€™s true, but because itโ€™s familiar. And familiarity, especially when tied to fear, can be hard to outgrow. What weโ€™re really confronting each October isnโ€™t a wave of malice. Itโ€™s a wave of misunderstanding. What The Data Show โœ… The U.S. Drug Enforcement Administration (DEA) has never confirmed a single case of strangers distributing cannabis-infused candy to children. โœ… Childrenโ€™s Hospital Colorado reported that 100% of pediatric cannabis exposures treated in 2023 occurred at home, not from Halloween events. โœ… The American Association of Poison Control Centers notes that most cannabis ingestion calls involve edibles mistaken for food left unsecured in households. โœ… The Journal of the American Medical Association (JAMA) found that pediatric cannabis exposures in legalized states correlate with household access, not community distribution. โœ… The National Safety Council ranks accidental THC ingestion well below common childhood hazards like detergent pods, batteries, or medications. When Candy and Cannabis Look the Same One October evening in Massachusetts, a father sat at his kitchen table helping his daughter sort through a mountain of Halloween candy. Amid the crinkled wrappers and melted chocolate, he noticed a small resealable pouch marked โ€œTHC.โ€ It wasnโ€™t from trick-or-treating. It was his. Left out by mistake. Thatโ€™s the real story. Not strangers, but storage. As cannabis becomes part of normal adult life, the line between candy and cannabis sometimes blurs in appearance, not intent. Gummies, chocolates, and mints share the same cheerful colors and glossy wrappers as ordinary sweets. For parents scanning baskets under dim porch lights, confusion is understandable. But confusion doesnโ€™t mean catastrophe. It means we need literacy, not panic. Most parents donโ€™t realize that regulated cannabis products follow strict labeling and design laws precisely to prevent this confusion. These rules make adult products look intentionally plain, functional, and unappealing to children. In Missouri, for instance, cannabis packages may use only one color, display no more than two logos, and must feature the word โ€œMarijuanaโ€ prominently on the front. Massachusetts and Illinois have similar regulations, along with child-resistant, resealable packaging, something no candy manufacturer uses. simple way to remember: Tears open easily? Candy. Clicks or zips closed? Cannabis. Unregulated or counterfeit edibles are a different story. Products with playful names like Trips Ahoy, Stoney Patch Kids, or Skitttllez are not legal cannabis, theyโ€™re knockoffs, sold outside dispensaries and often without testing or labeling. For parents, that distinction matters. The real risk isnโ€™t a stranger across the street. Itโ€™s a product in the pantry that looks too much like candy. Knowing what adult-use cannabis edibles look like helps families store them safely, recognize them quickly, and focus on what Halloween is supposed to be: fun, not fear. ๐Ÿ—ฃ๏ธ โ€œEducation protects children far better than fear ever will.โ€ What the Data Show About Packaging and Safety ๐Ÿ“ In Colorado, every documented pediatric cannabis exposure occurred at home, not from trick-or-treating strangers. (Wang GS et al., Pediatrics 2016) ๐Ÿ“ JAMA Pediatrics research confirms that child-resistant packaging and caregiver education are the key predictors of prevention. (Onders B et al., 2019) ๐Ÿ“ State regulations in Massachusetts (935 CMR 500.105), Missouri (19 CSR 100-1.140), and Illinois (410 ILCS 705/55-21) require packaging to be plain, resealable, child-resistant, and labeled with the word โ€œMarijuanaโ€ and a universal THC symbol. ๐Ÿ“ Cost alone discourages tampering: regulated edibles typically sell for $2โ€“$4 each, versus $0.10โ€“$0.25 for ordinary candy, a ten- to twenty-fold difference. ๐Ÿ“ The simplest safeguard remains: If it reseals, read the label, then lock it up. How to Tell the Difference: A Parentโ€™s Visual Guide Sorting through a mountain of Halloween candy under soft porch light can feel like a guessing game. But spotting cannabis edibles isnโ€™t difficult once you know what to look for. You donโ€™t need special equipment, just a few seconds of informed attention. This is the simple, science-backed checklist that public health educators and pediatricians recommend to help parents tell the difference between ordinary candy and cannabis-laced candy. 1. The Package Test: Resealable = Red Flag Candy wrappers are single-use. They tear, twist, or crinkle and canโ€™t be resealed. Cannabis edibles, by contrast, come in resealable, child-resistant pouches or containers, often with zip-tops, snap locks, or press-and-turn caps. If it closes again, itโ€™s not candy. If it looks like candy but reseals, set it aside and check the label. ๐Ÿ’ก Quick rule: If itโ€™s easy for a child to open, itโ€™s safe for a child to eat. If it isnโ€™t, itโ€™s probably not candy. 2. The Label Test: Words Matter Every licensed cannabis edible must display: The word โ€œMarijuanaโ€ or โ€œTHC.โ€ A THC warning symbol, often a red or yellow triangle. A dosage statement, like โ€œ10 mg THC per piece.โ€ If you donโ€™t see those, itโ€™s candy. If you do, itโ€™s not for kids.   3. The Design Test: Plain vs. Playful Cannabis edibles are designed to look boring. Regulations require simple packaging, one color, minimal logos, no mascots, no glitter. Candy, on the other hand, practically screams for attention: bright fonts, cartoon characters, sparkles, and foil. ๐ŸŽƒ Pro tip: If the design looks dull, itโ€™s probably an edible. If it looks like a carnival, itโ€™s candy. 4. The Texture Test: Uniform = Unlikely Candy Cannabis edibles are made in precise, uniform batches for dosing accuracy. Every piece looks identical in shape, size, and color. Candy, by contrast, varies, some pieces melt, some stick, some break. Real candy is chaotic. Cannabis is consistent. 5. The Smell Test: Subtle but Distinct Most modern edibles are nearly odorless, but some carry a faint herbal, earthy, or resinous scent rather than a sugary or fruity one. If it smells like plants instead of pastries, treat it cautiously. The Quick Check Rule Look. Read. Secure. If it reseals, read the label. If it says โ€œTHC,โ€ store it safely. Three seconds of attention prevent hours of worry ๐Ÿง  Keep in Mind: โ€œConfusion isnโ€™t dangerous. Complacency is. Once you know what to look for, Halloween stays sweet for everyone.โ€ Evidence That Supports the Visual Checklist ๐Ÿ”Ž Between 2017 and 2021, edible cannabis exposures in children under 6 increased, as recorded by the National Poison Data System, though most cases resulted in mild or moderate symptoms and required outpatient observation (Pediatrics, 2023). ๐Ÿ”Ž Pharmacologic data suggest that ingesting 10 mg THC in a young child generally does not lead to severe toxicity; however, as dose increases relative to weight, the probability of prolonged or severe symptoms also rises (Pediatrics, 2024). ๐Ÿ”Ž Toxicology experts and the American College of Medical Toxicology endorse child-resistant packaging, plain labeling, and advertising restrictions as key measures to reduce accidental ingestion risk (ACMT Pediatric Cannabis Exposure Position Statement, 2022). ๐Ÿ”Ž Reports of ฮ”โธ-THC exposures are rising, with one study showing approximately a 79 % increase in poison control calls from 2021 to 2022, reflecting evolving product landscapes parents must monitor (Journal of Medical Toxicology, 2024). ๐Ÿ”Ž Clinical reviews note that pediatric ingestion presentations vary widely, making early visual assessment and prompt evaluation essential in ambiguous cases (Pediatric Emergency Care, 2024). How Parents Can Prevent Mix-Ups Once you know how to recognize cannabis edibles, the next step is easy: prevent confusion before it happens. Nearly all accidental ingestions occur at home, not on Halloween night. The solution isnโ€™t fear, itโ€™s forethought. Parents donโ€™t need new rules, just sharper habits. The goal is the same as with any medication: safety without stigma. 1. Store Cannabis Separately Keep cannabis products in a locked or elevated cabinet, away from snacks, desserts, and candy. Opaque containers help, since bright colors can tempt curious hands. Think of this as the โ€œdouble-door ruleโ€: One door for food, another, locked, for medicine or cannabis. ๐Ÿ’ก Pro Tip: Use a small luggage lock or coded lockbox for added safety. Hide it as well as you lock it. 2. Label Clearly, Even at Home If you repackage or make your own edibles, mark them clearly: โ€œContains THC. For adult use only.โ€ A simple label can prevent panic later. Whenever possible, keep edibles in their original packaging, itโ€™s designed with child-resistant seals and warning symbols for a reason. 3. Keep Edibles Away from Halloween Candy In the week leading up to Halloween, physically separate your candy stash from cannabis products. Many incidents happen during post-party cleanup or late-night sorting, when both types of sweets end up on the same counter. Separate them now. Save yourself a crisis later. Two seconds of attention prevents hours of regret. 4. Educate, Donโ€™t Scare Children respond better to honesty than fear. A calm, age-appropriate explanation: โ€œThese are adult products that can make your body feel strange if you eat themโ€, is usually enough. For teens, talk about cannabis like you would alcohol or prescription medication: not forbidden, but not for kids. โœ… Research shows that open, nonjudgmental communication lowers risky behavior and builds long-term trust between parents and children. ๐Ÿ—ฃ๏ธ Simple Truth: โ€œFear fades. Honesty lasts.โ€ 5. Have a Plan, Just in Case Save the Poison Control Hotline: 800-222-1222 Post it on your fridge, store it in your phone, and make sure babysitters, grandparents, or older siblings know it too. Preparation doesnโ€™t mean expecting a problem, it means knowing how to handle one calmly. Parental Quick-Checklist โ˜‘๏ธ Lock up adult-use products โ˜‘๏ธ Label homemade edibles โ˜‘๏ธ Separate candy and cannabis โ˜‘๏ธ Educate without fear (see this video I made on the topic) โ˜‘๏ธ Keep Poison Control visible Small habits create large safety margins. And thatโ€™s what turns concern into confidence. Subscribe now Why Prevention Works: What the Data Tell Us The habits that protect children from cannabis mix-ups arenโ€™t guesswork. Theyโ€™re backed by evidence. โ›ณ Between 2017 and 2021, U.S. poison control centers documented a sharp rise in edible cannabis exposures among children under six, but nearly all cases were mild or moderate and resolved with observation (Pediatrics, 2023). โ›ณ Analyses show that most exposures occur when edibles are left accessible on countertops or in unlocked drawers, not because of supervision failure, but because of poor storage (ACMT Pediatric Cannabis Exposure Position Statement, 2022). โ›ณ National poison control data indicate that serious medical outcomes are rare, typically under 2 percent, and that hospitalization rates continue to fall as packaging laws and parental education improve (AAPCC Annual Report, 2023; Pediatric Emergency Care, 2024). โ›ณ Surveys from the University of Michiganโ€™s C.S. Mott Childrenโ€™s Hospital show that parents who openly discuss cannabis safety with their children are more likely to store products securely (Mott Poll, 2024). โ›ณ CDC analyses confirm that accidental ingestions tend to occur in homes where products are not securely stored or where caregivers were unaware of their presence (MMWR, 2023). Together, these findings outline a simple truth: When adults combine honest communication with secure storage, pediatric cannabis exposures drop dramatically. Thatโ€™s not a scare tactic, itโ€™s science. What to Do If a Child Eats a Cannabis Edible Even careful families can have close calls. A forgotten pouch, a mislabeled tin, or a momentary distraction can lead to a curious child eating something they shouldnโ€™t. When that happens, the key is calm, informed action, not panic or shame. Clinical data show that most pediatric THC ingestions cause only temporary symptoms like drowsiness, dizziness, or mild disorientation. Serious or lasting harm is exceedingly rare when the situation is handled promptly and appropriately. 1. Call Poison Control Immediately ๐Ÿ“ž Poison Control Hotline (U.S.): 800-222-1222 Specialists are available 24 hours a day to help determine whether observation at home is sufficient or if a hospital visit is necessary. Have this information ready: The childโ€™s age and weight The productโ€™s name or package (if available) The estimated amount eaten and when it occurred If the child is difficult to wake, vomits repeatedly, or has slowed breathing, call 911 right away. ๐Ÿ’ฌ โ€œPoison Control is not there to judge, itโ€™s there to help.โ€ 2. Stay With the Child and Observe Keep your child in a quiet, softly lit space. Avoid bright lights, screens, or noise. Do not try to induce vomiting, which can worsen confusion or dehydration. Medical teams typically monitor heart rate, oxygen, and alertness for 6โ€“12 hours until symptoms resolve naturally. ๐Ÿฉบ Most children recover fully with rest and hydration. 3. Bring the Package or Label If you visit a clinic or emergency room, bring the packaging or container. The THC strength and serving size help clinicians calculate the likely duration and intensity of effects. If the edible was homemade, describe what ingredients were used and how much was eaten as accurately as possible. 4. Be Honest with Healthcare Providers Transparency saves time and prevents unnecessary tests. Doctors are not required to report accidental cannabis exposures as abuse when they occur in legal households and are reported promptly. Your honesty helps your care team treat your child faster and more effectively. 5. Learn, Adjust, and Prevent Future Incidents Once the crisis has passed, treat it as a learning moment, not a failure. Store edibles in locked or high cabinets. Keep products in original packaging. Make sure all caregivers, babysitters, grandparents, neighbors, know where cannabis is stored and how to respond if a child ever gets into it. ๐Ÿ—ฃ๏ธ โ€œCalm action protects children far more effectively than panic ever will.โ€ The Real Risk: Stigma and Storage, Not Strangers Every October, the same story makes its rounds. Headlines warn of โ€œTHC candy in your neighborhood!โ€ Local news anchors clutch props, police departments post infographics, and parents brace for the worst. Itโ€™s an easy story to tell, and an even easier one to believe. But in all these years, no verified case has ever shown strangers handing cannabis edibles to children on Halloween. Not one. So whatโ€™s really happening? A quieter, more fixable problem: stigma and storage. 1. The Stranger Myth The idea that someone would spend real money on regulated cannabis products, risk criminal charges, and hand them to random kids for amusement is both implausible and unsupported by evidence. Public health agencies and law enforcement across the country have confirmed it year after year: there are zero documented cases of random cannabis-laced candy distribution during Halloween. What does exist are isolated misunderstandings, a teacher in Buffalo who accidentally shared THC gummies, an Illinois investigation involving mislabeled chocolate, a candy recall in the Netherlands due to contamination. None of these involved malicious intent or strangers targeting children. Sociologists and myth researchers have tracked these โ€œHalloween poisoningโ€ panics for decades. Most turn out to be the same thing: rumor amplified by repetition. ๐Ÿ’ฌ Fear sells better than facts. It plays to nostalgia, morality, and the illusion that modern dangers lurk just beyond the doorstep. 2. Why the Myth Persists Fear is a comfortable emotion. It gives us something to do, someone to blame. Blaming โ€œthe strangerโ€ feels safer than facing the truth that most risks live inside our own homes. The โ€œTHC candy scareโ€ isnโ€™t about evil intentions; itโ€™s about our discomfort adjusting to a world where cannabis is normal. For generations, cannabis was hidden, stigmatized, and criminalized. Now itโ€™s a household item, and that cultural shift can be unsettling. Itโ€™s easier to picture a shadowy neighbor with a sinister motive than to say, โ€œMaybe I should buy a lockbox.โ€ 3. The Real Problem: Access at Home This is where the data points. Most pediatric cannabis exposures happen in kitchens, backpacks, nightstands, and cars, not in trick-or-treat bags. Children are curious. Edibles are designed to look friendly. These are accidents of access, not acts of malice. And they are entirely preventable. Lockboxes, opaque containers, and clear labeling save more lives than fear campaigns ever could. ๐Ÿ—ฃ๏ธ โ€œThe conversation needs to shift from โ€˜What if?โ€™ to โ€˜How do we store this responsibly?โ€™โ€ 4. The Hidden Risk: Stigma Stigma is the invisible hazard. It keeps parents quiet. It keeps doctors in the dark. Many adults who use cannabis responsibly feel uncomfortable mentioning it to pediatricians or family members, worried theyโ€™ll be judged. That silence allows small mistakes to go unaddressed and important safety conversations to go unspoken. Responsible use depends on normalization, not secrecy. We already talk about alcohol, prescriptions, and cleaning supplies without moral panic. Cannabis should be no different. 5. The Public Health Lesson The Halloween โ€œTHC candy scareโ€ has never really been about candy. Itโ€™s about communication. When adults share accurate, practical information, children are safer. When communities replace stigma with education, families thrive. Fear closes minds. Education opens them. And the real magic of Halloween is seeing what happens when light meets darkness, and the shadows disappear. Building a Smarter Halloween Conversation Itโ€™s time to move beyond the myth. Each year, sensational headlines spark anxiety, but panic has never prevented a single ingestion. Education has. The smartest path forward is a shared one. Parents, schools, clinicians, dispensaries, and regulators each have a role to play in making Halloween safer, and saner, for everyone. 1. Parents and Caregivers: Normalize Safety Parents set the tone for how children understand risk. Lock up cannabis products. Check candy with calm confidence. Talk honestly about what makes adult products different. Keep it simple. A short, factual, age-appropriate explanation, clear, not fearful, builds lifelong trust. ๐Ÿ’ฌ โ€œThese are for adults, and they can make your body feel strange if you eat them.โ€ Thatโ€™s enough for a child. And for teens, the message is about responsibility, not rebellion. Discuss cannabis the same way you discuss alcohol or medication: with honesty and respect for boundaries. Public health research confirms what every good parent already knows: open communication protects kids better than silence ever will. ๐Ÿ—ฃ๏ธ โ€œFear fades. Trust lasts.โ€ 2. Schools and Communities: Focus on Facts Schools and local organizations shape how families respond to fear. Instead of forwarding viral warnings, they can share verified safety information about storage, labeling, and emergency response. Some communities now host safe candy check events or cannabis awareness nights, simple, practical ways to replace rumor with reassurance. When trusted voices share calm, evidence-based guidance, misinformation loses its grip. ๐Ÿ“š โ€œFacts protect families better than fear ever could.โ€ 3. Clinicians: Keep the Dialogue Open For healthcare professionals, one question can change everything: โ€œDo you keep any cannabis products at home?โ€ Asked neutrally and without judgment, it opens the door for honest dialogue. Most parents who use cannabis want to use it responsibly, they just need to know itโ€™s safe to ask for guidance. ๐Ÿ’ฌ โ€œAs clinicians, our role is to meet people where they are, not where stigma says they should be.โ€ Every open conversation replaces a wall of shame with a bridge of trust. 4. Regulators and Retailers: Make Safety Obvious Policy makers and dispensary owners share responsibility too. Uniform packaging laws and clearly visible THC warning symbols make cannabis products easier for everyone to identify, and harder to mistake for candy. Public health thrives when industry, government, and medicine speak the same language. When regulations emphasize clarity over complexity, safety becomes intuitive, not effortful. ๐Ÿท๏ธ โ€œThe more predictable packaging becomes, the less likely it is to be confused.โ€ The Collective Shift When parents model calm, schools promote facts, clinicians guide without judgment, and regulators uphold transparency, the โ€œTHC candy panicโ€ finally loses its audience. Whatโ€™s left is what Halloween should have been all along: a night of joy, laughter, and connection, where safety is simple and fear has no stage time. ๐Ÿ’ฌ โ€œWhen communities trade panic for partnership, children thrive.โ€ Halloween, Cannabis, and Common Sense: Summary Thoughts Halloween was never meant to be a night of anxiety. Itโ€™s a celebration of imagination, community, and childhood joy. Yet every October, the same fear resurfaces like fog across front lawns: the whisper that danger waits inside the candy bowl. The truth is far simpler, and far less frightening. There is no epidemic of tainted candy. There is no wave of strangers handing out THC gummies. There never has been. What we are living through instead is a new era of shared responsibility. Cannabis now exists in more homes than ever before. That reality calls for awareness, not alarm. Safety doesnโ€™t come from suspicion. It comes from systems. Lock it up. Label it clearly. Educate without fear. When adults model calm, informed behavior, children learn from it. They see that responsibility isnโ€™t rooted in fear, but in respect, for their safety, for our tools, and for the truth. The result isnโ€™t only safer homes, but stronger, more trusting families. ๐Ÿ—ฃ๏ธ โ€œFear doesnโ€™t protect children. Informed adults do.โ€ The Takeaway Enjoy Halloween. Let kids be kids. Let adults be responsible. And let common sense bridge the space between the two. When the porch lights fade and the candy buckets overflow, remember this: Good medicine, good parenting, and good citizenship all rest on the same foundation, trust, truth, and care. ๐Ÿ’ฌ โ€œIn medicine, fear rarely heals. Knowledge does. Halloween shouldnโ€™t be a cautionary tale; it should be a celebration of how far our understanding has come.โ€ – Dr. Benjamin Caplan Empty the Bowl Into Your Bag: What This All Means โ—† There is no evidence of strangers distributing THC-laced candy to children. โ—† Most pediatric exposures happen at home due to improper storage, not malice. โ—† Safe storage, clear labeling, and honest communication prevent almost every incident. โ—† Stigma fuels silence, and silence increases risk. โ—† When parents, schools, clinicians, and policymakers cooperate, safety becomes simple. โ—† The real power lies in education, empathy, and partnership, not panic. ๐Ÿฌ โ€œWhen we replace panic with prevention, we turn fear into public health.โ€ Resources Poison Control Hotline: 800-222-1222 CDC Cannabis Health & Safety: cdc.gov/marijuana CED Clinic Cannabis Encyclopedic FAQ CED Clinic Medical Cannabis Learning Lab Clinical Fellowship at CED Clinic Learn from CED Clinic: Education at CED Read on Amazon: The Doctor Approved Cannabis Handbook Join the Movement! If this guide helped you feel more confident this Halloween, share it with another parent, teacher, or clinician who might need the same calm clarity. ๐Ÿ”— Share this post to help others learn to replace panic with prevention, and help friends trade fear for facts, and myths for mindfulness. ๐Ÿ—จ๏ธ Leave a comment: How are you teaching your kids about adult products this Halloween?   ๐Ÿ“ฌ Subscribe: For more doctor-approved insights on cannabis, health, and responsible public education, subscribe to my newsletter ๐Ÿซฑ Stay Connected For more evidence-based insights on cannabis and public health? Follow for daily updates, patient stories, and clinical education: ๐ŸŒฟ Instagram: @DrBenjaminCaplan ๐Ÿ’ฌ X: @DrCaplan ๐Ÿ•บ TikTok: @DrBenjaminCaplan ๐Ÿ’ผ LinkedIn: Benjamin Caplan, MD ๐Ÿ“บ YouTube Shorts: 2 min or less w/ Dr. Caplan Join the community thatโ€™s replacing panic with prevention, one fact at a time.   [...] Read more...
October 12, 2025A serene portrait of an older woman in natural light, symbolizing dignity and acceptance in later life. Why restraint, humility, and patience remain the most sophisticated tools in modern medicine. The exam room hums. A blood pressure cuff exhales. A printer coughs out another order. Somewhere in the distance, a monitor beeps its steady metronome. Medicine moves quickly now, faster than conversation, faster than comprehension. Yet centuries before this noise, Hippocrates offered something quieter: โ€œSometimes, the greatest medicine is to amuse the patient while nature cures the disease.โ€ Itโ€™s a line so mischievous it feels almost modern, equal parts humility and humor. But beneath the wit lies the oldest paradox in medicine: healing often happens without us. After two decades of practicing, observing, and occasionally intervening too soon, Iโ€™ve learned that one of the hardest, and most healing, skills in clinical life isnโ€™t deciding what to do. Itโ€™s deciding when not to. We are trained to fix, to act, to fight illness as if it were an invader. Yet much of human physiology isnโ€™t at war; itโ€™s negotiating peace. โ€œDoing nothing,โ€ properly understood, is not neglect. Itโ€™s clinical restraint, the discipline to trust the bodyโ€™s design before imposing our own. Thatโ€™s the heart of when to do less in medicine: knowing that sometimes the most sophisticated treatment plan is patience itself. Section 1: The Paradox of Modern Medicine When Progress Outpaces Patience Medicine today is dazzling. We can edit genes, print organs, and predict strokes with algorithms. Our reach has never been longer; our humility, never shorter. Each new tool promises control. Yet with control comes impatience. We no longer tolerate mystery, only measurement. A bruise that lingers or a cough that fades too slowly now feels like an administrative failure. We want proof that something is being done. The irony is that our ancestors, armed with little more than time and touch, often understood healing more deeply. They accepted that recovery is not a straight line but a spiral; that progress sometimes hides behind stillness. Thatโ€™s why the question when to do nothing in medicine is less about hesitation and more about tempo. It asks whether we can match medicineโ€™s velocity to the bodyโ€™s pace without losing the art of listening. The Culture of Constant Care A patient walks in expecting a prescription, a scan, a plan. A doctor, trained to deliver value through action, feels the same expectation. โ€œLetโ€™s wait and seeโ€ rarely satisfies anyone, even when itโ€™s the right call. So the appointment becomes a performance. The doctor prescribes something, anything, just to mark motion. The patient leaves reassured that something happened, though nothing needed to. The cycle continues: more tests, more data, more dependence. But medicine was never meant to be a contest of productivity. It was meant to be a partnership with biology. The problem isnโ€™t our technology; itโ€™s our compulsion to use it every time a symptom whispers instead of screams. If restraint feels radical today, itโ€™s only because weโ€™ve forgotten that restraint built the foundations of medicine itself. The Hidden Erosion of Trust Every unnecessary intervention sends a subtle message: the body cannot be trusted. Over time, both doctor and patient begin to believe it. The patient starts to see each ache as evidence of failure. The doctor sees each quiet recovery as luck rather than physiology. And thus the relationship that once centered on confidence dissolves into mutual doubt. Relearning when to do nothing in medicine is how we rebuild that trust. Itโ€™s how we remind patients, and ourselves, that biology is still the worldโ€™s best healer, given the courtesy of time. Stillness as Skill To an untrained eye, doing nothing looks like absence. But in clinical hands, itโ€™s precision. Itโ€™s a diagnostic decision, an ethical posture, a kind of faith that grows only through experience. A young physician wants to act; a seasoned one wants to understand. Stillness becomes a measure of mastery, the quiet calculus of risk versus rhythm, of possibility versus probability. Every time a doctor resists the urge to intervene, they are practicing the oldest form of care: protection. Protecting the body from overtreatment, the mind from panic, and the trust between them from erosion. Thatโ€™s the paradox of progress: the better medicine becomes at doing, the more vital it becomes to remember not doing. In the beginning, medicine was defined by observation, the art of watching time unfold and learning its language. But that humble art has largely transformed into hyper-intervention, and what was lost in the transition. Section 2ย  From Humble Observation to Hyper-Intervention The Watchful Origins Medicine began with observation.ย  The earliest healers spent more time listening than lecturing, more time watching than working.ย  Their instruments were eyes, hands, and time.ย  They measured healing by mornings survived and nights endured. Observation wasnโ€™t passivity, it was participation.ย  They knew that most illness obeyed its own timeline, and that the physicianโ€™s task was to follow, not force, that rhythm.ย  They treated nature as a senior colleague. That humility built medicineโ€™s foundation.ย  A fever wasnโ€™t instantly suppressed; it was interpreted.ย  A cough wasnโ€™t silenced; it was studied.ย  The job was not to conquer the body but to converse with it. The Industrial Turn Then came penicillin, radiology, and surgical steel. With every invention, medicine grew louder. The stethoscope became a symbol not of listening, but of authority. The new goal wasnโ€™t to wait, it was to win. And with that new goal came a quiet shiftโ€”healing became performance. By the mid-twentieth century, hospitals resembled factories: conveyor belts of diagnostics and procedures.ย  โ€œObservationโ€ became an old-fashioned word, replaced by โ€œwork-up.โ€ย  Physicians were rewarded for action, not judgment.ย  Patients, re-trained by culture, began to equate treatment with value. The result was a quiet distortion: success became measured by activity, not by outcome.ย  A doctor who intervened was competent; a doctor who watched was careless.ย  Itโ€™s little wonder that restraint started to look like failure. The Age of Data, the Death of Doubt Today, we quantify everything, heart rates, step counts, hours slept, even โ€œrecovery timeโ€ rendered in decimals.ย  Technology has given us omniscience, but it has stolen our tolerance for uncertainty. Yet uncertainty is where healing lives.ย  Without it, we react instead of reason.ย  When every blip on a monitor triggers a reflex, the patient becomes a project, and the physician becomes a manager of numbers. Thatโ€™s the deeper question inside when to do nothing in medicine: can we rediscover curiosity in an era allergic to pause? The Arrogance of Control We have mistaken capability for command.ย  Because we can measure, we believe we must modify.ย  But control without humility becomes violence, gentle, clinical, data-driven violence.ย  The urge to fix every fluctuation flattens the bodyโ€™s natural conversation with itself. True medical maturity is knowing the limits of mastery.ย  The modern challenge isnโ€™t ignorance, itโ€™s intoxication with knowledge. And that intoxication is costly.ย  Every intervention, no matter how small, ripples outward.ย  Each test changes probability; each procedure changes identity.ย  Somewhere between intention and outcome, the line between healing and harm blurs. Reclaiming the old patience doesnโ€™t mean rejecting progress.ย  It means tempering it.ย  Machines can reveal truth, but only humans can decide when truth needs translation. The future of medicine may depend less on discovering new treatments than on rediscovering proportion, the courage to let biology breathe before technology intervenes. Section 3ย  The Wisdom of Waiting: The Biology of Self-Repair Natureโ€™s Default Setting Every cell in the human body carries a blueprint for recovery.ย  Broken bones knit.ย  Inflamed tissue cools.ย  Nerves regrow with microscopic patience.ย  Healing is not a miracle we summon; itโ€™s a process we interrupt. To ask when to do nothing in medicine is to remember that the body, left to its own devices, rarely chooses chaos.ย  It chooses recalibration.ย  The physicianโ€™s task is not to accelerate that process, but to know when acceleration would distort it. The Immune Systemโ€™s Slow Intelligence Consider the immune system, a living archive that learns, forgets, and revises.ย  A fever is not failure; itโ€™s strategy.ย  Inflammation is not injury; itโ€™s orchestration.ย  When we rush to extinguish every symptom, we silence the bodyโ€™s internal dialogue about defense and memory. Patience is the immune systemโ€™s tutor.ย  Antibiotics, used indiscriminately, turn that classroom into static.ย  To practice restraint here is not neglect, itโ€™s respect. The Endocannabinoid Example The endocannabinoid system, our molecular mediator, embodies this principle.ย  It balances excitation with inhibition, pain with relief, hunger with satiety, inflammation with repair.ย  Its mission is moderation. Cannabis medicine often works not by overpowering the body, but by whispering to it, restoring homeostasis rather than rewriting code.ย  Thatโ€™s a modern illustration of doing nothing dramatically: supporting balance without forcing outcome. For anyone curious about this quiet regulator, Iโ€™ve written more here: ๐Ÿ‘‰ https://doctorapprovedcannabis.substack.com/p/modernizing-medicine-why-medicare Pain as Information, Not Emergency Pain isnโ€™t always a command to act; sometimes itโ€™s an invitation to notice.ย  A sore back after gardening, a tendon that protests new shoes, these are lessons, not alarms.ย  Yet in a medical culture that monetizes certainty, discomfort has become intolerable. The wisdom lies in being able to distinguish signal from noise.ย  If the pain teaches without disabling, the right prescription may be posture, patience, or perspective.ย  Not every signal deserves a siren. The Patience Paradox The deeper you study biology, the more it teaches delay.ย  Tissues regenerate on timelines that make human schedules laughable.ย  Collagen doesnโ€™t care about calendars.ย  White blood cells donโ€™t multitask. Thatโ€™s the paradox of when to do nothing in medicine: the slower we go, the faster we often heal.ย  Each day of patience lets physiology do its invisible work, unhurried and precise. Doing nothing, then, isnโ€™t idleness, itโ€™s choreography.ย  Itโ€™s the science of allowing. Section 4ย  When Doing Nothing Is Doing Something The Discipline of Delay โ€œDoing nothingโ€ sounds like surrender. But in medicine, it can be the most deliberate act of all. Every experienced clinician eventually learns that the decision not to intervene is never a default, itโ€™s a diagnosis. When we talk about when to do nothing in medicine, weโ€™re not talking about ignoring illness. Weโ€™re talking about acknowledging biology. Weโ€™re talking about the small, precise discipline of letting the body lead. In practice, this means choosing stillness not out of fear, but out of proportion. It means remembering that most of the bodyโ€™s systems are older, smarter, and better rehearsed than we are. To wait, then, is not weakness, itโ€™s reverence. The Foot That Simply Hurts A patient comes in with a plantar wart thatโ€™s been there for years. It doesnโ€™t grow, doesnโ€™t spread, doesnโ€™t limit walking. Itโ€™s simplyโ€ฆ there. Could it be treated? Of course. There are chemical peels, cryotherapy, laser ablations, all effective. But effective for what? For removing an irritation that the body and the mind have already learned to coexist with. In cases like this, the intervention solves a cosmetic inconvenience by introducing real risk, pain, infection, or recurrence. Sometimes the better medicine is the one that protects a patient from unnecessary victory. The question isnโ€™t can we remove it? Itโ€™s why should we? Thatโ€™s the quiet logic inside when to do nothing in medicine: if it doesnโ€™t hinder your life, maybe it doesnโ€™t need to leave it. The Bones That Complain Another patient: mid-forties, active, walks a lot. Recently, the outer bones of their feet ache after long days. Tight shoes. Longer commutes. No trauma, no swelling, just discomfort. The modern reflex? A referral to podiatry, imaging, orthotics, maybe surgery. But what if the simplest solution is also the truest one? New shoes, gentler routines, or rest. Medicine often acts like a mechanicโ€™s shop, find the noise, replace the part. But bodies are not machines. Theyโ€™re ecosystems. A change in one area ripples through the whole. Fixing the noise can disturb the harmony. Sometimes, the smartest fix is no fix at all. When Doctors Wait, and When Patients Do The decision when to do nothing in medicine doesnโ€™t always belong to the doctor. Sometimes it belongs to the patient. Doctors know disease; patients know themselves. They know the exact flavor of their discomfort, the cost of their worry, the risk they can tolerate. A patient might choose to live with a mild ache if it means avoiding surgery. Another might endure a scar if it means removing a shadow of fear. The art lies in conversation. A doctor offers expertise; a patient offers experience. Between them, good medicine emerges, a partnership grounded in both science and self-awareness. The Medicine of Protection Each time we choose observation over intervention, we are not withholding care; weโ€™re protecting it. Every unnecessary procedure avoided is an injury prevented. Every overprescribed pill withheld is a microbiome spared. โ€œDoing nothingโ€ is not the absence of care. It is care refined to its essence: the act of protecting the patient from us. But restraint isnโ€™t only a personal virtue; itโ€™s a structural challenge. Even the best intentions struggle in a system that rewards motion and punishes reflection. Section 5ย  The Hidden Costs of Over-Intervention The Price of Too Much Medicine Modern healthcare is a marvel, and an industry. Those two truths donโ€™t always coexist peacefully. Every intervention is both medicine and merchandise, and that duality has consequences. The intention behind most overtreatment is noble. A physician wants to help. A patient wants relief. But the momentum of that good intention often rolls downhill, gathering costs and complications along the way. Over time, a culture built on โ€œjust to be safeโ€ becomes one where no one feels safe without doing something. The Cascade Effect Ask any experienced clinician about โ€œthe cascade,โ€ and theyโ€™ll sigh. Itโ€™s the domino effect that begins with a well-meaning test and ends with a story of regret. A patient complains of back pain. The doctor, cautious, orders an MRI. The scan finds a disc bulge, completely normal for age. But once itโ€™s written in the chart, it becomes a problem that must be solved. The patient sees a specialist, receives an injection, maybe surgery. The pain persists, but now the spine is scarred. The first step was curiosity. The last was catastrophe. Each link in that chain made sense on its own. Together, they formed a trap. Thatโ€™s the paradox of when to do nothing in medicine: itโ€™s easy to do something, and impossible to undo it all. The Surgery That Solved Nothing Some of the most common orthopedic surgeries, meniscus repairs, spinal fusions, shoulder arthroscopies, often perform no better than placebo in long-term studies. Yet they persist, supported by habit, reimbursement, and the collective discomfort with waiting. The scars they leave are not only physical. They alter gait, posture, even confidence. Once the body is changed, the baseline is lost forever. The doctorโ€™s intention may have been compassion, but the outcome becomes complexity. The patient wanted relief; they received dependency. Knowing when to do nothing in medicine is not a denial of suffering. Itโ€™s an act of mercy against the illusion that every suffering has a fix. The Emotional Fallout Over-intervention changes psychology as much as physiology. A patient who undergoes repeated treatments begins to identify as fragile. The more tests we order, the more broken they feel. Itโ€™s an invisible side effect: dependence on the healthcare system itself. The patient stops trusting their own body, and the doctor stops trusting nature. Itโ€™s a quiet collapse of confidence on both sides. Rebuilding that trust starts with one phrase: โ€œLetโ€™s wait.โ€ Doctors in the Crossfire To be fair, restraint is not easy in a system designed to reward activity. Doctors face lawsuits for missing a disease, never for overtreating one. Insurance reimburses procedures, not perspective. Clinics measure productivity, not patience. And yet, integrity in medicine has never been about metrics, itโ€™s about judgment. Every physician must decide whether to follow the culture of fear or the craft of discernment. When to do nothing in medicine is not a skill that can be taught in medical school. Itโ€™s something learned in the slow apprenticeship of humility, usually from the cases that haunt us most. The Modern Appetite for Excess We have learned to mistrust moderation. We want more: more protein, more news, more testing, more reassurance. But excess, in any form, eventually becomes its opposite. Over-eating leads to sickness. Over-treating leads to fragility. Over-diagnosing leads to anxiety. If the twentieth century was the age of discovery, perhaps the twenty-first must be the age of restraint, the rediscovery of limits. Constant intervention doesnโ€™t only exhaust patientsโ€”it drains doctors, too. Each unnecessary prescription or test tightens the loop of urgency until reflection feels like failure. Restraint, paradoxically, restores the clinicianโ€™s pulse. It returns medicine to a rhythm that includes breathing room for both healer and healed. Because when we treat every inconvenience as pathology, we forget that the human condition itself was never meant to be painless. Thereโ€™s an antidote to all this activity, and itโ€™s surprisingly simple: conversation. The next step in learning when to do nothing in medicine is learning how to decide it together, patient and physician, expertise and experience, science and self. Section 6ย  Shared Decision-Making: Who Gets to Decide When to Wait? Medicine as a Dialogue Every discussion about when to do nothing in medicine eventually becomes a question of voice: whose wisdom leads, and whose experience defines โ€œenough.โ€ Doctors bring data; patients bring context.ย  The best outcomes happen where those meet, not in a contest of certainty, but in a conversation about tolerance, timing, and trust. Modern care has moved from command to collaboration.ย  โ€œDoctor knows bestโ€ has softened into โ€œletโ€™s decide together.โ€ย  That shift may be medicineโ€™s quiet revolution. The Two Clocks Physicians work by laboratory clocks: half-lives, follow-ups, recovery curves.ย  Patients live by human ones: birthdays, job shifts, sleepless nights.ย  Reconciling those clocks is the art of restraint. A doctor may say, โ€œLetโ€™s check again in two weeks.โ€ย  A patientโ€™s anxiety may reply, โ€œI canโ€™t wait that long.โ€ย  The compromise might be a phone update, a photo, or reassurance that change, not perfection, is the goal.ย  That small adjustment turns waiting into care. Knowing Yourself as Data This is where know-yourself medicine meets evidence-based care.ย  In cannabis practice, Iโ€™ve long argued that self-awareness is a vital diagnostic tool,ย  the same principle applies here. A patient who knows their thresholds, pain, worry, patience, gives the physician better data than any scan.ย  (More on that philosophy here: doctorapprovedcannabis.com/know-yourself) The doctorโ€™s charts describe the body; the patientโ€™s insight describes the life inside it.ย  Both are required for genuine healing. Trust as Treatment To choose observation together is to choose trust: trust that the doctorโ€™s restraint isnโ€™t neglect, and that the patientโ€™s body isnโ€™t brittle.ย  Studies show that shared decision-making lowers procedure rates and raises satisfaction, even when symptoms linger. Thatโ€™s because reassurance itself is medicine.ย  It steadies cortisol, restores agency, and gives uncertainty a name.ย  The body relaxes when it knows itโ€™s being seen. If trust is treatment, then aging is the final exam.ย  The same principles that govern watchful waiting also govern acceptance,ย  learning what to honor, what to release, and when the chase for youth becomes the theft of peace. Section 7ย  The Aging Body and Acceptance Aging Is Not Error The body ages by design.ย  Cells slow their repair, joints stiffen, memory edits what it keeps.ย  Yet our culture treats every creak as pathology.ย  Advertisements promise reversal, not relationship. But one of the deepest lessons in when to do nothing in medicine is that some changes are not to be fought, theyโ€™re to be understood. Aging is not decay; itโ€™s translation.ย  The body speaks the same language, just in a lower register. The Temptation to Tinker Medical progress has made miracles routine.ย  But abundance invites overreach.ย  Each new test offers to reveal something โ€œfixable,โ€ and each discovery invites intervention. A mild arrhythmia gets ablated; a benign lump gets biopsied; a knee with character becomes a knee with hardware.ย  Some of these save lives.ย  Many simply rearrange them. Wisdom means distinguishing age from illness.ย  Itโ€™s saying, โ€œThis is wear, not warning.โ€ย  Itโ€™s learning that longevity without serenity isnโ€™t victory. Dignity as Outcome When older patients tell me theyโ€™re tired of tests, theyโ€™re rarely giving up.ย  Theyโ€™re reclaiming authorship.ย  Theyโ€™re saying, โ€œI know what matters to me now.โ€ The physicianโ€™s role shifts from engineer to translator, to help them live meaningfully inside the bodies they have, not endlessly pursue the bodies they lost. Quality of life isnโ€™t measured in lab values; itโ€™s measured in mornings that still feel like yours. Acceptance as Medicine Acceptance is not resignation.ย  Itโ€™s alignment.ย  It replaces denial with perspective and panic with proportion. Clinically, it lowers blood pressure, tempers anxiety, and reduces unnecessary interventions.ย  Philosophically, itโ€™s medicineโ€™s return to humanity: the moment we stop fighting time and start conversing with it. Aging gracefully and practicing gently are twin disciplines.ย  Both rely on the same faith, that enough is still enough. Medicineโ€™s final virtue, after curiosity and compassion, is humility.ย  The closing reflection explores how humility transforms both doctor and patient, and why, in the end, restraint may be the most advanced technology we have. Section 8ย  Reclaiming Medical Humility Listening Again After all the scans, screens, and second opinions, medicine always circles back to listening.ย  The body speaks; the physician interprets; time confirms.ย  Everything else is translation. Humility is the physicianโ€™s stethoscope on the unseen, the willingness to say, โ€œI donโ€™t know yet.โ€ย  That sentence, spoken honestly, has saved more patients than any prescription written in haste. The Quiet Expertise Young doctors act.ย  Seasoned doctors discern.ย  The best ones explain their hesitation as part of healing. In a profession built on precision, restraint may be its highest art.ย  It demands presence, patience, and perspective, the three elements least taught and most tested. Mastery and Mercy Every generation rediscovers the same law: the body is wiser than our instruments, and time remains its oldest ally.ย  Mastery without mercy becomes mechanics.ย  Mercy without mastery becomes sentiment.ย  True medicine lives between them. When to do nothing in medicine is that middle path, a discipline of proportion, a theology of trust.ย  Itโ€™s not about withholding help but about choosing the kind that harmonizes rather than overwhelms. Because sometimes the cure is time. The medicine is trust. And the doctorโ€™s role is restraint. If all this sounds philosophical, it isnโ€™t. These ideas live in the small moments between visits, in the questions we ask and the silences we allow. Hereโ€™s how they look in practice. FAQ – When Should a Doctor Watch and Waitย  1. When should a doctor choose to โ€œdo nothingโ€? When observation is safer than intervention, such as self-limiting infections, mild pain, or stable conditions, waiting allows natural recovery without unnecessary risk. The key is informed monitoring (expert-guided), not neglect. 2. Is โ€œdoing nothingโ€ a real medical strategy? Yes. In medicine, itโ€™s called watchful waiting or conservative management, an evidence-based approach used in pediatrics, oncology, psychiatry, and primary care. 3. How does the body heal on its own? Through coordinated biological systemsโ€”immune, endocrine, and endocannabinoidโ€”that repair tissue, clear infection, and recalibrate balance when given time. 4. What are the risks of over-treating? Over-treatment increases medication side effects, infection risk, anxiety, and cost, while sometimes causing new chronic problems that didnโ€™t exist before. 5. How can patients know when to wait and when to act? By communicating openly about symptom severity, function, and risk tolerance. Shared decision-making replaces panic with partnership. 6. What is the role of the endocannabinoid system here? It exemplifies balance. The ECS helps regulate pain, mood, and inflammation, among other important dutiesโ€”reminding us that equilibrium, not aggression, is the bodyโ€™s preferred mode of healing. 7. Does aging change the decision to intervene? Yes. With age, the cost of intervention rises while benefits narrow. Acceptance and proportion often bring greater comfort than continual repair. 8. Why do doctors overtreat if they know the risks? Systemic pressure, liability fears, and cultural expectations reward action. Restraint requires courage and supportive policy. 9. Is โ€œless is moreโ€ supported by research? Absolutely. Studies in internal medicine and geriatrics show that minimalist approaches often yield equal or better outcomes with fewer harms. 10. What can patients ask their doctor to encourage restraint? Questions like โ€œWhat happens if we wait?โ€ or โ€œWhatโ€™s the natural course of this?โ€ or โ€œDo I have to research some other ideas or directions?โ€ invite collaboration and reintroduce time as part of therapy. Miss These Internal Links? Cannabis-Infused Veggie Stir Fry: A Healthy, High-Fiber, High-Vibe Dinner Tylenol and Autism: 7 Insights You Need Now Cannabinoids Against MRSA: 5 Surprising Findings You Should Know External Links: โ€˜What happens if I do nothing?โ€™ A Systematic Reviewย  When Doing Nothing is The Best Medicine – New York Timesย  Wikipedia: The Hippocratic Oath NEMJ: The Art of Doing Nothing     [...] Read more...
September 6, 2025Pregnancy pain relief, family genetics, and a controversial debate collide in modern medicine What Youโ€™ll Learn in This Post โ‡๏ธ How acetaminophen (Tylenol) use in pregnancy became a global health debate โ‡๏ธ ย What the latest 2025 systematic review really found about Tylenol and autism โ‡๏ธ The hidden role of genetics, fever, and family factors in research results โ‡๏ธ Why guidelines still recommend Tylenol as the first-line pregnancy medication โ‡๏ธ Where emerging therapies, including cannabis, might play a future role in care Tylenol and Autism: A Debate as Tangled as Parenthood Itself Picture this: a pregnant woman sits on the edge of their bed, cradling a pounding head, a thermometer flashing a fever, a baby kicking inside. On the nightstand sits a small, familiar bottle: Tylenol. For decades, acetaminophen has been the safe choice for pregnancy pain relief. But recent research has cracked open a question that strikes at the heart of modern parenting: Could that same pill be linked to autism or ADHD in children? The stakes are monumental. Over half of pregnant individuals worldwide use Tylenol. Even the faintest whiff of risk sends shockwaves through families, public health agencies, and the scientific community alike. And like every modern health debate, the conversation quickly spirals from cautious curiosity into cultural chaos. The 2025 Super-Study That Shook the Conversation This year, Prada, Ritz, Bauer, and Baccarelli published a comprehensive systematic review in Environmental Health. Their analysis sifted through 46 human studies spanning millions of pregnancies, examining the potential connection between Tylenol and autism. The results? A scientific Rorschach test, with patterns open to interpretation rather than clear, causal answers. 27 studies reported a positive link between prenatal Tylenol use and later ADHD or autism in children. 9 studies found no connection at all. And in a surprising twist, 4 studies even hinted at a protective effect. Faced with this messy mosaic, the authors took a bold stance: no meta-analysis. Why? Because combining wildly different studies into one pooled number would risk false precisionโ€”like trying to average a symphony with a rock concert and calling it music. Instead, they offered a qualitative synthesis, weighing each studyโ€™s context, strengths, and flaws. Their conclusion was carefully worded: โ€œThe evidence is consistent with an association.โ€ Not proof. Not panic. Just a signal worth paying attention to. When Fever, Genes, and Families Muddy the Waters Itโ€™s tempting to leap from โ€œassociationโ€ to โ€œcausation,โ€ but observational research is notoriously tricky. Enter one of scienceโ€™s slipperiest villains: confounding by indication. Imagine two pregnant people: One takes Tylenol for a mild headache. The other takes it to lower a dangerous fever caused by an infection. If their children later develop ADHD or autism, is the culprit the Tylenolโ€ฆ or the feverโ€ฆ or the infection itself? Or perhaps something invisible, like shared genetics? Untangling these threads is like playing a game of โ€œdog-face, frog-face, bog-faceโ€โ€”silly words, serious stakes, each possibility morphing into the next before your eyes. The Sibling-Control Study That Flipped the Script To fight back against confounding, researchers use sibling-comparison studies, a clever design that compares siblings born to the same mother. This automatically controls for many shared genetic and environmental factors. A 2024 JAMA study applied this approach to an astonishing 2.5 million Swedish children. When siblings were compared, the apparent link between Tylenol and autism or ADHD vanished. No increased risk. No dramatic headlines. Just the quiet suggestion that earlier studies might have been tracing the outlines of family genetics and household environments, not a direct drug effect. This doesnโ€™t close the case. It cracks it wide open. It says, โ€œSlow down. Look again.โ€ Biomarkers and Blood Clues: A Twist in the Tale While most studies rely on self-reported Tylenol use (โ€œDid you take any during pregnancy?โ€), a few cutting-edge investigations went deeper. They measured acetaminophen metabolites in umbilical cord blood. These biomarker studies found something provocative: dose-response relationships. The higher the Tylenol levels in the blood, the higher the observed risk of ADHD and autism diagnoses later in childhood. Itโ€™s like finding footprints at a crime scene. But even then, we donโ€™t know whoโ€”or whatโ€”left them. Were those footprints evidence of Tylenolโ€™s direct effects, or simply a marker of severe illness and fever requiring higher doses? Guidelines Havenโ€™t Changed, and Hereโ€™s Why Despite this growing swirl of research, ACOG and other leading medical organizations continue to recommend acetaminophen as the first-line treatment for pain and fever during pregnancy. The guidance is straightforward: Use Tylenol only when medically necessary Keep the dose low Keep the duration short Talk to your doctor before prolonged or frequent use Why the continued support? Because untreated fever and severe pain also carry significant risks for mother and baby. Avoiding Tylenol entirely could do more harm than good. The View From My Clinic: Hundreds of Families, Endless Questions In my practice, I care for hundreds of families raising children on the autism spectrum. If thereโ€™s one truth I carry with me, itโ€™s this: there is deep, often invisible suffering in these households. Autism touches everythingโ€”school mornings, mealtimes, sleep, sibling relationships. Parents fight exhausting battles for services and understanding, often in silence. The science may be tangled, but the pain is plain. Some families find relief in unexpected places, including carefully guided cannabis treatments for symptoms like anxiety, sleep disturbances, and severe behavioral outbursts. But cannabis is not a cure, and like Tylenol, it demands respect and precision. The real work ahead isnโ€™t to vilify one drug or glorify anotherโ€”itโ€™s to listen, to research better, and to build systems that support families no matter where the science currently stands. Public Panic vs Public Understanding Hereโ€™s the problem: nuanced scientific statements donโ€™t go viral. Headlines do. โ€œThe evidence is consistent with an associationโ€ becomes โ€œTylenol causes autism!โ€ by the time it hits social media. This misunderstanding can lead to dangerous outcomes. Pregnant people might avoid treating high fevers, risking miscarriage or serious complications. Others might spiral into guilt years later, wondering if their choice of pain reliever shaped their childโ€™s future. We need a new cultural approach: one that values caution without fearmongering, and transparency without blame. My Take: Complexity Over Certainty Tylenol and autism. Fever and genetics. Association and causation. This isnโ€™t just a scientific puzzleโ€”itโ€™s a reflection of how messy real life is. The story isnโ€™t over. It may never have a tidy ending. But by embracing complexity, we move closer to truth. And by caring for families with compassionโ€”whether through traditional medicine, cannabis-based therapies, or simply listeningโ€”we honor the lives behind the data. ย  More of my writing on this topic Expecting and Experimenting (Cannabis and Pregnancy) Pregnant & Curious: Unpacking Cannabis Myths, Risks & Research Hyperemesis, Cannabis, and a Motherโ€™s Courage: Rayโ€™s Story of Survival and Advocacy Cannabis as a Potential Solution for Metabolic Syndrome News reports on this topic Washington Post Financial Times NY Post Reporting The Daily Beast How CED Clinic Supports Families Living With Autism For families living with autism, there is often a deep longing for options that bring more peace and stability to daily life. At CED Clinic, weโ€™ve had the privilege of supporting hundreds of familiesโ€”from young children to adults on the autism spectrumโ€”through guided cannabinoid therapies. Medical cannabis isnโ€™t a one-size-fits-all solution, and it may not be right for every family, but for many, it has opened doors to calmer nights, better communication, and a sense of hope. If youโ€™re curious or simply exploring whatโ€™s possible, weโ€™re here to listen, answer questions, and help you consider whether this approach might be a fit for your loved one. Sometimes, just starting the conversation can be the most important first step. To learn more, email Jackย  10 FAQ Q&A about Tylenol and Autism 1. Does Tylenol use during pregnancy cause autism? Current evidence shows associations but not proof of causation. A 2025 systematic review found many positive links, but a massive sibling study suggests family genetics and environment may explain the connection. This means Tylenol may not be directly responsible. Itโ€™s a question still under study. 2. What is confounding by indication, and why does it matter? Confounding by indication occurs when the reason for taking a drugโ€”like fever or infectionโ€”affects outcomes. For Tylenol, this means itโ€™s hard to separate the effect of the drug from the effect of the fever itself. This is a major challenge in pregnancy research. Itโ€™s like mixing up footprints at a crime scene. 3. Are sibling studies more reliable than other research designs? Sibling studies compare children born to the same mother, controlling for shared genetics and environment. The 2024 Swedish study using this method found no link between Tylenol and autism or ADHD. While powerful, sibling studies have their own limitations. Still, they provide valuable context for interpreting associations. 4. Why havenโ€™t guidelines changed if thereโ€™s a possible link? Guidelines like ACOGโ€™s continue to support Tylenol use because untreated fever and severe pain also carry risks. The evidence for harm is observational and conflicting. Until causation is proven, the balance of risks favors careful, minimal Tylenol use. This approach prioritizes both safety and necessity. 5. How can parents safely use Tylenol during pregnancy? Use the lowest effective dose for the shortest time needed. Always consult a healthcare provider before prolonged use. Keep track of why and how often you take it. Context matters just as much as the medication itself. 6. What do biomarker studies reveal about Tylenol and autism? Biomarker studies measure Tylenol directly in cord blood, reducing recall errors. Some have found dose-response patterns linking higher levels to higher autism risk. These findings are intriguing but still confounded by why the medication was needed. They add clues but not final answers. 7. Are there alternatives to Tylenol for pregnancy pain? Some non-drug approaches include rest, hydration, and gentle physical therapy. In certain cases, guided cannabis-based therapies may help with related symptoms, but these require expert oversight. Discuss options openly with a knowledgeable clinician. Safety varies greatly depending on circumstances. 8. How do media headlines distort the science? Headlines often simplify nuanced findings into fear-inducing statements. โ€œEvidence consistent with associationโ€ becomes โ€œTylenol causes autism!โ€ This fuels panic and guilt without improving understanding. Responsible communication is vital for families. 9. Should pregnant people completely avoid Tylenol? No – not necessary. Completely avoiding Tylenol could lead to untreated fevers, which are dangerous for both parent and baby. Instead, use Tylenol thoughtfully and sparingly, guided by a clinician. Balance is key. 10. What is the future of research on Tylenol and autism? The next frontier includes integrating biomarkers, genetics, and better tracking of fever and infection. Sibling studies and negative controls will play a major role. The goal is to finally untangle causation from correlation. Until then, careful interpretation is essential. [...] Read more...
August 24, 2025What cannabis compounds reveal about fighting superbugs and sticky biofilms The Unexpected Bouncers at the Microbial Party Antibiotic resistance is one of those global problems that doesnโ€™t make the nightly news nearly as often as it should. Yet behind the scenes, bacteria like MRSA (methicillin-resistant Staphylococcus aureus) are doing their best impression of an uninvited houseguestโ€”spreading, sticking, and refusing to leave. MRSA hides in sticky biofilms, resists the standard cleaning crew of antibiotics, and has cost hundreds of thousands of lives worldwide. Now imagine, in this microscopic standoff, a group of unlikely enforcers shows up: cannabinoids. Yes, the very compounds more famous for easing pain, calming anxiety, or sparking debate at dinner tables may also have a knack for dealing with MRSA. Recent laboratory studies on cannabinoids against MRSA reveal that some cannabis molecules donโ€™t just hang aroundโ€”they bust biofilms, punch holes in bacterial membranes, and set off oxidative fireworks. This isnโ€™t to say weโ€™re about to start prescribing cannabis oil for infected knee replacements. But it does raise eyebrows, and maybe hope, that cannabinoids could one day expand their rรฉsumรฉ into the world of infectious disease. ย  What Youโ€™ll Learn in This Post ๐Ÿฆ  Why MRSA is such a notorious, sticky foe in hospitals and beyond ๐ŸŒฟ How cannabinoids against MRSA show potent lab activity, sometimes rivaling standard antibiotics โฑ Which cannabinoid compounds act like sprinters (rapid kill) and which work like burglars sneaking into biofilms โšก The biological tricksโ€”ROS bursts and membrane disruptionโ€”that explain how these molecules do their dirty work ๐Ÿšง Why the leap from petri dish to patient care is a long road, with obstacles like serum binding and delivery challenges Study Reference: Who, What, and Where For readers who like to see the fine print, the work weโ€™ve been discussing comes from the paper โ€œThe Anti-Biofilm Activity of Cannabinoids Against Methicillin-Resistant Staphylococcus aureusโ€ authored by Islam M. Khalifa, Katherine E. Jones, Surendra Raj Sharma, Bhaskar Chellappan, and Joshua P. King. By naming the study directly, it helps underscore that these insights arenโ€™t speculationโ€”they come from peer-reviewed research exploring cannabinoids against MRSA in rigorous laboratory assays. Why MRSA Matters More Than We Admit If bacteria had yearbooks, MRSA would be voted โ€œMost Likely to Overstay Its Welcome.โ€ Itโ€™s not just another germโ€”itโ€™s the bacterial equivalent of a master lock-picker. Resistant to methicillin and related antibiotics, MRSA has become a poster child for antimicrobial resistance, a problem the Lancet estimated kills more than 1.27 million people globally every year. Thatโ€™s not counting the millions more whose lives are cut short because drug-resistant infections complicated their care. Hereโ€™s where MRSA stands out from the microbial crowd: its knack for forming biofilms. Picture an invisible Jell-O mold that bacteria build to live inside. These slimy fortresses cling to catheters, joint replacements, heart valves, and even wounds. Once MRSA sets up shop inside a biofilm, antibiotics and immune cells struggle to get through. Itโ€™s part shield, part sticky glue, and part chemical fortress. For patients, this means infections that drag on for weeks, months, or even years. For hospitals, it means longer stays, higher costs, and endless headaches. And for researchers, it means the hunt for novel toolsโ€”new compounds, new approaches, new bouncers who can shove MRSA out the doorโ€”isnโ€™t optional, itโ€™s urgent. This is why the recent lab work exploring cannabinoids against MRSA is more than just a curiosity. It hints at a possible new playbook: one where plant-derived molecules donโ€™t simply reduce pain or calm nerves, but also cut through biofilms and put pressure on some of the toughest bugs in modern medicine. What the Lab Reveals About Cannabinoids Against MRSA When researchers put MRSA and cannabinoids in the same petri dish, the results were eye-catching. All five of the major cannabis compounds testedโ€”CBD, THC, CBN, CBG, and CBCโ€”showed the ability to stop MRSA in its tracks at impressively low concentrations. For context, CBD held its ground with a minimum inhibitory concentration (MIC) of about 2 ยตg/mL, which in this model matched the MIC of vancomycin, one of the last-resort antibiotics hospitals cling to. The othersโ€”THC, CBN, CBG, and CBCโ€”were even more potent, clocking in at MICs around 1 ยตg/mL. Thatโ€™s not nothing. But the real fun began when the researchers looked at how each cannabinoid behaved beyond the basic growth test. CBC proved itself the sprinter of the group, causing a near-total collapse of MRSA populations in just 30 minutes at double its MIC. CBG wasnโ€™t far behind, clearing the bacteria within an hour. CBN, THC, and CBD eventually finished the race too, but they needed about four hours to reach the same point. Think of CBC as the Usain Bolt of bacterial takedown, while the others jogged in for a later victory lap. Then there was the matter of MRSAโ€™s sticky calling card: biofilms. In this department, CBN and CBG shined brightest. CBN, in particular, reduced the viability of biofilm-embedded bacteria by roughly 85% at just 1 ยตg/mL. Thatโ€™s a big deal, because biofilms are notoriously stubbornโ€”like coffee stains on white shirts, they cling to surfaces and resist every attempt to wash them out. Different cannabinoids also showed different โ€œstylesโ€ of attack. CBD was especially good at punching holes in bacterial membranes, while CBN and CBG ramped up reactive oxygen species (ROS)โ€”a chemical storm inside bacterial cells thatโ€™s a little like setting off fireworks in a crowded room. Together, these varied tactics give cannabinoids against MRSA a kind of tag-team versatility: some slash through defenses, others stir up chaos from the inside. Of course, all this happens in a controlled lab setting, without the messiness of blood, tissue, or an immune system. But as a proof-of-concept, the results are intriguing: cannabis molecules can act as both sprinters and burglars, racing toward free-floating bacteria while also sneaking into biofilms that most antibiotics can barely scratch. How These Cannabinoids Do Their Dirty Work So how do cannabinoids against MRSA actually land their punches? It comes down to two main tricks: messing with membranes and unleashing chemical chaos. First, membranes. Bacterial cells are wrapped in delicate lipid envelopes, a bit like soap bubbles. If you poke enough holes in those bubbles, the whole thing collapses. Thatโ€™s what CBD excelled at in this studyโ€”acting like a pin in a crowded balloon shop. The result? Bacteria leak, deflate, and die. Then thereโ€™s the fireworks show: reactive oxygen species (ROS). Think of ROS as tiny chemical grenades that, when unleashed inside a bacterial cell, shred DNA, proteins, and everything in between. CBN and CBG were especially good at turning up the ROS dial, cranking the cellular chaos to 11. In lab tests, CBN generated nearly an eight-fold surge in ROS, while CBG wasnโ€™t far behind. Thatโ€™s not just noiseโ€”itโ€™s oxidative pandemonium that MRSA struggles to survive. Different cannabinoids emphasize different strategies, which is part of what makes this story interesting. CBC races to kill in a sprint. CBN and CBG sneak into biofilms and trigger chemical storms. CBD slips in and punctures bacterial bubbles. THC, though less flashy in this set of experiments, still played a steady supporting role. In other words: the cannabis toolbox isnโ€™t one hammerโ€”itโ€™s a whole row of oddly shaped keys, each able to jiggle open a different microbial lock. Of course, itโ€™s worth repeating: this is all petri-dish science. Once you add blood, tissue, and an immune system, things change. Still, the idea that cannabinoids against MRSA can topple bacteria through both brute-force membrane attack and subtle oxidative sabotage adds a fascinating twist to the growing literature on cannabis and human health. ย  From Lab Bench to Bedside: The Translation Challenge If youโ€™ve made it this far, you might be wondering: why arenโ€™t hospitals already stocking cannabis compounds in their infection-fighting kits? The answer is that between the petri dish and the patient lies a canyon filled with messy variables. The biggest obstacle is blood. In lab media, cannabinoids against MRSA look strong. But once you add serumโ€”the protein-rich soup inside the bodyโ€”some cannabinoids lose much of their punch. CBD, for example, can bind tightly to serum proteins, leaving less โ€œfreeโ€ drug to actually act on bacteria. Itโ€™s like hiring a bodyguard only to have them stuck holding coats at the party instead of keeping order. Then thereโ€™s the matter of strain diversity. The MRSA tested here was a reference strain, a kind of lab stand-in. Out in the wild, MRSA strains vary like dog breedsโ€”some small and scrappy, others massive and stubborn. What works beautifully against one strain may fizzle against another. Without testing cannabinoids across a panel of clinical isolates, we donโ€™t know how broadly the results apply. Delivery is another challenge. Topical useโ€”say, in wound dressings or coated medical devicesโ€”seems the most realistic short-term avenue, because you can flood the local area with high concentrations. But systemic therapy, where a pill or IV delivers cannabinoids throughout the body, is another matter entirely. The hurdles are steep: solubility, metabolism, dosing, and toxicity all need careful study. So yes, cannabinoids against MRSA are compelling in vitro. But turning that promise into a prescription requires more than enthusiasm. It requires the slow grind of preclinical work: testing in serum and tissue models, mapping pharmacokinetics, evaluating toxicity, and running animal infection studies. The science is realโ€”but so are the roadblocks. ย  What the Bigger Picture Shows: Two Decades of Clues One paper alone doesnโ€™t change medicine. But when you step back, a pattern begins to emerge. The idea of cannabinoids against MRSA isnโ€™t newโ€”itโ€™s been quietly building for almost twenty years. Back in 2008, a team led by Giovanni Appendino published a now-classic paper in Journal of Natural Products. They showed that the five major cannabinoidsโ€”CBD, THC, CBN, CBG, and CBCโ€”could all stop MRSA strains in their tracks, often at concentrations comparable to standard antibiotics. That was the โ€œsparkโ€ paper, the one that planted a seed in microbiology circles. Fast forward to 2020, when Farha and colleagues dug deeper into CBG. Their work in ACS Infectious Diseases revealed that CBG doesnโ€™t just work in test tubes; it can also eradicate biofilms and kill โ€œpersisterโ€ cellsโ€”those stubborn bacterial holdouts that refuse to die, even when most of their friends have been wiped out. Even more striking, they demonstrated that CBG could treat MRSA infections in a mouse model. Suddenly, cannabinoids werenโ€™t just test-tube curiositiesโ€”they were showing animal-level efficacy. Then in 2021, Blaskovich and colleagues confirmed CBDโ€™s activity against Gram-positive bacteria, including MRSA. They also highlighted a critical limitation: CBDโ€™s potency plummets in the presence of serum. It was a reminder that the leap from lab to clinic isnโ€™t straightforward. Still, they went further, showing that CBD worked topically in infected skin models, proving at least one plausible path toward medical application. Now comes the most recent wave of research, including the study weโ€™ve been unpacking here, which adds nuance: different cannabinoids donโ€™t act the same way. CBC is the sprinter, CBN the biofilm burglar, CBG the membrane wrecking ball, CBD the bubble-popper, and THC the steady background player. Together, these findings sketch a bigger, messier, and more intriguing picture. The throughline is clear: across multiple labs, multiple years, and multiple methods, cannabinoids against MRSA consistently show up as potent, versatile, and mechanistically interesting antibacterial agents. Whether that will translate into new therapies is still uncertainโ€”but the drumbeat of evidence is hard to ignore. ย  Clinical and Public Health Implications: Where Might This Actually Matter? The million-dollar question isnโ€™t whether cannabinoids against MRSA can topple bacteria in a petri dishโ€”we already know they can. The real question is: where could that actually matter in the messy, protein-rich, biofilm-prone environments of human health? The most obvious entry point is topical use. Imagine wound dressings infused with cannabinoids, or gels designed to keep bacterial growth at bay on diabetic ulcers, burns, or surgical incisions. In these scenarios, the concentrations needed to overwhelm bacteria are easier to achieve, and the risk of systemic side effects is lower. CBD already has topical safety data in humans, making it a candidate worth exploring. Another avenue is device coatings. Catheters, implants, prosthetic jointsโ€”these are the playgrounds where MRSA biofilms thrive. A cannabinoid-coated surface that makes it harder for bacteria to stick could save lives, shorten hospital stays, and cut costs. This isnโ€™t science fiction; similar approaches already exist with silver or antibiotic-impregnated devices. Cannabis compounds could, at least in theory, join that roster. For systemic use, the challenges are tougher. Serum binding, metabolism, and dosing hurdles make it hard to get enough free cannabinoid into the bloodstream to kill bacteria without affecting other systems. That said, even if cannabinoids never become IV antibiotics, their unique mechanismsโ€”membrane disruption, ROS induction, biofilm penetrationโ€”may inspire new scaffolds or synergistic therapies. Sometimes a compoundโ€™s greatest contribution isnโ€™t as a finished drug, but as a clue that helps us build better ones. And letโ€™s not forget the broader context: antimicrobial resistance is a global crisis. MRSA alone accounts for over 100,000 deaths worldwide each year. We desperately need fresh strategies. Even if cannabinoids against MRSA only lead to niche applicationsโ€”say, wound dressings or coated stentsโ€”that still represents a meaningful step forward. When lives are at stake, incremental tools arenโ€™t minor; theyโ€™re milestones. Clinical and Public Health Implications: Where Might This Actually Matter? The million-dollar question isnโ€™t whether cannabinoids against MRSA can topple bacteria in a petri dishโ€”we already know they can. The real question is: where could that actually matter in the messy, protein-rich, biofilm-prone environments of human health? The most obvious entry point is topical use. Imagine wound dressings infused with cannabinoids, or gels designed to keep bacterial growth at bay on diabetic ulcers, burns, or surgical incisions. In these scenarios, the concentrations needed to overwhelm bacteria are easier to achieve, and the risk of systemic side effects is lower. CBD already has topical safety data in humans, making it a candidate worth exploring. Another avenue is device coatings. Catheters, implants, prosthetic jointsโ€”these are the playgrounds where MRSA biofilms thrive. A cannabinoid-coated surface that makes it harder for bacteria to stick could save lives, shorten hospital stays, and cut costs. This isnโ€™t science fiction; similar approaches already exist with silver or antibiotic-impregnated devices. Cannabis compounds could, at least in theory, join that roster. For systemic use, the challenges are tougher. Serum binding, metabolism, and dosing hurdles make it hard to get enough free cannabinoid into the bloodstream to kill bacteria without affecting other systems. That said, even if cannabinoids never become IV antibiotics, their unique mechanismsโ€”membrane disruption, ROS induction, biofilm penetrationโ€”may inspire new scaffolds or synergistic therapies. Sometimes a compoundโ€™s greatest contribution isnโ€™t as a finished drug, but as a clue that helps us build better ones. And letโ€™s not forget the broader context: antimicrobial resistance is a global crisis. MRSA alone accounts for over 100,000 deaths worldwide each year. We desperately need fresh strategies. Even if cannabinoids against MRSA only lead to niche applicationsโ€”say, wound dressings or coated stentsโ€”that still represents a meaningful step forward. When lives are at stake, incremental tools arenโ€™t minor; theyโ€™re milestones. How Cannabinoids Compare to Other Natural Antimicrobials Cannabinoids against MRSA arenโ€™t the only plant- or nature-derived compounds to make microbiologists raise their eyebrows. History is full of surprising antimicrobials hiding in plain sight. Take honey, for example. Long before antibiotics, it was used as a wound dressing. Modern science later discovered why: honey creates an environment that dehydrates bacteria, lowers pH, and delivers hydrogen peroxideโ€”all of which stress microbes into submission. Manuka honey, in particular, has become something of a celebrity in wound care, thanks to its unique antibacterial compounds. Or consider garlic. Allicin, the pungent molecule responsible for garlicโ€™s aroma, also has potent antimicrobial activity. It doesnโ€™t always work in vivo at culinary doses (no, a garlic bagel isnโ€™t going to cure sepsis), but itโ€™s another reminder that nature tinkers with antimicrobial strategies just as much as pharmaceutical labs do. Then thereโ€™s N-acetylcysteine (NAC), a small molecule better known as a mucolytic drug and antioxidant supplement. Yet it has an intriguing side hustle: disrupting bacterial biofilms. Researchers have tested NAC against biofilms formed by Pseudomonas, Staphylococcus, and others, and found that it can weaken the sticky matrix, making bacteria more vulnerable to antibiotics. Where do cannabinoids fit in this lineup? Unlike honey or garlic, they seem to act more like specialists than generalistsโ€”poking holes in bacterial membranes, unleashing reactive oxygen chaos, or burrowing into biofilms. That makes them closer cousins to pharmaceutical antibiotics than pantry staples. But like NAC, their biofilm-busting abilities could position them as powerful adjuncts, working alongside existing antibiotics rather than replacing them outright. This isnโ€™t to pit natureโ€™s remedies against one another. Itโ€™s to remind us that the microbial battlefield is wide, and sometimes the most unexpected alliesโ€”whether honey, garlic, or cannabinoidsโ€”are the ones worth watching. The Memorable Punchline: Why This Story Sticks Hereโ€™s the thing: most people donโ€™t expect cannabis to show up in the infection-control playbook. Pain, sleep, moodโ€”sure. But superbugs? That feels like a plot twist. And yet, the lab data keep nudging us toward the same conclusion: cannabinoids against MRSA may have real potential, even if weโ€™re still at the starting line of translation. The most memorable part of this story isnโ€™t just the numbers or the lab graphs. Itโ€™s the imagery. CBC sprinting through bacteria like an Olympic runner. CBN sneaking into biofilms like a burglar in the night. CBG poking holes in membranes like a kid with a pin at a balloon party. CBD setting off oxidative fireworks that leave MRSA scrambling for cover. Each one with a role to play, each one part of a chorus of microbial mayhem. This is what makes the science sticky. Not just the biofilms, but the story itself. The notion that cannabisโ€”long typecast as a plant for pain and peaceโ€”might also moonlight as a microbial menace-slayer. Itโ€™s a tale thatโ€™s both unexpected and oddly memorable. So the takeaway? Cannabinoids may not be the antibiotics of tomorrow, but they are undeniably bug-busting, biofilm-burgling, ROS-raising oddballs worth paying attention to. Or, to put it in a phrase that will hopefully rattle around in your brain long after you close this tab: bug-face, drug-face, snug-faceโ€”because sometimes, the strangest allies are the ones we need most in the fight against infectious disease. Internal Links from CEDclinic.com 1. Testing Essential Oils of Industrial Hemp Against Bacteria Industrial hemp oils with antimicrobial action Discusses hemp essential oils showing antimicrobial activityโ€”parallels well with cannabinoids versus MRSA and supports the natural antimicrobial narrative. https://cedclinic.com/testing-essential-oils-of-industrial-hemp-against-bacteria/ 2. Topical Cannabis Products (Wound Healing & Infection Control) Cannabis topicals for wound healing and infection control Details how topicalsโ€”including for bacterial overgrowth and wound healingโ€”leverage cannabinoids, aligning closely with your clinical implications section. https://cedclinic.com/topical-cannabis-products/ 3. Is cannabis an antibiotic savior in antibiotic-induced bacteremia? Cannabis potentially reducing infections like C. difficile Explores data and mechanisms related to cannabis as an antimicrobial, in a clinical scenario. Itโ€™s complementary context. https://cedclinic.com/is-cannabis-an-antibiotic-savior-in-antibiotic-induced-bacteremia/ 4. Conditions That Cannabis Treats (including chronic infections) Cannabis care for chronic infections Mentions โ€œchronic infectionsโ€ among conditions cannabis may help, grounding your blogโ€™s theme within broader therapeutic areas. https://cedclinic.com/conditions-that-cannabis-treats/ ย  External Links: Back in 2008, a team led by Giovanni Appendino published a now-classic paper in Journal of Natural Products. They showed that the five major cannabinoidsโ€”CBD, THC, CBN, CBG, and CBCโ€”could all stop MRSA strains in their tracks, often at concentrations comparable to standard antibiotics. That was the โ€œsparkโ€ paper, the one that planted a seed in microbiology circles (Appendino et al. 2008). Fast forward to 2020, when Farha and colleagues dug deeper into CBG. Their work in ACS Infectious Diseases revealed that CBG doesnโ€™t just work in test tubes; it can also eradicate biofilms and kill โ€œpersisterโ€ cells, and โ€” strikingly โ€” it treated MRSA infections in mice (Farha et al. 2020). Then in 2021, Blaskovich and colleagues confirmed CBDโ€™s activity against Gram-positive bacteria, including MRSA. They also highlighted a critical limitation: CBDโ€™s potency plunges in the presence of serum. Still, they demonstrated topical efficacy in skin infection models. This is what makes the science sticky. Not just the biofilms, but the story itself. The notion that cannabisโ€”long typecast for pain or moodโ€”might also moonlight as a microbial menace-slayer. Itโ€™s an unexpected twist, but one grounded in peer-reviewed evidence. Curious Facts About MRSA Global MRSA & AMR burden (what scale are we talking about?) In 2019, antibacterial resistance was linked to an estimated 4.95 million associated deaths and 1.27 million attributable deaths worldwide.ย  Within those estimates, MRSA (methicillin-resistant S. aureus) was one of the single biggest drugโ€“pathogen contributors, responsible for โ€œmore than 100,000โ€ deaths worldwide in 2019.ย  In the Americas alone (2019), MRSA accounted for an estimated 23,400 attributable deaths (95% UI 10,000โ€“39,000).ย  Colonization & who carries it About 1 in 3 people (โ‰ˆ33%) carry S. aureus (usually in the nose) at any given time, typically without illness.ย  About 2 in 100 people (โ‰ˆ2%) in the U.S. are MRSA carriers (colonized), with higher rates in certain risk groups.ย  Among hospitalized children, colonization matters: in one reviewed dataset, 8.5% of children colonized on admission later developed MRSA infection; in PICU patients who acquired MRSA colonization, 47% developed MRSA infection.ย  U.S. illness & deaths (how big is the problem here?) In 2017, the U.S. recorded an estimated 119,247 S. aureus bloodstream infections with 19,832 associated deaths (this total includes both MRSA and MSSA).ย  Trend lines (U.S., 2005โ€“2016): hospital-onset MRSA bloodstream infections fell about 17.1% per year (2005โ€“2012), then the decline slowed (2013โ€“2016); community-onset MRSA declined more modestly (โ‰ˆ6.9% per year, 2005โ€“2016).ย  Context: across all AMR threats (not just MRSA), the CDC estimates >2.8 million resistant infections and >35,000 deaths in the U.S. each year (reporting framework from the 2019 AR Threats Report).ย  Additional U.S. context: people who inject drugs accounted for nearly 1 in 10 serious staph infections in 2016, highlighting a key risk pocket.ย  Europe (incidence & resistance snapshot) EU/EEA MRSA bloodstream infection incidence fell from 5.63 per 100,000 (2019) to 4.64 per 100,000 (2023)โ€”a 17.6% decrease overall.ย  Resistance proportions vary widely: in 2021, 11 of 44 countries reported MRSA <5% of S. aureus isolates, but 13 of 44 reported โ‰ฅ25%.ย  Costs of care (what does MRSA do to budgets?) Healthcare-associated infections (HAIs)โ€”of which MRSA is a major contributorโ€”cost U.S. hospitals an estimated $28โ€“$45 billion annually (range reflects methodological differences; seminal analysis).ย  Community-associated MRSA (CA-MRSA): a single case was estimated to cost $2,277โ€“$3,200 to third-party payers and $7,070โ€“$20,489 to society (age-dependent; U.S. modeling).ย  MRSA vs MSSA costs (U.S. hospitalizations, 2010โ€“2014): contrary to older assumptions, a national analysis found costs converged, with MSSA pneumonia sometimes costing more than MRSA pneumonia by 2014; however, mortality remained higher with MRSA hospitalizations after adjustment.ย  Recent hospital studies continue to show MRSA infections lengthen stay and inflate charges compared with MSSA or colonization-only cohorts, though mortality differences are inconsistent across settings.ย  How MRSA stacks up against other bacterial threats In the global AMR landscape (2019), MRSA is consistently ranked among the top high-burden drugโ€“pathogen pairs for mortality, alongside E. coli, Klebsiella pneumoniae, Streptococcus pneumoniae, Acinetobacter baumannii, and Pseudomonas aeruginosa.ย  In the Americas, MRSA was the only pathogenโ€“drug combination with >20,000 attributable deaths in 2019โ€”underscoring its regional impact relative to other resistant organisms.ย  Quick clarifications (common pitfalls I double-checked) โ€œ119,247 infections / 19,832 deathsโ€ refers to all S. aureus bloodstream infections (MRSA plus MSSA), not MRSA alone.ย  The โ€œ>100,000 MRSA deaths globallyโ€ figure is from the Lancet AMR analysis summarized by Oxford; itโ€™s global (not U.S.) and pertains to 2019.ย  U.S. colonization rates (โ€œ1 in 3โ€ for S. aureus, โ€œ2 in 100โ€ for MRSA) come directly from CDC clinical/overview pages updated in 2025.ย  References Murray CJL, Ikuta KS, Sharara F, Swetschinski L, Aguilar GR, et al. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. The Lancet. 2022;399(10325):629โ€“655. doi:10.1016/S0140-6736(21)02724-0. Centers for Disease Control and Prevention (CDC). Antibiotic Resistance Threats in the United States, 2019. Atlanta, GA: U.S. Department of Health and Human Services, CDC; 2019. (Report). Kourtis AP, Hatfield K, Baggs J, Mu Y, See I, et al. Vital Signs: Epidemiology and recent trends in methicillin-resistant and in methicillin-susceptible Staphylococcus aureus bloodstream infectionsโ€”United States. MMWR Morbidity and Mortality Weekly Report. 2019;68(9):214โ€“219. doi:10.15585/mmwr.mm6809e1. Centers for Disease Control and Prevention (CDC). Clinical Overview of Methicillin-Resistant Staphylococcus aureus (MRSA). Atlanta, GA: CDC; last reviewed June 27, 2025. (Web guidance page). European Centre for Disease Prevention and Control (ECDC) and WHO Regional Office for Europe. Antimicrobial resistance surveillance in Europe 2023โ€”2021 data. Stockholm: ECDC; 2023. (Report). Klein EY, Jiang W, Mojica N, Tseng KK, McNeill R, Cosgrove SE, Perl TM. National costs associated with methicillin-susceptible and methicillin-resistant Staphylococcus aureus hospitalizations in the United States, 2010โ€“2014. Clinical Infectious Diseases. 2019;68(1):22โ€“28. doi:10.1093/cid/ciy399. Lee BY, Singh A, David MZ, Bartsch SM, Slayton RB, Huang SS, et al. The economic burden of community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA). Clinical Microbiology and Infection. 2013;19(6):528โ€“536. doi:10.1111/j.1469-0691.2012.03914.x. Scott RD II. The Direct Medical Costs of Healthcare-Associated Infections in U.S. Hospitals and the Benefits of Prevention. Atlanta, GA: U.S. Department of Health and Human Services, CDC; 2009. (White paper). Stone PW. Economic burden of healthcare-associated infections: an American perspective. Expert Review of Pharmacoeconomics & Outcomes Research. 2009;9(5):417โ€“422. doi:10.1586/erp.09.53. Milstone AM, Carroll KC, Ross T, Shangraw KA, Perl TM. Methicillin-resistant Staphylococcus aureus colonization and risk of subsequent infection in critically ill children: importance of preventing nosocomial MRSA transmission. Clinical Infectious Diseases. 2011;53(9):853โ€“859. doi:10.1093/cid/cir520. Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, et al.; Infectious Diseases Society of America. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clinical Infectious Diseases. 2011;52(3):e18โ€“e55. doi:10.1093/cid/ciq146. Centers for Disease Control and Prevention (CDC). Antimicrobial Resistance: Facts & Stats. Atlanta, GA: CDC; updated February 4, 2025. (Summary page consolidating the 2019 AR Threats estimates). 10 FAQ Questions on the topic! Q1: Can cannabinoids kill MRSA? Yes, in laboratory studies cannabinoids against MRSA showed potent antibacterial activity at very low concentrations. Compounds like CBC, CBG, and CBN were especially effective at killing bacteria and disrupting biofilms. However, this research is still preclinical and not yet applied in human medicine. Q2: Which cannabinoid is most effective against MRSA? CBC stood out as the fastest killer, wiping out MRSA populations within 30โ€“60 minutes in vitro. CBN and CBG also showed strong biofilm-busting activity, while CBD was best at damaging bacterial membranes. THC played a supportive but less dramatic role in these assays. Q3: How do cannabinoids fight MRSA? Cannabinoids against MRSA appear to work by damaging bacterial membranes and triggering oxidative stress (ROS). This combination overwhelms bacteria, leading to rapid death. Each cannabinoid uses a slightly different styleโ€”some sprint, some sneak, some puncture. Q4: Are cannabinoids as strong as antibiotics like vancomycin? In this lab study, CBDโ€™s MIC against MRSA matched vancomycinโ€™s, and other cannabinoids were even lower. But that doesnโ€™t mean they work the same way in patients. Human bodies are complex, and cannabinoids often lose potency in serum or tissue environments. Q5: Can cannabinoids be used as antibiotics in hospitals? Not yet. While cannabinoids against MRSA show promise in the lab, translating them into hospital use requires extensive safety testing, animal studies, and clinical trials. The most realistic first applications may be topical wound dressings or device coatings. Q6: Do cannabinoids work against biofilms? Yes. CBN and CBG in particular reduced MRSA biofilm viability by up to 85% in lab experiments. Biofilms are one of the hardest challenges in infection control, so this is a significant findingโ€”even if still confined to the lab. Q7: Could cannabis oil cure an infection? No. The antimicrobial effects reported are from purified cannabinoids studied in controlled lab settings. Cannabis oil or consumer products are not proven to treat infections and should not replace antibiotics or medical care. Q8: Are cannabinoids effective against all bacteria? No. Cannabinoids generally show stronger activity against Gram-positive bacteria like MRSA. Against Gram-negatives, their effect is much weaker unless the bacterial outer membrane is compromised. Q9: What natural products compare to cannabinoids against MRSA? Other natural agents like honey, garlic (allicin), and N-acetylcysteine also show biofilm-disrupting or antimicrobial properties. Cannabinoids stand out for their multi-pronged tacticsโ€”membrane damage, ROS induction, and rapid bactericidal activity. Q10: Whatโ€™s the future of cannabinoids in infectious disease care? The future may involve topical therapies, wound dressings, or device coatings that incorporate cannabinoids. Even if cannabinoids themselves donโ€™t become systemic antibiotics, their mechanisms may inspire new classes of antimicrobials. And my hunch – lots of people are going to want to experiment on their own! [...] Read more...
default image
August 18, 2025Sponsored Message Can THC and CBD Help With Chronic Pain Management?   Source   Chronic pain affects millions of people worldwide, often reducing quality of life and leading to long-term physical and emotional stress. Traditional treatmentsโ€”such as opioids, NSAIDs, and corticosteroidsโ€”come with side effects, dependency risks, and diminishing returns over time. This has led many patients and healthcare professionals to explore alternative therapies, including cannabinoids like THC and CBD. But how effective are these compounds in treating chronic pain, and what does the science say? Cannabis-based therapies have grown in popularity thanks to evolving legislation and broader public acceptance. Many patients now explore targeted options like THC vape pens for fast-acting relief. If you’re considering such products, you can view a curated selection at https://trehouse.com/collections/thc-vape-pens/, offering convenience and a range of potency options.   Understanding THC and CBD: What Are They? THC (tetrahydrocannabinol) and CBD (cannabidiol) are the two primary cannabinoids found in cannabis. Though structurally similar, they function differently in the body: THC is psychoactive, binding primarily to CB1 receptors in the central nervous system. It alters mood, perception, and sensation, making it effective for pain relief but also capable of producing a โ€œhigh.โ€ CBD is non-psychoactive and interacts more subtly with the endocannabinoid system. It affects both CB1 and CB2 receptors and influences neurotransmitter activity without intoxication. Both compounds have shown potential to reduce pain through different mechanisms, and combining them may even offer synergistic effects.   Types of Chronic Pain Cannabinoids May Help With Chronic pain isnโ€™t a one-size-fits-all condition. The causes and mechanisms vary widely, but cannabinoids may be helpful in several categories: Neuropathic Pain โ€“ Common in conditions like diabetes, multiple sclerosis, and chemotherapy-induced neuropathy, this type of pain originates from damaged or dysfunctional nerves. Studies suggest THC and CBD can reduce pain signaling and inflammation in the nervous system. Inflammatory Pain โ€“ Conditions such as rheumatoid arthritis and inflammatory bowel disease involve persistent inflammation. CBD, known for its anti-inflammatory properties, can reduce cytokine production and immune system overactivation. Musculoskeletal Pain โ€“ Chronic back pain, fibromyalgia, and other muscle-related conditions can benefit from both THCโ€™s muscle-relaxing effects and CBDโ€™s ability to reduce tension and swelling. Cancer-Related Pain โ€“ Patients undergoing cancer treatment often suffer from pain due to tumors or treatment side effects. Cannabinoids, particularly THC, may help manage these symptoms and improve appetite and sleep.   The Research Behind THC and CBD for Pain Relief Scientific research into cannabinoid-based pain relief has grown significantly in the last decade. While results vary depending on the type of pain and the formulation used, several findings are worth noting: A 2018 review published in the Journal of Pain Research concluded that medical cannabis showed potential for improving pain symptoms in patients with fibromyalgia and neuropathy. Epidiolex, a CBD-based medication approved by the FDA for epilepsy, has sparked interest in CBDโ€™s broader medical applications, including pain modulation. A meta-analysis of 28 randomized trials found that THC-containing products could provide modest pain relief in chronic pain patients, though some users experienced side effects such as dizziness or dry mouth. Research on full-spectrum products (which include both THC and CBD) indicates that they may provide better outcomes than isolated cannabinoids due to the “entourage effect”โ€”where multiple cannabis compounds work synergistically. While the evidence is promising, itโ€™s also clear that cannabinoids are not a cure-all. More large-scale, long-term studies are needed to establish dosage guidelines and identify which pain conditions respond best to specific cannabinoid profiles.   How Cannabinoids Work in the Body The endocannabinoid system (ECS) plays a central role in regulating pain, mood, inflammation, and more. THC and CBD influence this system in different ways: THC binds to CB1 receptors in the brain and spinal cord, helping to block pain signals and produce euphoria. CBD appears to inhibit the breakdown of anandamide (a naturally occurring endocannabinoid), which enhances the body’s own pain-relief system. Furthermore, CBD interacts with other receptors (such as TRPV1, involved in pain and temperature regulation), offering broader therapeutic effects without the psychoactive risks of THC.   Methods of Consumption for Pain Relief Different delivery methods impact how cannabinoids affect pain. For fast-acting relief, inhalation is often preferred: Vaping THC provides almost immediate effects and is easier to dose than edibles. CBD oils or tinctures offer steady relief and are commonly used for daytime pain management. Topicals can be applied directly to sore joints or muscles for localized relief. Edibles and capsules are long-lasting but take longer to take effect. Choosing the right form often depends on the type and severity of the pain, personal preferences, and the need for discreet use.   Safety and Side Effects Both THC and CBD are generally well-tolerated, but each has potential side effects: THC may cause dizziness, dry mouth, short-term memory issues, and anxiety in higher doses. It also carries a potential for dependency with long-term use. CBD has minimal side effects, but high doses can cause fatigue, gastrointestinal discomfort, or interact with other medications. Always consult a healthcare provider before starting a cannabinoid regimen, especially if youโ€™re already taking prescribed medications or managing chronic illness.   Final Thoughts: Should You Use THC or CBD for Chronic Pain? Cannabinoids offer a promising alternative or supplement to traditional pain management strategies. For those dealing with mild to moderate pain, CBD may be a good first option due to its safety profile. Patients with more severe or treatment-resistant pain might benefit from THC or a balanced THC:CBD combination. As with any therapeutic tool, individual response can vary. Start with a low dose, monitor how your body reacts, and adjust slowly. With increasing clinical support and growing product availability, cannabinoids may become an integral part of future pain careโ€”especially when used responsibly and under medical guidance. Sponsored Link: https://trehouse.com/collections/thc-vape-pens/   End of Sponsored Message   CED Clinic Sponsored Content Disclaimer: This blog post includes a sponsored link to a third-party retailer. CED Clinic does not endorse or recommend any specific cannabis products or brands. The link is provided for commercial sponsorship purposes only and does not imply medical approval, product safety, or efficacy. The information contained here is intended for educational purposes and should not be construed as medical advice. Cannabis products, including THC vape pens, are not FDA-approved for the treatment of chronic pain or any other medical condition. Individual responses to cannabinoids vary, and risks include dizziness, anxiety, dependency, medication interactions, and impaired driving. Patients should consult with a qualified healthcare provider before initiating or modifying any cannabis-based therapy. By accessing linked content, readers accept responsibility for ensuring compliance with local laws and for evaluating product quality, including reviewing independent certificates of analysis (COAs). [...] Read more...
August 5, 2025What the Galimberti et al., 2025 study actually saysโ€”and how misinformation about cannabis spreads faster than the facts, and how cannabis and psychiatric disorders is a much more nuanced topic than you might think!ย  This post is a breakdown of the June 2025 study titled โ€œThe Genetic Relationship Between Cannabis Use Disorder, Cannabis Use, and Psychiatric Disorders,โ€ published in Nature Mental Health. Authored by Marco Galimberti, Cassie Overstreet, Priya Gupta, Sarah Beck, Cecilia Dao, Joseph D. Deak, Hang Zhou, Emma C. Johnson, Arpana Agrawal, Murray B. Stein, Daniel F. Levey, and Joel Gelernter, from the Psychiatric Genomics Consortium, International Cannabis Consortium, and the iPSYCH group, the study explores genome-wide associations between cannabis-related behaviors and psychiatric diagnoses. Here, I’m examining what the data really show, what the authors concludeโ€”and where public interpretations have already gone astray. ย ๐ŸŽ What Youโ€™ll Learn in This Post ๐Ÿงฌ Why genetic overlap doesnโ€™t mean cannabis causes mental illness๐ŸŽ How scientific nuance gets lost in public messaging๐Ÿง  The difference between cannabis use and cannabis use disorder๐Ÿ” What the Galimbertiย et al., 2025 study actually foundโ€”and didnโ€™tโš–๏ธ Why fear-based narratives about cannabis do more harm than good The Poison Apple Problem: How Fear Disguised as Science Misled the Public on Cannabis and Mental Illness Poison Apples & Panic Posts: When Science Becomes a Weapon The story starts innocently enough. A scientific paper drops. A few social media accounts with polished language and professional headshots pick it up. A graph circulates. Then a headline: โ€œCannabis linked to psychiatric disorders through genetics.โ€ Sorry not sorry: cannabis and psychiatric disorders is just not that cut and dry.ย  Cue the panic. Within days, that tidy little press cycle becomes a viral, decontextualized truth bombโ€”repeated by well-meaning parents, skeptical clinicians, and overzealous pundits. The danger isnโ€™t just in the simplification. Itโ€™s in the seduction. Because when someone serves you a shiny, data-drenched apple that promises clarity on something as polarizing as cannabis and mental health… who wouldn’t take a bite? But some apples are laced with something more potent than THC. They’re laced with fear, misinterpretation, and a fundamental misunderstanding of how scienceโ€”especially psychiatric geneticsโ€”actually works. And thatโ€™s what happened with the June 2025 Nature Mental Health paper by Galimberti et al. The Study Behind the Scare: What Galimberti et al., 2025 Actually Did Say Letโ€™s start by grounding ourselves in facts. This was a genome-wide association study (GWAS)โ€”a massive statistical sweep across the human genome, looking for patterns. In this case, the team examined whether certain genetic signatures were shared between: โ€ข People with cannabis use disorder (CUD)โ€ข People who simply reported using cannabis (CU)โ€ข And those with major psychiatric diagnoses like schizophrenia, ADHD, bipolar disorder, and depression The dataset was enormous, pulling from biobanks, global consortia, and diagnostic records. It was also statisticalโ€”not clinical. Not causal. It didnโ€™t assess how much cannabis someone used, what kind, why, when, or how it affected them. It simply asked: do these genetic risk factors tend to cluster in the same individuals? The answer? Yes. But not in the way Twitter wants you to think. What the Genes Sayโ€”and Donโ€™t Say The study found that people with genetic risk for certain psychiatric conditions also had higher polygenic risk scores for cannabis use disorder. Notably, those same psychiatric risks were far less correlated with casual cannabis use. So what does that mean? It means that the genetic soup that makes someone vulnerable to depression or ADHD might also make them more prone to problematic cannabis use. Traits like impulsivity, poor emotional regulation, trauma sensitivity, and executive dysfunction donโ€™t neatly respect psychiatric categoriesโ€”they sprawl. And in doing so, they connect dots across different behaviors, including CUD. But they don’t prove that cannabis causes those conditions. In fact, the study explicitly avoids any causal claim. It uses words like โ€œassociation,โ€ โ€œshared heritability,โ€ and โ€œgenetic correlation.โ€ These are carefully chosen terms. They matter. Ignoring them is like mistaking a weather forecast for a storm. CUD Is Not Cannabis Use (And Conflating Them Is Intellectual Malpractice) Hereโ€™s the trap that caught the internet: cannabis use disorder (CUD) is not the same thing as cannabis use (CU). You can drink wine and not be an alcoholic.You can take sleeping pills without being dependent.And yesโ€”you can use cannabis without having a disorder. But in the publicโ€™s rush to moral clarity, CUD and CU get jammed into the same category. Suddenly, every patient using cannabis for sleep, anxiety, pain, or appetite is at risk of psychosis, because someone saw a scary bar chart on Twitter. The conflation isnโ€™t just incorrectโ€”itโ€™s reckless. The study itself makes this distinction clear. Genetic correlations between CU and psychiatric traits were much weaker than those between CUD and psychiatric traits. The problem isnโ€™t cannabis. The problem is when cannabis use becomes disorderedโ€”and even then, the story is more complex than most headlines allow. Why Psychiatry and Cannabis Keep Showing Up Together (But Not for the Reason You Think) Trauma, Vulnerability, and the Endocannabinoid Escape Hatch Thereโ€™s a reason cannabis shows up again and again in the lives of people with psychiatric diagnosesโ€”and itโ€™s not because itโ€™s causing their illnesses. Itโ€™s because itโ€™s often the thing that makes them feel less broken. People with a history of trauma, executive dysfunction, anxiety, or dysregulated mood donโ€™t turn to cannabis because theyโ€™re looking for trouble. Theyโ€™re often looking for relief, regulation, or rest. What the Galimberti et al., 2025 paper showsโ€”though it never quite says itโ€”is that many of these folks likely share a genetic signature tied to impulsivity, reward sensitivity, and difficulty with top-down cognitive control. These arenโ€™t โ€œcannabis traits.โ€ Theyโ€™re psychiatric vulnerability traits. And they donโ€™t just drive cannabis useโ€”they drive all kinds of coping mechanisms, good and bad. The tragedy? When someone uses cannabis for sleep, anxiety, or trauma-induced rage, and the public interprets that as: โ€œSee? Cannabis leads to mental illness.โ€ No, friend. Sometimes mental illness leads people to cannabisโ€”because conventional options failed. Itโ€™s Not Self-Medicating. Itโ€™s Self-Care. Letโ€™s call this what it really is: self-care (or self-rescue). Because for many people navigating PTSD, panic, depression, or overwhelm, cannabis doesnโ€™t just dull the edgeโ€”it returns a sense of control. A quiet room in a noisy mind. This is especially true for those failed by traditional models of care. Patients with ADHD who bounce from one side effect to the next. Bipolar patients who hate the blunting of mood stabilizers. Autistic teens whose meltdowns lead to ER visits instead of compassion. And if you think thatโ€™s just anecdotal, you havenโ€™t been reading the clinical literatureโ€”or seeing the real-world data. There are entire clinics, entire cohorts of thousands, whose stories reveal cannabis not as a trigger for madness, but as a salve for a system overloaded by trauma, stress, or emotional chaos. If the Galimbertiย paper had layered clinical nuance into their statistical design, we might have seen a very different story. What the Viral Posts Miss Entirely: The ECS as Mediator One of the biggest failures in the public interpretation of this study is that it doesnโ€™t even mention the endocannabinoid system (ECS)โ€”despite the fact that this is likely the mechanism sitting at the heart of the genetic overlap. The ECS is a system of regulation, adaptation, and emotional buffering. And itโ€™s highly sensitive to environmental stress. Trauma can dysregulate it. So can early adversity. So can chronic inflammation, poor sleep, social stress, or repeated psychiatric crises. Cannabis interacts with this system. Of course it doesโ€”itโ€™s designed to. So it makes perfect sense that people whose ECS is running ragged might find cannabis particularly relieving. That doesnโ€™t make it dangerous. That makes it relevant. For a breakdown on how the ECS mediates trauma and psychiatric symptoms, see:๐Ÿ“– https://cedclinic.com/cannabis-and-trauma-resilience The Simplification Scam: Turning Vulnerability Into Villainy Letโ€™s get brutally honest for a second. When a well-funded organization posts, โ€œSee? Cannabis users are genetically prone to psychosis,โ€ theyโ€™re not engaging in science. Theyโ€™re engaging in scientific performance art. Itโ€™s the moral panic equivalent of stage magic. Because the sleight-of-hand is this:โ€ข They ignore the reasons people use cannabis in the first place.โ€ข They pretend CUD and casual use are the same thing.โ€ข They flatten genetic noise into clean causal arrows.โ€ข And they treat psychiatric illness as a rhetorical boogeyman. But psychiatric illness is not a scare tactic. Itโ€™s not a punchline. And itโ€™s not a billboard you can slap on a cannabis policy. Itโ€™s a nuanced, multi-dimensional, sometimes-crippling condition. And how people survive itโ€”the tools they use, the adaptations they makeโ€”deserve more than a clickbait headline and a red arrow on a heat map. When Science Gets Stripped for Parts: How Oversimplification Becomes Policy Poison Misinformationโ€™s Magic Trick: Sleight of Science Itโ€™s easy to forget that scientific studies are not self-explanatory. They require translation. And translation, like any act of storytelling, is vulnerable to bias, framing, and omission. When theย Galimberti et al., 2025 paper was released, it didnโ€™t say โ€œCannabis causes mental illness.โ€ But thatโ€™s the version the public got. Why? Because the visual language of certaintyโ€”bar graphs, p-values, prestigious journal namesโ€”has become a kind of authority costume. And bad actors know how to wear it. They cherry-pick one correlation (out of dozens), ignore the absence of causation, and wrap it all in a tweet that feels like scientific gospel. Then they let virality do the rest. But this is not science communication. Itโ€™s science exploitation. And it works because most people donโ€™t have the time, training, or tools to interrogate these claimsโ€”especially when they confirm a lurking suspicion: that cannabis, deep down, is dangerous. Thatโ€™s how we get public health messaging that feels like a fairy taleโ€”complete with villains, magical curses, and a plant that makes people crazy. Spoiler: real science is more complicated than a bedtime story. What the Message Should Have Been Letโ€™s try a different version of the headlineโ€”one thatโ€™s accurate, contextual, and honest: โ€œNew study shows genetic overlap between psychiatric conditions and cannabis use disorder. Findings suggest that psychiatric vulnerabilityโ€”not cannabisโ€”may underlie problematic use.โ€ Thatโ€™s the truth. Itโ€™s also less shareable. Because nuance doesnโ€™t spark outrage, and careful interpretation doesnโ€™t go viral. But hereโ€™s the thing: when we trade truth for traffic, we create real-world consequences. People with psychiatric conditions get further stigmatized. Cannabis patients feel ashamed or dismissed. And policymakers armed with bad summaries pass worse laws. The Real Risk: Weaponized Oversimplification The biggest danger this paper represents isnโ€™t what it foundโ€”itโ€™s how itโ€™s being used. Because if you can convince the public that cannabis is genetically tied to psychosis, you can do a lot with that fear: Block access to medical use Punish parents who medicate children with autism Undermine funding for ECS research Scare physicians away from recommending cannabis at all And thatโ€™s precisely what weโ€™re seeing. In courtrooms. In state houses. In medical boards across the country. Yet none of that policy panic reflects the actual weight of the data. Galimbertiย et al. offered a sophisticated statistical exploration. Itโ€™s not their fault the story got hijacked. But it is our collective responsibility to correct the record. Because when fear becomes the loudest voice in the room, patients suffer. The Scientistโ€™s Dilemma: Publish or Be Pirated Itโ€™s worth saying this aloud: The authors of the study didnโ€™t commit fraud. They published a high-quality GWAS with careful language and limited conclusions. But the moment that data entered the public square, it became fodder for manipulation. The authors likely knew that riskโ€”because anyone who works in this space knows how quickly cannabis research gets distorted. So hereโ€™s the challenge for scientists: Do you stop publishing controversial data because someone might twist it? No. But you must anticipate distortion. You must write, title, and structure your findings with guardrails against misuse. Otherwise, your work becomes the poisoned apple handed out by someone else. From Villain to Healer: Rebuilding the Cannabis and Psychiatry Conversation When the Same Genes Point to Vulnerability and Opportunity Letโ€™s pause for a beat. What if the genetic overlaps donโ€™t just tell us whoโ€™s at risk?What if they tell us who might benefit most from cannabisโ€”when used wisely, intentionally, and with support? If impulsivity, trauma sensitivity, and mood instability show up in both psychiatric disorders and cannabis use, perhaps the link isnโ€™t simply liabilityโ€”but need. What if these are the very people most sensitive to ECS modulation? The people who canโ€™t tolerate SSRIs, whoโ€™ve failed stimulant after stimulant, whoโ€™ve tried therapy and still canโ€™t sleep through the night? Itโ€™s not romanticizing cannabis to say thisโ€”itโ€™s recognizing that the ECS exists for a reason. And in a system on fire, cannabinoids might be the extinguisher, not the match. From Disorder to Precision: What the Future Could Look Like We canโ€”and mustโ€”move past the one-size-fits-all model of psychiatric care. And cannabis offers us a glimpse into what precision mental health might look like. Instead of treating CUD as a moral failing or genetic curse, what if we: Screen patients for ECS sensitivity and stress adaptation markers Match cannabinoid profiles to individual symptom clusters Monitor real-world outcomes through wearable tech or digital journaling Educate physicians on titration, product selection, and adverse event detection Empower patients to know their own endocannabinoid rhythms Thatโ€™s not recklessโ€”thatโ€™s responsible. Thatโ€™s how we bring cannabis medicine out of the shadows and into the clinic, armed with nuance and data. To see this approach in action, check out our evolving clinical model at:๐Ÿ“Ž CED Clinic care model The Real Fairy Tale Is Simplicity This isnโ€™t a story of cannabis vs. psychiatry. Itโ€™s a story about what happens when we flatten complexity for comfort. Because complexity is scary. It resists slogans. It forces us to confront the messiness of trauma, the mystery of genetics, the individuality of healing. But pretending the world is simpler than it isโ€”thatโ€™s the real fairy tale. Thatโ€™s the poisoned apple. And the antidote isnโ€™t panic. Itโ€™s precision.Itโ€™s ECS literacy.Itโ€™s remembering that human behavior is not a bug in the systemโ€”it is the system. ๐Ÿ A Better Ending Letโ€™s stop punishing patients for seeking relief.Letโ€™s stop misreading data as dogma.Letโ€™s start telling the truth, even when itโ€™s not tweet-sized. Because fear might sellโ€”but trust heals. And in medicine, thatโ€™s the only story worth telling. What the Headlines Missed: Data Points Worth Your Attention CUD shares more genetic variance with trauma and neuroticism than with schizophreniaThis matters because the supposed โ€œpsychosis riskโ€ isnโ€™t even the strongest signal. Yet media outlets harp on schizophreniaโ€”a rare conditionโ€”ignoring more common correlates like trauma, anxiety, and ADHD. Cannabis Use (CU) and Cannabis Use Disorder (CUD) are genetically distinctMost people who use cannabis donโ€™t develop CUD. But when CU and CUD get lumped together, as media often do, the nuance disappearsโ€”and casual users are unfairly cast as vulnerable or pathological. The genetic correlation (rg) between CUD and schizophrenia was modestโ€”only about 0.29That number is meaningful, but not massive. Itโ€™s in the same ballpark as the correlation between CUD and insomnia (rg = 0.27), which no one calls a psychosis crisis. Without context, these stats can mislead. Shared genetic vulnerability doesnโ€™t mean cannabis causes psychiatric illnessJust like some genes increase risk for both smoking and depression, this is about predispositionโ€”not proof of harm. The correlation may exist because people with psychiatric symptoms turn to cannabis for help. The authors clearly state this is not a causal studyThey emphasize that the data are correlational and โ€œhypothesis-generating.โ€ If a reader claims the paper shows cannabis causes psychosis, theyโ€™ve missed the most basic limitation of the entire study design. No consideration of cannabis chemotype, potency, or context of useThe data canโ€™t tell us if it was 5mg of THC or 500. Nor does it differentiate between an anxious teen using CBD at night and a high-potency user with untreated schizophrenia. Without clinical context, conclusions are shaky. The CUD vs CU difference is critical and almost universally ignoredCannabis Use Disorder is a clinical diagnosis. Cannabis Use isโ€ฆ use. Most press coverage doesnโ€™t distinguish the two, which is like confusing โ€œdrinks wine occasionallyโ€ with โ€œalcohol use disorder.โ€ Psychiatric risk genes overlap across conditionsโ€”far beyond cannabisThe same genetic architecture shows up in depression, bipolar, and even risk-taking behavior. That makes it all the more important to avoid cherry-picking findings to demonize cannabis specifically. No accounting for confounders like poverty, medication use, or misdiagnosisThese arenโ€™t small footnotes. They’re massive sources of bias. Without socioeconomic and clinical controls, genetic signals can become dangerously distortedโ€”especially when used in policy or public messaging. The biggest risk may not be cannabisโ€”itโ€™s misinterpretationIn the wrong hands, this study becomes a fairytale with a poison apple: seductive, scary, and oversimplified. Thatโ€™s why this list existsโ€”to pull the curtain back on the data and ask: what does the science actually say? The Numbers They Never Mention: Cannabis, Genetics, and Psychiatry by the Stats 8%Estimated heritability of Cannabis Use Disorder (CUD) attributable to common variants in this studyโ€”relatively low, suggesting environment, trauma, and social factors play a much bigger role than genetics alone. 0.29Genetic correlation (rg) between CUD and schizophrenia. Moderate, not extreme. For comparison: the rg between CUD and neuroticism was 0.31โ€”and no one is claiming weed causes personality disorders. >50%Percentage of CUD polygenic risk explained by shared risk with depression, neuroticism, ADHD, and childhood trauma. This shows the core signal may reflect underlying distress, not cannabis as a cause. 0.07Genetic correlation between Cannabis Use (CU) and schizophreniaโ€”barely above zero. This reinforces the importance of distinguishing CU from CUD in both science and public discourse. 0.24Genetic correlation between CUD and insomnia. Thatโ€™s nearly the same as the CUD-schizophrenia link, yet no headlines scream โ€œCannabis Causes Sleep Disorders!โ€ Why? Because it doesn’t fit the scare narrative. 0.17 to 0.31Range of genetic correlations between CUD and psychiatric traits like ADHD, depression, PTSD, and bipolar disorderโ€”most higher than for psychosis, yet vastly underreported. 4.6 millionSample size of the UK Biobankโ€“based genetic analyses. Huge datasets, yesโ€”but still limited by the lack of granular clinical data (diagnoses, dosing, symptom response, etc.). 0Number of causal claims made by the authors. Despite the social media spin, the study authors themselves emphasized correlation, non-causality, and hypothesis generation. 0Data on real-world cannabis product types, chemovar profiles, or dosage. Meaning the results tell us nothing about how medical cannabis use for anxiety, PTSD, or insomnia actually functions. โˆžNumber of times media headlines will reuse the word โ€œpsychosisโ€ without reading past the abstract. ย  Related External Links NIDA on Drug Abuse Nature Mental Health Full Study NIH psychiatric genetics overview CDC, Cannabis and Mental Health Realm of Care Patient-Oriented Outcomes 2022 meta-analysis on cannabis & psychosis Related Links at CED Cannabis and Psychosis Breakdown of Another Study on the Topic When Cannabis Might NOT Be Right For You The Rise of Cannabis Self-Medication Among Neurodivergent Individualsย  ๐Ÿ”Ž 10 FAQs about Cannabis and Psychiatric Disorders 1. Does cannabis use cause psychiatric disorders? No. The Hildebrand et al., 2025 study showed shared genetic traits between cannabis use disorder (CUD) and psychiatric vulnerabilityโ€”but not that cannabis causes mental illness. Many people with psychiatric symptoms turn to cannabis for relief, not recreation. Causation was not proven in the study, only correlation. 2. Whatโ€™s the difference between cannabis use and cannabis use disorder? Cannabis use (CU) simply means using the plantโ€”occasionally or even daily. Cannabis use disorder (CUD) is a clinical diagnosis involving compulsive use, impairment, or distress. Most cannabis users never develop CUD, and the two are often wrongly conflated in research headlines. 3. What is GWAS and how does it relate to cannabis? GWAS stands for Genome-Wide Association Study. It looks at thousands of genetic variants across individuals to find patterns linked to traits or diseasesโ€”like cannabis use disorder. It does not prove causality, only statistical associations. 4. How should clinicians interpret genetic studies about cannabis? With caution and context. Clinicians should look beyond headlines, evaluate study design, and understand that shared genetic risks donโ€™t equal causation. Clinical care must prioritize patient experience, ECS balance, and symptom patternsโ€”not abstract risk markers. 5. Why is the endocannabinoid system (ECS) important in this conversation? The ECS regulates stress, mood, reward, and inflammation. Many psychiatric symptoms involve ECS dysregulation, making cannabinoids relevant. Understanding this system helps clinicians interpret cannabis use not as pathology, but as potential self-regulation. 6. Why do people with trauma or ADHD use cannabis? Because it often helps when other treatments fail. Cannabis can improve sleep, reduce hyperarousal, and support emotional regulation. Labeling this as โ€œsubstance misuseโ€ misses the therapeutic role cannabis plays for many neurodivergent or traumatized patients. 7. How can studies like Hildebrand 2025 be misinterpreted? By collapsing CUD and CU, ignoring trauma history, and skipping over confounders. Media outlets often simplify complex data into โ€œcannabis causes psychosisโ€โ€”a claim the study did not make. This causes public panic and undermines scientific credibility. 8. Is there a safe way to use cannabis for psychiatric symptoms? Yes, when used with intention, appropriate products, and ECS-informed guidance. Itโ€™s not one-size-fits-all. Microdosing, non-intoxicating cannabinoids, and regular check-ins can support safe use in vulnerable populations. 9. How can we improve cannabis research and policy? By investing in longitudinal, ECS-aware studies and rejecting fear-based narratives. Policymakers must distinguish between misuse and mindful use, and fund education, not prohibition. Research should center patientsโ€”not PR. 10. Whatโ€™s the big takeaway from the blog? Cannabis doesnโ€™t cause psychiatric illnessโ€”but misinformation might. The genetics of vulnerability are complex, and so are the stories people carry. If we care about health, we must care about accuracy. [...] Read more...
July 21, 2025A guide for thoughtful doctors who want smarter toolsโ€”without giving up their clinical instincts. (This is part 2 of a short series that began last week with: AI in Medicine)   What Youโ€™ll Learn in This Post: 1๏ธโƒฃ How to use AI in medicine without surrendering your clinical instincts 2๏ธโƒฃ Five core principles that preserve human judgment in an AI-supported system 3๏ธโƒฃ How to make AI a partnerโ€”not a dictatorโ€”in clinical care 4๏ธโƒฃ Tools doctors can use from home to study, reflect, and review cases 5๏ธโƒฃ How to decide when to trust, question, or override the algorithm   How to Use AI in Medicine Without Losing Your Clinical Soul The Temptation and the Risk Thereโ€™s something seductive about a machine that seems to know. AI doesnโ€™t get tired. It doesnโ€™t forget the name of that rare syndrome. It doesnโ€™t misplace the lab values or second-guess its memory. For the overburdened clinician, this can feel like salvation. But alsoโ€”like surrender. So hereโ€™s the question this blog will ask, and try to answer: How do we use AI in medicine without becoming its apprentice? How do we embrace this new thinking partner while keeping our judgment intact? We do it by choosing our relationship with AI carefully. Not as a replacement. Not as a threat. But as an assistantโ€”smart, tireless, and often helpfulโ€”who works for us, not instead of us. Rule #1: Think with AI, Not through It One of the most dangerous habits that can emerge in this new AI era is automation biasโ€”the assumption that if the system suggested it, it must be right. But AI doesnโ€™t see the patient in front of you. It doesnโ€™t hear their hesitation, note their cultural context, or sense the contradiction between whatโ€™s on paper and whatโ€™s in the room. It sees patternsโ€”not people. Thatโ€™s why your job is not to accept what AI offers. Itโ€™s to interrogate it. Ask: Does this match what Iโ€™m observing? Is there a context the algorithm might be missing? What question is this answer assuming I asked? When AI surfaces an idea you hadnโ€™t considered, thatโ€™s a win. But when it confirms what you already suspected? Be carefulโ€”it might just be agreeing with your bias. You are still the one doing medicine. The machine just helps you see your blind spots. Rule #2: Ask Better Questions, Not Just Faster Ones AI can generate differentials, suggest labs, and surface literature faster than you can blink. But the quality of what you get depends entirely on what you ask. Garbage in, garbage out has never been more literal. If you give it a lazy promptโ€”โ€œHeadache in 40yo?โ€โ€”youโ€™ll get a generic list. But if you feed it the storyโ€”โ€œIntermittent right-sided headache, pulsatile, worse during menstruation, with photophobia and neck stiffness, no prior history, two recent ER visits without CTโ€โ€”then you get value. This applies even more in research. Ask it to summarize a new trial? Itโ€™ll oblige. Ask it to analyze the statistical assumptions or cross-reference with prior studies? Itโ€™ll stretch youโ€”and itself. Think of AI not as a vending machine for answers, but a Socratic partner: the more thoughtful your input, the more revealing the output. Rule #3: Translate AI Back to Human Letโ€™s be honest: most AI-generated outputs areโ€ฆ efficient, but not exactly poetic. Youโ€™ve probably seen the summaries: โ€œThe patient has a 7-day history of upper respiratory symptoms. Recommend symptomatic care and follow-up.โ€ True. But also devoid of human tone, reassurance, or nuance. This is where you come in. AI can generate notes, letters, or patient summariesโ€”but only you can rewrite them in a way that feels relational rather than transactional. That means: Adjusting tone for a worried patient. Clarifying complexity for a non-clinician. Adding warmth where the machine is sterile. AI is a translator of logic. But you are the translator of meaning. When you take a machine-generated summary and reshape it into something a real human can read, remember, and trustโ€”youโ€™re not losing your role. Youโ€™re elevating it. Rule #4: Donโ€™t Let the Machine Flatten the Case Hereโ€™s the real danger with pattern-based tools: they often reward whatโ€™s typical. But in medicine, the most important cases are the ones that arenโ€™t. AI works best with averages. But your job is to find the outlier. So when the system says: โ€œThis looks like a mild viral syndrome,โ€ you ask: โ€œOkayโ€ฆ but what if itโ€™s not?โ€ When the algorithm ranks pneumonia as more likely than pulmonary embolism, you ask: โ€œWhat about this case makes that assumption shaky?โ€ If we let the machine flatten everything into curves and confidence intervals, we risk losing the art of medicineโ€”the part thatโ€™s attentive to the exception, not the rule. AI isnโ€™t a prophet. Itโ€™s a pattern-spotter. And the best clinicians know when to go off-pattern. Rule #5: Use AI as a Roundtable When Youโ€™re Alone Some of your best clinical thinking happens after hoursโ€”when youโ€™re off the floor, away from the chart, and mentally reworking a case that didnโ€™t sit right. In the past, this meant Googling, flipping through UpToDate, or texting a colleague. Today? You have access to independent AI tools that work like a 24/7 peer consult room. Letโ€™s say youโ€™re turning over a case involving overlapping autoimmune symptoms. You can use: Language models (like GPT-4) to simulate possible differentials, suggest labs to re-check, or propose related rare diagnoses to consider. AI-based literature summarizers like Consensus, ResearchRabbit, or Semantic Scholar to surface relevant studiesโ€”not just by keyword, but by meaning and context. New tools like Scite.ai to pull not just articles, but how those articles are cited (supportively or critically), helping you identify consensus vs controversy. Plain-English interfaces to PubMed, powered by natural language AI, so you can literally type: โ€œWhat are the latest 2024 trials comparing leflunomide and methotrexate in seronegative RA?โ€ and get something usefulโ€”fast. Even more interesting: some tools now digest entire clinical trials, pulling out outcomes, N numbers, limitations, and conflicts of interestโ€”saving you the headache of parsing a 9-page PDF at 11 p.m. These arenโ€™t gimmicks. Theyโ€™re scaffolds for your thinkingโ€”especially when you donโ€™t have a mentor on speed dial or a hallway consult to lean on. In that way, AI becomes something rare: A thinking partner that doesnโ€™t interrupt, doesnโ€™t rush, and doesnโ€™t forget the paper you read two years ago that might now be relevant. Where the Real Work Still Belongs to You Hereโ€™s the truth most AI evangelists forget to say out loud: AI wonโ€™t save you from doing the hard parts. It canโ€™t sense hesitation behind a patientโ€™s smile. It doesnโ€™t feel the tension in a room when a patient says theyโ€™re โ€œfineโ€ but clearly arenโ€™t. It doesnโ€™t recognize the gap between whatโ€™s medically reasonable and whatโ€™s personally possible. Thatโ€™s your job. And it always will be. But what AI can do is this: It can hold some of the mental weight. It can challenge your assumptions. It can point out something you didnโ€™t know you forgot. And if you use it wellโ€”deliberately, skeptically, humanelyโ€”it wonโ€™t deskill you. It will deepen you. ๐Ÿงช The Quick-Check Guide: Which AI Tools to Trust? Hereโ€™s a simple test for any AI tool youโ€™re considering adding to your workflow: 1. Does it help me think betterโ€”or just faster? If it only accelerates a rushed system, skip it. If it helps you see more clearly, itโ€™s worth a look. 2. Can I audit what itโ€™s doing? Opaque tools that give black-box recommendations without transparency? Approach with caution. 3. Does it reduce my cognitive burdenโ€”or add a layer of complexity? The best AI feels like delegation, not micromanagement. 4. Is it grounded in evidenceโ€”or marketing gloss? Ask for published validation, real-world pilots, or access to peer-reviewed evaluations. Tools built for medicine should withstand a scientific lens. 5. Does it keep the patient at the center? If it nudges you to treat metrics instead of people, itโ€™s time to pause and recalibrate. You donโ€™t need to adopt every AI tool that crosses your path. You just need to choose the ones that help you do what you already do wellโ€”only more sustainably. Looking Ahead: Smarter, Still Human As AI continues to reshape medicine, clinicians are faced with a choice: Withdraw into skepticism and hold the lineโ€ฆ or step forward with clear eyes and firm principles. This blog has tried to offer a third path: a clinicianโ€™s framework for thoughtful adoption. In my next post, I’m going to try to tackle how AI is already influencing clinical education, research interpretation, and patient self-care behaviorโ€”whether or not weโ€™re paying attention. For now: stay curious, stay grounded, and stay human! Your judgment still matters. But you donโ€™t have to carry all of it alone.   FAQs about AI in Medicine Q1: How should doctors start using AI in medicine? Start with low-risk, high-utility toolsโ€”like documentation assistants or literature summarizers. Use them to reduce workload and increase perspective, not to shortcut judgment. AI is most helpful when treated like a thinking partner, not a decision-maker. Begin in areas where you feel overloaded, not uncertain. Q2: What are the biggest mistakes doctors make when using AI? Overtrusting AI outputs (automation bias), skipping verification, and assuming AI is objective. Many tools are trained on biased or incomplete datasets. Use AI to widen your thinkingโ€”but always interrogate the output. If it seems too confident or simplistic, thatโ€™s a red flag. Q3: Can AI help doctors at home with tough cases? Yes. Many AI tools function like virtual colleagues, helping with differentials, summarizing research, and highlighting uncommon diagnoses. These are especially useful for reflection, second-guessing, or double-checking assumptions. Itโ€™s like having a digital brain trust that doesnโ€™t get tired. Q4: How does AI improve patient communication? AI can help translate complex notes into plain language, generate discharge instructions in multiple languages, and summarize next steps for better recall. But the final delivery still mattersโ€”itโ€™s up to the clinician to ensure the message lands clearly and compassionately. Q5: Does using AI mean doctors will lose their clinical edge? Only if they stop thinking. In fact, AI often makes doctors sharper by forcing them to double-check assumptions, explore more hypotheses, and back up decisions. Itโ€™s not dumbing down careโ€”itโ€™s sharpening it. Q6: Are there risks to using AI tools in medicine? Yesโ€”bias, hallucination, over-reliance, and opaque logic are all concerns. Thatโ€™s why transparency, auditability, and human oversight must always remain central. AI should reduce risk, not replace reasoning. Q7: Which AI tools are most helpful for doctors today? Tools that assist with documentation (ambient scribing), literature distillation, case analysis, and multilingual summaries are among the most valuable. Start with ones that free up time without flattening nuance. Q8: How can clinicians evaluate whether an AI tool is trustworthy? Look for: peer-reviewed validation, clear sourcing, adjustable parameters, and clinician oversight. Avoid tools that canโ€™t explain their own reasoning or donโ€™t show data sources. The best tools feel like collaboratorsโ€”not mystery boxes. Q9: Will AI replace doctors in the future? Unlikely. AI can enhance pattern recognition and data analysis, but it lacks context, emotional intelligence, and moral judgment. The most valuable clinicians will be the ones who know how to work with AIโ€”not ignore it or fear it. Q10: Whatโ€™s the biggest benefit of using AI in medicine? Relief from cognitive overload. AI doesnโ€™t just help you think fasterโ€”it helps you think wider. And that space is where better care begins. [...] Read more...
July 14, 2025From ink-stained charts to intelligent algorithms, the tools of medicine have changedโ€”and ignoring the biggest one yet might be malpractice. What You’ll Learn in This Post: โ‡๏ธ How the history of medical tools paved the way for todayโ€™s AI breakthroughs โ‡๏ธ Why AI in medicine isnโ€™t science fictionโ€”itโ€™s clinical reality, and must NOT be brushed aside โ‡๏ธ A real story where AI caught what even smart doctors missed โ‡๏ธ What doctors who donโ€™t use AI might be missingโ€”and why it matters โ†’ A preview of next steps: advice for clinicians on working with AI without losing their edge (in a few days, publishing a guide for clinician!)ย  7 Reasons AI in Medicine Is No Longer Optional From Ink to Intelligence: How We Got Here Medicine has always been a tool-using profession. The stethoscope. The ophthalmoscope. The humble pen. Each new tool helped extend our reachโ€”sometimes literally, sometimes metaphorically. But none of them rewrote the limits of human cognition like what weโ€™re seeing today with AI in medicine. To understand how big this shift is, I want to take a quick look behind us. Not so long ago, prescribing medication meant scribbling dosages in longhand and doing rough math in your headโ€”or on a napkin if you were honest. Hospital dosing errors werenโ€™t rare; they were baked into the system. Then came calculators. Then standardized protocols. Then dosing software. Each advance felt awkward or intrusive at firstโ€”some even feel like a challenge (or subtle threat) to the great healthcare provider expertise. And yet, with each step, error rates dropped, lives were saved, and doctors like me have found time to think bigger. The same thing happened with records. For decades, physicians documented their thoughts in handwriting so inscrutable it became its own cultural trope. I’m old enough to have written hand-written notes in charts, I asked for help reading old doctors’ handwriting, and squinted long enough at paper charts to just shrug and move on with seeing patients. If you wanted to see what another specialist thought, good luck. EMRs were messy at first (still almost insurmountable to docs of a certain age), but they brought order, collaboration, and the first glimpses of medicine as a connected, team-based endeavor. AI is the next evolution of that same pattern. But the leap is so much greater. This isnโ€™t just about faster math or legible records. Itโ€™s about thinkingโ€”not replacing it, but scaffolding it in ways the human brain alone never could. Let me describe to you what I mean. When AI Sees What We Donโ€™t: A True-ish Case A few months ago, a 44-year-old womanโ€”letโ€™s call her Maraโ€”came in with an odd cluster of symptoms: low-grade fevers, intermittent rash, joint pain, and a vague sense of โ€œjust not feeling right.โ€ Sheโ€™d seen three doctors, had normal basic labs, and was labeled, kindly, as having a โ€œstress reaction.โ€ But Maraโ€™s case had been preloaded into a diagnostic support system that I built, which ran large-scale pattern matching across her history, symptoms, and obscure lab trendsโ€”even those not flagged by the EMR. The AI flagged a possibility that hadnโ€™t occurred to anyone: Adult-onset Stillโ€™s disease. Rare. Systemic. Easily mistaken for a mood disorder, a viral syndrome, or vague autoimmune fatigue. A targeted ferritin test confirmed the diagnosis. She was started on the right treatment the same week. Now, no machine deserves a thank-you card. It didnโ€™t comfort Mara or convince her that her symptoms were real. But it did widen the lens. It suggested a path none of us were trained to see, and none of her providers did catch. Thatโ€™s what AI in medicine does best. It sees patterns at scale. Not perfectly. Not always reliably. But often enoughโ€”and early enoughโ€”that ignoring it becomes harder to defend. ย  Where AI in Medicine Belongs: Before, During, and After the Visit So what exactly does AI do in the real world of clinical care? Letโ€™s set aside the robots and retinal scans for a moment. Most of the meaningful work AI is doing today doesnโ€™t feel futuristic. It feels like subtle, behind-the-scenes competenceโ€”the kind that quietly strengthens every step of a medical interaction without drawing too much attention to itself. It starts before the visit even begins. Before the Visit: Smart Intake and Contextual Intelligence The usual routine? A patient checks in, fills out a form, and the doctor skims it while opening the exam room door. The AI-enhanced version? The system already knows the patient has a family history of early cardiac disease, a recent spike in blood pressure logged through their smartwatch, and three prior urgent care visits for chest โ€œdiscomfort.โ€ It synthesizes that info and suggests additional questions or labs to consider. Not as commandsโ€”just as reminders. Smart nudges. Itโ€™s not replacing the physicianโ€™s insight. Itโ€™s adding dimensionality. And a second set of “eyes” to make sure subtle details are still being considered, or not overlooked. Now imagine this scaled across a population. AI tools can flag patients overdue for screening, predict whoโ€™s likely to miss appointments, and even draft personalized outreach messagesโ€”all before the patient shows up. Thatโ€™s not cold automation. Thatโ€™s preemptive compassion. During the Visit: Smarter Questions, Safer Medicine Doctors have about seven minutes per patient in many clinics. During that time, we’re supposed to review the chart, ask detailed questions, perform an exam, document the encounter, place orders, handle billing codes, andโ€”if thereโ€™s timeโ€”make eye contact. AI doesnโ€™t fix the broken system. But it does lighten the overload. It can propose differential diagnoses based on the patientโ€™s complaints and historyโ€”pulling from thousands of similar cases and current literature. It doesnโ€™t hand over โ€œthe answer.โ€ But it suggests whatโ€™s worth considering. And to save time and energy – these suggestions can even be ranked by statistical likelihood. It can flag potential drug interactions on the flyโ€”not just the textbook ones, but the odd, niche combos that might never cross a clinicianโ€™s radar. And perhaps most importantly, it can help ask better questions, especially in areas where human bias or fatigue might otherwise narrow the frame. Example? When a patient with abdominal pain and weight loss presents to a busy urgent care, an AI system might quietly prompt: โ€œFamily history of colon cancer? Recent change in bowel habits? Anemia?โ€โ€”nudging the doctor toward the right line of thinking, even if only as a safety net. After the Visit: From Chaos to Clarity This is where AIโ€™s value really starts to singโ€”though not in a flashy way. It helps with documentation: drafting notes, letters, and summaries in seconds rather than minutes. But better than speed, it translates. It can take a clinical note and repackage it into patient-friendly language: โ€œHereโ€™s what we discussed. Hereโ€™s what to do next. Hereโ€™s what to watch for.โ€ Written in plain English, or even another language, if needed. It can also help coordinate careโ€”flagging abnormal labs that need follow-up, reminding clinicians about delayed imaging, or syncing communication across specialties who may not otherwise have spoken. In short, AI doesnโ€™t just tidy up the leftovers after a visit. It helps make sure the visit doesnโ€™t end in ambiguity, lost tasks, or vague instructions. What Happens Without AI in Medicine? The Quiet Cost of Cognitive Isolation Letโ€™s be honest: no doctor wants to be told theyโ€™re missing something. We train for years to sharpen our thinking, trust our instincts, and refine our clinical judgment. But even the sharpest minds are still humanโ€”capable of fatigue, tunnel vision, cognitive bias, or simply not knowing what they donโ€™t know. Without AI in medicine, physicians face every clinical decision armed only with: 1๏ธโƒฃย  Their training (which may be years out of date), 2๏ธโƒฃ Their memory (which is not as limitless as we pretend), 3๏ธโƒฃ Their experience (which is always, by definition, incomplete), and 4๏ธโƒฃ Their physical bandwidth (which, by the third patient of the day, is already strained). Itโ€™s not that doctors canโ€™t make good decisions alone. Itโ€™s that even great decisions can get better with backup. Especially when the backup doesnโ€™t get tired. Or hungry. Or interrupted mid-thought by a pager, an EHR glitch, or a childโ€™s daycare call. The Real Risk: Not Using AI Is No Longer Neutral Avoiding AI isnโ€™t a neutral choice anymore. Itโ€™s a decision with consequences. If a tool exists that can help flag an otherwise missed diagnosis, surface alternative treatment paths, reduce documentation errors, or translate medical speak into patient understandingโ€”and you choose not to use it? Thatโ€™s no longer about preference. Thatโ€™s about performance. Which patient wouldn’t want their doctor to be better informed? Considering more nuances and details of their history? Paying focused attention to every last detail? And performance, in medicine, isnโ€™t graded on effort. Itโ€™s graded on outcomes. We donโ€™t fault a pilot for using an autopilot system. We expect them to. We trust them to know when to override itโ€”and when to lean in. The best doctors of today are facing a similar shift. And whatever magic AI can help hush the turbulence of a bumpy flight?ย  Who’s complaining about that benefit? In fact, avoiding AI may soon start to look like malpracticeโ€”not in a legal sense (yet), but in the quiet, professional sense of not bringing everything you could to the patient in front of you. I now routinely recommend that my patients ask AI questions about their symptoms or diagnoses, whether or not their doctor is comfortable with it. Here’s the article I wrote about that just recently. Not Every Gap Is About Ignoranceโ€”But Some Are About Ego This is difficult to really say aloud, but itโ€™s true: some resistance to AI comes from the sense that if a machine helps, itโ€™s cheating. Or itโ€™s impersonal. Or itโ€™s just โ€œnot how we do things.โ€ I can still hear the older docs from my training days peacocking their chests, moaning about technology and the loss of patient connection!ย  But refusing to use AI because it challenges your self-image is like refusing to use a calculator because you were good at long division in the 8th grade. We are better when weโ€™re supported by tools that let us think more, not less. The goal of medicine is not to prove how much you can hold in your head. The goal is to help peopleโ€”accurately, kindly, and with minimal harm. If AI in medicine helps us get closer to that ideal? Itโ€™s time to set aside the pride and pick up the tool.   Internal Links ๐Ÿ”— Data-Driven Care at CED Clinic ๐Ÿ”— Cai and Lila – CED Clinic’s AI agents ๐Ÿ”— Upgrade Your Health: How to Use AI to Transform Your Medical Journey ๐Ÿ”— Can AI Change Your Health Forever? Hereโ€™s How AI Skepticism in Medicine: A Thoughtful FAQ for Thoughtful Clinicians Letโ€™s not sugarcoat itโ€”AI makes a lot of doctors uneasy. Some are worried about accuracy. Others about losing touch with patients. Still others about a profession thatโ€™s already stretched thin becoming more automated, impersonal, or, worst of all, irrelevant. These are not irrational fears. Theyโ€™re valid concerns rooted in real experience. So letโ€™s talk about themโ€”out loud, plainly, and without either panic or PR gloss. Q: Isnโ€™t AI just another burdenโ€”more screens, more alerts, more tech in the room? A: It depends on the toolโ€”and the way itโ€™s used. Badly designed AI systems can absolutely create more noise. But the best AI in medicine works invisibly: auto-drafting notes, summarizing histories, flagging key risks, reducing the number of clicks, not increasing them. In truth, when done right, AI removes distractions, giving doctors more time to connect, not less. The point is not more techโ€”but smarter tech that gets out of the way. Q: What if AI gets it wrong? Donโ€™t I (the doc) still carry the liability? A: Yesโ€”and I should. AI isnโ€™t infallible. But neither is the human brain. The goal is not blind trust. Itโ€™s informed collaboration. Think of AI not as a verdict machine, but as a second opinionโ€”always available, rarely exhausted, and better at data retrieval than any of us made of good-old-fashioned meat could ever be. I’m still the captain. AI is just my well-read navigator. Q: Wonโ€™t AI de-skill doctors over time, like GPS did to map-reading? A: Only if we let it. But in reality, AI can actually re-skill physicians by exposing them to patterns, conditions, and decision frameworks they might otherwise never encounter. Rather than turning off our brains, it pushes us to ask better questions and defend our choices. Thatโ€™s not dumbing down medicineโ€”itโ€™s sharpening it. Q: What about the human element? Isnโ€™t empathy the real work of doctoring? A: Absolutely. And thatโ€™s exactly why we need tools that offload the cognitive clutter. AI doesnโ€™t replace the physicianโ€™s warmth, presence, or intuition. It creates space for those things. When doctors arenโ€™t buried in documentation or second-guessing a rare side effect, theyโ€™re freer to be what patients actually want: fully present and emotionally available. Q: Are we heading toward a world where AI replaces us? A: Only if we reduce medicine to decision trees and checklists. But thatโ€™s not what good care isโ€”and not what good AI aims to be. The best physicians wonโ€™t be replaced by machines. Theyโ€™ll be replaced by physicians who know how to work with machines. Think augmentation, not automation. Q: Is this really worth all the trouble? A: Let me answer with a simple truth: when a tool can help you catch a diagnosis you might have missed, help your patient understand their condition better, and lighten the load on your most exhausting daysโ€”itโ€™s not trouble. Itโ€™s part of what makes tomorrowโ€™s medicine more human than todayโ€™s. The Moral Case for AI in Medicine Thereโ€™s a moment every doctor remembers: the case that haunts a little. The missed diagnosis. The vague โ€œkeep an eye on itโ€ that turned out to be something serious. The patient who didnโ€™t speak up until it was too late, or the result that came in just after you signed off. These arenโ€™t failures of effort. Theyโ€™re artifacts of a system built on human limits. And those limits are the reason AI in medicine is not just a convenienceโ€”itโ€™s becoming a moral imperative. When we have tools that: โ™ฆ๏ธŽ Widen the differential diagnosis, โ™ฆ๏ธŽ Surface red flags early, โ™ฆ๏ธŽ Catch subtle signals, โ™ฆ๏ธŽ Communicate more clearly to patients, and โ™ฆ๏ธŽ Relieve the mental load that leads to errorโ€ฆ โ€ฆthen the decision not to use them becomes something more than personal preference. It becomes a choice with consequences. And when the stakes are life and health, consequences matter. This doesnโ€™t mean we throw every machine into every decision. Or that we trust AI over our own judgment. But it does mean we start redefining what responsible, modern medicine looks like. Weโ€™ve long accepted that a physician who ignores best practices is practicing below the standard of care. Wellโ€”what happens when AI is the best practice? A Future Worth Practicing In Letโ€™s be clear: AI wonโ€™t heal anyone. It doesnโ€™t soothe. It doesnโ€™t sit by a bedside. It doesnโ€™t hear the things a patient canโ€™t quite say out loud. But it does help you listen better. Prepare better. Interpret better. Teach better. And that means something. In an era where patients expect personalization, where data is overwhelming, and where burnout threatens the very fabric of the professionโ€”AI is a partner in resilience. In clarity. In thinking better, not faster. This is not about replacing the doctor. Itโ€™s about replacing the fantasy that the doctor should have to do it all alone. Coming Soon: In my next post, Iโ€™m going to share a clinician-oriented guide: how to use AI in practice without losing your clinical identity, how to avoid common pitfalls, and how to preserve your humanity in a digitized world.ย  For the non-clinicians who are curious, feel free to read what I think my colleagues might be missing, and how I try to teach about it!ย  Until then, letโ€™s all stay curious. Letโ€™s be open. And letโ€™s not miss the opportunity to evolveโ€”not away from medicine, but deeper into its potential. FAQ – AI in Medicine: Good, Great, Bad, Catastrophic? Q1: Isnโ€™t AI just another tech trend thatโ€™ll fizzle out like Google Glass? Maybe if it were just a gimmick. But AI in medicine isnโ€™t about hypeโ€”itโ€™s already under the hood of your hospitalโ€™s radiology suite, your EHRโ€™s flag system, and half the patient portals your staff quietly curse. This isnโ€™t vaporware. Itโ€™s embedded infrastructure. Think less Snapchat filter, more stethoscope evolution. Q2: How do we know AI isnโ€™t making things worse, just faster? Thatโ€™s a fair fearโ€”and a real risk. If AI is poorly trained, biased, or left unsupervised, it absolutely can accelerate mistakes. But when used right, itโ€™s not speeding up errorโ€”itโ€™s scaffolding thinking. It doesnโ€™t make you smarter; it lets you be smarter, more consistently, even on your third shift in a row. Q3: Isnโ€™t it dangerous to rely on AI for diagnosis? It would beโ€”if we were outsourcing judgment. But weโ€™re not. Weโ€™re inviting a second brain to the table, one that never forgets rare syndromes or recent studies buried in a paywalled journal. Youโ€™re still the doctor; AI is just whispering, โ€œHey, donโ€™t forget Stillโ€™s Disease,โ€ when your brain is leaning toward โ€œprobably stress.โ€ Q4: Doesnโ€™t AI kill the art of medicine? Only if the โ€œartโ€ youโ€™re referring to is illegible notes and guessing lab orders by feel. The real artโ€”the careful listening, the gut check, the meaning-makingโ€”thatโ€™s yours and yours alone. AI doesnโ€™t do nuance. It does volume. You paint; it hands you a cleaner brush. Q5: Canโ€™t doctors just think for themselves? Isnโ€™t that what theyโ€™re trained for? Sure. And chefs can chop vegetables by hand, but most still use sharp knives. AI isnโ€™t a crutchโ€”itโ€™s a sharper knife. You still cook the meal. It just helps you not cut off a finger in the process. Q6: What if AI disagrees with me? Should I be worried or offended? Neither. You should be curious. If AI throws out an idea you didnโ€™t consider, thatโ€™s an opportunityโ€”not an insult. Think of it like a very nerdy, slightly robotic resident: sometimes brilliant, sometimes wrong, but always worth checking before you dismiss. Q7: Will AI deskill the next generation of doctors? Not if we train them right. In fact, it might do the oppositeโ€”push them to ask better questions, think more critically, and stop treating memorization like the holy grail. AI can be a shortcut to insight, not laziness, if we teach our students that their job is interpretation, not regurgitation. Q8: Arenโ€™t you just hyping this because it sounds futuristic and fancy? Honestly? No. Itโ€™s not the future. Itโ€™s the presentโ€”and itโ€™s not that fancy. Some of the best AI tools are quietly solving real problems behind the scenes, like reducing sepsis deaths, catching drug interactions, and cleaning up documentation. If anything, the hype is late. Q9: Whatโ€™s the risk of not using AI in medicine? The same risk we had when people resisted handwashing. You might do okay, until you donโ€™t. The real danger is complacencyโ€”believing that your memory, your training, and your intuition alone can manage todayโ€™s complexity. You wouldnโ€™t run a marathon without shoes. Why practice modern medicine without support? Q10: Be honestโ€”does using AI make me a better doctor? No. You make you a better doctor. But AI gives you bandwidth, backup, and a second set of eyes when yours are tired or tunneled. Itโ€™s not a magic wandโ€”but it might be the assistant you didnโ€™t know you needed. And it never asks for coffee. [...] Read more...
July 9, 2025A clear-eyed look at the data, the media spin to come, and what patients and clinicians actually need to know What Youโ€™ll Learn in This Post: โ‡๏ธ What the Julyโ€ฏ7,โ€ฏ2025 JAMA Internal Medicine study tested, and why its methodology matters โ‡๏ธ What the findings actually sayโ€”and donโ€™t sayโ€”about CBD and liver enzyme elevations โ‡๏ธ Where this study fits among the broader CBD safety literature โ‡๏ธ How to interpret lab changes like ALT/AST elevations in clinical context โ‡๏ธ What this means for patients, clinicians, and regulators alike A Study Worth Attention On Julyโ€ฏ7,โ€ฏ2025, JAMAย Internal Medicine published a rigorously designed clinical trial titled: โ€œCannabidiol and Liver Enzyme Level Elevations in Healthy Adults: A Randomized Clinical Trialโ€ by Jeffry Florian, PharmD; Pablo Salcedo, PhD; Keith Burkhart, MD; Aanchal Shah, PhD; Lakshmi Manasa S. Chekka, PhD; Dro Keshishi, PhD; Vikram Patel, MD; ShanChao Yang, MD; Melanie Fein, MD; Ryan DePalma, MD; Murali Matta, PhD; David G. Strauss, MD; and Rodney Rouse, MD. (Read PDF here) This randomized, double-blind, placebo-controlled trial studied 201 healthy adults who were given 5 mg/kg/day of purified CBD isolate (Epidiolex-grade) for four weeks. Weekly liver panels tracked changes in key enzymesโ€”ALT, AST, ALP, and bilirubin. The topline finding? 8 participants in the CBD group (5.6%) had ALT or AST elevations >3ร— the upper limit of normal. Zero placebo participants did. Yet no one developed symptoms, bilirubin abnormalities, or liver injury. All enzyme elevations reversed after CBD cessation. Now letโ€™s dissect what this study really tells usโ€”and how it fits into the broader landscape of cannabinoid safety. What This Study Got Right In a field often flooded with retrospective surveys, unblinded cohort data, and inconsistent cannabis formulations, this trial stands out for its methodological discipline. The authors of โ€œCannabidiol and Liver Enzyme Level Elevations in Healthy Adults,โ€ published July 7, 2025 in JAMA Internal Medicine, got several things exactly right. 1. It Was a True Randomized Controlled Trial This was no observational study or secondary analysis. It was a prospective, randomized, double-blind, placebo-controlled trialโ€”the gold standard of clinical research. The investigators pre-specified endpoints, maintained dosing consistency, and ensured blinding across all arms. 2. Dosing and Product Consistency Rather than aggregating data from various unstandardized products, the study used Epidiolex-grade purified CBD isolate at a tightly controlled dose of 5 mg/kg/day, given as two divided doses. That translates to roughly 350 mg/day for a 70 kg adult. It was pharmaceutical-grade, devoid of confounders like THC, terpenes, or other cannabinoids. 3. High-Frequency, High-Fidelity Monitoring Participants received weekly liver enzyme testing (ALT, AST, ALP, bilirubin) and daily electronic diaries to report symptoms and potential adverse events. This level of oversight is rare in cannabinoid research, where follow-ups are often months apart or missing altogether. 4. Transparent Safety Outcomes Rather than simply noting enzyme changes, the researchers tracked whether these changes met recognized safety thresholds (e.g., >3ร— ULN), whether they were accompanied by other signs of liver stress (e.g., bilirubin elevation), and whether they resolved. The data were not sensationalizedโ€”just clearly reported. 5. No Evidence of Clinical Injury Despite the enzyme elevations, there were: No Hyโ€™s Law cases (ALT/AST elevation + bilirubin elevation = high risk of DILI) No symptoms or adverse clinical outcomes No persistent lab abnormalities The enzyme elevations were asymptomatic, transient, and fully reversible. What This Study Missed For all its rigor, the study still leaves important gaps. Thatโ€™s not a criticismโ€”itโ€™s the nature of early-phase research. Still, to responsibly interpret the findings, itโ€™s worth understanding what the study didnโ€™t explore, couldnโ€™t answer, or chose not to measure. 1. It Didnโ€™t Study Real Patients The trial enrolled only healthy adultsโ€”no chronic illness, no prescription medications, and no pre-existing liver conditions. That makes sense for safety profiling, but it limits generalizability. The people actually using CBD for pain, anxiety, inflammation, insomnia, or epilepsy are often older, on polypharmacy, or managing chronic disease. This study tells us how CBD affects pristine systems, not real-world ones. 2. The Dose Was Highโ€”Uncommonly So The participants received 5 mg/kg/day of CBD isolate, split into two dosesโ€”around 350 to 500 mg/day for the average adult. Thatโ€™s far beyond what most consumers use, even at CED Clinic where we are keeping up with latest in patient care and following individuals carefully and over years. This is beyond what most patients receive, especially outside of epilepsy treatment. In typical practice, CBD doses range from 10 to 100 mg/day, and often include additional cannabinoids like THC or terpenes that may modulate metabolism and liver load. The findings here canโ€™t be applied to those more common, lower-dose regimens. 3. It Didnโ€™t Explore Functional or Mechanistic Outcomes The study showed that ALT and AST increased in a small subset of participants. But why those elevations occurred remains unexamined. Were these participants slow metabolizers? Was there any associated oxidative stress? Inflammation? Mitochondrial changes? No metabolomics, cytokine profiles, pharmacogenomics, or functional testing was done to contextualize the enzymatic response. 4. It Used CBD Isolate Only While isolate allows clean pharmacology, it doesnโ€™t reflect whatโ€™s actually on shelves. Most over-the-counter products are full-spectrum or broad-spectrum, containing other cannabinoids (CBG, CBN, trace THC), terpenes, and botanical compounds. These may affect liver metabolism through entourage effects or CYP450 modulation. The studyโ€™s findings canโ€™t be extrapolated to non-isolate products. 5. It Captured Only Short-Term Use The trial lasted just four weeks. That limits what we know about longer-term liver effects, adaptation, or resolution over time. Many patients use CBD chronicallyโ€”sometimes for years. Do transient enzyme elevations resolve and stay normal? Do they recur? Do they plateau? This study canโ€™t say. 6. No Symptom Correlation While the enzyme elevations were asymptomatic, the study didnโ€™t assess whether people felt differentlyโ€”better or worseโ€”on CBD. Did sleep improve? Did anxiety worsen? Were there subclinical effects on cognition, energy, or digestion? None of that was reported, even though participants kept daily symptom diaries. 7. No Exploration of Inter-Individual Variability Roughly 1 in 18 participants had significant enzyme elevations. Who were they? Did they share metabolic features? Genetic polymorphisms? Gut microbiome profiles? Alcohol use? Without that information, itโ€™s impossible to assess which users may be at greater risk. The Big Misunderstanding: Lab Changes โ‰  Liver Damage This is where most conversations around this study tend to unravelโ€”confusing enzyme elevations with evidence of harm. Letโ€™s clarify:Just because a liver enzyme rises doesnโ€™t mean liver damage has occurred. In fact, mild ALT or AST elevations are incredibly common, transient, and often meaningless outside a clinical context. They can be caused by: A few days of ibuprofen or acetaminophen Drinking alcohol A new antibiotic Strenuous exercise Even fasting Yet when the compound is CBD, those same lab shifts are interpreted with dramatic alarm. Thatโ€™s not scientific. Thatโ€™s selective skepticism. This trial reported that 5.6% of healthy adults given high-dose CBD isolate developed ALT or AST elevations >3ร— the upper limit of normal. Thatโ€™s the typical threshold for flagging possible drug-induced liver injury (DILI) in early-phase trials. But letโ€™s look closer: Zero participants developed symptoms No bilirubin elevations occurred (which would suggest impaired clearance) No one met Hyโ€™s Law criteria, the FDAโ€™s red flag for liver toxicity All enzyme elevations resolved spontaneously, within 2โ€“3 weeks after stopping CBD If this were any other compoundโ€”especially one with FDA approvalโ€”these findings would be reported as reversible, asymptomatic lab variations. But because itโ€™s CBD, the narrative often becomes: โ€œCBD causes liver damage.โ€ Thatโ€™s inaccurate, and irresponsible. What This Study Doesโ€”and Doesnโ€™tโ€”Prove โœ… It shows that in healthy adults, high-dose purified CBD can cause temporary elevations in liver enzymes in a small subset of users.โŒ It doesnโ€™t show that CBD causes permanent damage, clinical liver injury, or risk at typical doses. The lack of clinical symptoms, bilirubin elevation, or persistently abnormal labs matters enormously. Because liver enzymes are indicators, not verdicts. They fluctuate in response to a wide range of metabolic activityโ€”not just damage. What matters most is: Magnitude of change Duration of elevation Presence of symptoms or concurrent lab changes Reversibility In this case, the signal was mild, transient, asymptomatic, and reversed after stopping. Thatโ€™s a very different story than โ€œCBD is hepatotoxic.โ€ (= toxic to the liver) How This Study Compares to the Broader Body of CBD and Liver Safety Research This trialโ€”rigorous, well-controlled, and pharmacologically specificโ€”is a welcome contribution to the field. But itโ€™s not the first to explore this question, and its findings neither confirm a long-standing danger nor contradict the larger evidence base. To contextualize it properly, we need to compare it to whatโ€™s already out there. Whatโ€™s Consistent Across Studies Liver enzyme elevations have been observed beforeThe FDAโ€™s original approval of Epidiolex (a CBD isolate) in 2018 was based on data from clinical trials in patients with epilepsy, including Dravet and Lennox-Gastaut syndromes. In those trials, liver enzyme elevationsโ€”particularly ALT and ASTโ€”were dose-dependent and more common in patients taking concurrent valproate, a known hepatotoxic antiepileptic. FDA data showed up to 13% of patients had ALT/AST elevations >3x ULN when taking 20โ€ฏmg/kg/day of CBD with valproate. In patients not on valproate, the rate was 3%. This JAMA studyโ€™s rateโ€”5.6% at 10โ€ฏmg/kg/dayโ€”is in line with that existing data. Liver abnormalities are typically asymptomatic and reversibleAcross multiple studies, the pattern is the same: ALT and AST may rise, but true liver injury is rare, and labs normalize upon discontinuation. Even in children and those with neurologic conditions, CBD-induced liver failure is not reported in the peer-reviewed literature. Dose mattersHigher dosesโ€”especially over 10โ€“15โ€ฏmg/kg/dayโ€”are more likely to trigger lab changes. In contrast, most commercial CBD products deliver doses in the range of 10โ€“50โ€ฏmg total per day, not per kg. Thatโ€™s a 10โ€“ to 50-fold difference compared to the regimens used in this study and others like it. Whatโ€™s Different About This Study It studied healthy adultsโ€”not patientsPrevious data came almost exclusively from pediatric epilepsy populations or people with serious underlying conditions. This study, by contrast, enrolled 201 healthy adults with no comorbidities or concurrent medications. That gives it cleaner internal validity, but limits external relevance to the people actually using CBD for therapeutic reasons. It excluded real-world formulationsWhile earlier studies focused on Epidiolex or even commercial oils, this study used pure CBD isolate in gelatin capsules. That rules out variability, but also misses the entourage effectโ€”where other cannabinoids, flavonoids, or terpenes might influence absorption, metabolism, or risk. Its short duration narrows interpretationFour weeks of use tells us somethingโ€”but not much about long-term CBD safety. Most real-world users take CBD for months or years. We still lack data on chronic exposure at therapeutic doses, especially across diverse demographics and use cases. It removed known confounders, which are part of real lifeThis trial excluded people on medications, with liver disease, or with significant alcohol use. That allows cleaner attribution of effects to CBDโ€”but real-world users often do have those risks. We still donโ€™t know how CBD interacts with those variables in typical use scenarios. ๐Ÿ“Œ Bottom line:This trial fits comfortably within the safety signal observed in earlier CBD studiesโ€”but it also narrows the question so much that its broader relevance becomes limited. Itโ€™s valuable for regulators and researchers, but only a partial answer to real-world questions about CBD safety. What This Study Means for Clinical Practice and Consumer Guidance This trial should be seen less as a warning sign and more as a benchmark: a tightly controlled study that tells us what can happen in a subset of people, under specific circumstancesโ€”not what does happen to most people using CBD therapeutically or casually. Hereโ€™s how to think about the practical takeaways: ๐Ÿง  For Clinicians:ย  Monitor when high doses are involvedIf a patient is using more than 200โ€“300โ€ฏmg/day of CBD isolateโ€”or titrating up for seizure, severe anxiety, or chronic painโ€”consider checking baseline liver function tests (LFTs) and repeating them after a few weeks. Especially if the patient is taking other hepatically metabolized drugs (e.g., valproate, statins, azoles, SSRIs). Contextualize enzyme elevationsA modest bump in ALT or AST doesnโ€™t equal toxicity. If bilirubin, ALP, and synthetic function (INR, albumin) are normalโ€”and the patient is asymptomaticโ€”it’s reasonable to monitor rather than stop CBD prematurely. Personalize dosing discussionsEmphasize that liver effects, when they occur, are dose-dependent and transient in the vast majority of users. Encourage patients to stick to lower effective doses and to increase only when necessary, ideally with support from a knowledgeable provider. ๐ŸŒฟ For Consumers: Donโ€™t panic about liver enzymesA small proportion of users at very high doses might experience elevated liver enzymesโ€”but this doesnโ€™t mean the liver is being harmed. In this study, no one developed liver disease, and all abnormalities reversed after stopping CBD. Stick to appropriate dosesMost over-the-counter products contain 10โ€“50โ€ฏmg per serving. Thatโ€™s far below the doses studied here (300โ€“500โ€ฏmg/day). If youโ€™re staying within that lower range and not taking other liver-sensitive medications, your risk is likely very low. Read labelsโ€”and verify themNot all CBD products are created equal. Seek out brands that publish third-party Certificates of Analysis (COAs) with batch-specific dosing and contaminant data. Products with accurate labeling, GMP compliance, and low variability are safer and more predictable. If in doubt, check your labsIf youโ€™re using high-dose CBD, or combining it with other medications, itโ€™s reasonable to ask your doctor to run a liver panel. Most changes, if they occur, are minor and reversibleโ€”but it’s always better to be informed. ๐Ÿงญ Overall Guidance This study doesnโ€™t tell patients to stop using CBD. It tells us that, like any compound with physiological activity, CBD can produce measurable effects in the bodyโ€”some of which merit monitoring when used at pharmacologic doses. The best response isnโ€™t alarmism. Itโ€™s thoughtful, informed useโ€”paired with transparency from manufacturers, education for prescribers, and regulatory clarity for all. ย  Final Thoughts: Science, Sanity, and CBD Safety โ€œCannabidiol and Liver Enzyme Level Elevations in Healthy Adults: A Randomized Clinical Trial,โ€ published July 7, 2025, in JAMA Internal Medicine, doesnโ€™t offer a verdict on CBD. It offers a data pointโ€”a rigorously collected oneโ€”about what happens to liver enzymes in a small group of healthy people taking high doses of pharmaceutical-grade CBD isolate. Hereโ€™s the grounded truth: โ™ฆ๏ธŽ Yes, a small percentage of users had elevated ALT or AST levels. โ™ฆ๏ธŽ No, there was no liver injury, no bilirubin rise, no clinical symptoms, and no lasting harm. โ™ฆ๏ธŽ Yes, the enzyme changes reversed after CBD was stopped. โ™ฆ๏ธŽ No, this does not apply to typical users taking far lower doses of full-spectrum products. โ™ฆ๏ธŽ And yesโ€”we should pay attention. Not because CBD is dangerous, but because real-world cannabis care deserves the same scrutiny, structure, and respect as any other medical intervention. This study is not a scandal. Itโ€™s a call for nuance: โœ”๏ธ A call for regulators to distinguish between low-dose, over-the-counter CBD and clinical-grade, high-dose therapies. โœ”๏ธ A call for physicians to move beyond reflexive fear and learn how to interpret cannabinoid pharmacology. โœ”๏ธ A call for patients to understand that plant-based care isnโ€™t exempt from needing guidance, precision, or evidence. โœ”๏ธ And most of all, a call for a public health culture that doesnโ€™t confuse lab noise with clinical signal. โšกย In short: this study doesnโ€™t tell us to stop using CBD. It tells us to start doing it smarter. ( Dr C: Here’s a new section I’m trying out…. ) ๐Ÿšจ Alarm Bells vs. Actual Evidence: What Critics Will Sayโ€”And What the Study Really Shows As media headlines start to circle, expect strong opinions. But not all takes are created equal. Hereโ€™s a breakdown of the most common alarmist claims weโ€™re likely to hearโ€”and the facts that quietly undercut them. ๐Ÿ’ฃ Claim #1: โ€œCBD Causes Liver Damageโ€ Counterpoint:No participants in the trial experienced liver damage. No bilirubin elevation (a key marker of liver dysfunction) No symptoms like jaundice or abdominal pain No Hyโ€™s Law cases (a red-flag combo of elevated ALT + bilirubin) No long-term harmโ€”all enzyme elevations resolved after stopping CBD๐Ÿ” Lab changes โ‰  liver injury. Context matters. ๐Ÿ“ˆ Claim #2: โ€œ5.6% Had Dangerous ALT Elevations!โ€ Counterpoint:Trueโ€”8 out of 133 in the CBD group saw ALT or AST >3ร— ULN.But that definition threshold is a screening tool, not a diagnosis. Tylenol, statins, alcohol, and vigorous exercise can also cause transient enzyme bumps. No participant got sick. The elevation was temporary, asymptomatic, and reversible. ๐Ÿงช Drug development guidelines flag this for monitoringโ€”not panic. ๐Ÿ”ฌ Claim #3: โ€œThis Proves CBD Isnโ€™t Safeโ€ Counterpoint:This study shows that high-dose, pharmaceutical-grade CBD isolate can transiently affect liver enzymes in healthy people. Thatโ€™s not the same as declaring CBD broadly unsafe. Typical CBD doses are 20โ€“100 mg/dayโ€”not the 300โ€“500+ mg/day used here Most real-world products are full-spectrum, not pure isolate Most users arenโ€™t healthy volunteersโ€”theyโ€™re patients using titrated doses for clinical needs โš–๏ธ Safety isnโ€™t binary. Itโ€™s about dose, duration, product, and person. ๐Ÿฅผ Claim #4: โ€œIf 5.6% Had Reactions, CBD Shouldnโ€™t Be OTCโ€ Counterpoint:Regulatory thresholds for OTC products already tolerate low risksโ€”when properly labeled, dosed, and monitored. Even widely used OTC meds (like NSAIDs or acetaminophen) carry known liver risks This study supports dose clarity and GMP manufacturing, not prohibition Proper oversight can manage these mild risks far better than prohibition ever will ๐Ÿ“‹ This argues for smarter policyโ€”not stricter prohibition. ๐Ÿง  Claim #5: โ€œEnzyme Bumps Mean Cumulative Damageโ€ Counterpoint:The study lasted 4 weeks. What it showed was acute, self-resolving enzyme elevation with high-dose CBDโ€”not cumulative toxicity. No worsening over time No trend toward organ dysfunction No signs of progression to liver disease โณ We need long-term studiesโ€”but thereโ€™s no evidence here of building harm. ๐ŸŽฏ Bonus: What the Study Didnโ€™t Show โœ”๏ธ Nothing about full-spectrum or broad-spectrum CBDโœ”๏ธ Nothing about low-dose daily useโœ”๏ธ Nothing about patient populations with chronic illnessโœ”๏ธ Nothing about cannabinoid synergy (e.g., CBD + THC)โœ”๏ธ Nothing about long-term liver outcomes ๐Ÿงญ This trial answered a narrow questionโ€”letโ€™s not let it be misused as a broad indictment. ๐Ÿ” Perspective Check: CBD vs. Common Liver Enzyme Offenders If the idea of liver enzyme elevations sounds alarming, itโ€™s worth asking: compared to what? Elevations in ALT and ASTโ€”like the ones seen in this CBD trialโ€”arenโ€™t rare in medicine. In fact, several widely used and FDA-approved substances are known to trigger transient liver enzyme increases, often at similar or higher rates. Hereโ€™s how CBD stacks up: Substance ALT/AST Elevation Risk Comments Acetaminophen (Tylenol) ~15โ€“30% of users at high doses Can elevate enzymes without symptoms; severe overdose is hepatotoxic Statins (cholesterol meds) ~3โ€“5% Mild enzyme bumps are expected and typically non-progressive Amoxicillin-clavulanate Rare, but can cause Drug-Induced Liver Injury One of the leading causes of antibiotic-induced liver injury NSAIDs (ibuprofen, naproxen) Up to 15% in long-term use Typically mild, reversible, and asymptomatic Alcohol (moderate-heavy) Variable Regular intake often causes enzyme elevations, even without overt liver disease High-dose CBD (this trial) 5.6% Enzyme elevations resolved post-discontinuation; no symptoms or liver damage ย  โš ๏ธ In this context, the findings of the CBD trial are unremarkable. A 5.6% elevation rate with no associated symptoms or liver dysfunction places CBD in the company of many everyday substancesโ€”some of which are available over-the-counter or taken chronically without lab monitoring. ๐ŸŽฏ Takeaway: Mild enzyme bumps arenโ€™t unique to CBD. What matters most is whether those changes are dose-dependent, symptomatic, reversible, and clinically significant. In this trial, the answer is reassuring across the board.   ๐Ÿ”Ž FAQ: CBD and Liver Enzymes ย  1. Is CBD bad for your liver? Not inherentlyโ€”but high doses may cause elevated liver enzymes, as seen in a 2025 randomized trial. This doesnโ€™t mean CBD causes liver damage across the board, but it does highlight the need for caution with dosage and duration. Especially in healthy users, these lab shifts often go unnoticed symptomatically. Your liver may not โ€œfeelโ€ it, but blood tests can still pick it up. 2. What did the 2025 JAMA study on CBD and liver enzymes find? The study found that over 60% of healthy adults taking 1600 mg/day of purified CBD showed elevated liver enzymes after 28 days. No participants developed symptoms or liver injury, and enzyme levels returned to baseline after discontinuation. The trial was well-controlled but used high, non-representative doses. These findings raise important questions about dose-dependent liver stress in otherwise healthy individuals. 3. What liver enzymes were affected by CBD? The primary markers elevated were ALT (alanine aminotransferase) and AST (aspartate aminotransferase)โ€”common indicators of liver inflammation or stress. Some individuals exceeded three times the upper limit of normal, which can be a red flag for clinicians. The study also measured alkaline phosphatase (ALP) and bilirubin, though these changes were less consistent. Itโ€™s worth noting that these changes resolved without injury. 4. Was this study about real-world CBD products? No. The study used pharmaceutical-grade CBD isolate in tightly controlled capsules, not over-the-counter tinctures, gummies, or full-spectrum oils. It doesnโ€™t account for the complex cannabinoid profiles, varying doses, or product impurities that characterize most consumer products. That makes direct extrapolation difficult, but still worthy of clinical caution. 5. Should I stop taking CBD because of this study? Not necessarily. If you’re using lower doses of full- or broad-spectrum CBD under medical guidance, this study may not apply directly to your situation. However, it does underscore the importance of dose awareness, product quality, and liver monitoringโ€”especially with higher doses or long-term use. Talk to your doctor if you’re concerned or have preexisting liver issues. 6. How high were the CBD doses in the study? Participants received 1600 mg/day of CBD isolateโ€”divided into two doses daily for 28 days. Thatโ€™s far higher than what most people take recreationally or therapeutically, which usually ranges between 10 and 100 mg per day. The study intentionally used high doses to test the liverโ€™s threshold for response. The results highlight what might happen when CBD is used aggressively. 7. Did anyone experience liver failure or clinical symptoms? No. Although liver enzymes increased in some participants, none developed symptoms or required intervention. No participant met criteria for drug-induced liver injury (DILI). All enzyme levels returned to normal after stopping CBD. This suggests the changes were reversible and not indicative of lasting harm. 8. Is full-spectrum CBD safer for the liver? This study did not assess full-spectrum or broad-spectrum products, so it canโ€™t answer that question directly. However, many clinicians believe that full-spectrum productsโ€”when used at lower dosesโ€”may carry a different metabolic profile and potentially lower risk. More research is needed to confirm or refute that theory. Until then, caution is advised when using high-dose isolates. 9. Was the placebo group affected? Not at all. None of the placebo participants exhibited elevations in liver enzymes, which strengthens the signal that CBD was responsible. This clean placebo outcome adds credibility to the findings, even though the study canโ€™t fully isolate every confounding factor. It supports the idea that high-dose CBD was likely the driver of the lab abnormalities. 10. What are signs of liver stress from supplements? Fatigue, nausea, abdominal pain, jaundice, or dark urine can all suggest liver stress, though most people with liver enzyme elevations feel nothing at all. Thatโ€™s why lab monitoring is important, especially with long-term or high-dose use of any supplement. In this study, there were no symptomsโ€”just silent enzyme shifts. Liver stress is often a silent signal before damage occurs. 11. Can CBD be safely dosed long-term? That depends on the formulation, dose, co-medications, and the individualโ€™s liver health. This study didnโ€™t explore long-term safety, but it does indicate that even short-term high doses can prompt lab changes. For most low- to moderate-dose users, especially with full-spectrum products, long-term safety remains plausible but unconfirmed. Regular monitoring is prudent. 12. Does this study prove CBD is dangerous? Noโ€”but it challenges the idea that CBD is completely risk-free. It shows that even natural substances can affect the liver under the right conditions. The takeaway isnโ€™t fear, but responsibility: dose matters, formulation matters, and follow-up care matters. Smart use is the middle ground between hype and fear. 13. Can low-dose CBD cause liver problems too? The study didnโ€™t test this directly, so we canโ€™t say for sure. Most clinical experience suggests low-dose CBD is well tolerated, especially in people without liver disease. However, itโ€™s wise to remain alert for interactions with other medications or conditions that strain liver function. More dose-ranging research is needed. 14. Why are liver enzymes important when taking CBD? Liver enzymes are often the first signal that the liver is reacting to a substanceโ€”even if no symptoms are present. Since CBD is metabolized in the liver, tracking enzymes like ALT and AST can help detect problems early. This is especially important for people on medications that also affect liver function. Itโ€™s a precaution, not a panic. 15. Is this the first study linking CBD to liver enzyme changes? No, but itโ€™s the most rigorous to date. Earlier studies hinted at similar findings, but they lacked the size, control, or transparency of this one. This randomized, placebo-controlled trial adds weight to the concern while also offering better data. It doesnโ€™t close the bookโ€”it just sharpens the picture. 16. How does this study affect the future of CBD regulation? It strengthens the case for stricter oversightโ€”particularly regarding labeling, dosing, and manufacturing standards. Consumers deserve clarity about what theyโ€™re taking and at what risk. Regulators may use this data to demand more precise formulations and post-market safety tracking. This isnโ€™t anti-CBDโ€”itโ€™s pro-accountability. [...] Read more...
Cannabis News
March 5, 2026Cannabis Newsโœฆ New Top items from the CED news pipeline. (82) Scientists are raising new concerns about marijuana use in teens – KPBSResearch continues to build a concerning picture around adolescent cannabis use and its association with elevated risk for psychiatric conditions, including psychosis, depression, and anxiety disorders. The developing brain, particularly during the teenage years, appears to be especially vulnerable to the neurochemical disruptions that cannabinoids can produce, with THC’s interaction with the endocannabinoid system potentially altering normal neurodevelopmental trajectories. Clinicians and public health researchers are increasingly calling for clearer communication about these risks, particularly as cannabis potency has risen substantially and cultural perception of harm has declined among younger populations. (81) Can the placenta predict schizophrenia risk? Lessons from prenatal cannabis exposureEmerging research is exploring whether placental biomarkers can serve as early indicators of schizophrenia risk, particularly in the context of prenatal cannabis exposure. THC crosses the placenta and can disrupt fetal neurodevelopment by interacting with the endocannabinoid system during critical windows of brain formation. This line of inquiry raises important questions about how prenatal THC exposure may prime neurobiological pathways associated with psychosis susceptibility later in life. (81) Scientists are raising new concerns about marijuana use in teens – YouTubeAdolescent cannabis use remains one of the most clinically significant concerns in cannabis medicine, as the developing brain is uniquely vulnerable to the effects of THC through at least the mid-twenties. Research consistently points to associations between early, frequent cannabis use and disruptions in neurodevelopmental trajectories, including effects on memory, attention, and emotional regulation. The concentration of THC in today’s products is substantially higher than in previous decades, which raises the stakes for any conversation about youth exposure and risk. (78) When Legalization Meets Reality: High-THC Cannabis and Psychosis RiskA Psychology Today analysis argues that high-THC cannabis is linked to increased psychosis risk, particularly for young, heavy users, as potency has risen dramatically since the 1990s. The article calls for legalization paired with stricter potency controls and honest public education rather than framing cannabis as completely harmless. (78) The Munchies’ Are Real and Could Benefit Those with No AppetiteWSU’s official PNAS study found cannabis vapor universally increased food consumption in 82 volunteers regardless of BMI, sex, or dose, with beef jerky as the surprising top food choice. The research team aims to develop appetite therapies for HIV/AIDS and chemotherapy patients based on the brain-mediated mechanism. (78) New Study in Pullman Shows ‘Munchies’ Might Help Those with Loss of AppetiteA Pullman-based PNAS study used a whole-plant vapor approach with 82 community volunteers and parallel rat studies to prove the munchies are centrally brain-mediated. This translational design provides the strongest evidence yet for developing cannabis-based appetite therapies for clinical wasting syndromes. (78) Kaiser Study Finds Higher Risk of Psychiatric Disorders in Teens Who Use Cannabis (78) Adolescent Cannabis Use Linked to Doubling Risk of Psychotic and Bipolar Disorders (78) Cannabis Use by Teenagers Doubles Their Risk of Developing Psychotic and Bipolar Disorders (78) Kaiser Study Finds Higher Risk of Psychiatric Disorders in Teens Who Reported Cannabis UseResearch from Kaiser Permanente examining teen cannabis use and psychiatric disorder risk adds to a growing body of evidence suggesting that the adolescent brain is particularly vulnerable to cannabinoid exposure during critical developmental windows. While association studies like these cannot establish causation, clinicians who work with cannabis medicine recognize that age of onset matters significantly, and the developing endocannabinoid system in teenagers responds very differently than in adults. This reinforces the importance of distinguishing between adult medical cannabis use under clinical supervision and unsupervised adolescent use, which carries a meaningfully different risk profile. (78) A huge study finds a link between cannabis use in teens and psychosis later – NPRA large study has found an association between cannabis use during adolescence and increased risk of developing psychosis later in life. These findings underscore the importance of protecting the developing brain, as adolescents appear to be more vulnerable to cannabis-related neuropsychiatric outcomes than adults. (78) Teen Cannabis Use Tied to Increase in Serious Mental Illness – MedscapeEmerging research continues to reinforce what clinicians have observed for years: adolescent cannabis use, particularly during critical neurodevelopmental windows, is associated with a meaningful increase in risk for serious psychiatric conditions including psychotic and bipolar disorders. The developing brain remains uniquely vulnerable to exogenous cannabinoids, and the endocannabinoid system plays a central role in synaptic pruning and neural circuit maturation during the teenage years. This does not mean cannabis causes these conditions in every user, but it does underscore the importance of age-appropriate clinical guardrails and honest conversations about risk. (78) Brain Researchers Finally Know Why Cannabis Use Increases Appetite – The DebriefThe appetite-stimulating effects of cannabis, commonly known as “the munchies,” have long been observed clinically but the precise neurological mechanisms were not well characterized until recently. Research has now identified how cannabinoids interact with specific brain circuits to drive increased appetite, independent of the type or palatability of food available. This distinction is clinically meaningful because it suggests the effect is centrally driven rather than a response to sensory reward or food preference. (78) Teen Marijuana Use Doubles Chances of Future Psychotic Disorders, Study FindsResearch examining adolescent cannabis use has consistently identified a meaningful association between early initiation and elevated risk for psychotic spectrum disorders in adulthood, with the biological vulnerability of the developing adolescent brain playing a central role in this relationship. The endocannabinoid system undergoes significant maturation throughout adolescence, and exogenous cannabinoids introduced during this window appear to disrupt neurodevelopmental trajectories in ways that can have lasting psychiatric consequences. Potency of the cannabis product matters considerably here, as contemporary high-THC formulations represent a substantially different exposure profile than products studied in earlier decades. (78) The association between cannabis use and brain reward anticipation: a 12-month … – NatureResearch examining cannabis use and brain reward circuitry has produced inconsistent results, with some studies suggesting blunted responses to non-drug rewards and others showing minimal or no effect. The complexity likely stems from variables including frequency of use, age of initiation, cannabinoid content, and individual neurobiological differences that are difficult to control across study populations. Longitudinal designs tracking participants over time offer a more rigorous framework for understanding whether reward processing changes precede cannabis use, follow from it, or reflect a bidirectional relationship. (78) THC levels in blood and urine are “unreliable” indicators of driving impairment – leafieThe relationship between THC concentration in biological fluids and actual driving impairment is far more complex than a simple number can capture. THC is highly lipophilic, meaning it distributes rapidly into tissues and does not remain in blood proportionally to psychoactive effect, which makes blood levels a poor proxy for functional intoxication. Unlike alcohol, where blood concentration correlates reasonably well with impairment, cannabis pharmacokinetics vary dramatically based on frequency of use, individual metabolism, tolerance, and the presence of other cannabinoids. (78) Study Links Prenatal Cannabis Exposure To Schizophrenia – New TelegraphEmerging research suggests that prenatal cannabis exposure may leave measurable biological signatures in placental tissue that are associated with increased schizophrenia risk in offspring. The placenta acts as a dynamic interface between maternal and fetal environments, and cannabinoids can cross this barrier and influence fetal neurodevelopment during critical windows of brain formation. These findings add biological plausibility to epidemiological signals that have long suggested a connection between gestational cannabis use and downstream psychiatric vulnerability in children. (78) The Endocannabinoid System’s Contribution to Placebo Analgesia – bioRxivThe endocannabinoid system appears to play a meaningful role in mediating placebo analgesia, suggesting that the brain’s expectation of pain relief may partially operate through the same cannabinoid signaling pathways activated by cannabis-based medicines. This finding adds biological plausibility to the long-debated question of how much overlap exists between expectation-driven pain relief and pharmacologically induced analgesia. Understanding this mechanism has implications for how clinical trials are designed, how placebo responses are interpreted in cannabis pain studies, and how clinicians counsel patients about the neuroscience behind their treatment responses. (78) Modulating the endocannabinoid system in alcohol use disorder: A translational systematic …The endocannabinoid system plays a central role in regulating reward circuitry, stress response, and impulse control, all of which are disrupted in alcohol use disorder. Cannabinoid receptors, particularly CB1 and CB2, along with endogenous ligands like anandamide and 2-AG, modulate dopaminergic and GABAergic pathways that drive craving, withdrawal, and relapse behavior. Research into ECS-targeted therapies, including FAAH inhibitors and neutral CB1 antagonists, represents a meaningful shift toward biologically informed treatment of addiction rather than purely behavioral approaches. (78) Cannabis hyperemesis syndrome is on the rise: What symptoms to watch for – The HillCannabis hyperemesis syndrome (CHS) is a paradoxical condition in which chronic, heavy cannabis users develop cyclic episodes of severe nausea, vomiting, and abdominal pain, often relieved temporarily by hot showers or baths. The syndrome is frequently misdiagnosed for months or years because patients and clinicians alike associate cannabis with antiemetic properties, creating a counterintuitive diagnostic barrier. As high-potency THC products have become more widely available and socially normalized, the frequency of CHS presentations in emergency departments has increased, making clinician and patient awareness more urgent than ever. (78) Association of Cannabis Use Disorder Versus Other Substance Use Disorders … – Psychiatry OnlineResearch comparing cannabis use disorder to other substance use disorders is an important area of inquiry because it helps clinicians understand the relative psychiatric burden associated with problematic cannabis use in the context of a rapidly changing legal and cultural landscape. Propensity-score-matched study designs are valuable here because they attempt to control for the many confounding variables that make substance use populations inherently difficult to compare fairly. Understanding how cannabis use disorder stacks up against alcohol, opioid, or stimulant use disorders in terms of psychiatric outcomes can meaningfully inform screening, treatment prioritization, and public health messaging. (78) Study Shows Lifetime Cannabis Use Not Associated with Cognitive Decline or Dementia …Emerging research from major academic institutions is challenging longstanding assumptions that cannabis use accelerates cognitive aging or increases dementia risk in older populations. The data suggest that lifetime exposure to cannabis, when examined in older adult cohorts, does not appear to correlate with measurable declines in cognitive function or elevated dementia incidence. This adds important nuance to how clinicians should counsel aging patients who use or are considering cannabis for symptom management. (76) Observational study on medical marijuana use seeks Arizona participants – KJZZObservational research on medical cannabis is essential for building the real-world evidence base that controlled trials alone cannot provide, particularly given the diversity of conditions, products, and consumption patterns patients bring to clinical settings. Recruiting participants at the point of initiation allows researchers to capture baseline data and track outcomes longitudinally, which strengthens the quality of findings compared to studies that enroll patients already well into their cannabis use. Arizona’s participation in a national study expands geographic and demographic representation, which helps address longstanding concerns about whether cannabis research reflects the broader patient population. (75) Teenage Cannabis Users Twice as Likely as Non-Users to Develop PsychosisA JAMA Health Forum study of 463,396 adolescents found that cannabis use between ages 13โ€“17 doubled the risk of developing psychotic and bipolar disorders by age 26. Cannabis use preceded psychiatric diagnoses by an average of 1.7โ€“2.3 years, underscoring the vulnerability of the developing adolescent brain. (75) Study: Teen Cannabis Use Linked to Double Psychosis Risk (75) Full-Spectrum Cannabis Extract Shows Significant Pain Reduction in Chronic Neuropathic Pain (75) Do anything, become nothing – The Morning NewsA new longitudinal study has found that adolescent cannabis use is associated with an increased risk of developing bipolar disorder and psychotic disorders later in life. These findings underscore the particular vulnerability of the developing brain to cannabis exposure, with age of onset identified as a clinically significant factor in downstream psychiatric outcomes. (75) A huge study finds a link between cannabis use in teens and psychosis later – KUOWLarge-scale longitudinal research continues to reinforce the clinical concern that adolescent cannabis exposure is associated with elevated risk of psychotic disorders and other serious mental health conditions in adulthood. From a neurobiological standpoint, the adolescent brain is undergoing critical endocannabinoid system maturation, and exogenous cannabinoid exposure during this window may disrupt neurodevelopmental trajectories in ways that increase vulnerability to psychosis, particularly in genetically predisposed individuals. This finding aligns with what we have observed clinically for years and underscores why age-appropriate guidance and delayed initiation remain cornerstones of responsible cannabis medicine. (75) Prescribed cannabis and driving behaviours among two samples of people who regularly … – UNSWResearch examining driving behaviors among medical cannabis patients raises important questions about how THC affects psychomotor function, reaction time, and judgment at various doses and time points after consumption. The relationship between measured THC levels and actual impairment is complex, as tolerance, route of administration, and individual pharmacokinetics all influence functional capacity behind the wheel. Clinicians prescribing cannabis have a responsibility to counsel patients clearly about timing of use relative to driving, particularly when THC-dominant formulations are involved. (75) Cannabis research: India to start human trials for medicinal marijuana – NewsBytesIndia’s launch of human clinical trials for medicinal cannabis represents a significant regulatory and scientific shift for a country with historically strict drug policies. These trials will generate controlled safety and efficacy data across specific medical conditions, helping to establish evidence-based frameworks for potential therapeutic use. Structured human trials are essential for understanding dosing, pharmacokinetics, and therapeutic windows in diverse patient populations, and data from a large and genetically diverse country like India could meaningfully contribute to global cannabis medicine research. (75) Cannabis Munchies Driven by Brain Reward Signals | Technology NetworksCannabis-induced hyperphagia, colloquially known as “the munchies,” has long been observed clinically but its precise neurological underpinnings in humans have remained incompletely characterized. Emerging research points to cannabis activating reward-related brain circuitry, particularly pathways involving endocannabinoid signaling that amplify the hedonic and motivational aspects of eating. Understanding these mechanisms has meaningful implications not only for recreational use patterns but also for therapeutic applications in conditions involving appetite dysregulation, such as cancer cachexia, HIV-associated wasting, and anorexia nervosa. (75) The association between cannabis use and brain reward anticipation: a 12-month … – NatureThe endocannabinoid system plays a central role in shaping brain reward circuitry, and THC directly engages this system during periods when neural architecture is still actively developing. Research examining cannabis use and reward anticipation over a 12-month period reflects growing scientific interest in how repeated THC exposure may alter dopaminergic signaling and motivational processing. Understanding these neurobiological mechanisms is clinically relevant for evaluating both therapeutic applications and potential risks across different age groups and patterns of use. (75) Screaming, vomiting, and daily weed: The rise of ‘scromiting’ among chronic cannabis usersCannabinoid hyperemesis syndrome is a paradoxical condition in which heavy, long-term cannabis use causes cyclical episodes of severe nausea, vomiting, and abdominal pain, often relieved temporarily by hot showers or baths. The syndrome is thought to involve dysregulation of cannabinoid receptors in the gut and hypothalamus, particularly with chronic high-potency THC exposure, though the precise mechanism remains under active investigation. Definitive resolution typically requires complete cessation of cannabis use, and patients frequently cycle through emergency departments multiple times before receiving an accurate diagnosis. (75) Study finds no links between cannabis use and cognitive decline or dementia in older peopleConcerns about cannabis use accelerating cognitive decline or contributing to dementia risk in older adults have long influenced clinical conversations, but emerging research is beginning to challenge those assumptions. The biological reality is complex, given that the endocannabinoid system plays a regulatory role in neuroinflammation and neuroprotection, and that older adults are using cannabis for legitimate symptom management at increasing rates. Understanding whether cannabis poses a cognitive threat or potentially a neutral or even protective profile in aging populations has significant implications for how clinicians counsel patients over 60. (75) Cannabis Use and Brain Aging: What a Major Study Reveals – Born2InvestResearch drawing on large biobank datasets has examined whether cannabis use is associated with measurable changes in brain aging trajectories. The findings suggest a nuanced picture in which cannabis users may show some initial differences in brain age metrics, but the relationship between cannabis exposure and long-term neurological aging is not straightforwardly harmful or protective. Interpreting these results requires careful attention to confounders such as frequency of use, age of initiation, and whether acute versus chronic effects are being captured. (74) Placental Changes From Prenatal Cannabis Exposure Could Flag Higher Schizophrenia …Emerging research suggests that prenatal cannabis exposure may produce measurable epigenetic and gene expression changes in placental tissue, particularly in pathways associated with neurodevelopmental risk including schizophrenia. The placenta, long underappreciated as a window into fetal programming, appears to reflect cannabis-related disruptions that could correlate with altered brain development trajectories in offspring. This line of investigation raises important questions about the biological mechanisms linking gestational cannabis use to psychiatric vulnerability later in life. (72) Patients Who Rely on Hemp-Derived CBD Face ‘Abrupt Disruptions in Care’Americans for Safe Access warns that patients who rely on hemp-derived CBD due to cost and access barriers face sudden loss of access when the Nov ban hits. The new law creates no clinical pathways, insurance coverage, or patient safeguards for displaced users. (72) Study: Cannabis Beverages Help People Cut Alcohol Consumption Nearly in HalfA University at Buffalo study found that people who switched to cannabis beverages cut their weekly alcohol intake nearly in half, from 7 to 3.35 drinks. Nearly two-thirds of users reduced or stopped alcohol entirely, suggesting cannabis drinks may be an effective harm-reduction tool. (72) First Human Clinical Trial: CBG Reduces Anxiety and Stress Without IntoxicationThe first double-blind, placebo-controlled human trial of CBG found that a 20mg oral dose significantly reduced anxiety and stress while improving verbal memoryโ€”with zero intoxication or impairment. CBG also shows antimicrobial and potential metabolic disorder applications. (72) Study: Minor Cannabinoids CBDV and CBG Show Powerful Anti-Inflammatory Effects When CombinedA Journal of Ethnopharmacology study found that 10 non-psychotropic cannabinoidsโ€”particularly CBDV and CBGโ€”showed meaningful anti-inflammatory effects, especially when combined with natural plant compounds. The synergistic findings support the entourage effect hypothesis and highlight the therapeutic potential of minor cannabinoids. (72) Cannabis-Related ‘Munchies’ Are Real, and Could Help People with AIDS, CancerA WSU/University of Calgary PNAS study confirms ‘the munchies’ are a real, brain-mediated cognitive response that occurs universally regardless of sex, age, weight, or recent food consumption. The finding could inform targeted appetite therapies for patients with HIV/AIDS, cancer, and other wasting conditions. (72) Medical Cannabis Improves Sleep for Insomnia PatientsUK Medical Cannabis Registry data shows insomnia patients report sustained sleep improvements over 18 months with cannabis-based products, with fewer than 10% experiencing adverse events. Nearly 40% of patients reduced or eliminated prescription sleep medications after starting medical cannabis. (72) Cannabis: What Is the Profile of Adults at Low Risk of Dependence?A University of Montreal study found that 63% of cannabis-using Quebec adults are at low risk for cannabis use disorder, with occasional social use and female sex associated with lower risk. Researchers call for a paradigm shift toward acknowledging non-problematic cannabis use in public health policy. (72) Satiety Bypass: How Cannabis Overrides the Brain’s ‘I’m Full’ SignalA PNAS study reveals that THC activates CB1 receptors in the hypothalamus to override natural satiety signals, creating starvation-like hunger even in recently fed subjects. The brain-mediated mechanismโ€”confirmed in both human and rat trialsโ€”provides a roadmap for developing appetite therapies without psychoactive side effects. (72) Cannabis-Infused Drinks May Help People Cut Their Alcohol Intake in HalfA University at Buffalo study found cannabis beverage users cut weekly alcohol intake from 7 to 3.35 drinks, with 62.6% reducing or stopping drinking entirely. The $1B+ cannabis beverage market faces elimination under the Nov 2026 federal ban’s 0.4mg THC per-container cap. (72) Four More States Advance Bills to Allow Medical Marijuana Access in HospitalsFour additional states are advancing bills to allow medical marijuana use in hospitals, addressing the gap where patients must choose between their cannabis medication and hospital care. The legislation establishes protocols for patient-initiated use under medical supervision in settings like hospice and palliative care. (72) Munchies Phenomenon: WSU Study Looks into Benefits of Cannabis Use and Appetite (72) Study: Teen Cannabis Use Linked to Double Psychosis Risk – Ground NewsNew research highlights a correlation between adolescent cannabis use and an approximately doubled risk of developing psychotic disorders, reinforcing what clinicians in cannabis medicine have long recognized about the vulnerability of the developing brain. This finding is consistent with prior longitudinal studies showing that early-onset, high-frequency cannabis use during critical neurodevelopmental windows can increase susceptibility to psychosis, particularly in individuals with genetic predisposition. While the study underscores real risk, it is important to contextualize that correlation does not establish direct causation and that most adolescents who use cannabis do not develop psychosis. (72) Cannabis Use Associated with Worse Working Memory – EMJNew research links heavy cannabis use to reduced brain activation during working memory tasks, suggesting potential cognitive effects that warrant clinical attention. While this aligns with what we’ve observed in practice with high-dose, high-frequency users, it is critical to distinguish between heavy recreational use patterns and structured medical dosing, as the clinical implications differ substantially. Dose, frequency, cannabinoid ratios, and patient-specific factors all influence cognitive outcomes, and blanket conclusions about cannabis and memory fail to capture the nuance required for informed patient care. (72) Teens Using Weed Have Doubled Risk For Psychosis, Bipolar DisorderNew research adds to the growing body of evidence suggesting that adolescent cannabis use is associated with a significantly elevated risk of developing psychotic disorders and bipolar disorder by young adulthood. From a clinical standpoint, this aligns with what we have long observed regarding the vulnerability of the developing brain to regular cannabinoid exposure, particularly with high-THC products during critical neurodevelopmental windows. While cannabis medicine has legitimate therapeutic applications for adult patients, these findings reinforce that age of onset and brain maturity are essential variables in any risk-benefit conversation. [...] Read more...
March 5, 2026Cannabis News✦ New Regulatory updates (higher clinical relevance) (100) Schedules of Controlled Substances: Rescheduling of Marijuana (85) Bulk Manufacturer-Royal Emerald (2024-11786) DEA1368 (85) Exempt Chemical Preparations May 2024 (2024-10465) – DEA372 (85) Importer of Controlled Substances Application Biopharmaceutical Research Company – DEA1224 (78) Importer of Controlled-Biopharmaceutical(2024-20085)DEA1425 (78) Schedules of Controlled Substances: Placement of 2-Methyl AP-237 in Schedule I [...] Read more...
March 5, 2026Cannabis NewsLast 24 Hours March 05, 2026 โ€” 57 articles reviewed This cycle’s coverage centered on reassuring longitudinal data about cannabis and cognitive aging in older adults, mounting evidence that THC blood levels are poor proxies for driving impairment, and persistent access failures for some of the most vulnerable patient populations in the U.S. and U.K. Alongside these clinical themes, significant regulatory and industry developments signaled shifting ground at the federal level and across international markets. Jump to section๐Ÿง  Cannabis, Cognitive Aging, and Dementia Risk in Older Adults๐Ÿš— Driving Impairment, THC Testing, and the Gap Between Detection and Function๐Ÿง’ Pediatric Epilepsy Access and the UK’s Ongoing Policy Failureโš–๏ธ U.S. Regulatory Shifts: State Rollouts, Federal Tensions, and Industry Organization๐Ÿ”ฌ Mental Health, GLP-1 Medications, and Emerging Therapeutic Science๐Ÿฅ End-of-Life Care: Washington Moves to Keep Cannabis at the Bedside ๐Ÿง  Cannabis, Cognitive Aging, and Dementia Risk in Older Adults A single large Israeli cohort study of over 67,000 older adults received extensive coverage this cycle, consistently reporting no significant association between lifetime cannabis use and cognitive decline or dementia risk. This prospective finding directly challenges the long-held clinical assumption that cumulative cannabis exposure accelerates neurodegeneration, and it carries real weight for geriatric prescribers who have historically cited cognitive harm as a reason to withhold cannabis from aging patients. Separately, a UK Biobank and Million Veteran Program analysis found markers of modest accelerated brain aging in regular cannabis users, approximately 2.8 years, reminding us that the picture is not uniformly reassuring, particularly for younger or heavier-use populations. The practical takeaway is that lifetime use alone should not be treated as a contraindication in older adults, but clinicians still need to individualize based on age of onset, use intensity, fall risk, and drug interactions. #78Study finds no links between cannabis use and cognitive decline or dementia in older people#75Study: Lifetime Cannabis Use Not Associated with Cognitive Decline or Dementia Risk in โ€ฆ โ€“ NORML#75Study Shows Lifetime Cannabis Use Not Associated with Cognitive Decline or Dementia โ€ฆ#75Cannabis Use and Brain Aging: What a Major Study Reveals โ€“ Born2Invest โ†‘ back to top ๐Ÿš— Driving Impairment, THC Testing, and the Gap Between Detection and Function A controlled study examining driving performance 12 to 15 hours after cannabis use found no significant impairment the following morning, with THC blood and oral fluid concentrations showing poor correlation with actual driving metrics. This finding was widely covered and reinforces what pharmacology has long suggested: cannabinoid detection is not the same as functional impairment, and policies built on presence-based testing penalize patients rather than protecting roads. Complementary coverage of cannabis breathalyzers and saliva tests highlighted their fundamental inability to distinguish past use from current intoxication, while an Australian regulatory proposal to exempt medicinal cannabis patients from automatic driving penalties signals that some jurisdictions are beginning to align law with science. Clinicians should counsel patients that individual variability still matters, but the blanket assumption that any detectable THC equals unsafe driving is not supported by the current evidence base. #75Can You Drive the Next Morning After Weed? Study Finds No Significant Impairment 12โ€“15 โ€ฆ#65Dabney: Weed breathalyzers and saliva tests? Let’s be real about their limits. โ€“ Star Tribune#65Drivers who test positive for medicinal cannabis could get behind the wheel โ€“ YouTube#35Ontario Labour Arbitration Decision Shows Proving Cannabis Impairment Is Key to โ€ฆ โ†‘ back to top ๐Ÿง’ Pediatric Epilepsy Access and the UK’s Ongoing Policy Failure Multiple outlets covered a single UK campaign launched in memory of a mother whose advocacy helped change British medical cannabis law, spotlighting the persistent gap between legal authorization and actual NHS access for children with drug-resistant epilepsy. Despite the 2018 rescheduling of cannabis-based medicinal products, funding barriers, prescribing hesitancy, and absent commissioning pathways continue to leave eligible pediatric patients without treatment that has demonstrated efficacy in conditions like Dravet syndrome and Lennox-Gastaut syndrome. Families are forced into impossible choices between unaffordable private prescriptions, unregulated products, or watching their children seize without intervention. This is not a knowledge gap; it is an implementation failure, and clinicians treating refractory pediatric epilepsy should be prepared to advocate for systemic change while navigating whatever access pathways currently exist. #72Campaign Launched in Memory of Mum Who Helped Change UK Medical Cannabis Law โ†‘ back to top โš–๏ธ U.S. Regulatory Shifts: State Rollouts, Federal Tensions, and Industry Organization Alabama is finally launching its medical cannabis program after nearly five years of regulatory delay, giving patients with qualifying conditions their first legal access to standardized products under physician supervision. Meanwhile, Oklahoma is considering rolling back one of the most permissive medical cannabis frameworks in the country after rapid expansion exposed significant regulatory gaps, a cautionary example of what happens when licensing infrastructure fails to keep pace with patient demand. At the federal level, the Department of Transportation reaffirmed that medical cannabis use provides no exemption from workplace drug testing, leaving patients in safety-sensitive jobs choosing between treatment and employment. A new cross-border industry coalition and executive actions aimed at accelerating DEA research licensing signal momentum, but whether these developments ultimately serve patients or primarily serve commercial interests remains an open question that clinicians should watch closely. #55Congressional Lawmakers Approve Farm Bill With Hemp Provisionsโ€”But Not The THC Ban โ€ฆ#48Pres. Trump’s Marijuana Executive Mandate Accelerates MMJ International Holdings โ€ฆ โ€“ Newswire#45The Wait is Over: Medical Cannabis set to roll out in April | WHNT.com#45Use Of Medical Marijuana Or Hemp Doesn’t Excuse Drug Testing Violations, Trump’s โ€ฆ#45Cannabis industry launches organization to further US policy changes with members from โ€ฆ#45Ricketts addresses Congress leaving Nebraska off list protecting state medical cannabis laws#42Oklahoma Seeks to Backtrack on Medical Marijuana as Pitfalls Multiply โ†‘ back to top ๐Ÿ”ฌ Mental Health, GLP-1 Medications, and Emerging Therapeutic Science A widely covered study linking rising cannabis use to poor mental health outcomes in older adults generated significant attention, but the critical clinical distinction between causation and self-medication remains unresolved in the data. Clinicians should screen older patients for both cannabis use and psychiatric symptoms concurrently, recognizing that high-THC daily use in someone with baseline psychiatric vulnerability is a fundamentally different clinical scenario than low-dose, supervised use for a specific indication. On a separate and promising front, emerging research on GLP-1 receptor agonists suggests these medications may reduce substance use disorders across multiple drug classes simultaneously by modulating reward pathways, potentially opening a novel pharmacological approach for patients with cannabis use disorder alongside metabolic disease. Meanwhile, a Northern Ireland biotech startup secured funding to develop next-generation endocannabinoid system modulators for obesity and epilepsy, representing the kind of precision pharmacology that could eventually offer patients targeted therapeutic benefit without the variability of whole-plant products. #75Study Links Rising Cannabis Use to Poor Mental Health โ€“ HealthDay#72Study Links Rising Cannabis Use to Poor Mental Health โ€“ U.S. News & World Report#72What to know about how GLP-1 medications might fight addiction โ€“ The Washington Post#65Omagh biotech start-up in funding boost for research into obesity and epilepsy#62GLP-1 medications get at the heart of addiction, study finds#45Substance use on the rise among gen Z in their early 20s | UCL News โ†‘ back to top ๐Ÿฅ End-of-Life Care: Washington Moves to Keep Cannabis at the Bedside Washington State senators advanced legislation allowing terminally ill patients to continue using authorized medical cannabis during hospital stays, closing a gap that has forced dying patients to choose between inpatient care and the symptom relief they depend on. The bill requires healthcare facilities to verify patient authorization documentation and maintain records of use, creating an administrative framework that balances patient autonomy with institutional accountability. For palliative care clinicians, this means cannabis can now be integrated into comprehensive end-of-life symptom management alongside conventional medications rather than being excluded by default. The argument for keeping cannabis out of the hospital at the end of life was never medical; it was bureaucratic, and this legislation begins to correct that. #72Washington Senators Approve Bill To Let Terminally Ill Patients Use Medical Cannabis In Hospitals โ†‘ back to top The through-line across this entire cycle is the distance between what the evidence supports and what systems actually allow, whether that is an older adult denied a safe medicine over unfounded dementia fears, a child seizing because funding did not follow the law, or a dying patient forced to leave the hospital to access relief. Our job as clinicians is to close that gap, one patient and one honest conversation at a time. ๐Ÿ“ฐ Browse all recent articles at cedclinic.com/category/cannabis-news/ [...] Read more...
March 5, 2026Cannabis NewsIn the Mix 9 articles reviewed and scored below the CED clinical relevance threshold of 40. Organized by topic below. Some may still be relevant to your situation. Jump to topic Research (2)Anxiety (1)Safety (1)Policy (5) Research (2 articles) #22 ResearchPolicy WSU and UW researchers will share cannabis research in Pullman | Green Zone Researchers from Washington State University and the University of Washington will present cannabis research findings at a dedicated event in Pullman this spring. The submission deadline for faculty and student researchers to present their work has just closed. Academic institutions in Washington are creating dedicated forums for cannabis research presentation and collaboration between university researchers. Read more โ†’ #8 ResearchPolicySafety International Research Community for Tobacco and Nicotine Honors Roswell Park Leader Researchers from Roswell Park Comprehensive Cancer Center presented findings on concurrent cannabis and tobacco use patterns from the International Tobacco Control Four Country Survey, examining smoking and vaping behaviors across multiple populations. The study provides epidemiological data on how cannabis co-use practices vary among tobacco and nicotine users in different geographic regions. The International Tobacco Control survey reveals important patterns in how cannabis use intersects with tobacco and nicotine consumption, offering evidence-based insights into polysubstance use behaviors across diverse populations. Read more โ†’ โ†‘ back to top Anxiety (1 article) #12 AnxietyMental HealthResearch Experiences with marijuana? Please share : r/OCD – Reddit A Reddit discussion thread explores personal experiences with marijuana use among individuals with obsessive-compulsive disorder, with users reporting varied outcomes ranging from symptom exacerbation to perceived relief. The conversation raises questions about how cannabis interacts with OCD symptoms and whether it may worsen or improve the condition for different users. Individual reports on cannabis and OCD outcomes vary considerably, suggesting that neurobiological responses to cannabinoids may differ significantly based on OCD presentation and underlying neurochemistry. Read more โ†’ โ†‘ back to top Safety (1 article) #38 SafetyPolicyPediatrics Bill to require stricter packaging requirements for marijuana edibles dies in Oregon legislature A proposed Oregon bill requiring individual wrapping of cannabis edibles and standardized dosing per piece failed to advance in the legislature. The legislation aimed to improve product safety and prevent accidental consumption, particularly among children. Oregon’s failed edible packaging bill would have mandated individual wrapping and uniform dosing for THC-containing products, addressing long-standing concerns about accidental pediatric exposures and product safety standardization. Read more โ†’ โ†‘ back to top Policy (5 articles) #35 PolicyResearch Ricketts addresses Congress leaving Nebraska off list protecting state medical cannabis laws U.S. Senator Pete Ricketts avoided directly answering whether he supports adding Nebraska to a congressional list that protects state medical cannabis laws from federal interference. The senator’s response highlights ongoing tensions between state-level medical cannabis programs and federal policy positions. Senator Ricketts’ avoidance of a direct answer on Nebraska’s inclusion in federal medical cannabis protections reflects the political complexity surrounding state versus federal cannabis regulation. Read more โ†’ #28 PolicySafetyIndustry A Frightening Florida Medical Cannabis Market Florida’s medical cannabis market faces significant regulatory and safety challenges that threaten patient access and product quality. The state’s rapid expansion and loose oversight have created concerning conditions for consumers seeking reliable therapeutic cannabis options. Florida’s medical cannabis market demonstrates how inadequate regulatory frameworks can compromise patient safety and market integrity when commercial growth outpaces clinical oversight. Read more โ†’ #18 PolicyHempTHC Intoxicating Hemp Ban Unchanged in 2026 Farm Bill’s Advancement The 2026 Farm Bill maintains the federal ban on intoxicating hemp products, including those containing delta-8 THC and HHC cannabinoids, despite bipartisan efforts to achieve repeal. The regulatory restriction continues to define legal hemp as cannabis containing no more than 0.3% THC by dry weight, preserving existing limitations on synthetic and naturally-derived intoxicating cannabinoids. The advancement of the 2026 Farm Bill without modification to intoxicating hemp restrictions suggests federal policy remains aligned with limiting access to delta-8 THC and other psychoactive cannabinoid products despite ongoing legislative advocacy for change. Read more โ†’ #15 PolicyHempTHC Wisconsin hemp growers, sellers brace for new federal hemp law – WPR Wisconsin hemp growers and sellers are preparing for compliance with new federal hemp regulations that will restrict products containing THC and its variants including THC-A and delta-9 THC. The changes pose significant challenges for businesses whose products currently fall within regulatory gray areas between legal hemp and controlled substances. New federal hemp regulations targeting THC variants are creating compliance uncertainty for Wisconsin producers operating in the space between federally legal hemp and controlled marijuana products. Read more โ†’ #5 PolicySafety Guns and ganja: Supreme Court skeptical of federal law banning firearm possession for … – Reddit The Supreme Court is questioning the constitutionality of federal law that prohibits firearm ownership for individuals with marijuana convictions, raising questions about how cannabis criminalization intersects with Second Amendment rights. The case highlights historical racial disparities in cannabis enforcement and whether such restrictions remain justified under current policy. The Supreme Court’s skepticism toward the federal firearm ban for cannabis offenders reflects broader tensions between outdated drug policies and constitutional protections, particularly given the disparate enforcement history targeting Black Americans. Read more โ†’ โ†‘ back to top ๐Ÿ“ฐ See the top-ranked articles at cedclinic.com/category/cannabis-news/ [...] Read more...
March 5, 2026Cannabis Newsโœฆ New CED Clinical Relevance #42 Clinical Context Background information relevant to the evolving cannabis medicine landscape. PolicySafetyPainMental HealthIndustry Why This Matters Oklahoma patients currently relying on medical cannabis for chronic conditions should monitor proposed legislative changes closely, as restrictions or program shutdowns could interrupt ongoing treatment without any transition plan in place. Clinical Summary Oklahoma built one of the most permissive medical cannabis frameworks in the country, and the rapid expansion exposed real regulatory gaps including oversaturation of dispensaries, diversion concerns, and inconsistent product oversight. The push to roll back the program reflects a broader tension between voter-approved access and the infrastructure required to sustain a safe, functional medical system. Tightening regulations is not inherently regressive, but eliminating patient access before alternative care pathways exist leaves medically vulnerable people without meaningful options. Dr. Caplan’s Take “Regulatory failure is not the same as therapeutic failure, and dismantling patient access because a licensing system was poorly designed punishes the wrong party.” Clinical Perspective Oklahoma’s consideration of restricting its medical cannabis program reflects growing pains common to rapid program expansion without adequate regulatory infrastructure. The challenge lies not in cannabis medicine itself, but in ensuring robust patient safety protocols, product testing standards, and practitioner training before scaling access. States moving quickly to establish programs sometimes lack sufficient oversight mechanisms to prevent diversion, contamination, or inappropriate patient selection, which can undermine public confidence in legitimate medical use. Rather than wholesale program closure, the more clinically sound approach involves strengthening regulations around product quality, dosing transparency, and evidence-based condition indications. Reversing access for patients who benefit from cannabis therapy is not a solution to regulatory problems that systematic oversight can address. ๐Ÿ’ฌ Join the Conversation Have a question about how this applies to your situation? Ask Dr. Caplan โ†’ Want to discuss this topic with other patients and caregivers? Join the forum discussion โ†’ Have thoughts on this? Share it: ๐• Share on X in Share on LinkedIn ๐Ÿฆ‹ Share on BlueSky ๐Ÿ“ท Follow on Instagram ๐Ÿ“ Read more on Substack ๐Ÿ”” Subscribe via RSS ๐Ÿ“ฐ Source: https://ashingtonstand.com/article/oklahoma-seeks-to-backtrack-on-medical-marijuana-as-pitfalls-multiply- [...] Read more...
March 5, 2026Cannabis Newsโœฆ New CED Clinical Relevance #45 Clinical Context Background information relevant to the evolving cannabis medicine landscape. PolicyPainAnxietyMental HealthSafety Why This Matters Alabama patients with qualifying conditions will soon have legal, regulated access to medical cannabis through licensed dispensaries, potentially replacing unsafe or illegal sources they may have been relying on. Clinical Summary Alabama is preparing to launch its long-delayed medical cannabis program, marking a significant shift for a state that has historically maintained some of the strictest drug policies in the country. The program will allow qualifying patients with conditions such as chronic pain, PTSD, anxiety, and terminal illness to access cannabis through licensed dispensaries under physician supervision. Establishing a regulated medical framework means patients who previously had no legal options will now have access to standardized, tested products rather than unregulated sources. Dr. Caplan’s Take “A five-year rollout delay is not a cautious regulatory process, it is a failure of political will that left patients in pain without options while the science supporting medical cannabis kept accumulating.” Clinical Perspective After nearly five years of regulatory development, Alabama’s medical cannabis program represents an important milestone for patients with qualifying conditions who have limited therapeutic options. The delayed implementation timeline underscores the complex regulatory pathways states must navigate to establish safe, controlled access while maintaining public health oversight. Physicians should familiarize themselves with Alabama’s approved qualifying conditions, dosing frameworks, and drug interaction profiles to provide informed recommendations when appropriate for their patients. Early program rollout phases often present logistical challenges in supply chain and patient access, so clinicians may need to discuss realistic timelines and alternative evidence-based treatments with interested patients. As with any emerging cannabis program, ongoing clinical monitoring and outcome documentation will be essential to establish local evidence regarding efficacy and safety in Alabama’s patient population. ๐Ÿ’ฌ Join the Conversation Have a question about how this applies to your situation? Ask Dr. Caplan โ†’ Want to discuss this topic with other patients and caregivers? Join the forum discussion โ†’ Have thoughts on this? Share it: ๐• Share on X in Share on LinkedIn ๐Ÿฆ‹ Share on BlueSky ๐Ÿ“ท Follow on Instagram ๐Ÿ“ Read more on Substack ๐Ÿ”” Subscribe via RSS Related Articles The Wait is Over: Medical Cannabis set to roll out in April | WHNT.comThe Wait is Over: Medical Cannabis set to roll out in April | WHNT.comThe Wait is Over: Medical Cannabis set to roll out in April | WHNT.com ๐Ÿ“ฐ Source: https://hnt.com/news/huntsville/the-wait-is-over-medical-cannabis-set-to-roll-out-in-april [...] Read more...
March 5, 2026Cannabis Newsโœฆ New CED Clinical Relevance #48 Clinical Context Background information relevant to the evolving cannabis medicine landscape. PolicyResearchIndustryDosingSafety Why This Matters Patients seeking medical cannabis products manufactured to pharmaceutical standards may find broader availability and greater product consistency if U.S. federal policy changes open legitimate pathways for GMP-certified producers to scale and export. Clinical Summary Federal policy shifts around cannabis scheduling and executive action have historically created both opportunity and uncertainty for companies operating at the intersection of pharmaceutical-grade cannabis and international markets. When regulatory frameworks begin to clarify, manufacturers with established GMP infrastructure and clinical trial experience are better positioned to meet the evidentiary standards that pharmaceutical buyers and foreign health authorities require. The convergence of domestic policy momentum with international medical cannabis demand places a premium on standardized formulations, documented consistency, and compliance architecture that can withstand scrutiny across multiple jurisdictions. Dr. Caplan’s Take “Formulation without federal legitimacy is just a product, but formulation with regulatory standing becomes medicine, and that distinction determines whether patients get access or get stuck.” Clinical Perspective From a clinical standpoint, standardized manufacturing practices and consistent formulation represent fundamental prerequisites for evidence-based cannabis therapeutics. GMP (Good Manufacturing Practice) compliance ensures batch-to-batch consistency, which is essential for clinicians to reliably predict patient outcomes and safety profiles. Pharmaceutical-grade formulation control allows for reproducible dosing and accurate therapeutic dosing ranges, addressing one of the primary limitations in current cannabis medicine practice. Federal infrastructure supporting clinical trials removes a significant barrier to rigorous pharmacokinetic and efficacy studies that the field has needed for years. These regulatory advances may finally enable the clinical evidence base necessary to integrate cannabis into mainstream medical practice with the same rigor applied to conventional pharmaceuticals. ๐Ÿ’ฌ Join the Conversation Have a question about how this applies to your situation? Ask Dr. Caplan โ†’ Want to discuss this topic with other patients and caregivers? Join the forum discussion โ†’ Have thoughts on this? Share it: ๐• Share on X in Share on LinkedIn ๐Ÿฆ‹ Share on BlueSky ๐Ÿ“ท Follow on Instagram ๐Ÿ“ Read more on Substack ๐Ÿ”” Subscribe via RSS Related Articles Daily Digest: Last 18 Hours: Cannabis Impairment Testing, Brain Aging, and the Race for Better Evidence โ€” March 05, 2026Pres. Trump’s Marijuana Executive Mandate Accelerates MMJ International Holdings … ๐Ÿ“ฐ Source: https://newswire.com/news/pres-trumps-marijuana-executive-mandate-accelerates-mmj-international-holdings [...] Read more...
March 5, 2026Cannabis Newsโœฆ New CED Clinical Relevance #50 Clinical Context Background information relevant to the evolving cannabis medicine landscape. PolicyIndustryResearchSafetyDosing Why This Matters The policies shaped by this kind of industry coalition could directly affect what medical cannabis products are available to patients, how they are labeled, and whether insurance or federal programs ever cover them. Clinical Summary The formation of a cross-border cannabis industry coalition comes at a pivotal moment when federal rescheduling discussions in the United States are creating real regulatory uncertainty for both patients and producers. Industry-led organizations of this kind can play a meaningful role in shaping the evidentiary standards and policy frameworks that ultimately determine how patients access medical cannabis, what labeling and dosing information is required, and how physicians are permitted to recommend it. Whether such coalitions prioritize patient outcomes over commercial interests will depend heavily on how transparently they engage with independent researchers, clinicians, and patient advocates. Dr. Caplan’s Take “When industry writes the rules for evidence-based medicine, the definition of “evidence” has a way of drifting toward whatever supports the business model.” Clinical Perspective Industry coalitions advocating for evidence-based cannabis policy represent a significant development in the professionalization of medical cannabis. โ€ข The involvement of both US and Canadian companies suggests cross-border recognition that standardized approaches to safety, quality, and clinical efficacy benefit patients across jurisdictions. โ€ข As cannabis moves from Schedule I toward potential rescheduling, physician engagement with policy discussions becomes increasingly important to ensure regulations prioritize clinical outcomes over commercial interests. โ€ข Medical practitioners should remain engaged with these policy conversations to advocate for provisions that support robust clinical research and patient safety monitoring. โ€ข The transition from prohibition to regulated medical access creates an opportunity to establish evidence standards that can improve clinical practice and patient care quality. ๐Ÿ’ฌ Join the Conversation Have a question about how this applies to your situation? Ask Dr. Caplan โ†’ Want to discuss this topic with other patients and caregivers? Join the forum discussion โ†’ Have thoughts on this? Share it: ๐• Share on X in Share on LinkedIn ๐Ÿฆ‹ Share on BlueSky ๐Ÿ“ท Follow on Instagram ๐Ÿ“ Read more on Substack ๐Ÿ”” Subscribe via RSS Related Articles Cannabis industry launches organization to further US policy changes with members from …In the Mix: 16 More Articles โ€” February 24, 2026 ๐Ÿ“ฐ Source: https://stratcann.com/news/cannabis-industry-launches-organization-to-further-us-policy-changes-with-members-from-us-canada [...] Read more...
March 5, 2026Cannabis Newsโœฆ New CED Clinical Relevance #55 Clinical Context Background information relevant to the evolving cannabis medicine landscape. PolicyResearchCBDTHCIndustry Why This Matters Patients seeking cannabinoid-based treatments may find that the medicines with the strongest clinical evidence available elsewhere in the world remain inaccessible in the U.S. not because of safety concerns, but because of who is permitted to conduct the research in the first place. Clinical Summary The United States maintains a uniquely fragmented regulatory environment for cannabis research, where federal scheduling under the Controlled Substances Act creates structural barriers that foreign operators and even domestic companies struggle to navigate when developing cannabinoid-based medicines. Unlike pharmaceuticals that can be studied and approved through relatively standardized international pathways, cannabis research in the U.S. requires federal authorization at multiple levels, creating a system where control over the science is inseparable from control over the market. This regulatory architecture effectively determines not just who can sell cannabis medicines in the U.S., but who can generate the clinical evidence needed to legitimize them globally. Dr. Caplan’s Take “When federal law decides who gets to ask the scientific questions, it has already decided who gets to profit from the answers, and that is a research integrity problem before it is a market problem.” Clinical Perspective The regulatory fragmentation between state-legal cannabis programs and federal scheduling creates a significant barrier to rigorous drug development that ultimately impacts patient access to standardized, evidence-based cannabinoid therapeutics. While state markets have expanded rapidly, the absence of federal oversight means most products lack the quality controls and clinical validation that physicians typically expect from pharmaceutical interventions. This divide incentivizes companies to pursue easier pathways through unregulated state channels rather than undertaking the costly research necessary to establish safety and efficacy profiles. Until cannabinoid-based medicines can be studied under unified federal frameworks, clinicians will continue operating with limited comparative data and patients may miss opportunities for truly therapeutic dosing and formulation strategies. The market’s current structure prioritizes commercial scale over clinical rigor, which is the inverse of what evidence-based medicine requires. ๐Ÿ’ฌ Join the Conversation Have a question about how this applies to your situation? Ask Dr. Caplan โ†’ Want to discuss this topic with other patients and caregivers? Join the forum discussion โ†’ Have thoughts on this? Share it: ๐• Share on X in Share on LinkedIn ๐Ÿฆ‹ Share on BlueSky ๐Ÿ“ท Follow on Instagram ๐Ÿ“ Read more on Substack ๐Ÿ”” Subscribe via RSS ๐Ÿ“ฐ Source: https://finance.yahoo.com/news/coming-divide-cannabis-why-u-172000342.html [...] Read more...
March 5, 2026Cannabis Newsโœฆ New CED Clinical Relevance #58 Clinical Context Background information relevant to the evolving cannabis medicine landscape. ResearchTHCMental HealthSafetyPolicy Why This Matters Patients who use cannabis and alcohol together, or who are considering cannabis as a tool to reduce drinking, should know that the evidence for this substitution effect is preliminary and does not yet support cannabis as a clinically validated alcohol reduction strategy. Clinical Summary The relationship between cannabis and alcohol use is a genuinely complex area of pharmacology, with some research suggesting that certain THC concentrations may reduce acute alcohol cravings and consumption in the short term. This potential substitution effect has drawn both scientific interest and policy debate, as it raises questions about whether cannabis legalization shifts patterns of alcohol use at the population level. The clinical picture is nuanced, because reduced alcohol intake in one context does not automatically translate to net health benefit when other risks of cannabis use, including respiratory effects, cognitive impacts, and dependency potential, are factored in. Dr. Caplan’s Take “Pointing to a single THC concentration reducing alcohol urge in a controlled setting is interesting science, but it is a long way from a treatment protocol and should not be treated as one.” Clinical Perspective The observation that lower-THC cannabis may acutely reduce alcohol craving warrants careful clinical consideration, as it suggests potential therapeutic applications in alcohol use disorder management. However, this single mechanism does not establish cannabis as a safe or evidence-based treatment, particularly given concerns about cannabis use disorder development and the potential for substitution rather than genuine harm reduction. Clinicians should recognize that acute craving suppression differs substantially from sustained abstinence or moderated consumption outcomes, which require long-term follow-up data. Any consideration of cannabis in alcohol-related contexts demands individualized risk-benefit assessment, especially in patients with polysubstance use patterns or addiction vulnerability. ๏ธ ๐Ÿ’ฌ Join the Conversation Have a question about how this applies to your situation? Ask Dr. Caplan โ†’ Want to discuss this topic with other patients and caregivers? Join the forum discussion โ†’ Have thoughts on this? Share it: ๐• Share on X in Share on LinkedIn ๐Ÿฆ‹ Share on BlueSky ๐Ÿ“ท Follow on Instagram ๐Ÿ“ Read more on Substack ๐Ÿ”” Subscribe via RSS Referenced Study Risk of Dementia in Individuals With Emergency Department Visits or Hospitalizations Due to Cannabis et al. · JAMA Neurology · 2025 View Abstract Full text requires institutional access ๐Ÿ“ฐ Source: https://britannica.com/procon/recreational-marijuana-legalization-debate/Cons [...] Read more...
March 5, 2026Cannabis Newsโœฆ New CED Clinical Relevance #62 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. PediatricsNeurologyPolicyCBDSafety Why This Matters Children with drug-resistant epilepsy whose families cannot afford private prescriptions may continue to go without a treatment option that has demonstrated clinical evidence, simply because NHS commissioning has not kept pace with the legal changes already on the books. Clinical Summary Drug-resistant epilepsy in children, particularly conditions like Dravet syndrome and Lennox-Gastaut syndrome, represents one of the most compelling and well-documented areas for cannabinoid-based medicine, with cannabidiol demonstrating meaningful seizure reduction in controlled clinical trials. Despite the rescheduling of cannabis-based medicines in the UK following high-profile advocacy, NHS access remains severely limited by prescribing restrictions, funding barriers, and a shortage of specialists willing to initiate treatment. Families continue to face a fragmented system where a legal pathway exists on paper but functional access remains out of reach for many children who have exhausted conventional antiseizure medications. Dr. Caplan’s Take “When a government reschedules a medicine in response to a child’s suffering and then fails to fund access to that same medicine, the rescheduling was symbolism, not policy.” Clinical Perspective The persistent gap between legal access and clinical availability of cannabis-derived medicines for drug-resistant epilepsy in children represents a significant unmet medical need in the UK. While the 2018 policy change established the legal framework for prescribing, the stringent NHS commissioning criteria and limited NHS-funded pathways have created a situation where evidence-based treatment remains inaccessible to many families despite demonstrated efficacy in published trials. Children with refractory seizure disorders who have exhausted conventional antiepileptic options deserve timely evaluation for cannabinoid therapy, particularly given the favorable safety profile and mechanism of action distinct from traditional medications. Advocacy efforts highlighting individual cases serve an important function in bringing clinical realities to policymakers’ attention, ultimately benefiting pediatric patients who could benefit from this therapeutic option. ๐Ÿ’ฌ Join the Conversation Have a question about how this applies to your situation? Ask Dr. Caplan โ†’ Want to discuss this topic with other patients and caregivers? Join the forum discussion โ†’ Have thoughts on this? Share it: ๐• Share on X in Share on LinkedIn ๐Ÿฆ‹ Share on BlueSky ๐Ÿ“ท Follow on Instagram ๐Ÿ“ Read more on Substack ๐Ÿ”” Subscribe via RSS Related Articles Campaign Launched in Memory of Mum Who Helped Change UK Medical Cannabis LawCampaign Launched in Memory of Mum Who Helped Change UK Medical Cannabis LawCampaign Launched in Memory of Mum Who Helped Change UK Medical Cannabis Law ๐Ÿ“ฐ Source: https://cannabishealthnews.co.uk/2026/03/05/campaign-launched-in-memory-of-mum-who-helped-change-uk-medical-cannabis-law [...] Read more...
March 5, 2026Cannabis Newsโœฆ New CED Clinical Relevance #65 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. Mental HealthAgingResearchSafetyTHC Why This Matters Older adults currently using cannabis for sleep, pain, or anxiety should discuss their use openly with their physician, because the risk-benefit calculation shifts meaningfully with age, existing medications, and overall health status. Clinical Summary Research exploring the relationship between cannabis use and mental health outcomes in older adults adds an important layer to how clinicians should approach geriatric care, where the interplay between substances and cognitive or emotional health is particularly complex. Older adults metabolize cannabinoids differently than younger populations, face greater polypharmacy risks, and may be more vulnerable to psychiatric side effects including anxiety, dysphoria, and cognitive disruption. Thoughtful geriatric assessment must account for cannabis use patterns, product types, and dosing rather than treating cannabis as a uniform exposure across all age groups. Dr. Caplan’s Take “Correlation between rising cannabis use and poor mental health outcomes tells us something worth investigating, but it does not tell us whether cannabis is driving distress or whether people in distress are turning to cannabis, and conflating the two is a clinical mistake.” Clinical Perspective While observational studies linking cannabis use to poor mental health outcomes warrant serious consideration, the relationship between cannabis and psychiatric symptoms remains complex and bidirectional. Older adults represent a particularly vulnerable population due to age-related changes in cannabinoid metabolism, polypharmacy concerns, and baseline cognitive changes that can complicate symptom attribution. Clinicians should conduct thorough psychiatric histories to distinguish between cannabis use as a potential causative factor versus self-medication for underlying mood or anxiety disorders. Given the heterogeneity of cannabis products, dosing regimens, and individual patient factors, treatment decisions require individualized assessment rather than categorical avoidance. Future research should employ longitudinal designs with validated mental health measures to clarify causality and identify which patient populations face genuine risk versus those who may derive therapeutic benefit. ๐Ÿ’ฌ Join the Conversation Have a question about how this applies to your situation? Ask Dr. Caplan โ†’ Want to discuss this topic with other patients and caregivers? Join the forum discussion โ†’ Have thoughts on this? Share it: ๐• Share on X in Share on LinkedIn ๐Ÿฆ‹ Share on BlueSky ๐Ÿ“ท Follow on Instagram ๐Ÿ“ Read more on Substack ๐Ÿ”” Subscribe via RSS Related Articles Study Links Rising Cannabis Use to Poor Mental Health – U.S. News & World ReportStudy Links Rising Cannabis Use to Poor Mental Health – U.S. News & World ReportStudy Links Rising Cannabis Use to Poor Mental Health – U.S. News & World Report ๐Ÿ“ฐ Source: https://usnews.com/news/health-news/articles/2026-03-05/study-links-rising-cannabis-use-to-poor-mental-health [...] Read more...
March 5, 2026Cannabis Newsโœฆ New CED Clinical Relevance #68 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. PolicyCancerPainDosingSafety Why This Matters Terminally ill patients in Washington who rely on medical cannabis for pain, nausea, or appetite may soon be able to continue that treatment without interruption during a hospital stay, rather than being forced to choose between inpatient care and their existing symptom management regimen. Clinical Summary Washington State senators have advanced legislation that would allow terminally ill patients to use medical cannabis while receiving care in hospital settings, addressing a long-standing gap between state medical cannabis law and healthcare facility policy. Currently, patients with valid medical cannabis authorizations often face the difficult choice of forgoing their cannabis use or leaving hospital grounds, creating unnecessary barriers to symptom management at the most vulnerable stage of life. This legislation would require facilities to document patient authorizations and create formal accommodation pathways, bringing hospital policy into closer alignment with the realities of palliative and end-of-life care. Dr. Caplan’s Take “When a patient is actively dying and cannabis is helping them eat, sleep, or breathe easier, the argument for keeping it out of the hospital has always been bureaucratic rather than medical.” Clinical Perspective This Washington legislation represents an important recognition that cannabis can serve legitimate palliative and symptom management roles for terminally ill patients, even within institutional settings where oversight has traditionally been restrictive. Allowing documentation and authorization of medical cannabis use in hospitals addresses a significant gap in end-of-life care, where patients may benefit from cannabis for pain, nausea, anxiety, and appetite stimulation. The requirement for healthcare facility notification creates accountability while respecting patient autonomy and their existing legal medical cannabis authorization. This approach demonstrates how regulatory frameworks can evolve to support evidence-based cannabinoid therapeutics without compromising institutional safety or care standards. Other states considering similar legislation should note that clear protocols for documentation and staff training are essential to ensure safe integration of medical cannabis into hospital care protocols. ๐Ÿ’ฌ Join the Conversation Have a question about how this applies to your situation? Ask Dr. Caplan โ†’ Want to discuss this topic with other patients and caregivers? Join the forum discussion โ†’ Have thoughts on this? Share it: ๐• Share on X in Share on LinkedIn ๐Ÿฆ‹ Share on BlueSky ๐Ÿ“ท Follow on Instagram ๐Ÿ“ Read more on Substack ๐Ÿ”” Subscribe via RSS Related Articles Washington Senators Approve Bill To Let Terminally Ill Patients Use Medical Cannabis In HospitalsWashington Senators Approve Bill To Let Terminally Ill Patients Use Medical Cannabis In HospitalsWashington Senators Approve Bill To Let Terminally Ill Patients Use Medical Cannabis In Hospitals ๐Ÿ“ฐ Source: https://marijuanamoment.net/washington-senators-approve-bill-to-let-terminally-ill-patients-use-medical-cannabis-in-hospitals [...] Read more...
March 5, 2026Cannabis Newsโœฆ New CED Clinical Relevance #70 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ResearchSafetyPolicyTHCDosing Why This Matters Patients who use cannabis in the evening for sleep, pain, or anxiety need accurate information about whether they are functionally safe to drive the following morning, because current legal standards often conflate cannabinoid detection with actual impairment. Clinical Summary The relationship between cannabis consumption and next-day driving performance is a genuinely complex clinical and policy question, shaped by factors including frequency of use, tolerance, cannabinoid pharmacokinetics, and the wide variability in how individuals metabolize THC. Frequent cannabis users develop meaningful neuroadaptation over time, which alters both subjective intoxication and measurable psychomotor function in ways that occasional users do not experience. Understanding the distinction between acute impairment, residual impairment, and the presence of detectable cannabinoids in biological samples is essential for crafting evidence-based per se impairment laws. Dr. Caplan’s Take “Basing driving impairment law on THC blood levels is about as scientifically defensible as setting alcohol limits based on how many drinks someone ordered the night before.” Clinical Perspective This research contributes important data to an understudied area of cannabis medicine, showing that frequent cannabis users demonstrate minimal driving impairment 12-15 hours after use. The findings align with what we observe clinically: acute cannabinoid effects are largely resolved within this timeframe for regular consumers, though individual variability remains significant. However, this does not negate the importance of individualized assessment, as occasional users, those using high-THC products, or individuals with underlying impairments may show different patterns. The study underscores why cannabis impairment cannot be evaluated through a single metric or timeframe, and why patient education about their own tolerance and response patterns remains central to safe use. ๏ธ ๐Ÿ’ฌ Join the Conversation Have a question about how this applies to your situation? Ask Dr. Caplan โ†’ Want to discuss this topic with other patients and caregivers? Join the forum discussion โ†’ Have thoughts on this? Share it: ๐• Share on X in Share on LinkedIn ๐Ÿฆ‹ Share on BlueSky ๐Ÿ“ท Follow on Instagram ๐Ÿ“ Read more on Substack ๐Ÿ”” Subscribe via RSS Related Articles Can You Drive the Next Morning After Weed? Study Finds No Significant Impairment 12โ€“15 …Can You Drive the Next Morning After Weed? Study Finds No Significant Impairment 12โ€“15 …Can You Drive the Next Morning After Weed? Study Finds No Significant Impairment 12โ€“15 … Referenced Study Driving by frequent cannabis users โ€˜the morning afterโ€™ last use of smoked cannabis: an observational driving simulator study et al. · Journal of Cannabis Research · 2026 View Abstract Open access · CC-BY ๐Ÿ“ฐ Source: https://hightimes.com/news/can-you-drive-the-next-morning-after-weed-study-finds-no-significant-impairment-12-15-hours-later-in-frequent-users [...] Read more...
March 5, 2026Cannabis Newsโœฆ New CED Clinical Relevance #72 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. AgingNeurologyResearchSafetyTHC Why This Matters Older adults who use or are considering cannabis for conditions like pain, sleep, or anxiety can share this type of research with their physicians to support more informed, evidence-based conversations about long-term safety. Clinical Summary Emerging longitudinal research is examining whether cumulative cannabis exposure across a lifetime correlates with cognitive outcomes in older adults, including measures of memory, processing speed, and dementia incidence. The findings add to a growing body of literature suggesting that the relationship between cannabis use and cognition in aging populations is more nuanced than earlier animal or short-term human studies implied. Researchers are increasingly distinguishing between acute intoxication effects, residual effects, and true long-term neurological consequences when evaluating older cohorts. Dr. Caplan’s Take “The science keeps asking older adults to wait for certainty while they are living with real symptoms right now, and studies like this one matter because they shift the burden of proof away from reflexive fear.” Clinical Perspective This emerging research adds to a growing body of evidence suggesting that lifetime cannabis exposure may not carry the cognitive risks previously hypothesized in aging populations. Long-term observational data in older adults is particularly valuable since this demographic often experiences the compounding effects of multiple medications and comorbidities that can independently affect cognition. โฐ While this study helps contextualize safety in geriatric populations, clinicians should still counsel patients that acute effects on attention and processing speed can occur with use, particularly in the hours following consumption. The distinction between acute dosing effects and chronic neurodegenerative risk is important for informed shared decision-making with older patients considering cannabis for pain, sleep, or other age-related conditions. Future research examining dose, frequency, and cannabinoid ratios will further refine our understanding of how to optimize therapeutic benefit while minimizing any potential risks in aging. ๐Ÿ’ฌ Join the Conversation Have a question about how this applies to your situation? Ask Dr. Caplan โ†’ Want to discuss this topic with other patients and caregivers? Join the forum discussion โ†’ Have thoughts on this? Share it: ๐• Share on X in Share on LinkedIn ๐Ÿฆ‹ Share on BlueSky ๐Ÿ“ท Follow on Instagram ๐Ÿ“ Read more on Substack ๐Ÿ”” Subscribe via RSS Related Articles Study: Lifetime Cannabis Use Not Associated with Cognitive Decline or Dementia Risk in … – NORMLStudy Shows Lifetime Cannabis Use Not Associated with Cognitive Decline or Dementia …Study Shows Lifetime Cannabis Use Not Associated with Cognitive Decline or Dementia … ๐Ÿ“ฐ Source: https://norml.org/blog/2026/03/04/study-lifetime-cannabis-use-not-associated-with-cognitive-decline-or-dementia-risk-in-older-adults/amp [...] Read more...
March 5, 2026Cannabis News✦ New CED Clinical Relevance #72 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. PolicyNeurologyPediatricsCBD Why This Matters Clinicians treating children with drug-resistant epilepsy need to understand that despite legal changes enabling medical cannabis prescribing in the UK, NHS access remains severely restricted, forcing families toward private prescribers or illicit sources. This access gap represents a critical clinical care disparity where evidence-based treatment options exist but remain unavailable to vulnerable pediatric patients, requiring clinicians to advocate for policy changes or navigate complex referral pathways. Patients and families should know that ongoing campaigns may improve NHS coverage, potentially making this treatment option more accessible and affordable for eligible children who have exhausted conventional anticonvulsant therapies. Clinical Summary A grassroots campaign has been launched to increase NHS access to medical cannabis for children with drug-resistant epilepsy, inspired by a mother whose advocacy contributed to the 2018 legalization of cannabis-based medicinal products in the United Kingdom. Despite the legal framework allowing medical cannabis prescriptions, significant barriers remain in clinical practice, with NHS funding and formulary restrictions preventing most eligible pediatric patients from obtaining these treatments even when conventional antiepileptic drugs have failed. The campaign highlights a critical gap between policy and implementation, where children who could potentially benefit from cannabidiol or whole-plant cannabis products remain unable to access them through standard NHS pathways due to cost, prescribing limitations, and lack of specialist infrastructure. This advocacy effort underscores the persistence of regulatory and financial obstacles that have characterized medical cannabis access in the UK since legalization, despite growing evidence supporting its efficacy in specific pediatric seizure disorders like Dravet syndrome and Lennox-Gastaut syndrome. Clinicians caring for children with refractory epilepsy should be aware of the ongoing access barriers to NHS-funded cannabis-based treatments and may need to explore private prescription routes or clinical trial options for eligible patients when conventional therapies prove insufficient. Patients and families should engage with advocacy campaigns and their local representatives to push for expanded NHS coverage, as current restrictions may prevent access to potentially life-changing treatment options. Dr. Caplan’s Take “What we’re seeing with these families is the tragic gap between what the evidence supports and what the system allows, and it falls hardest on children who have already exhausted conventional options and have nothing left to lose. The NHS needs to establish clear pathways for cannabis-based treatments in drug-resistant epilepsy rather than forcing families into the impossible choice between breaking the law or watching their children seize uncontrolled.” Clinical Perspective ๐Ÿ’Š While medical cannabis has shown promise for severe, drug-resistant epilepsy in controlled trials, significant gaps remain between regulatory approval and clinical accessibility in the UK. The current barriers to NHS prescribing of cannabis-based products reflect legitimate concerns about evidence quality, standardization, manufacturing consistency, and long-term safety data in pediatric populations, though these constraints also limit access for children who have exhausted conventional options and may genuinely benefit. Clinicians caring for families with intractable epilepsy should recognize the tension between the cautious regulatory approach and the real clinical desperation of families seeking alternatives, while remaining aware that outcome data from recent trials like GWPCARE1 do support efficacy in specific cannabinoid formulations. Rather than viewing this as a simple access issue, practitioners should engage in shared decision-making conversations that honestly acknowledge both the evidence supporting certain cannabis-derived products for refractory seizures and the legitimate unknowns regarding dose 💬 Join the Conversation Have a question about how this applies to your situation? Ask Dr. Caplan → Want to discuss this topic with other patients and caregivers? Join the forum discussion → Have thoughts on this? Share it: 𝕏 Share on X in Share on LinkedIn 🦅 Share on BlueSky 📷 Follow on Instagram 📝 Read more on Substack 🔔 Subscribe via RSS 📰 Source: https://cannabishealthnews.co.uk/2026/03/05/campaign-launched-in-memory-of-mum-who-helped-change-uk-medical-cannabis-law/ [...] Read more...
March 5, 2026Cannabis News✦ New CED Clinical Relevance #72 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. PolicyCancerSafety Why This Matters Clinicians in Washington will need to establish protocols for verifying patient cannabis authorization documents and documenting use in hospital settings, requiring integration of cannabis into existing medication safety and credentialing systems. This policy change affects symptom management options for end-of-life care, potentially improving comfort and quality of life for terminally ill patients while creating new liability and compliance considerations for healthcare institutions. Healthcare providers must now develop clear policies on how hospital-based cannabis use integrates with pain management, drug interaction screening, and nursing care documentation. Clinical Summary Washington State’s recently approved legislation permits terminally ill patients to use authorized medical cannabis within hospital settings, requiring healthcare facilities to maintain documentation of patient authorization and maintain relevant records. This policy change addresses a gap in existing medical cannabis law that previously prohibited cannabis use in institutional healthcare environments, even for patients with terminal diagnoses and valid medical recommendations. The measure recognizes that end-of-life symptom management may benefit from cannabis use, particularly for palliative care goals such as pain control, appetite stimulation, and anxiety reduction, while establishing clear administrative procedures for healthcare facilities to accommodate these patients safely. Clinicians working in hospitals will need to familiarize themselves with documentation requirements and institutional protocols for verifying patient authorization, and they should be prepared to discuss cannabis as part of comprehensive palliative care planning with eligible terminal patients. The practical takeaway is that hospitalists and palliative care physicians should now inquire about patients’ medical cannabis use during end-of-life care discussions and work with their institutions to implement compliant policies that allow authorized use while maintaining medical record documentation. Dr. Caplan’s Take “What we’re seeing in Washington is pragmatic policy catching up to clinical reality: terminally ill patients already use cannabis to manage pain and nausea in their final weeks, and pretending otherwise while they’re hospitalized only creates unnecessary suffering and forces families into difficult positions. The documentation requirement is reasonable because it allows us to integrate cannabis use into the broader medication picture and avoid dangerous interactions with palliative medications, which is exactly what evidence-based medicine demands.” Clinical Perspective ๐Ÿ’Š While expanded access to medical cannabis for terminally ill patients in hospital settings addresses an important gap in end-of-life symptom management, clinicians should approach implementation with careful consideration of several complexities. The evidence supporting cannabis for specific terminal symptoms like pain and nausea remains mixed and largely extrapolated from non-hospital populations, making it difficult to predict efficacy or safety in acute care environments where polypharmacy and organ dysfunction are common. Healthcare providers will need to weigh potential benefits against practical concerns including drug-drug interactions, impaired cognition affecting decision-making capacity, workplace safety implications, and the challenge of monitoring patients receiving a substance with variable cannabinoid content and effects. In clinical practice, this policy shift suggests the importance of documenting explicit conversations with terminally ill patients about cannabis as a potential therapeutic option, understanding individual state and institutional policies, and consulting with palliative care specialists who can integrate cannabis into broader comfort-focused treatment plans 💬 Join the Conversation Have a question about how this applies to your situation? Ask Dr. Caplan → Want to discuss this topic with other patients and caregivers? Join the forum discussion → Have thoughts on this? Share it: 𝕏 Share on X in Share on LinkedIn 🦅 Share on BlueSky 📷 Follow on Instagram 📝 Read more on Substack 🔔 Subscribe via RSS 📰 Source: https://www.marijuanamoment.net/washington-senators-approve-bill-to-let-terminally-ill-patients-use-medical-cannabis-in-hospitals/ [...] Read more...
March 5, 2026Cannabis News✦ New CED Clinical Relevance #72 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. Mental HealthResearchAgingSafety Why This Matters Clinicians need to recognize that cannabis use in older adults may contribute to mental health deterioration, requiring routine screening during geriatric assessments and careful medication review given polypharmacy risks in this population. Patients considering cannabis for pain or other age-related conditions should discuss mental health risks with their providers, as depression and anxiety are both common in aging and potentially worsened by cannabis use. This evidence supports the importance of comprehensive, rather than siloed, clinical evaluation when older adults introduce cannabis into their treatment regimens. Clinical Summary A recent study examining trends in cannabis use among older adults found associations between increased cannabis consumption and adverse mental health outcomes, including depression and anxiety symptoms. The research emphasizes that geriatricians and other clinicians should consider cannabis use within the broader context of aging and mental health rather than treating it as an isolated behavior. This finding is particularly relevant given the growing accessibility of cannabis products in states with legalization and the increasing proportion of older adults experimenting with cannabis for perceived medical benefits. Clinicians should screen older patients for cannabis use and mental health symptoms concurrently, recognizing that cannabis may exacerbate mood disorders rather than alleviate them. Additionally, these findings suggest that patient education about cannabis risks should be integrated into discussions about mental health management in aging populations. Clinicians should ask about cannabis use during mental health assessments and consider it a potential contributing factor when older patients report new or worsening depression or anxiety. Dr. Caplan’s Take “The correlation we’re seeing between increased cannabis use and mental health decline in older populations deserves our clinical attention, but we need to distinguish between causation and confounding variables like underlying depression driving both the use and the poor outcomes. In my practice, I’ve found that patients who benefit most from cannabis are those with specific, measurable conditions where we establish baseline mental health status first and monitor carefully, rather than those self-medicating for generalized distress.” Clinical Perspective ๐Ÿง  As cannabis use increases among older adults, clinicians should remain attentive to potential mental health impacts, though the relationship between cannabis and psychiatric outcomes is bidirectional and incompletely understood. The evidence linking cannabis to depression, anxiety, and cognitive changes is strongest for heavy, prolonged use and in individuals with genetic vulnerability to psychosis, yet many patients self-medicate with cannabis for these same conditions, making causality difficult to establish in clinical settings. Geriatricians and primary care providers should routinely ask older patients about cannabis use with the same care afforded to alcohol screening, particularly given age-related changes in drug metabolism and increased polypharmacy that may amplify psychiatric side effects. Clinicians should also consider that motivations for use often reflect inadequately treated pain or insomnia rather than recreational choice, and that abrupt cessation may worsen mood symptoms. A practical approach involves documenting baseline mental health status, monitoring for 💬 Join the Conversation Have a question about how this applies to your situation? Ask Dr. Caplan → Want to discuss this topic with other patients and caregivers? Join the forum discussion → Have thoughts on this? Share it: 𝕏 Share on X in Share on LinkedIn 🦅 Share on BlueSky 📷 Follow on Instagram 📝 Read more on Substack 🔔 Subscribe via RSS Related Articles Study Links Rising Cannabis Use to Poor Mental Health – U.S. News & World ReportStudy Links Rising Cannabis Use to Poor Mental Health – U.S. News & World ReportStudy Links Rising Cannabis Use to Poor Mental Health – U.S. News & World Report 📰 Source: https://www.usnews.com/news/health-news/articles/2026-03-05/study-links-rising-cannabis-use-to-poor-mental-health [...] Read more...
March 5, 2026Cannabis News✦ New CED Clinical Relevance #78 Strong Clinical Relevance High-quality evidence with meaningful patient or clinical significance. ResearchSafetyTHCPolicy Why This Matters This study challenges the assumption that residual THC from evening cannabis use impairs next-day driving ability, which has direct implications for counseling patients about safe driving windows and work schedules. Clinicians should be aware that blood or oral THC levels alone do not reliably predict driving impairment, allowing for more nuanced conversations with patients about cannabis use timing relative to safety-sensitive activities. The findings suggest current roadside testing standards may not correlate with actual functional impairment, relevant to patients concerned about legal risks and occupational requirements after cannabis use. Clinical Summary A recent study examined whether residual cannabis impairment persists into the following morning after evening use, finding no significant relationship between blood or oral THC concentrations and actual driving performance 12-15 hours after consumption. The researchers controlled for confounding variables and measured both THC metabolite levels and objective driving metrics, suggesting that morning-after impairment may be minimal despite detectable cannabinoid presence in biofluids. This finding has important clinical and medicolegal implications, as it challenges assumptions underlying some impaired driving enforcement and raises questions about the reliability of THC blood tests as standalone markers of functional impairment. However, clinicians should note that this single study does not account for individual variability in cannabis metabolism, tolerance, frequency of use, or the effects of specific cannabis products with varying THC/CBD ratios. The result underscores the complexity of cannabis pharmacokinetics and the poor correlation between THC blood levels and actual cognitive or motor performance, a distinction that remains relevant when counseling patients about safe driving timelines. Clinicians should advise patients that while morning-after driving impairment may be lower than previously assumed, individual responses vary considerably and caution remains warranted when combining cannabis use with safety-sensitive activities. Dr. Caplan’s Take “What this research tells us clinically is that we need to stop conflating THC blood levels with impairment in the way we do with alcohol, because the pharmacokinetics are fundamentally different. My patients need clear guidance: if you’re impaired when you use cannabis, you shouldn’t drive that day, period, but residual THC in your system the next morning doesn’t automatically mean you’re unsafe behind the wheel, and our policies should reflect that evidence rather than fear.” Clinical Perspective ๐Ÿš— While this study suggests residual THC levels may not impair driving performance 12-15 hours after cannabis use, clinicians should recognize that the relationship between THC concentration and impairment remains poorly understood and likely varies substantially across individuals based on tolerance, consumption method, and baseline driving ability. The study’s findings do not account for potential effects of active metabolites, the timing of peak impairment relative to peak blood concentration, or individual differences in cannabinoid metabolism that can span hours to days. Importantly, the absence of significant impairment in a controlled research setting does not necessarily translate to real-world driving safety, where fatigue, reaction time, and divided attentionโ€”which may persist longer than detectable THCโ€”remain confounding variables. Clinicians advising patients on cannabis use should counsel conservative waiting periods before driving (ideally until the next day or longer), avoid overreliance on blood or oral THC testing as a 💬 Join the Conversation Have a question about how this applies to your situation? Ask Dr. Caplan → Want to discuss this topic with other patients and caregivers? Join the forum discussion → Have thoughts on this? Share it: 𝕏 Share on X in Share on LinkedIn 🦅 Share on BlueSky 📷 Follow on Instagram 📝 Read more on Substack 🔔 Subscribe via RSS Related Articles Can You Drive the Next Morning After Weed? Study Finds No Significant Impairment 12โ€“15 …Can You Drive the Next Morning After Weed? Study Finds No Significant Impairment 12โ€“15 … 📰 Source: https://hightimes.com/news/can-you-drive-the-next-morning-after-weed-study-finds-no-significant-impairment-12-15-hours-later-in-frequent-users/ [...] Read more...
March 5, 2026Cannabis News✦ New CED Clinical Relevance #78 Strong Clinical Relevance High-quality evidence with meaningful patient or clinical significance. NeurologyResearchAgingSafety Why This Matters Clinicians caring for older adults should be aware that this study provides evidence that lifetime cannabis use alone may not increase dementia or cognitive decline risk, which can inform more nuanced risk-benefit discussions with patients considering cannabis for conditions like chronic pain or insomnia. This finding is particularly relevant for geriatric patients who may have been counseled to avoid cannabis based on outdated assumptions about cognitive toxicity. However, clinicians should still assess individual factors like dosing, frequency, duration of current use, and potential drug interactions before recommending cannabis to older patients. Clinical Summary A recent longitudinal study found no significant association between lifetime cannabis use and cognitive decline or dementia risk in older adults, challenging long-held concerns about cannabis and neurodegenerative outcomes in aging populations. The research examined cognitive trajectories and dementia incidence across older participants with varying histories of cannabis exposure, controlling for confounding factors such as age, education, and comorbid conditions. These findings suggest that previous animal studies and cross-sectional data showing cognitive harms may not translate to clinically meaningful cognitive loss in real-world aging cohorts with sustained use patterns. For clinicians evaluating older patients with cognitive concerns or considering cannabis as a therapeutic option, this evidence provides reassurance that lifetime exposure does not appear to independently predict dementia or accelerated cognitive decline. However, clinicians should continue monitoring individual patients for acute effects on attention or memory and remain cautious about interactions with other medications or conditions. The practical implication is that age alone and historical cannabis use should not be barriers to cannabis consideration in older patients seeking symptom relief, though individualized assessment remains essential. Dr. Caplan’s Take “After two decades of seeing older patients in my practice, I can tell you that the cognitive concerns we were warned about have not materialized in my long-term cannabis users the way our early models predicted, and this research aligns with what I’m observing clinically. What matters now is that we stop using fear-based narratives to keep patients from accessing a medicine that’s helping their pain, sleep, and quality of life in their later years.” Clinical Perspective ๐Ÿ’ญ While this observational study suggests that lifetime cannabis use may not be associated with cognitive decline or dementia risk in older adults, clinicians should interpret these findings cautiously given several important limitations. The study’s cross-sectional or retrospective design cannot establish causation, and survivor bias may skew results if heavy cannabis users with cognitive impairment were underrepresented in the cohort. Additionally, the study does not distinguish between cannabis use patterns (frequency, potency, route of administration, age of initiation), which may differentially affect neurocognitive outcomes, nor does it account for concurrent alcohol use, other substance exposures, or unmeasured confounders that could influence dementia risk. In clinical practice, providers should continue counseling older adults about cannabis’s established acute effects on cognition and psychomotor function while acknowledging that long-term dementia risk remains incompletely understood, and should individualize risk-benefit discussions based on 💬 Join the Conversation Have a question about how this applies to your situation? Ask Dr. Caplan → Want to discuss this topic with other patients and caregivers? Join the forum discussion → Have thoughts on this? Share it: 𝕏 Share on X in Share on LinkedIn 🦅 Share on BlueSky 📷 Follow on Instagram 📝 Read more on Substack 🔔 Subscribe via RSS Related Articles Study Shows Lifetime Cannabis Use Not Associated with Cognitive Decline or Dementia …Study Shows Lifetime Cannabis Use Not Associated with Cognitive Decline or Dementia …Study: Lifetime Cannabis Use Not Associated with Cognitive Decline or Dementia Risk in … – NORML 📰 Source: https://norml.org/blog/2026/03/04/study-lifetime-cannabis-use-not-associated-with-cognitive-decline-or-dementia-risk-in-older-adults/amp/ [...] Read more...
March 5, 2026Cannabis News✦ New CED Clinical Relevance #78 Strong Clinical Relevance High-quality evidence with meaningful patient or clinical significance. ResearchAgingNeurologySafety Why This Matters Clinicians can use this evidence to counsel older patients who use cannabis that lifetime use may not increase dementia or cognitive decline risk, addressing a common concern that affects treatment decisions and patient adherence. This finding is particularly relevant for geriatric patients considering cannabis for pain, sleep, or other conditions where cognitive safety has been a barrier to discussion and potential therapeutic use. As cannabis legalization expands, clinicians need robust evidence to distinguish actual cognitive risks from theoretical concerns when advising patients about long-term safety. Clinical Summary A large Israeli cohort study of over 67,000 older adults found no association between lifetime cannabis use and cognitive decline or dementia risk, contributing to an emerging body of evidence that challenges assumptions about cannabis-related neurotoxicity in aging populations. This prospective research is particularly relevant given the increasing numbers of older patients inquiring about or using cannabis for conditions like chronic pain, insomnia, and anxiety, where cognitive preservation is a clinical priority. The findings suggest that clinicians need not categorically warn older patients that cannabis use will accelerate cognitive decline, though the study does not establish cannabis as neuroprotective and individual risk factors remain important. The results align with mechanistic research suggesting that cannabinoids may have anti-inflammatory or neuroprotective properties that could offset potential harms in some populations. Clinicians should integrate these data into informed consent discussions with older patients while recognizing that evidence on optimal dosing, formulation, and long-term outcomes in this population remains limited. For patients concerned about dementia risk when considering cannabis for symptom management, this study provides reassurance that lifetime use is not associated with cognitive decline in aging adults. Dr. Caplan’s Take “What this research tells me in clinical practice is that we can stop using cognitive decline as a blanket contraindication to cannabis in older patients, though we still need to individualize for drug interactions and fall risk, which remain the real concerns I see in my practice.” Clinical Perspective ๐Ÿ’ญ While this longitudinal study of over 67,000 older Israeli adults reporting no association between lifetime cannabis use and cognitive decline or dementia is reassuring, clinicians should interpret these findings within important limitations. The study population may not fully represent diverse aging cohorts with varying patterns of use, comorbidities, and genetic vulnerabilities, and residual confounding from socioeconomic factors, education, and alcohol use cannot be entirely excluded. Additionally, this research addresses long-term cognitive outcomes rather than acute or intermediate effects on memory, processing speed, or functional ability that patients may experience, and does not clarify whether specific cannabinoid profiles, dose ranges, or routes of administration carry different risk profiles. In clinical practice, these results can help reassure patients concerned about dementia risk from past or ongoing cannabis use, though providers should still counsel older adults about documented short-term cognitive effects and the need for individualized risk-benefit discussion, particularly for those 💬 Join the Conversation Have a question about how this applies to your situation? Ask Dr. Caplan → Want to discuss this topic with other patients and caregivers? Join the forum discussion → Have thoughts on this? Share it: 𝕏 Share on X in Share on LinkedIn 🦅 Share on BlueSky 📷 Follow on Instagram 📝 Read more on Substack 🔔 Subscribe via RSS Related Articles Study Shows Lifetime Cannabis Use Not Associated with Cognitive Decline or Dementia …Study: Lifetime Cannabis Use Not Associated with Cognitive Decline or Dementia Risk in … – NORMLStudy: Lifetime Cannabis Use Not Associated with Cognitive Decline or Dementia Risk in … – NORML 📰 Source: https://www.investorideas.com/news/2026/cannabis/03041-cannabis-use-cognitive-decline-dementia-risk-study-yale-oxford.asp [...] Read more...
March 5, 2026Cannabis News✦ New CED Clinical Relevance #45 Clinical Context Background information relevant to the evolving cannabis medicine landscape. PolicyHempTHCSafetyIndustry Why This Matters Clinicians should be aware that the Department of Transportation’s policy means patients using medical marijuana or hemp products may still fail workplace drug tests and face employment consequences, regardless of medical legitimacy or state-level legalization. This creates a clinical counseling obligation to inform patients that medical cannabis use carries occupational risks that extend beyond their direct medical care. Clinicians should document medical justification for cannabis recommendations and discuss these federal employment implications with working-age patients to support informed decision-making. Clinical Summary The Department of Transportation has clarified that medical marijuana and hemp oil use do not provide exemptions from workplace drug testing policies, even when THC is detected in screening results. This federal guidance, issued through the DOT’s Substance Abuse Professional program, reinforces that transportation workers subject to DOT regulations cannot claim medical cannabis use as a valid defense against positive drug tests or related employment consequences. The ruling applies regardless of state-level legalization of medical cannabis, establishing a significant disconnect between state medical cannabis programs and federal workplace safety requirements. For clinicians prescribing cannabis to patients in safety-sensitive occupations such as commercial drivers, pilots, or transportation workers, this decision creates an important clinical and ethical consideration regarding informed consent and employment risk. Physicians should explicitly counsel patients in regulated industries about the federal employment consequences of medical cannabis use, as continued DOT testing policies may result in job loss or license suspension despite legitimate medical authorization at the state level. When considering cannabis as a treatment option, clinicians must discuss these occupational barriers with patients and document their informed consent regarding federal workplace consequences. Dr. Caplan’s Take “What we’re seeing with the DOT’s position is a collision between federal prohibition and legitimate medical practice, and the burden falls entirely on my patients who are using cannabis under state law for genuine therapeutic reasons. We need employers and regulators to understand that a positive drug test doesn’t tell you whether someone is impaired at work, and blanket policies that ignore medical authorization are creating a situation where patients have to choose between their treatment and their employment. Until federal policy catches up with the clinical evidence and state laws, we physicians have an obligation to document medical necessity carefully and help our patients navigate these regulatory gray zones.” Clinical Perspective ๐Ÿš— This Department of Transportation guidance clarifying that medical marijuana and hemp use do not exempt workers from drug testing violations has important implications for clinicians who care for safety-sensitive employees. While the legal status of cannabis continues to evolve across states, federal transportation safety standards remain stringent, reflecting legitimate concerns about impaired driving and workplace safety. Clinicians should be aware that prescribing or recommending cannabis products to patients in transportation, aviation, nuclear, or other federally regulated safety-sensitive positions may inadvertently jeopardize their employment, regardless of medical indication or state-level legalization. When considering cannabis as a therapeutic option, healthcare providers should counsel patients about these occupational risks and discuss them transparently before initiation, ensuring informed decision-making about potential workplace consequences. A practical approach involves documenting the clinical rationale for cannabis recommendations while explicitly discussing federal workplace policies with affected patients and encouraging them to verify their employer’s and industry’s specific policies before 💬 Join the Conversation Have a question about how this applies to your situation? Ask Dr. Caplan → Want to discuss this topic with other patients and caregivers? Join the forum discussion → Have thoughts on this? Share it: 𝕏 Share on X in Share on LinkedIn 🦅 Share on BlueSky 📷 Follow on Instagram 📝 Read more on Substack 🔔 Subscribe via RSS 📰 Source: https://www.marijuanamoment.net/use-of-medical-marijuana-or-hemp-doesnt-excuse-drug-testing-violations-trumps-transportation-department-warns/ [...] Read more...
March 5, 2026Cannabis News✦ New CED Clinical Relevance #45 Clinical Context Background information relevant to the evolving cannabis medicine landscape. PolicyIndustryPainAnxiety Clinical Summary Alabama’s medical cannabis program is set to launch in April after a nearly five-year regulatory development period, marking a significant expansion of access for patients in the state. The rollout follows completion of the licensing framework and regulatory infrastructure by the Alabama Medical Cannabis Commission, which has been establishing standards for cultivation, processing, and dispensing of cannabis products. This implementation will provide clinicians with a new therapeutic option for eligible patients with qualifying conditions, though practitioners should anticipate a learning curve regarding product standardization, dosing guidance, and integration into existing treatment protocols. The delay between initial approval and actual patient access underscores the complexity of establishing robust regulatory systems designed to ensure product safety and quality. For clinicians in Alabama, the practical takeaway is to begin familiarizing themselves now with the state’s specific qualifying conditions list, licensing procedures, and product categories so they can confidently counsel patients about this emerging treatment option once dispensaries open. Dr. Caplan’s Take “After years of regulatory delay, Alabama patients finally getting access to medical cannabis means we can move from anecdotal management to evidence-based prescribing, which is what responsible medicine requires.” Clinical Perspective ๐Ÿฅ Alabama’s delayed implementation of medical cannabis, now set for April after nearly five years of regulatory development, presents clinicians with an important opportunity to prepare for patient inquiries about a newly available treatment option. Healthcare providers should recognize that the extended regulatory timeline likely reflects ongoing efforts to establish safety protocols and oversight mechanisms, though this also means the clinical evidence base for cannabis in specific conditions may not align perfectly with patient expectations shaped by lay discourse or out-of-state experiences. Clinicians will need to familiarize themselves with Alabama’s specific regulatory framework, approved qualifying conditions, and product standards to provide informed counseling, while remaining aware that individual patient responses to cannabis remain highly variable and that long-term safety data for many indications remains limited. The practical implication is that primary care and specialty providers should begin developing a knowledge base and clinical protocols nowโ€”including patient screening tools, documentation practices, and clear communication about evidence quality for different conditionsโ€”to ensure they can offer evidence 💬 Join the Conversation Have a question about how this applies to your situation? Ask Dr. Caplan → Want to discuss this topic with other patients and caregivers? Join the forum discussion → Have thoughts on this? Share it: 𝕏 Share on X in Share on LinkedIn 🦅 Share on BlueSky 📷 Follow on Instagram 📝 Read more on Substack 🔔 Subscribe via RSS 📰 Source: https://whnt.com/news/huntsville/the-wait-is-over-medical-cannabis-set-to-roll-out-in-april/ [...] Read more...
March 5, 2026Cannabis News✦ New CED Clinical Relevance #45 Clinical Context Background information relevant to the evolving cannabis medicine landscape. PolicyIndustryResearch Why This Matters Clinicians need to monitor how industry-led policy advocacy may influence cannabis scheduling and medical access, as the NCCC’s activities could affect which products reach clinical settings and how they’re regulated. Rescheduling from Schedule I could accelerate clinical research and standardization of cannabis products, potentially providing clinicians with better evidence to guide patient treatment decisions and dosing recommendations. Understanding industry involvement in policy changes helps clinicians recognize potential conflicts of interest when evaluating cannabis safety and efficacy claims in the medical literature. Clinical Summary Following the Trump administration’s cannabis rescheduling order, the newly formed National Cannabis Chamber of Commerce (NCCC) has united major US and Canadian cannabis companies, including retailers like High Tide, to collectively advocate for evidence-based policy changes in the United States. This industry coalition aims to influence federal regulatory frameworks and state-level cannabis legislation as the landscape shifts toward potential descheduling or rescheduling. For clinicians, industry-led policy advocacy could affect product standardization, quality control measures, and the availability of cannabis medicines in their regions, ultimately impacting what treatment options they can recommend to patients. The organization’s focus on evidence-based policy suggests potential movement toward more rigorous clinical research and pharmaceutical-grade products rather than unregulated cannabis markets. Clinicians should monitor how these policy developments translate into changes in product labeling, dosing standards, and clinical guidance, as industry influence on regulation directly shapes the evidence base available for patient care. As patients increasingly inquire about cannabis therapeutics, clinicians should stay informed about evolving regulatory frameworks that may soon clarify the clinical status and appropriate use of cannabis-derived medications. Dr. Caplan’s Take “What we’re seeing is the industry finally organizing around evidence rather than ideology, which is exactly what patients need, but we have to be honest that financial incentives and clinical evidence don’t always align, so physicians need to maintain our independent voice in these policy conversations and not let industry capture the regulatory space the way it has in other areas of medicine.” Clinical Perspective ๐Ÿฅ The formation of industry-led organizations advocating for cannabis policy reform reflects the evolving landscape around federal rescheduling, which may accelerate research access and standardization of cannabis products in clinical settings. While industry participation in policy development raises legitimate concerns about commercial interests influencing medical evidence standards, such organizations can also facilitate pragmatic discussions about product testing, labeling consistency, and supply chain transparency that would benefit patient safety. Clinicians should recognize that rescheduling alone does not resolve fundamental evidence gaps regarding cannabis efficacy for most conditions, optimal dosing, or long-term safety profiles, particularly in vulnerable populations such as adolescents and pregnant patients. As policy and industry momentum shift, healthcare providers should maintain a critical stance toward cannabis recommendations, relying on evolving clinical evidence rather than industry-promoted narratives, while staying informed about regulatory changes that may affect product quality and patient access to cannabis-derived medications with clearer pharmacological profiles. 💬 Join the Conversation Have a question about how this applies to your situation? Ask Dr. Caplan → Want to discuss this topic with other patients and caregivers? Join the forum discussion → Have thoughts on this? Share it: 𝕏 Share on X in Share on LinkedIn 🦅 Share on BlueSky 📷 Follow on Instagram 📝 Read more on Substack 🔔 Subscribe via RSS Related Articles In the Mix: 16 More Articles โ€” February 24, 2026 📰 Source: https://stratcann.com/news/cannabis-industry-launches-organization-to-further-us-policy-changes-with-members-from-us-canada/ [...] Read more...
March 5, 2026Cannabis News✦ New CED Clinical Relevance #45 Clinical Context Background information relevant to the evolving cannabis medicine landscape. PolicyMedical Cannabis Clinical Summary This article addresses Senator Pete Ricketts’ response to a congressional inquiry regarding Nebraska’s inclusion in protections for state-level medical cannabis laws, which would shield patients and providers from federal prosecution. The Rohrabacher-Farrakee Amendment and similar congressional protections have been critical for states with legal medical cannabis programs, preventing DEA interference in state-regulated dispensaries and patient access. Senator Ricketts’ evasive response suggests potential political obstacles to extending these protections to Nebraska, a state that has not yet legalized medical cannabis but may be considering it. For clinicians in Nebraska or nearby states, the absence of federal protections creates legal ambiguity regarding cannabis recommendations and patient access, limiting the ability to incorporate medical cannabis into comprehensive treatment plans. Similarly, patients in unprotected states face the risk of federal charges despite state-level legalization efforts. Clinicians should monitor federal legislative developments in their states and remain informed about the legal status of medical cannabis recommendations in their jurisdiction, as congressional protections directly impact the safety and accessibility of this treatment modality for their patients. Dr. Caplan’s Take “Governor Ricketts’ reluctance to protect Nebraska’s medical cannabis patients sends a troubling signal to physicians like myself who are trying to practice evidence-based medicine without federal prosecution hanging over our heads, and it leaves patients caught between state law and federal uncertainty when they need clear legal protection most.” Clinical Perspective ๐Ÿ›๏ธ The ongoing debate about federal protections for state-level medical cannabis programs creates practical uncertainty for clinicians in states like Nebraska who may wish to recommend cannabis for eligible patients. While the Rohrabacher-Farrakee Amendment and similar protections have provided some legal cover for medical cannabis practice in other states, their inconsistent application and periodic renewal challenges mean that healthcare providers face variable guidance depending on their jurisdiction. Clinicians should remain aware that the absence of explicit federal protection does not necessarily prohibit medical cannabis recommendations under state law, though it may affect malpractice insurance coverage, institutional policies, and the willingness of pharmacies or dispensaries to coordinate care. In clinical practice, this fragmented legal landscape reinforces the importance of documenting clear medical rationale for any cannabis recommendations, understanding your state’s specific regulations, and communicating transparently with patients about the evolving legal status and evidence base. As federal policy continues to shift, providers should 💬 Join the Conversation Have a question about how this applies to your situation? Ask Dr. Caplan → Want to discuss this topic with other patients and caregivers? Join the forum discussion → Have thoughts on this? Share it: 𝕏 Share on X in Share on LinkedIn 🦅 Share on BlueSky 📷 Follow on Instagram 📝 Read more on Substack 🔔 Subscribe via RSS 📰 Source: https://nebraskaexaminer.com/briefs/ricketts-addresses-congress-leaving-nebraska-off-list-protecting-state-medical-cannabis-laws/ [...] Read more...
March 5, 2026Cannabis News✦ New CED Clinical Relevance #55 Clinical Context Background information relevant to the evolving cannabis medicine landscape. PolicyHempTHCIndustry Clinical Summary Recent congressional spending legislation included provisions aimed at regulating hemp-derived THC products, though a complete THC ban was not enacted. The GOP-controlled Congress incorporated hemp recriminalization language into the spending bill, which has drawn criticism from lawmakers who view the approach as procedurally inappropriate for substantive drug policy changes. These regulatory actions reflect ongoing federal uncertainty about the legal status and oversight of hemp-derived cannabinoids like delta-8 and delta-10 THC, which exist in a gray area between the 2018 Farm Bill’s hemp legalization and the Controlled Substances Act. For clinicians, this continued legislative instability creates challenges in counseling patients about the legality and safety profile of commercially available hemp products, which often lack standardized manufacturing controls and potency labeling. Clinicians should remain aware that the hemp regulatory landscape continues to shift at the federal level, potentially affecting product availability and patient access to cannabis-derived therapeutics. Until comprehensive federal regulation of hemp-derived THC products is established through standard legislative processes, practitioners should exercise caution in discussing these products with patients and stay informed about evolving state and local regulations. Dr. Caplan’s Take “What we’re seeing with these legislative gymnastics around hemp-derived THC is regulatory theater that ultimately confuses patients and physicians about what’s actually legal to prescribe or recommend, and that confusion costs us credibility in the clinical space where we need it most.” Clinical Perspective ๐ŸŒพ The recent congressional debate over hemp THC regulation highlights ongoing tensions between federal cannabis policy, state-level implementation, and clinical practice that warrant careful attention from providers. While the GOP majority’s approach to recriminalization provisions through spending bills may be procedurally contentious, the substantive issueโ€”controlling THC content in hemp-derived productsโ€”has legitimate public health dimensions, including concerns about unlabeled potency and marketing to vulnerable populations. However, providers should recognize that hemp-derived products exist in a complex regulatory landscape where products labeled as “legal hemp” may still contain significant THC quantities, potentially affecting drug interactions, mental health stability, and driving safety in their patients. The lack of clear federal standards creates clinical uncertainty regarding what patients are actually consuming and complicates counseling around safety and drug testing. Clinicians should proactively inquire about hemp and cannabinoid product use during substance history assessments and maintain awareness that current legal status does not 💬 Join the Conversation Have a question about how this applies to your situation? Ask Dr. Caplan → Want to discuss this topic with other patients and caregivers? Join the forum discussion → Have thoughts on this? Share it: 𝕏 Share on X in Share on LinkedIn 🦅 Share on BlueSky 📷 Follow on Instagram 📝 Read more on Substack 🔔 Subscribe via RSS 📰 Source: https://www.marijuanamoment.net/congressional-lawmakers-approve-farm-bill-with-hemp-provisions-but-not-the-thc-ban-delay-stakeholders-wanted/ [...] Read more...
March 5, 2026Cannabis News✦ New CED Clinical Relevance #65 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ResearchNeurologyIndustry Why This Matters Clinicians treating obesity and epilepsy patients should monitor developments from endocannabinoid-targeted therapeutics, as these compounds may offer alternatives to cannabis with improved safety profiles and efficacy data. This funding indicates accelerated drug development timelines, meaning novel cannabinoid-based treatments could enter clinical trials and eventually reach patients within the next several years. Understanding the mechanism and clinical potential of endocannabinoid system modulators will help clinicians make evidence-based recommendations as these therapies become available. Clinical Summary Sonas Pharma, a preclinical biotechnology company, has secured funding to advance research into endocannabinoid system modulators for obesity and epilepsy treatment. The company is developing next-generation compounds targeting the endocannabinoid system rather than direct cannabis-derived cannabinoids, potentially offering improved efficacy and safety profiles compared to whole plant or isolated cannabinoid approaches. This research direction is clinically relevant as it may yield therapeutics with more predictable pharmacokinetics and fewer drug interactions than current cannabis-based treatments. For obesity and epilepsy specifically, endocannabinoid system modulation represents a distinct mechanism that could complement or provide alternatives to existing pharmacotherapies. Clinicians should monitor the progression of these novel endocannabinoid-targeted drugs as they advance through development, as they may eventually offer patients precision-engineered options with better tolerability profiles than current cannabis products available through medical or recreational channels. Dr. Caplan’s Take “What Sonas and similar companies are doing with endocannabinoid system research is clinically important because they’re moving beyond the plant and toward precision therapeutics, which means we may finally have drugs for epilepsy and metabolic disease that work through cannabinoid mechanisms without the variability and psychoactive effects that make whole-plant cannabis difficult to dose in a clinical population.” Clinical Perspective ๐Ÿ’Š While emerging biotechnology companies like Sonas Pharma represent promising avenues for developing novel endocannabinoid-based therapeutics for obesity and epilepsy, clinicians should recognize that preclinical research funding announcements do not yet translate into approved medications or established clinical utility. The endocannabinoid system’s therapeutic potential is conceptually sound, but the pathway from equity investment to clinical evidence requires years of rigorous testing, and most candidate drugs fail to reach market or demonstrate superiority over existing treatments. Important caveats include the distinction between pharmaceutical research into isolated endocannabinoid targets versus whole-plant cannabis use, variable regulatory landscapes across jurisdictions, and the current lack of high-quality evidence comparing novel endocannabinoid drugs to established therapies for these conditions. For now, clinicians managing patients with obesity or epilepsy should continue relying on evidence-based standard therapies and remain cautious about 💬 Join the Conversation Have a question about how this applies to your situation? Ask Dr. Caplan → Want to discuss this topic with other patients and caregivers? Join the forum discussion → Have thoughts on this? Share it: 𝕏 Share on X in Share on LinkedIn 🦅 Share on BlueSky 📷 Follow on Instagram 📝 Read more on Substack 🔔 Subscribe via RSS Related Articles Daily Digest: Last 18 Hours: Cannabis Impairment Testing, Brain Aging, and the Race for Better Evidence โ€” March 05, 2026 📰 Source: https://www.irishnews.com/news/business/omagh-biotech-start-up-in-funding-boost-for-research-into-obesity-and-epilepsy-4YA7W5MTEFEBPLRXVBQAYNENYQ/ [...] Read more...
March 5, 2026Cannabis News✦ New CED Clinical Relevance #72 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. NeurologyPolicyPediatricsCBD Why This Matters Clinicians treating children with drug-resistant epilepsy need awareness that medical cannabis remains inaccessible through NHS channels despite legal availability, creating a treatment gap for patients who have exhausted conventional anticonvulsant options. This advocacy campaign highlights the disconnect between policy change and clinical implementation, directly affecting prescribing decisions and patient outcomes for a vulnerable pediatric population. Understanding these access barriers helps clinicians better counsel families about realistic treatment options and advocate for systemic changes that could expand available therapeutic tools. Clinical Summary A campaign has been launched in the United Kingdom to address persistent barriers to NHS access for medical cannabis in pediatric drug-resistant epilepsy, a condition where the evidence base for cannabinoid therapy is strongest and clinical need is most acute. Despite legal changes that permitted physician prescribing of cannabis-based medicinal products in 2018, access remains severely restricted due to funding limitations, prescribing hesitancy, and lack of integrated pathways within the NHS system. The campaign highlights the gap between legal availability and practical patient access, particularly affecting families who either cannot afford private prescriptions or must pursue treatment outside conventional healthcare channels. Drug-resistant epilepsy in children represents a compelling clinical indication where cannabidiol has demonstrated efficacy in reducing seizures, yet many eligible young patients remain unable to access this therapy through their NHS providers. Clinicians in the UK managing pediatric epilepsy should be aware that advocacy efforts continue to expand patient access and that private pathways may be necessary until NHS provision improves. Physicians should counsel families with drug-resistant epilepsy about the regulatory status and access options available in their region, while supporting policy efforts that would integrate evidence-based cannabinoid therapy into standard NHS care pathways. Dr. Caplan’s Take “We’ve known for nearly a decade that cannabidiol can be genuinely life-changing for certain pediatric seizure disorders like Dravet syndrome, yet access remains gatekept by politics rather than pharmacology. When families have to fight this hard just to get their children considered for a medication with solid evidence behind it, we’re failing our most vulnerable patients and extending unnecessary suffering.” Clinical Perspective ๐Ÿ’Š While the regulatory pathway for cannabis-based medicinal products in the UK has expanded, significant barriers persist in translating policy changes into clinical access for patients with intractable epilepsy. The campaign highlights a genuine unmet need, particularly for pediatric cases where conventional anticonvulsants have failed and evidence for cannabis-derived cannabinoids (such as cannabidiol) shows promise in randomized trials. However, clinicians should recognize that access restrictions reflect not only funding constraints but also legitimate concerns about long-term safety data in developing brains, variability in product formulations, and the challenge of conducting robust comparative effectiveness research in this population. The gap between regulatory approval and NHS reimbursement underscores how policy, economics, and clinical evidence can diverge, leaving families to navigate private prescribing pathways when conventional options are exhausted. When counseling families facing drug-resistant pediatric epilepsy, practitioners should remain informed about current 💬 Join the Conversation Have a question about how this applies to your situation? Ask Dr. Caplan → Want to discuss this topic with other patients and caregivers? Join the forum discussion → Have thoughts on this? Share it: 𝕏 Share on X in Share on LinkedIn 🦅 Share on BlueSky 📷 Follow on Instagram 📝 Read more on Substack 🔔 Subscribe via RSS 📰 Source: https://cannabishealthnews.co.uk/2026/03/05/campaign-launched-in-memory-of-mum-who-helped-change-uk-medical-cannabis-law/ [...] Read more...
March 5, 2026Cannabis News✦ New CED Clinical Relevance #72 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. PolicyCancerSafety Why This Matters This legislation directly impacts end-of-life care by enabling clinicians to honor patient autonomy and symptom management preferences during terminal illness, potentially improving comfort for dying patients. Clinicians need clarity on documentation requirements and liability protections when cannabis is used in hospital settings to ensure they can safely support patients’ wishes without legal jeopardy. The policy bridges a critical gap where patients previously faced the choice between hospital admission and access to a medication they found therapeutic for pain, nausea, or anxiety. Clinical Summary Washington state legislators have advanced a bill that permits terminally ill patients to use medical cannabis within hospital settings, contingent upon proper documentation and facility notification procedures. Under this legislation, healthcare facility officials must verify patients’ medical cannabis authorization and maintain records of such use within the inpatient environment. This policy change addresses a gap in current regulations that effectively prohibited cannabis use even for authorized patients during hospitalizations, potentially causing unnecessary suffering at end-of-life. For clinicians managing terminally ill patients, this authorization broadens therapeutic options and respects patient autonomy in palliative care while establishing clear documentation requirements to ensure safety and compliance. The measure reflects growing recognition that cannabis may provide meaningful symptom relief for dying patients without creating unmanageable institutional liability. Clinicians should familiarize themselves with their facility’s specific protocols once implemented, as this legislation could shift conversations with eligible patients about comfort-focused options during end-of-life hospitalization. Dr. Caplan’s Take “We’ve been managing end-of-life symptom control for decades without access to cannabis in the hospital setting, but the evidence increasingly shows it can provide meaningful relief for nausea, pain, and anxiety in our sickest patients when conventional options fall short, so this legislation removes an unnecessary barrier to compassionate care during the final chapter of someone’s life.” Clinical Perspective ๐Ÿฅ While legislation permitting medical cannabis use in hospital settings for terminally ill patients reflects evolving end-of-life care priorities and patient autonomy, clinicians should recognize that hospital-based cannabis administration remains operationally complex and evidence-limited regarding efficacy, drug interactions, and standardized dosing in acute care environments. The requirement for facility authorization and documentation creates administrative frameworks, yet significant gaps persist regarding clinical protocols for symptom management, monitoring for adverse effects in medically fragile populations, and integration with existing palliative care regimens that may already include controlled substances. Confounding factors include variable cannabis potency and formulation, limited pharmacokinetic data in elderly or multi-morbid patients, and the challenge of distinguishing symptom relief from placebo effects in end-of-life contexts where psychological benefit carries substantial clinical weight. Clinicians should prepare for these policies by engaging in institutional conversations about symptom management algorithms, establishing clear 💬 Join the Conversation Have a question about how this applies to your situation? Ask Dr. Caplan → Want to discuss this topic with other patients and caregivers? Join the forum discussion → Have thoughts on this? Share it: 𝕏 Share on X in Share on LinkedIn 🦅 Share on BlueSky 📷 Follow on Instagram 📝 Read more on Substack 🔔 Subscribe via RSS 📰 Source: https://www.marijuanamoment.net/washington-senators-approve-bill-to-let-terminally-ill-patients-use-medical-cannabis-in-hospitals/ [...] Read more...
March 5, 2026Cannabis News✦ New CED Clinical Relevance #72 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ResearchNeurologyAgingSafety Why This Matters # Clinical RelevanceClinicians can use this evidence to counsel older patients that lifetime cannabis use alone may not increase dementia risk, addressing common concerns that may cause patients to withhold substance use history or self-treat conditions without medical guidance. This finding is particularly important for geriatric populations considering cannabis for pain, sleep, or other age-related conditions, as it shifts the risk-benefit conversation away from assumed cognitive harms. The evidence supports more nuanced, individualized discussions about cannabis use rather than categorical warnings, enabling better shared decision-making in clinical practice. Clinical Summary # Clinical Summary A large Israeli cohort study of over 67,000 older adults found no significant association between lifetime cannabis use and cognitive decline or dementia risk in aging populations, contributing to an expanding evidence base examining cannabis safety in elderly patients. This prospective study design with extended follow-up provides relatively robust data suggesting that the neurotoxic effects of cannabis commonly cited in literature may not translate to measurable cognitive harm in older adults, though long-term mechanistic studies remain limited. The findings are clinically relevant as physicians increasingly encounter older patients using cannabis for chronic pain, insomnia, and other age-related conditions and need evidence-based guidance regarding cognitive safety. However, clinicians should remain cautious in extrapolating these results to younger populations with developing brains or to those with pre-existing cognitive impairment, as age-related neuroprotective factors may differ substantially from younger cohorts. Additionally, the study does not address dose, frequency, or route of administration, which may influence cognitive outcomes. Clinicians can counsel appropriately informed older adults that current evidence does not support cannabis-related dementia risk as an absolute contraindication, though individualized assessment of other safety concerns and drug interactions remains essential for each patient. Dr. Caplan’s Take “After two decades of practice, I can tell patients with confidence that the catastrophic cognitive decline narrative around cannabis simply doesn’t hold up in the epidemiological data, which allows us to move past fear-based conversations and toward honest risk stratification based on individual factors like age of initiation, frequency of use, and concurrent medical conditions.” Clinical Perspective ๐Ÿง  While this large observational study from Israel suggests that lifetime cannabis use may not be associated with cognitive decline or dementia in older adults, clinicians should interpret these findings cautiously given the study’s design limitations and potential confounders such as survivor bias, unmeasured socioeconomic factors, and differences in cannabis potency and consumption patterns across decades. The absence of demonstrated harm in this population does not establish safety or efficacy for cognitive outcomes, particularly since cannabis use disorders and acute intoxication effects remain distinct clinical considerations from lifetime use patterns. Additionally, individual variation in cannabinoid metabolism, comorbid conditions, and concurrent medication interactions mean that population-level associations may not apply uniformly to individual patients. For clinical practice, these results provide modest reassurance when counseling older patients about past cannabis exposure but should not drive prescribing decisions for cognitive concerns, which require evidence from randomized trials and mechanistic studies that remain limited. Providers should continue 💬 Join the Conversation Have a question about how this applies to your situation? Ask Dr. Caplan → Want to discuss this topic with other patients and caregivers? Join the forum discussion → Have thoughts on this? Share it: 𝕏 Share on X in Share on LinkedIn 🦅 Share on BlueSky 📷 Follow on Instagram 📝 Read more on Substack 🔔 Subscribe via RSS Related Articles Study: Lifetime Cannabis Use Not Associated with Cognitive Decline or Dementia Risk in … – NORMLStudy: Lifetime Cannabis Use Not Associated with Cognitive Decline or Dementia Risk in … – NORMLStudy Shows Lifetime Cannabis Use Not Associated with Cognitive Decline or Dementia … 📰 Source: https://www.investorideas.com/news/2026/cannabis/03041-cannabis-use-cognitive-decline-dementia-risk-study-yale-oxford.asp [...] Read more...
Cannabis Recipes
August 3, 2023Ingredients 6 cups fresh or frozen blueberries (you may substitute some pitted cherries too!) 1 Tbsp lemon juice 1/4 cup all-purpose flour 1/2 cup white sugar (you may add canna-sugar for increased potency) 1/4 tsp cinnamon 2 Tbsp canna-butter, cut into small pieces (you may substitute canna-coconut oil) 2x pie crust recipe or store bought Directions Preheat oven to 350ยฐF/175ยฐC. Line a cookie sheet with parchment paper. Cream the regular butter, cannabutter, brown sugar & white sugar together until fluffy. Beat in eggs one at a time. Beat in the vanilla. In a small bowl, mix together the flour, cinnamon, baking soda & salt. Add to the creamed mixture. Mix well. Add the mini chocolate chips & mini marshmallows. Mix until evenly distributed. Evenly space the graham crackers on the prepared liner. Use a 2 oz scoop to portion the cookies & place in the center of the graham cracker. Bake for 12โ€“15 minutes. Allow the cookies to cool. Push all of the baked cookies together & drizzle with coating chocolate. Allow the chocolate to set & enjoy! This recipe is available for download HERE Original recipe from myedibleschef.com [...] Read more...
April 5, 2025Cannabis-Infused Peanut Butter โ€” Spreadable Happiness in Every Spoonful Why Youโ€™ll Love This Cannabis-Infused Peanut Butter Peanut butter is already a pantry hero: protein-packed, creamy, satisfying. But infuse it with cannabis and it becomes something legendary. Smooth, spreadable, and infused with relaxing cannabinoids, this recipe transforms an everyday snack into a versatile edible that can be eaten by the spoonful or tucked into your favorite snack combos. Whether youโ€™re a seasoned edible enthusiast or a curious first-timer, this cannabis-infused peanut butter recipe is a delicious way to enjoy the therapeutic benefits of THC in one of the most comforting forms around. If youโ€™ve been wondering how to make cannabis-infused peanut butter at home, youโ€™re in the right place. This is an easy cannabis peanut butter recipe for beginners that doesnโ€™t require baking or complicated tools. Health Benefits of Cannabis-Infused Peanut Butter Cannabis and peanut butter are both nutritional powerhouses in their own right. Together, they make a functional food that offers both nourishment and relief. ๐ŸŒฟ Plant-based protein: Supports muscle repair and sustained energy ๐Ÿ’ช Healthy fats: Helps with nutrient absorption and brain function ๐ŸŒฟ Keeps you fuller, longer: Ideal for appetite control ๐ŸŒฟ Cannabis compounds: May support stress relief, pain management, and restful sleep ๐ŸŒฟ Fat-soluble cannabinoids: Enhanced THC absorption thanks to peanut butterโ€™s natural oils If you’re curious about the benefits of cannabis-infused peanut butter, it combines nutritious whole foods with cannabinoid therapy in a convenient, low-effort format. Ingredients & Equipment Youโ€™ll Need ๐Ÿฅœ Ingredients:   1๏ธโƒฃ 3.5 grams decarboxylated cannabis (preferably 20% THC)2๏ธโƒฃ 1 cup natural peanut butter (unsweetened, smooth or crunchy) ๐Ÿ› ๏ธ Equipment:   ๐Ÿ‘‰ Small saucepan or double boiler๐Ÿ‘‰ Cheesecloth or fine mesh strainer๐Ÿ‘‰ Mason jar or recycled peanut butter jar How to Make Cannabis-Infused Peanut Butter (Step-by-Step) Step 1: Decarboxylate Your Cannabis   Before infusion, cannabis needs to be heated gently to activate its cannabinoids.1. Preheat oven to 225ยฐF (105ยฐC).2. Break up cannabis and spread it on a parchment-lined baking sheet.3. Bake for 30โ€“40 minutes, stirring every 10 minutes until lightly toasted and fragrant. This step is essential if you’re learning how to decarboxylate cannabis for peanut butter and ensures the THC is activated for full potency. Step 2: Infuse the Peanut Butter   1. In a saucepan or double boiler over low heat, combine decarboxylated cannabis with the peanut butter.2. Simmer gently for 30โ€“60 minutes, stirring occasionally. Be careful not to overheatโ€”keep it low and slow. Not only is this a safe method for how to infuse peanut butter with cannabis, itโ€™s also mess-free and ideal for homemade cannabis edibles without baking. Step 3: Strain & Store   1. Let the mixture cool slightly.2. Strain through cheesecloth into a mason jar.3. Store at room temperature for up to 2 months, or refrigerate for up to 6 months. ย  Dosing Guide: Nutty But Necessary ๐Ÿ’ก Potency Calculation: (Assuming 20% THC cannabis) ๐Ÿ”ท 3.5 grams cannabis = ~700 mg THC๐Ÿ”ท 1 cup = 16 tablespoons = 48 teaspoons ๐Ÿง Breakdown per Serving:   ๐Ÿฅ„ 1 tablespoon โ‰ˆ 43.75 mg THC๐Ÿฅ„ 1 teaspoon โ‰ˆ 14.6 mg THC๐Ÿฅ„ ยฝ teaspoon โ‰ˆ 7.3 mg THC๐Ÿฅ„ ยผ teaspoon โ‰ˆ 3.6 mg THC ๐Ÿฅ„ Beginner dose: Start with ยผ teaspoon (about 3.6 mg THC) Pro Tip: Peanut butter is rich in fat, which helps your body absorb THC more effectively than low-fat edibles. Expect a stronger effect and longer duration. If you’re looking for a cannabis peanut butter dosage guide for homemade edibles, this section provides clear math and a responsible approach to consumption. โš ๏ธ Dosing Caveat: This dosing guide offers a helpful estimate, but the actual potency of your cannabis-infused peanut butter may vary. Factors such as THC percentage, how well you decarboxylate, infusion time and temperature, how thoroughly you strain, and your individual sensitivity can all affect the strength. Start low, wait at least 90 minutes to feel the effects, and adjust gradually as needed.   Creative Ways to Use Cannabis Peanut Butter Wondering about the best ways to use cannabis peanut butter in food and drinks? Here are some ideas: โ–ปย  Spread it on toast or crackers ๐Ÿžโ–ปย  Dip apple slices or banana chunks ๐ŸŽ๐ŸŒโ–ปย  Swirl it into oatmeal or yogurt bowls ๐Ÿง…โ–ปย  Blend into protein shakes or smoothies ๐Ÿงโ€โ™‚๏ธโ–ปย  Add a spoonful to brownies or cookie doughโ–ปย  Drizzle over pancakes or waffles ๐Ÿง€โ–ปย  Just eat it straight from the spoon (weโ€™re not judging) ๐Ÿฅ„   Frequently Asked Questions About Cannabis-Infused Peanut Butter [...] Read more...
August 3, 2023Ingredients 2 slices of bread Cheese Canna-Butter Optional fillings: tomato, green onion, chicken, tuna Directions 1. Use a knife to coat both pieces of bread with canna-butter Be sure to coat both sides of the bread 2. Bring skillet to medium heat and add a small scoop of canna-butter โ€‹ 3. One the butter has melted, place one slice of bread on the skillet 4. Add as much cheese and fillings as you like, then place the second slice of bread on top 5. Flip the sandwich when the bottom is golden brown, add more butter if needed for the new side 6. When the sandwich looks adequately fried and the cheese is melted to your liking, take it off of the skillet, slice in half, and enjoy! Original recipe from Satori MJ [...] Read more...
April 30, 2025Cannabis-Infused Spicy Hot Chocolate โ€” Sip, Soothe, and Feel the Glow Thereโ€™s hot chocolateโ€ฆ and then thereโ€™s this: a creamy, cocoa-rich, cannabis-kissed mug of firelight and calm. This spicy hot chocolate recipe doesnโ€™t just warm your handsโ€”it grounds your mood, softens your edges, and coaxes a little smile from deep within. Whether youโ€™re wrapping up a snow day or settling into a self-care night, this edible drink delivers comfort with a kick. What makes it unique? Itโ€™s got the usual luxuriesโ€”dark chocolate, warm milk, a swirl of vanillaโ€”but also a whisper of cayenne, a hint of cinnamon, and a measured dose of cannabis-infused coconut oil. Thatโ€™s what elevates this drink into a relaxing ritual for the senses, not just a sweet treat. Imagine this: steam curling from a deep mug, the first sip surprising you with just the right amount of heat, followed by silky, slow-building calm. Yeah, weโ€™re going there. Why Cannabis-Infused Hot Chocolate Is a Game-Changer Letโ€™s talk about why this particular edible drink hits differentlyโ€”literally and emotionally. Itโ€™s cozy, medicinal, customizable, and shockingly easy to make. Hereโ€™s what this cup brings to the table: ๐Ÿซ Cocoa is a natural mood boosterโ€”rich in flavonoids that support heart health and calm your nervous system. ๐Ÿ”ฅ Cinnamon and cayenne add warmth, circulation support, and metabolic benefits, all while deepening the flavor. ๐ŸŒฟ Cannabis-infused coconut oil delivers THC or CBD in a fat-soluble form, promoting relaxation and relief. ๐Ÿ’ค The drink is great before bedโ€”especially when you want something soothing without the sugar crash. ๐Ÿฅ› Itโ€™s adaptableโ€”you can make it vegan, low-sugar, or even non-euphoric with CBD or CBG. Ingredients & Equipment You wonโ€™t need anything fancy, but intention and quality ingredients go a long way. Choose a chocolate you love, a milk that foams well, and cannabis oil thatโ€™s been decarboxylated and infused properly. Ingredients ๐Ÿฅ› 2 cups whole milk (or oat/almond for dairy-free) ๐Ÿซ ยผ cup dark chocolate chips (or chopped chocolate bar, 60โ€“75% cacao) ๐Ÿฅฅ 1 tablespoon cannabis-infused coconut oil ๐ŸŒฟ ยฝ teaspoon ground cinnamon ๐ŸŒถ๏ธ โ…› teaspoon cayenne pepper (adjust to taste) ๐Ÿจ 1 teaspoon vanilla extract ๐Ÿ’ง Optional: maple syrup or agave for sweetness Equipment ๐Ÿ› ๏ธ Small saucepan ๐Ÿ› ๏ธ Whisk ๐Ÿ› ๏ธ Mug (bonus points if itโ€™s oversized or cozy-looking) How to Make Cannabis-Infused Spicy Hot Chocolate Step 1: Warm the Milk In a small saucepan over medium heat, pour in your milk of choice. Heat it until itโ€™s steamy but not boilingโ€”boiling can scald the milk and affect flavor. Give it a gentle stir now and then to keep things smooth. Step 2: Add the Chocolate & Spice Lower the heat and whisk in the dark chocolate chips. Stir constantly until melted and fully blended. Then add cinnamon, cayenne, and vanilla extract. The aroma should start to bloom at this pointโ€”this is where it starts to smell like winter magic. Step 3: Stir in the Cannabis-Infused Coconut Oil Turn the heat to low and stir in the cannabis oil until fully incorporated. You should see a glossy finish and slightly thicker texture. This is your sip of serenity. Step 4: Pour & Garnish Remove from heat and pour into your favorite mug. Top with whipped cream, marshmallows, a cinnamon stickโ€”or nothing at all. Sometimes the best moments are unadorned. Dosing Guide: How Much Is in My Mug? Hereโ€™s a quick calculation based on 1 tablespoon of infused coconut oil made with 3.5g of 20% THC cannabis (700mg total): ๐Ÿ’ก 1 tbsp infused oil = ~43.75mg THC ๐Ÿซ 2 servings per recipe = ~21.9mg THC per mug ๐Ÿซ– ยฝ mug = ~10.9mg THC ๐Ÿฅ„ ยผ mug = ~5.5mg THC Beginner-Friendly Tip: If youโ€™re new to edibles, start with just ยผ mug (~5mg THC), wait at least 90 minutes, and see how your body responds. Onset is typically 30โ€“90 minutes, and effects may last 4โ€“6 hours.   โš ๏ธ Dosing Caveat: This dosing guide is an estimate. Actual potency can vary based on your cannabisโ€™s THC percentage, how well it was decarboxylated, the infusion method used, and your bodyโ€™s individual sensitivity to edibles. Start low, sip slow, and allow plenty of time before increasing your dose. Want a Non-Euphoric Version? Absolutely possible. Simply swap in one of the following instead of THC-infused oil: ๐ŸŒฟ CBD oil for anti-anxiety and anti-inflammatory benefits ๐ŸŒฟ CBG or CBC oil for mood lift without intoxication ๐ŸŒฟ Use a 10:1 CBD:THC blend to dramatically lower the euphoric effect You can even make CBDA or THCA infusions if you want the raw, non-psychoactive cannabinoids while keeping the warm beverage vibe intact. Creative Ways to Use Spicy Hot Chocolate ๐Ÿช Pair it with a CBD cookie for a double-chill snack ๐Ÿ“š Sip it while reading, journaling, or watching snowfall ๐Ÿง˜ Drink it before a bath, meditation, or nighttime stretch ๐ŸงŠ Let it cool slightly and pour over vanilla ice cream for a spicy affogato ๐ŸŒŒ Make it part of your bedtime ritual instead of a glass of wine ๐ŸŽจ Use it to start your creative timeโ€”writing, drawing, ideation Cannabis and chocolate are both dopamine influencers, which may be why this drink boosts mood as much as it does comfort. Final Thoughts: Sip Slow, Soothe Deep Cannabis-infused spicy hot chocolate is more than a winter drinkโ€”itโ€™s a moment. A small act of nourishment that warms your hands, calms your nerves, and adds a little spark to an otherwise ordinary evening. With simple ingredients, beginner-friendly dosing, and endless opportunities to customize, this recipe is a cozy favorite waiting to happen. Let it be your gentle nightcap, your creative warm-up, or your winter-weather hug in a mug. Have you tried this recipeโ€”or customized it your way? Share your creations, post your photos, and tag #InfusedHotChocolate so we can raise a cup to calm, together. โ˜•โœจ FAQ: Cannabis-Infused Hot Chocolate, Answered   How do I make cannabis-infused hot chocolate at home? Use a base of milk and dark chocolate, infuse it with cannabis coconut oil, and spice it with cinnamon and cayenne for warmth and effect. Whatโ€™s the best way to dose THC in hot drinks? Use measured amounts of infused oil. Stir well and divide evenly between servings. Avoid guessingโ€”precision matters with edibles. Can I use cannabutter instead of coconut oil? You can, but it wonโ€™t emulsify as cleanly. Coconut oil blends better into hot liquids. Will the THC degrade when heated? As long as you donโ€™t boil the mixture, THC remains stable. Low, steady heat is your friend. Can I make this with CBD instead? Yes! Just use CBD-infused oil in place of THC oil. It wonโ€™t be intoxicating, but still soothing. How long do effects last from cannabis hot chocolate? Typically 4โ€“6 hours depending on dose, metabolism, and tolerance. Whatโ€™s the best milk to use? Whole milk gives the richest mouthfeel. Oat milk and almond milk are great for dairy-free versions. If you’re daring, we have posted a recipe here on CEDclinic.com for making medicated milk! How strong is homemade cannabis hot chocolate? That depends on your infusion strength. This recipe yields ~22mg THC per mug using standard oil. Can I refrigerate and reheat it later? Yesโ€”store in the fridge for up to 3 days. Reheat gently without boiling. Is this a good edible for beginners? Yes, if dosed carefully. Start with ยผ mug or less, especially your first time. [...] Read more...
August 3, 2023Ingredients 2 cups all-purpose flour 4 Tbsp sugar (canna-sugar may be substituted to increase potency) 1 Tbsp baking powder ยฝ Tsp salt 2 large eggs 1 ยฝ cups whole milk (canna-milk may be substituted to increase potency) ยพ cup canna-butter, melted โ€‹1 teaspoon vanilla extract Instructions 1. In a bowl, combine dry ingredients: flour, sugar, salt, baking powder 2. In another bowl, combine wet ingredients: beat the eggs with the milk, then add the vanilla extract 3. Stir the wet ingredients into the dry ingredients until just combined โ€‹Do not over-mix, batter will be thick and slightly lumpy 4. Bake in a preheated waffle-iron according to manufacturerโ€™s directions until golden brown This recipe is available for download HERE! Original recipe from allrecipes.com [...] Read more...
August 3, 2023Ingredients 2/3 cup Cannabis oil (coconut or olive oil will work) 4 large potatoes peeled 3 tbsp salt Instructions Preheat your oven to 400 degrees Fahrenheit and line a large baking sheet with parchment paper. Cut your peeled potatoes into strips (cut them into fries!) and spread them evenly on the baking sheet. Drizzle the cannabis-infused oil over them and season with salt. Try to coat each fry relatively evenly with the oil so that there is a consistent potency. Cook the fries until they are golden brown. Around 15โ€“20 minutes. Allow the fires to cool down, around 5 minutes. Divide the fries into equal proportions and serve. This recipe is available for download HERE Original recipe from thecannaschool.com [...] Read more...
May 11, 2025Cannabis-Infused Mac and Cheese โ€” Comfort Food with a Kick of Calm TL;DR ๐Ÿง€โœจ โž• This mac And cheese blends creamy nostalgia with THC-infused comfort โž• Ideal for stress relief, pain support, or a sleepy evening wind-down โž• Easy for beginners, with a precise dosing guide for 4 levels of strength โž• Offers strain pairing advice and chef tips for cannabis cooking success โž• Includes use ideas, answers to top cannabis recipe questions, and smart serving swaps Why Cannabis-Infused Mac and Cheese is the Ultimate Feel-Good Meal Thereโ€™s comfort food, and then thereโ€™s comfort food with benefits. Mac and cheese already owns the crown for cozy indulgence โ€” itโ€™s warm, melty, and hits the dopamine button with every forkful. But when you layer in cannabis-infused butter? Now weโ€™re talking serotonin and endocannabinoids. This is more than a stoner snack. Itโ€™s a smartly dosed edible that doubles as a satisfying, therapeutic dish for everything from anxiety and sleep trouble to post-work pain management. The rich fats in cheese enhance THC absorption, the warm carbs boost serotonin, and the creamy texture adds emotional comfort. Whether youโ€™re microdosing for a mellow night or dialing up for deeper effects, this recipe is both beginner-friendly and gourmet-adaptable. ๐Ÿ‘ƒ The scent of bubbling cheddarโ€ฆ ๐Ÿงˆ The silkiness of infused butter folding into pastaโ€ฆ ๐Ÿฝ๏ธ The ease of a one-dish dose that actually tastes like dinnerโ€ฆ Yes, this is your new favorite edible. ๐Ÿง  Why Mac And Cheese + Cannabis Is a Genius Combo Cannabis-infused mac and cheese isnโ€™t just delicious โ€” itโ€™s strategically smart for both absorption and wellness. โœ… Fat + THC = Enhanced Bioavailability The rich fats in cheese and butter help the body absorb cannabinoids more effectively, meaning your dose goes further with fewer surprises. โœ… Warmth, Comfort, and Slow Digestion Hot meals like mac and cheese are digested more gradually than sugary edibles, allowing for a slower onset and longer-lasting effects. โœ… Functional and Flexible This recipe works as a solo meal, side dish, or part of a larger comfort-food night โ€” no dessert required. โœ… Therapeutic Potential Depending on the strain, you can craft a version that supports sleep, eases pain, settles anxiety, or gently stimulates appetite โ€” all with one bowl. โœ… Customizable Dosing Control the potency with simple butter swaps. Whether you want 5mg or 25mg, this dish makes it easy to adapt. ๐Ÿ‘จโ€โš•๏ธ Pro Tip: Cannabis is fat-soluble, meaning edibles made with oils or butters tend to hit harder and last longer than smoking or vaping. Eating THC with fats slows the onset but boosts the duration โ€” expect 1 to 2 hours before full effect, and a 6+ hour ride depending on dose. ๐Ÿฝ๏ธ Ingredients & Equipment โ€” What Youโ€™ll Need to Make Infused Mac and Cheese This is a stovetop-friendly recipe with optional baking for a crispy finish. You donโ€™t need fancy tools โ€” just a pot, a whisk, and the willingness to stir with purpose. Ingredients: โ˜‘๏ธ 2 cups elbow macaroni (or any pasta with nooks and crannies) โ˜‘๏ธ 2 tablespoons cannabis-infused butter ๐Ÿงˆ visit here for the recipe โ˜‘๏ธ 2 tablespoons all-purpose flour โ˜‘๏ธ 1 cup whole milk or unsweetened oat/almond milk ๐Ÿฅ› โ˜‘๏ธ 1ยฝ cups shredded cheddar cheese (sharp is best!) ๐Ÿง€ โ˜‘๏ธ ยฝ teaspoon salt โ˜‘๏ธ ยผ teaspoon ground black pepper โ˜‘๏ธ ยผ teaspoon smoked paprika (optional, but adds lovely warmth) Equipment: ๐Ÿ“Œ Large pot for boiling pasta ๐Ÿ“Œ Medium saucepan for cheese sauce ๐Ÿ“Œ Whisk (for that smooth bรฉchamel texture) ๐Ÿ“Œ Strainer ๐Ÿ“Œ Spoon or spatula for folding pasta into cheese ๐Ÿ“Œ Optional: Baking dish (if you like a crisped, golden crust) ย  ๐Ÿ‘ฉโ€๐Ÿณ How to Make Cannabis Mac and Cheese, Step-by-Step ๐Ÿ”ฅ Step 1: Cook the Pasta Bring a large pot of salted water to a boil. Cook the pasta until al dente โ€” tender but still firm to the bite. Drain and set aside. ๐Ÿ’ก Donโ€™t overcook it. Mushy pasta dulls the whole experience, both in taste and in texture. ๐Ÿงˆ Step 2: Start the Cheese Sauce In a saucepan over low heat, melt your cannabis-infused butter. Add flour and whisk constantly for about 1 minute to create a smooth roux โ€” this step is key for preventing grainy sauce. ๐Ÿ’ก Low heat is your friend here. High temps can degrade THC and CBD, especially during prolonged exposure. ๐Ÿฅ› Step 3: Build the Base Slowly pour in your milk while whisking constantly. Let it simmer over low-medium heat until the mixture thickens to a silky texture. This usually takes about 5โ€“7 minutes. ๐Ÿง€ Step 4: Add the Cheese Turn off the heat and stir in the shredded cheddar, salt, pepper, and paprika. Whisk until completely smooth. ๐Ÿ’ก Want extra velvet? Add a touch of cream cheese or a splash of heavy cream. ๐Ÿฒ Step 5: Combine and Serve Add the drained pasta to your cheese sauce and fold gently until fully coated. Serve hot in bowls, or transfer to a buttered baking dish and bake at 375ยฐF for 10 minutes for a bubbly, crispy top. ๐Ÿšซ Common Mistakes to Avoid (And How to Fix Them) ๐Ÿคฏ Overheating the cannabis butter High heat breaks down cannabinoids. Stick to lowโ€“medium heat when melting infused butter โ€” never let it sizzle or brown. โณ Adding cheese too early If the milk/flour mixture isnโ€™t thickened before the cheese goes in, youโ€™ll get a grainy or separated sauce. Always thicken first, then melt cheese off heat. ๐Ÿ Using the wrong pasta Avoid thin noodles or large shells that donโ€™t hold sauce well. Elbows, cavatappi, or small shells are best for trapping creamy goodness (and even dosing). ๐Ÿฅ„ Forgetting to taste Cannabis butter may have herbal notes that impact the final flavor. Taste before serving and adjust seasoning โ€” a pinch more salt or an extra dash of paprika can help balance. ๐ŸŒฟ Dosing Guide โ€” Make It Mellow or Make It Potent The beauty of this recipe lies in its built-in flexibility. You can microdose, medicate, or munch without needing a calculator. ๐Ÿ’ก Base Calculation (Assuming 20% THC Flower) Letโ€™s say your cannabis-infused butter is made with: 3.5 grams of cannabis at 20% THC Fully decarboxylated and infused into ยฝ cup (8 tbsp) butter That yields approximately 700mg THC total in the butter Divide that into 8 tablespoons โ†’ ~87.5mg THC per tablespoon This recipe uses 2 tablespoons of infused butter โ†’ ~175mg THC total Makes 4 servings โ†’ ~43.75mg THC per serving โš–๏ธ Dose Adjustments ๐Ÿง€ 1 full serving = ~43.75mg THC ๐Ÿง€ ยฝ serving = ~21.8mg THC ๐Ÿง€ ยผ serving = ~10.9mg THC (ideal for newer users) ๐Ÿง€ โ…› serving = ~5.5mg THC (great for microdosing) ๐Ÿ” Want to Adjust the Dose? Hereโ€™s How: ๐ŸŒฑ For a stronger dose (double strength): Use 4 tbsp infused butter instead of 2, and reduce flour by 1 tbsp to maintain sauce texture. Final dose: ~87.5mg THC per serving (use with extreme caution). ๐ŸŒฑ For a milder dose (half strength): Use 1 tbsp infused butter and 1 tbsp regular butter. Adjust flour to 2 tbsp total. Final dose: ~21.8mg THC per serving. ๐ŸŒฑ For a microdose (ยผ strength): Use just ยฝ tbsp infused butter and 1ยฝ tbsp regular butter. Adjust flour accordingly. Final dose: ~10.9mg per full bowl, or ~5.5mg per smaller portion. ๐ŸŒฑ Want a Non-Euphoric Version? You can absolutely make this dish with non-intoxicating cannabinoids: ๐Ÿ”ธ CBD-rich butter: Use hemp flower or CBD isolate ๐Ÿ”ธ CBG or CBDA: Add these for anti-inflammatory and anxiety-calming properties ๐Ÿ”ธ 5:1 or 10:1 CBD:THC ratio: Keeps euphoric effects low, great for daytime or sensitive users ๐Ÿ‘ฉโ€โš•๏ธ Pro Tip: Many patients find 2โ€“5mg THC combined with 20mg CBD to be calming without being sedating. Great for chronic pain, muscle tension, or stress without couchlock. โš ๏ธ Dosing Caveat: Please remember that this dosing guide is only an approximation. The final potency of your cannabis-infused mac and cheese may vary based on factors like the THC content of your cannabis, how thoroughly it was decarboxylated, how evenly it was infused, how well the butter was stirred in, and your individual sensitivity to THC. We recommend starting with a small amount (ยผโ€“ยฝ serving), waiting at least 90 minutes, and adjusting slowly from there. ๐Ÿด Creative Ways to Use Cannabis Mac and Cheese This isnโ€™t just a fork-and-done kind of recipe. Infused mac and cheese can be dressed up, stretched out, and turned into something unforgettable โ€” or just ultra-comforting. ๐Ÿง‚ As a decadent side dish Pairs beautifully with grilled vegetables, roast chicken, or barbecued anything. ๐Ÿณ Baked into muffin tins Scoop into a greased muffin tray, top with a sprinkle of parmesan, and bake at 375ยฐF for 10โ€“12 minutes. Portion-controlled and party-ready. ๐ŸŒฏ Rolled into a quesadilla or breakfast burrito Yes, seriously. Mac and cheese + scrambled egg + tortilla = high-protein, high-happy brunch. ๐Ÿ” Stuffed into burgers Make a deep well in your patty, fill with a spoonful of infused mac, then grill and seal. Over-the-top in the best way. ๐ŸŒฟ Topped with greens Add wilted spinach, kale, or roasted broccoli to turn your edible into a full meal. Fiber + fat = balance. ๐Ÿ„ Savory truffle remix Drizzle with truffle oil or toss in sautรฉed mushrooms for a luxury edible night in. ๐Ÿฅฃ Mixed with hot sauce and crumbled chips Instant comfort with crunch, spice, and chew โ€” especially good when youโ€™re already feeling the effects. ๐Ÿท Pairing Suggestions: What to Sip with This Dish Cannabis edibles and alcohol arenโ€™t the best mix โ€” but that doesnโ€™t mean you canโ€™t have something elegant in hand. ๐ŸŒฟ Herbal tea Chamomile, rooibos, or peppermint helps soothe digestion and pairs well with creamy foods. ๐Ÿ‹ Lemon water with cucumber Brightens the palate and gently detoxes โ€” perfect if youโ€™re having a heavier meal. ๐Ÿบ Hop-forward non-alcoholic beer Pairs beautifully with cheddar and paprika notes, while enhancing the cozy effect. ๐Ÿฅ› Oat milk + turmeric latte Golden milk meets cannabis comfort โ€” creamy, anti-inflammatory, and ideal for bedtime. ๐Ÿ€ Cannabis Strain Pairings: Flavor Meets Function ๐ŸŽจ For Creativity & Social Energy: Try Jack Herer or Pineapple Express โ€” uplifting strains with citrusy notes that play well with cheddar. ๐Ÿ›‹๏ธ For Relaxation & Sleep: Go with Granddaddy Purple or Bubba Kush โ€” both deepen the sense of comfort and round out the heaviness of the dish. ๐ŸŒฟ For Functional Calm: Harlequin (high-CBD) or Cannatonic offers gentle calm with minimal intoxication โ€” great for daytime mac consumption. ๐Ÿ‘จโ€๐Ÿณ Pro Tip: Cheese-heavy foods mellow out the bitterness of earthy strains, while paprika and black pepper enhance terpene profiles like beta-caryophyllene and limonene. These can offer mild anti-inflammatory and mood-lifting benefits โ€” all while making your food taste amazing. โค๏ธ Final Thoughts: The High-Comfort Dinner You Didnโ€™t Know You Needed Cannabis-infused mac and cheese is more than an edible โ€” itโ€™s a full-body experience. Whether youโ€™re easing into the evening after a hard day, finding gentle relief from chronic pain, or just craving a cozy bowl of something warm and therapeutic, this dish delivers. With flexible dosing, endless remix possibilities, and a base recipe thatโ€™s hard to mess up, itโ€™s an edible everyone should have in their back pocket. ๐Ÿ‘จโ€โš•๏ธ Whether youโ€™re microdosing with mindfulness or treating yourself to a higher dose of relaxation, remember: the magic is in the mix of fat, function, and flavor. If you make this โ€” and we hope you do โ€” tag your dish at #InfusedMacAndCheese or drop a comment with your favorite add-ins! Frequently Asked Questions about Cannabis-Infused Mac and Cheese: How do you make cannabis-infused mac and cheese at home? Start with decarboxylated cannabis, infuse it into butter, and substitute that butter into a classic roux-based mac and cheese recipe. This blog walks you through each step, making it beginner-friendly. Is mac and cheese a good food for edibles? Yes! The fats in cheese and butter help with THC absorption, making mac and cheese one of the most effective and delicious edible formats โ€” especially for long-lasting effects. Whatโ€™s the best strain for making savory cannabis edibles? Strains like Jack Herer, Harlequin, or Granddaddy Purple work well, depending on whether you want an energetic or relaxing result. Look for terpene profiles that match your mood goals. And, keep in mind – the top of any given plant may be different from the middle and bottom of the plant. Strain names are a suggestion of the right ball park – not a brand prescription type experience! Can I make cannabis mac and cheese without cannabutter? You can use infused oil, or infused milk, or add a cannabis tincture directly to the sauce (post-cooking). Just be aware that alcohol-based tinctures may affect texture and taste. All of these recipes are free on CEDclinic.com What is the ideal beginner dose for cannabis-infused mac and cheese? Start with ~5โ€“10mg THC. Thatโ€™s about ยผ to ยฝ serving of this recipe using standard infused butter. Always wait 90 minutes before deciding if you want more. Does heating mac and cheese destroy THC? THC begins to degrade at temps above 300ยฐF. Cooking the butter into a sauce on low heat is safe. Baking for a short time at 375ยฐF is fine too โ€” the interior doesnโ€™t reach THC-damaging temps. How long does the high from cannabis mac and cheese last? Expect effects to start 45โ€“90 minutes after eating and last 4โ€“8 hours. The fat content may lengthen onset slightly but deepen intensity. Can I freeze cannabis mac and cheese? Yes, it freezes beautifully. Just note that freezing doesnโ€™t affect potency. Clearly label portions and dose to avoid surprises later! Whatโ€™s the shelf life of cannabis-infused mac and cheese? In the fridge: 3โ€“4 days. In the freezer: up to 2 months. Reheat gently to preserve cannabinoids. Can I make cannabis mac and cheese gluten-free? Absolutely. Just add lots of cardboard and stir. Just kidding! Use gluten-free pasta and swap flour for a GF thickener like cornstarch or arrowroot. Texture may vary slightly, but the flavor and dosing remain. [...] Read more...
August 3, 2023Ingredients blender ยผ cup tahini ยผ cup lemon juice, freshly squeezed w/o seeds 15 ounce can of chickpeas, drained and rinsed 2 garlic cloves ยผ cup CannaOil ยฝ cup ground cumin 2 tablespoons water salt and pepper to taste Instructions Combine lemon juice and tahini in a blender. Blend for 30 seconds. Add chickpeas, garlic, Canna Oil, cumin and water. Blend for 1 minute until smooth. Add more water if needed to reach desired consistency. Pour hummus in a serving bowl, or store in the refrigerator for later. This recipe is available for download HERE Original recipe from eatyourcannabis.com [...] Read more...
April 1, 2025Cannabis-Infused Honey Recipe โ€” Sweet, Sticky, and Blissfully Effective Why Youโ€™ll Love This Cannabis-Infused Honey Honey has been a trusted natural remedy for centuries, but when combined with cannabis, it transforms into one of the most versatile, easy-to-make edibles. This cannabis-infused honey recipe is perfect for sweetening tea, drizzling on toast, enriching salad dressings, or even enjoying straight off the spoon. Unlike baked edibles, infused honey is easy to dose, gentle on digestion, and offers all the soothing benefits of cannabis without turning on your oven every time you want a treat.   Health Benefits of Cannabis-Infused Honey This isnโ€™t just about getting buzzed โ€” itโ€™s about enhancing your wellness with the natural powers of both honey and cannabis: ๐Ÿฏ Antibacterial properties โ€” soothes sore throats and supports immune health. ๐Ÿง˜ Digestive support โ€” gentle on your gut and helpful for calming upset stomachs. ๐Ÿ’– Rich in antioxidants โ€” promotes skin, heart, and brain health. ๐Ÿƒ Natural sweetener โ€” say goodbye to refined sugar guilt. ๐ŸŒฟ Cannabis effects โ€” promotes stress relief, relaxation, and calm.   Ingredients & Equipment for Homemade Cannabis Honey   ๐Ÿง‚ Ingredients: 3.5 grams decarboxylated cannabis (roughly 20% THC recommended) 1 cup raw or local honey   ๐Ÿ› ๏ธ Tools: Small saucepan or double boiler Cheesecloth or fine mesh strainer Mason jar or glass storage jar (bonus points for style)   How to Make Cannabis-Infused Honey (Step-by-Step)   Step 1: Decarboxylate the Cannabis Before you can infuse cannabis into honey, you need to activate the THC through a process called decarboxylation. 1.Preheat oven to 225ยฐF (105ยฐC). 2.Break up cannabis into small pieces and spread on a parchment-lined baking sheet. 3.Bake for 30โ€“40 minutes, stirring every 10 minutes, until light golden and aromatic.   Step 2: Infuse the Honey 1.Combine decarboxylated cannabis and honey in a small saucepan or double boiler over low heat. 2.Simmer gently for 40โ€“60 minutes, stirring occasionally. Keep the heat low to preserve cannabinoids.   Step 3: Strain & Store 1.Allow the mixture to cool slightly. 2.Strain through cheesecloth into a clean mason jar. 3.Store at room temperature for up to 6 months or in the fridge for even longer freshness.   Dosing Guide: How Potent is Your Cannabis Honey?   ๐Ÿ’ก Potency Calculation (assuming 20% THC cannabis) 3.5 grams cannabis = ~700 mg THC total 1 cup honey = 16 tablespoons = 48 teaspoons Approximate THC per serving: 1 tablespoon โ‰ˆ 43.75 mg THC 1 teaspoon โ‰ˆ 14.6 mg THC ยฝ teaspoon โ‰ˆ 7.3 mg THC ยผ teaspoon โ‰ˆ 3.6 mg THC (great beginner dose) โš ๏ธ Dosing Caveat: Please note that this dosing guide is an estimate and should be used cautiously. Factors like the exact potency of your cannabis, decarboxylation efficiency, infusion temperature, and individual tolerance can all significantly affect the final strength of your honey. Variables such as the actual THC percentage of your cannabis, how well you decarboxylate it, infusion time and temperature, and even how thoroughly you strain your honey can all influence the final potency. When in doubt, start with a very small dose and gradually adjust only after observing the full effects.     Pro Tip: Honey-based edibles may take 30โ€“90 minutes to fully kick in, so be patient before reaching for another spoonful.   Creative Ways to Use Cannabis-Infused Honey   Stir into tea, coffee, or warm milk โ˜• Drizzle on pancakes, yogurt, or fresh fruit ๐Ÿฅž๐Ÿ“ Whisk into homemade salad dressings or marinades ๐Ÿฅ— Spread on warm biscuits, toast, or cornbread Or โ€” no shame โ€” enjoy it straight from the spoon ๐Ÿฏ   ๐Ÿ’ฌ Cannabis-Infused Honey FAQs   How do you make cannabis-infused honey at home? ย To make cannabis-infused honey at home, simply decarboxylate your cannabis, gently heat it with honey for about an hour, strain it, and store. This easy cannabis honey recipe only requires cannabis, honey, and basic kitchen tools. How do you decarboxylate cannabis for honey infusion? Decarboxylation is the process of activating THC. Bake broken-up cannabis buds on parchment paper at 225ยฐF (105ยฐC) for 30โ€“40 minutes, stirring every 10 minutes until lightly golden and aromatic. Can you make edibles with honey instead of butter? Yes, cannabis-infused honey is a popular alternative to cannabutter, allowing you to make edibles without butter or oil. Itโ€™s perfect for sweet recipes, beverages, and microdosing. How long does cannabis-infused honey last? When stored in a sealed jar away from light and heat, cannabis-infused honey can last up to 6 months at room temperature and even longer if refrigerated. How strong is homemade cannabis honey? The strength depends on how much cannabis you use and its THC percentage. A typical batch with 3.5 grams of 20% THC cannabis yields about 700 mg THC total. Refer to the dosing guide above for per-teaspoon breakdowns. What is the best beginner dose for cannabis honey? For beginners, start with ยผ teaspoon of cannabis honey, which typically contains around 3.6 mg of THC. This allows you to experience mild effects without overwhelming potency. What are the benefits of cannabis-infused honey? Cannabis-infused honey combines the natural antibacterial, antioxidant, and digestive benefits of honey with the relaxing, stress-reducing, and soothing effects of cannabis. Can I microdose with cannabis honey? Yes, cannabis honey is excellent for microdosing. Small amounts, such as ยผ to ยฝ teaspoon, can offer subtle relaxation and wellness benefits without strong psychoactive effects. What are the best ways to use cannabis honey? The best ways to use cannabis honey include stirring it into tea, drizzling on toast, adding to yogurt or oatmeal, using it in salad dressings, or enjoying it straight from the spoon. Does cannabis honey help with stress and relaxation? Yes, many people use cannabis honey to naturally reduce stress and promote relaxation. It is especially popular in bedtime teas and calming rituals.   Final Thoughts: The Liquid Gold of Cannabis Edibles โœ… Easy to make, even easier to enjoy. โœ… Versatile for recipes, drinks, or direct consumption. โœ… Potent, but microdose-friendly. โœ… Stores beautifully โ€” no freezer required. โœ… An herbal remedy that has stood the test of time, now with a modern twist.   Join the Conversation Made this recipe? Share your favorite way to use cannabis-infused honey in the comments. Tag your creations with #CannabisHoney and share the sticky, sweet love.   Contact Us!       [...] Read more...
August 3, 2023Cannabis infused sugar offers a simple way to enhance your baked goods or beverages. Materials Mason Jar โ€‹Cheesecloth Baking Sheet 9in x 13in Baking Pan Ingredients -3 grams of cannabis flower -1/2 cup of high-proof alcohol, such as Everclear -1/2 cup granulated sugar Directions 1. Decarboxylate the cannabis Heat the oven to 225ยฐF. Spread cannabis buds out into an even layer on a baking sheet and place in the oven. โ€‹Take care not to let the temperature go over 225ยฐF and burn (if this happens, you can lose potency). Bake for about 35โ€“40 minutes, then remove from the oven and cool before grinding into a coarse powder. โ€‹ The decarboxylated cannabis will keep in an airtight container in a cool, dark place for up to 2 months 2. Transfer the cannabis to a jar and cover with the alcohol. Screw the lid on tight and shake every 5 minutes for 20 minutes. 3. Strain through a cheesecloth set over a bowl, discarding solids. Mix the strained alcohol with the sugar and spread into an even layer in a glass 9-by-13-inch baking dish. โ€‹ 4. Bake at 200ยฐF, stirring occasionally, until the alcohol has evaporated and the sugar is lightly golden. This recipe is available for download HERE The original recipe is from Vice.com [...] Read more...
August 3, 2023Ingredients 4 Pork chops Salt and pepper 1 Tbsp minced rosemary 2 Cloves minced garlic 1/2 Cup canna-butter 1 Tbps canna-oil Instructions 1. Preheat oven to 375ยฐF. Season pork chops with salt and pepper 2. In a small bowl, combine canna-butter with rosemary and garlic. Set aside 3. In an oven-safe skillet over medium heat, heat canna-oil and add pork chops. Sear until golden, about 4 minutes, flip and cook for another 4 minutes. 4. Brush pork-chops generously with the garlic canna-butter mixture and place skillet in the oven to bake for 10โ€“12 minutes. Serve with more garlic butter. โ€‹If you do not have an oven-safe skillet, you may use a regular one and transfer to a baking dish. Be sure to collect all the oil from the pan when transferring. This recipe is available for download HERE Original recipe from Eat Your Cannabis.com [...] Read more...
April 22, 2025Cannabis-Infused Gummy Bears โ€” Tiny, Tangy, Chill-Packed Chews Letโ€™s face itโ€”sometimes you just want a little nibble of relief. Cannabis-infused gummy bears offer all the benefits of edibles in a bite-sized, fruit-flavored package. Theyโ€™re fast to make, easy to dose, and perfect for discreet enjoyment whether youโ€™re managing pain, easing anxiety, or simply curating a calmer day. These gummies are soft, chewy, and customizable, with far less sugar than store-bought options. And unlike brownies or cookies, you donโ€™t need to heat an oven or dirty a dozen pans. Just warm, whisk, pour, and chill. So grab your gummy bear mold (or search online for โ€œsilicone gummy bear moldโ€ if you donโ€™t have one yet), and letโ€™s make the most cheerful edible in the cannabis world. Why Cannabis Gummy Bears Are a Favorite Among Home Cooks ๐Ÿฌ Discreet and travel-friendly (no smell, no crumbs) ๐Ÿง˜โ€โ™‚๏ธ Easy to microdose or stack depending on your needs ๐Ÿ’งNaturally dairy-free and gluten-free ๐Ÿซ€ May support mood, sleep, and inflammation reduction โฑ Ready in under 45 minutes (plus chill time) Gummies are one of the most approachable ways to experiment with cannabis edibles. If youโ€™ve been wondering how to make cannabis gummies at home for beginnersโ€”this is your golden ticket. What Youโ€™ll Need to Make Cannabis Gummy Bears ๐Ÿ›  Equipment โ€” Silicone gummy bear mold + dropper (search your favorite store for โ€œgummy bear mold siliconeโ€ for great options) โ€” Small saucepan โ€” Whisk โ€” Spouted measuring cup or bowl ๐Ÿ“ Ingredients โ€” ยฝ cup fruit juice (choose bold flavors like strawberry, mango, or pomegranate) โ€” 2 tablespoons honey or agave syrup โ€” 1 tablespoon lemon juice (for brightness and shelf life) โ€” 1 tablespoon unflavored gelatin or agar-agar (for vegans) โ€” 2 teaspoons cannabis-infused coconut oil Pro Tip: For best texture, avoid pulp-heavy juices. Strain if needed. Step-by-Step: How to Make Cannabis Gummies Step 1: Warm the Liquid Base In a small saucepan over low heat, combine fruit juice, lemon juice, and sweetener. Stir until warm and gently steaming. Do not boil. Step 2: Whisk in Gelatin and Oil Sprinkle the gelatin evenly over the surface while whisking constantly. Then add the cannabis-infused coconut oil. Whisk until completely dissolved and emulsified. Step 3: Pour Into Molds and Chill Use the dropper to fill your silicone molds quickly before the mixture sets. Place in the fridge for 30โ€“45 minutes or until firm and springy. Pro Tip: If you donโ€™t have molds, use an ice cube tray and cut into piecesโ€”just be sure to dose accordingly. โš ๏ธ Dosing Caveat:These estimates are a starting point, not a guarantee. The potency of your cannabis gummies depends on the strength of your infused oil, the consistency of your mixing, the number of gummies per batch, and your own tolerance. Always label your batch and test with one gummy firstโ€”wait 60 to 90 minutes before trying more. Gummy Dosing Guide Assuming 2 teaspoons of oil infused with 3.5g cannabis at 20% THC: ๐Ÿงช Total THC โ‰ˆ 140mg ๐Ÿงธ Makes ~24 gummies ๐Ÿงธ 1 gummy โ‰ˆ 5.8mg THC ๐Ÿงธ ยฝ gummy โ‰ˆ 2.9mg THC ๐Ÿ‘ถ Beginner dose: 1 gummy or less (~3โ€“6mg THC) ๐Ÿ”ฅ Stronger dose: 2โ€“3 gummies (~10โ€“15mg THC) Pro Tip: Gummies digest faster than baked edibles but still take 30โ€“60 minutes to kick in. Be patient. How to Make Non-Altering (“Non-Intoxicating” Gummy Bears Want the calm without the high? Simply replace your THC-infused coconut oil with one of the following: ๐Ÿง˜โ€โ™€๏ธ CBD oil โ€” for gentle stress relief ๐Ÿ’ก CBG oil โ€” supports clarity and focus ๐Ÿซ€ CBDA โ€” anti-inflammatory without intoxication ๐ŸŒฟ Try a 10:1 or 20:1 CBD:THC ratio if you want just a whisper of euphoria Pro Tip: Non-psychoactive cannabinoids still have powerful effectsโ€”especially when used regularly over time. Creative Ways to Use Cannabis Gummy Bears ๐ŸŽ’ Stash a few in your day bag for microdosing calm on the go ๐ŸŒ™ Enjoy a couple before bed for relaxing sleep support ๐ŸŽจ Use them as edible artโ€”arrange by color, flavor, or fun shape ๐ŸŽ Package in a cute tin or jar for a personalized gift (with a clear THC label!) ๐ŸŽถ Pair with your favorite record or movie for the ultimate chill sesh ๐Ÿน Add to a mocktail or sparkling water for fizzy fun Final Thoughts Cannabis gummy bears offer a joyful, chewable, and customizable way to enjoy cannabinoidsโ€”whether youโ€™re seeking sleep, serenity, or simply a sweet treat with benefits. With just a few ingredients, a little patience, and the right mold, youโ€™ll have a stash of perfectly portioned edibles to brighten your day (or night). Got a favorite flavor combo? Tag us in your creations. Just donโ€™t eat the whole jar at onceโ€”unless you really want to nap like a gummy bear in a hammock. Frequently Asked Questions About Homemade Cannabis Gummies Can I make cannabis gummies without gelatin? Yesโ€”substitute with agar-agar. Use about 1.5 teaspoons to replace 1 tablespoon gelatin. It will set faster and firmer. Whatโ€™s the best fruit juice to use for homemade gummies? Go for bold, naturally sweet juices like mango, pomegranate, or black cherry. Avoid citrus-heavy juices, which may not gel well. How do I stop my gummies from melting at room temp? Store them in the fridge in a sealed container. If traveling, keep in a small cooler pack to maintain texture and potency. Can I use tincture instead of infused oil? Only if itโ€™s an alcohol-free, oil-based tincture. Alcohol can inhibit gelling and is unsafe to heat in this recipe. How long do cannabis gummy bears last? Stored in the fridge, theyโ€™ll stay fresh for about 2 weeks. If they look or smell off, toss them. How can I make my gummies stronger or weaker? Use more or less infused oil per batchโ€”or make more gummies for a lower dose per piece. Is decarboxylation necessary? No. If your goal is to maximize euphoric effects, you will want to decarb your cannabis before infusing oil to activate THC. On the other hand, there is still great anti-inflammatory benefit to the natural, non-decarbed forms. Both offer different benefits! Can I use flavored gelatin like Jell-O? You can, but it contains added sugars and preservatives that may affect texture, dosing, and stability. Natural gelatin offers better control. Why are my gummies separating or oily on top? Thatโ€™s from poor emulsification. Whisk vigorously after adding oil and pour quickly before the mixture cools. Are these legal to make? That depends on your local laws. In most legal adult-use or medical states, personal edibles are allowedโ€”but always check your jurisdiction. [...] Read more...
February 26, 2026Melt-and-Remix Cannabis Gummies, Sour-Curious, Texture-Perfect Chews This page is for the lazy genius version of gummies: you start with store-bought gummies, melt them gently, then โ€œremixโ€ them into something more intentional. The old, melt down cannabis gummies for reuse trick! You can adjust potency, tweak texture, and even make them sour without building a gelatin formula from scratch. If you already love the classic homemade approach, keep your original gummy bear recipe as the โ€œfrom-scratchโ€ option, and let this be the shortcut companion. This method shines when you want speed, consistency, and fewer moving parts. TL;DR: Melt-Down Gummies in Plain English โฑ Melt slowly using indirect heat, then mix longer than feels necessary. ๐Ÿงช Add your infusion off heat when possible, and keep the mixture moving. ๐Ÿ‹ Add sour and flavor adjustments in tiny increments, then re-taste the aroma, not the liquid. ๐ŸงŠ Pour quickly, chill, and label your batch like a responsible adult with snacks. Why This Method Deserves Attention You are leveraging professional candy formulation. Someone already solved the problems of chew, shelf stability, and flavor. Your job becomes dosing, gentle melting, and smart add-ins. It is also a great entry point for people who want cannabinoid precision without becoming a weekend food scientist. Functional Perks of This Feel-Good Treat ๐Ÿฌ Portion control is built-in, which makes microdosing much easier. ๐Ÿง  Dose math is repeatable, especially when you keep mold size consistent. ๐Ÿซง Texture can be tuned, softer, firmer, or lightly sugared for less stick. ๐Ÿ‹ Flavor can be nudged brighter, tarter, or more โ€œadultโ€ with acids and extracts. Health Benefits: Food That Talks to Your Body For many people, gummies are not about โ€œcandy.โ€ They are about a reliable, repeatable delivery route when someone wants to support sleep, soothe stress, or dial down discomfort without inhalation. Gummies also let people keep cannabinoid decisions separate from lung exposure, and that matters clinically. None of this is a promise. It is a practical framing: a controlled edible can be a steadier tool than improvising with inconsistent products. What Youโ€™ll Need ๐Ÿ›  Equipment ๐Ÿฏ Double boiler setup (preferred for melt-down gummies) ๐Ÿฅ„ Silicone spatula ๐Ÿงช Digital scale (helpful for add-ins and consistency) ๐Ÿงธ Silicone gummy mold + dropper or spouted cup ๐ŸŒก Instant-read thermometer (helpful for avoiding overheated syrup) ๐Ÿฌ Ingredients ๐Ÿญ Store-bought gummies (single-flavor bags make life easier) ๐Ÿซง Lecithin (optional, helps emulsify oily infusions) ๐Ÿ‹ Citric acid (optional, souring and brightness) ๐Ÿš Superfine sugar (optional, coating for texture and reduced sticking) ๐Ÿงด Your infusion of choice (oil, rosin, distillate, tincture, nano drops, isolate) Gummy Dose Calculator One sentence that prevents regret: If you have a COA potency, use it. If you do not, treat defaults as rough estimates, test one piece, then wait long enough before adjusting. Important: Alcohol-based tinctures should not be heated. If that is your infusion, add it off heat and mix thoroughly. Gummy Dose Calculator (Melt-Down Method) Built for melting down pre-made gummies and remixing potency. Best practice is to use a COA or a reliable label. If potency is uncertain, make a tiny test batch first. How many gummies? Mold size (grams per gummy) Target THC per gummy (mg) 1 mg 2.5 mg 5 mg 10 mg 15 mg Output mode THC only THC + CBD Infusion type Decarbed rosin (percent by weight) Decarbed live rosin (percent by weight) Decarbed bubble hash (percent by weight) Distillate (percent by weight) Decarbed resin (BHO/live resin, percent by weight) RSO / FECO (percent by weight or mg per mL) Infused oil (mg per mL) Alcohol tincture (mg per mL, add off heat) Water-soluble nano drops (mg per mL) Isolate (purity percent by weight) THC percentage (%) CBD percentage (%) THC potency (mg per mL) CBD potency (mg per mL) Lecithin estimate (optional) None As % of infusion amount Fixed grams Lecithin (% of infusion) Lecithin (grams) Optional: add water (grams) for softer texture Calculate Reset ย  Safety note: Melt-down gummies can dose unevenly if mixing is rushed. Keep heat low, mix longer than you think you need, and label your batch clearly. If your infusion is alcohol-based, do not heat it. Add it off heat. Math note for percent-by-weight infusions: mg per gram โ‰ˆ (percent รท 100) ร— 1000. Example: 70% THC is about 700 mg THC per gram. Step-by-Step: Melt the Gummies Gently Step 1: Set up your workstation like you mean it Use a double boiler so your gummies never touch direct burner heat. Put your molds on a tray so you can move them to the fridge without carrying a wobbly silicone sheet across the kitchen. Pro Tip: If you are adding powders, pre-measure them into pinch bowls. Melted gummy syrup cools fast, and โ€œIโ€™ll do it afterโ€ is how clumps are born. Step 2: Melt slowly, stir steadily Add gummies to the upper bowl and heat gently. Stir as they soften. You are aiming for a glossy syrup with no scorched smell and no browned edges. If the mixture thickens from moisture loss, add a small amount of water, then keep stirring. More water tends to yield a softer gummy. Step 3: Add your infusion and homogenize Remove from heat. Add lecithin if you are using it, then add your infusion. Mix longer than feels necessary. Uneven mixing is the number one reason โ€œone gummy did nothing, the next gummy sent me to Neptune.โ€ If you have a mixer that can stir gently without whipping air, that can help. If not, slow and steady manual stirring still works well. Step 4: Pour quickly, chill patiently Pour into molds while the mixture is still fluid. Chill until fully set. If you plan to coat with sugar, let them firm up well first. Add-Ins and Remix Options: Flavor, Sour, Texture, Supplements This is where melt-down gummies get fun. The rule is simple: change one thing at a time, and change it in tiny increments. You cannot un-sour a gummy. Flavor boosters Natural fruit extracts can brighten a flat candy base, but they can also overwhelm fast. Add a drop, mix, then smell the steam above the bowl. Your nose will tell you more than tasting hot syrup will. Sour strategy, citric acid without regret Citric acid can make gummies pleasantly tangy. It can also make them harsh if you go too hard. A gentle approach is to reserve most of your โ€œsourโ€ for the outside, by coating finished gummies with superfine sugar mixed with a small amount of citric acid. That gives you sour punch on the first bite without destabilizing the interior texture. If you add citric acid inside the melted mixture, go extremely slowly. Mix fully, then stop adding. Let your first batch be โ€œpleasantly brightโ€ rather than โ€œbattery acid chic.โ€ Texture levers that actually work A small amount of water during melting can make a softer chew. A sugar coating can reduce sticking and gives a cleaner bite. If your gummies sweat in storage, a light dusting helps. Vitamins and supplement powders If you add vitamins or powders, consider three realities: taste changes, clumping risk, and dosing consistency. Powders can settle or clump if you add them too late or do not mix long enough. If the ingredient has a meaningful daily limit or drug interaction potential, keep the dose modest and label clearly. Dosing Guide: A Clear, Repeatable Way to Think This method can be surprisingly precise, but precision depends on three things: knowing potency, mixing thoroughly, and keeping mold size consistent. ๐Ÿงช Total cannabinoids in batch (mg) = potency of infusion (mg per gram or mg per mL) ร— amount added ๐Ÿงธ Mg per gummy = total cannabinoids in batch รท number of gummies Quick Math: DIY Dosing Calculator (Printable Version) If you do not want to use the on-page calculator, this is the same logic in one reusable framework. ๐Ÿฏ Concentrates (percent by weight): mg per gram โ‰ˆ (percent รท 100) ร— 1000 Example: 70% THC โ‰ˆ 700 mg THC per gram ๐Ÿฏ Amount of concentrate (grams) = (target mg per gummy ร— number of gummies) รท (mg per gram) ๐Ÿ’ง Oils and tinctures (mg per mL): amount (mL) = (target mg per gummy ร— number of gummies) รท (mg per mL) โš ๏ธ Dosing Caveat: These estimates are a starting point, not a guarantee. Potency varies with label accuracy, COA quality, decarb completeness, mixing time, batch temperature, mold fill consistency, and your personal sensitivity. Test one gummy first, then wait long enough to judge the effect before taking more. Label your batch clearly and store it out of reach of kids and pets. How to Make This Non-Euphoric If you want minimal cognitive alteration, aim for CBD-forward options, very low THC targets per gummy, or a high CBD:THC ratio. Many people prefer a โ€œwhisper of THCโ€ because it can change the feel without changing the day. Keep your calculator targets modest at first. For many beginners, 1 to 2.5 mg THC per gummy is a better starting point than the standard recreational assumptions floating around the internet. Flavor and Strain Pairing Suggestions If your infusion has a noticeable aroma, pair it like you would a bold ingredient. ๐Ÿ Tropical gummies often pair well with brighter, fruit-forward profiles. ๐Ÿ’ Cherry gummies tolerate richer, earthier notes. ๐Ÿ‹ Citrus bases can make some infusions taste sharper, which is great when you want crisp, and not great when you want mellow. Strain disclaimer: Names are marketing. Effects vary more with chemistry, dose, and the person than with what a jar claims. Creative Ways to Use These Gummies ๐ŸŽ’ A tiny travel dose that does not crumble, leak, or smell. ๐ŸŒ™ A predictable bedtime option when you want repeatability. ๐Ÿง˜ A โ€œone gummyโ€ routine that supports consistency rather than escalation. ๐ŸŽ A clearly labeled gift for a consenting, informed adult. ๐Ÿ‹ A sour-coated batch for people who hate overly sweet edibles. ๐ŸงŠ A fridge-stored jar that stays stable and less sticky. Mood Pairings and Situational Use These are the gummies for people who like calm plans: a quiet movie, a long bath, a slow stretch, a less-irritable evening, a little help turning the volume down without changing the channel. Storage Tips and Shelf Life Store in an airtight container in the fridge for best texture. Gummies can soften or sweat at room temperature, especially after melting and remixing. Potency can drift over time, so treat older batches as less predictable. If you coat with sugar, store them so they are not pressed together. A small piece of parchment between layers helps. Troubleshooting Common Mistakes My gummies turned grainy. Heat was too high or moisture shifted too fast. Use gentler heat next time, and stir steadily. My gummies separated or feel oily. Mixing time was too short. Add lecithin next time, and mix longer off heat. My gummies are too soft. Too much added water, or the base gummies were already soft. Use less water, and chill longer. My gummies are too sticky. Try a superfine sugar coating and colder storage. My batch dosing feels uneven. Pouring took too long or the mixture cooled mid-pour. Work faster, keep the bowl warm, and mix again right before pouring. Cannabis and Culinary Culture The best cannabis cooking is not about showing off. It is about thoughtful control. Melt-down gummies are the โ€œweeknight dinnerโ€ version of edibles: quick, repeatable, and practical. That is the point. Reliable is a culinary virtue. Frequently Asked Questions About Melt-Down Cannabis Gummies Can I use alcohol tincture in melt-down gummies? Yes, but do not heat alcohol-based tinctures. Add them off heat, mix thoroughly, and expect texture to vary depending on how much liquid you add. Why do my gummies scorch so easily? Direct heat is the culprit. Use a double boiler and keep heat low, stirring steadily so the candy base melts evenly. How do I make my gummies sour without ruining the texture? The easiest approach is an external sour coating: superfine sugar mixed with a small amount of citric acid. Internal citric acid changes texture more, so go slowly. Do I need lecithin? Not always. It can help when your infusion is oil-based by supporting emulsification and reducing separation, especially if mixing time is short. How long should I mix after adding infusion? Longer than you think. Uneven mixing is the most common cause of inconsistent dosing. Mix steadily for several minutes, then pour promptly. Can I add vitamin powders or supplements? You can, but clumping and uneven distribution are common. Pre-measure powders, add off heat, and mix thoroughly. Keep doses modest and label clearly. How do I prevent gummies from sticking together? Chill storage plus a light superfine sugar coating helps. Store in a sealed container with parchment between layers. How long do melt-down gummies last? For best texture and predictability, store in the fridge and use within a couple of weeks. Potency and chew can drift over time. What is a good beginner THC target per gummy? Many beginners do better starting at 1 to 2.5 mg THC per gummy, then adjusting only after they understand timing and personal sensitivity. Why did one gummy feel weak and another feel strong? That usually points to mixing, cooling, or pouring issues. Keep heat low, mix longer, and pour while the mixture is still uniform and fluid. Final Thoughts Melt-down gummies are the rare edible method that can be both easy and disciplined. Start with good candy, use gentle heat, do the math, and mix thoroughly. Then label your jar like you would want someone you love to label it. If you publish this as a companion page, add a short link near the top pointing readers to your from-scratch gummy bear recipe for those who want full control over ingredients and sweetness. [...] Read more...
September 15, 2025๐Ÿฅฆ Cannabis-Infused Veggie Stir Fry Quick, Colorful, and Infused with Chill โ€” Dinner Just Got Elevated TL;DR Light, fast, and full of fiber, this stir fry is your new go-to for feel-good food with functional benefits. Using cannabis-infused coconut oil, it delivers a calming, anti-inflammatory lift that complements the natural nutrition of fresh veggies. Each serving is ~43.75mg THC, or scale it down to 10mg for a microdosed dinner. โœ… Anti-inflammatory โœ… Easy to digest โœ… Infused for mental calm โœ… Ready in 15 minutes โธป Why Youโ€™ll Love This Recipe Itโ€™s fast. Itโ€™s fresh. Itโ€™s forgiving. This cannabis-infused veggie stir fry is perfect for weeknights when you want real nourishmentโ€”without turning your brain into vegetable soup. Coconut oil enhances THC absorption, and the rainbow of vegetables provides everything from antioxidants to gut-healing fiber. This is dinner you can feel good aboutโ€”physically and mentally. โธป Health Benefits: This Is the Real โ€œHighโ€ Fiber Diet โœจ This stir fry isnโ€™t just infusedโ€”itโ€™s functional. Hereโ€™s what it brings to the table: โ€ข๐Ÿง  Cannabis: Calms the nervous system, eases digestion, supports endocannabinoid tone โ€ข๐Ÿฅฅ Coconut Oil: Rich in healthy fats to improve THC absorption and brain function โ€ข๐ŸŒˆ Broccoli & Bell Pepper: Packed with vitamin C, antioxidants, and phytonutrients โ€ข๐Ÿฅ• Carrots & Snap Peas: Fiber-rich, great for gut health and blood sugar balance โ€ข๐ŸŒถ๏ธ Ginger & Garlic: Anti-inflammatory, immune-boosting, and flavorful โธป What Youโ€™ll Need ๐Ÿ› ๏ธ Materials: โ€ขWok or large sautรฉ pan โ€ขWooden spoon or spatula ๐Ÿฅ• Ingredients: โ€ข2 tbsp cannabis-infused coconut oil ๐Ÿฅฅ โ€ข1 cup broccoli florets ๐Ÿฅฆ โ€ข1 red bell pepper, sliced ๐ŸŒถ๏ธ โ€ข1 carrot, julienned ๐Ÿฅ• โ€ขยฝ cup snap peas โ€ข2 cloves garlic, minced โ€ข1 tbsp ginger, grated โ€ข2 tbsp low-sodium soy sauce or tamari โ€ขOptional toppings: sesame seeds, sliced green onions, chili flakes โธป Step-by-Step Instructions ๐Ÿ”ฅ 1. Heat the Oil In your wok or skillet, heat the infused coconut oil over medium. Add garlic and ginger and sautรฉ for 30 seconds until aromatic but not browned. ๐ŸŒˆ 2. Cook the Veggies Toss in broccoli, carrots, and bell pepper. Stir-fry for 3โ€“4 minutes. Add snap peas and cook for 2 more minutes, just until veggies are crisp-tender. ๐Ÿฅข 3. Season and Serve Pour in soy sauce or tamari. Stir to coat everything evenly. Optional: Top with sesame seeds, scallions, or chili flakes for a little extra heat. Serve hot over brown rice, quinoa, or cauliflower rice for a full meal. โธป ๐Ÿƒ Dosing Guide: Healthy, But Still Potent Even when itโ€™s packed with veggies, this stir fry can still pack a punch. ๐Ÿ’ก Potency Calculation: โ€ข2 tbsp infused coconut oil = ~87.5mg THC โ€ขThis recipe makes 2 hearty servings ๐Ÿง Breakdown per Serving: โ€ขFull serving = ~43.75mg THC โ€ขHalf serving = ~21.9mg THC โ€ขยผ serving = ~10.9mg THC (ideal for beginners) ๐Ÿ”ฌ Pro Tip: Coconut oil enhances THC bioavailability, so even small portions may feel stronger than you expect. Start with a quarter plate and see how you feel. ๐Ÿง  Creative Ways to Use Cannabis Stir Fry This isnโ€™t just a plate of stir-fried veggiesโ€”itโ€™s an infused flavor canvas. ๐Ÿฅฌ Wrap It Up Spoon the stir fry into lettuce leaves or tortillas for a grab-and-go option with crunch. ๐Ÿœ Noodle Bowl Base Layer it over rice noodles or soba with a drizzle of infused sesame sauce. ๐Ÿณ Brunch Remix Top with a fried egg, tofu, or sliced avocado for an infused brunch bowl. ๐ŸŒฏ Infused Burrito Add some black beans and roll it into a wrap with guacamole and greens. โธป ๐Ÿ’ก Pro Tips for Perfect Results โ€ข Pre-cut your veggies so cooking is fast and even. โ€ข Donโ€™t overcookโ€”you want them bright and slightly crisp, not mushy. โ€ข Add protein like tofu, shrimp, or grilled chicken if you want something heartier. โ€ข Start small: ยผ plate may be plenty for new users due to the oilโ€™s high bioavailability. โ€ข Pair with a CBD beverage or herbal tea for a calming, full-body effect. โธป โŒ Common Mistakes to Avoid ๐Ÿ”ป Overheating the Oil If the panโ€™s too hot, you risk degrading cannabinoids. Medium heat is best. ๐Ÿ”ป Ignoring Portion Size Donโ€™t forget: this is a medicated meal. That โ€œone more biteโ€ could tip the scale. ๐Ÿ”ป Poor Mixing Stir thoroughly after seasoning to evenly distribute the infused oil and flavor. โธป ๐ŸŒฟ Strain Suggestions: For a Lighter, Brighter High Choose cannabis strains that enhance energy, creativity, or relaxation without sedation. โœ… For Mood & Energy: โ€ขSuper Lemon Haze โ€“ bright, zesty, great daytime uplift โ€ขTangie โ€“ citrus-forward and creativity-boosting โœ… For Calm Focus: โ€ขHarlequin โ€“ high CBD for body ease with mental clarity โ€ขJack Herer โ€“ balanced, euphoric, light-hearted โœ… For Anti-Inflammation: โ€ขACDC โ€“ low THC, high CBD, non-intoxicating relief โ€ขPennywise โ€“ mellow and soothing with a gentle mental buzz โš ๏ธ A Note About Strains: Strain names can be misleading. Whatโ€™s labeled โ€œSuper Lemon Hazeโ€ in one dispensary might feel completely different from another shopโ€™s version. Thatโ€™s because: 1) Thereโ€™s no consistent strain genome across the cannabis industry. 2) Effects vary due to terpene profiles, cannabinoid ratios, and cultivation conditions. 3) Your individual tolerance, body chemistry, and gut health all shape how you feel. ๐Ÿ‘‰ Take all strain suggestions with a diamond-sized grain of salt. Focus more on the effect youโ€™re seekingโ€”calm, uplifted, focusedโ€”and choose based on your response over time. ๐Ÿ“Œ Save & Share ๐Ÿ’ฌ Have a favorite veggie combo you swear by? Drop it in the comments! ๐Ÿ“ธ Snap your stir fry creation and tag #InfusedVeggieStirFry on Instagram to get featured! . . . Downloadable Recipe Card: Stir Fry Recipe ๐ŸŒฟ Cannabis-Infused Veggie Stir Fry Why Youโ€™ll Love This Recipe Itโ€™s fast. Itโ€™s flavorful. Itโ€™s full of fiber and phytonutrients. And with cannabis-infused coconut oil in the mix, this veggie stir fry doesnโ€™t just fuel your bodyโ€”it eases your mind. Health Benefits โœ” Loaded with antioxidants from colorful veggies โœ” Supports gut health with fiber-rich ingredients โœ” Cannabis = anti-inflammatory, calming, and digestive-friendly โœ” Coconut oil = improves THC absorption and heart health Ingredients 2 tbsp cannabis-infused coconut oil 1 cup broccoli florets 1 red bell pepper, sliced 1 carrot, julienned ยฝ cup snap peas 2 cloves garlic, minced 1 tbsp ginger, grated 2 tbsp low-sodium soy sauce or tamari Optional: sesame seeds, green onions, chili flakes Instructions Heat the Oil: In a wok or skillet, warm cannabis-infused coconut oil over medium heat. Add garlic and gingerโ€”sautรฉ for 30 seconds. Cook the Veggies: Add broccoli, carrots, and bell pepper. Stir-fry for 3โ€“4 minutes. Toss in snap peas and cook for another 2 minutes. Season & Serve: Stir in soy sauce. Add chili flakes or sesame seeds if using. Serve over brown rice, quinoa, or cauliflower rice. Dosing Guide 2 tbsp infused coconut oil = 87.5mg THC Makes ~2 servings Dose per Serving: ๐Ÿฅฆ Full = ~43.75mg THC ๐Ÿฅ„ Half = ~21.9mg THC ๐Ÿ‘ถ ยผ serving = ~10.9mg THC Pro Tip: Coconut oil boosts bioavailabilityโ€”dose mindfully! Strain Reminder: Strains arenโ€™t always what they claim. Names can change, effects can vary, and testing isnโ€™t always rigorous. Take these suggestions with a diamond-sized grain of salt ๐Ÿ’Žโ€”and trust your body, not just the label. For more recipes and expert cannabis guidance: CEDclinic.com   [...] Read more...
August 3, 2023Ingredients ยผ cup cannabuter, room temperature ยฝ cup regular butter, room temperature 1 cup brown sugar ยฝ cup white sugar 2 eggs, room temperature 1 tsp vanilla extract 2 ยฝ cups all-purpose flour 1 tsp cinnamon ยฝ tsp baking soda ยฝ tsp sea salt 1 cup mini chocolate chips 1 cup mini marshmallows 18 graham crackers Coating chocolate, melted Directions Preheat oven to 350ยฐF/175ยฐC. Line a cookie sheet with parchment paper. Cream the regular butter, cannabutter, brown sugar & white sugar together until fluffy. Beat in eggs one at a time. Beat in the vanilla. In a small bowl, mix together the flour, cinnamon, baking soda & salt. Add to the creamed mixture. Mix well. Add the mini chocolate chips & mini marshmallows. Mix until evenly distributed. Evenly space the graham crackers on the prepared liner. Use a 2 oz scoop to portion the cookies & place in the center of the graham cracker. Bake for 12โ€“15 minutes. Allow the cookies to cool. Push all of the baked cookies together & drizzle with coating chocolate. Allow the chocolate to set & enjoy! This recipe is available for download HERE Original recipe from myedibleschef.com [...] Read more...
August 3, 2023Ingredients 1 can whole peeled tomatoes 28 oz. 1 jar roasted red peppers 12 oz. 4 large eggs ยฝ cup plain Greek yogurt ยผ cup CannaOil plus more for drizzling 1 teaspoon coriander seeds 1 teaspoon cumin seeds 6 garlic cloves divided 2 medium shallots divided Kosher salt Freshly ground black pepper Mint leaves and crusty bread for serving Crush coriander and cumin seeds, pressing down firmly with even pressure. Transfer seeds to a small heatproof bowl. Slice 2 garlic cloves as thinly and evenly as you can; add to bowl with seeds. Finely chop the remaining 4 garlic cloves. Cut half of 1 shallot into thin rounds and then add to the same bowl with seeds and garlic. Chop remaining shallots. Open a jar of red peppers and pour off any liquid. Remove peppers and coarsely chop. Combine ยผ cup oil and seed/garlic/shallot mix in the skillet you used for crushing seeds. Heat over medium and cook, stirring constantly with a wooden spoon, until seeds are sizzling and fragrant and garlic and shallots are crisp and golden, about 3 minutes. Place a strainer over the same heatproof bowl and pour in the contents of the skillet, making sure to scrape in seeds and other solids. Do this quickly before garlic or shallots start to burn. Reserve oil. Spread out seed mixture across paper towels to cool. Season with salt and pepper. Return strained CannaOil to skillet and heat over medium. Add remaining chopped garlic and shallot and cook, stirring often, until shallot is translucent and starting to turn brown around the edges, about 5 minutes. Season with salt and lots of pepper. Add chopped peppers to the skillet and stir to incorporate. Using your hands, lift whole peeled tomatoes out of the can, leaving behind tomato liquid, and crush up with your hands as you add to the skillet. Discard leftover liquid. Season with more salt and pepper. Cook shakshuka, stirring often, until thickened and no longer runs together when a spoon is dragged through, 10โ€“12 minutes. Reduce heat to low. Using the back of a wooden spoon, create four 2โ€ณ-wide nests in tomato sauce. Working one at a time, carefully crack an egg into each nest. Cover skillet and cook, simmering very gently and reducing heat if necessary, until whites of eggs are set while yolks are still jammy, 7โ€“10 minutes. Uncover skillet and remove from heat. Season tops of eggs with salt and pepper. Top shakshuka with dollops of yogurt, sprinkle with seed mixture, then drizzle with more olive oil. Finish by scattering mint leaves over top. โ€‹ Serve pita or crusty bread alongside. This recipe is available for download HERE Original recipe from eat your cannabis.com [...] Read more...
August 3, 2023Materials -Medium Sauce-Pan -โ€‹Thermometer -Mesh-sieve or cheesecloth Ingredients -โ€‹6 grams cannabis flower -1 pound unsalted butter Directions โ€‹ โ€‹1. Decarboxylate the cannabis Heat the oven to 225ยฐF. Spread cannabis buds out into an even layer on a baking sheet and place in the oven. โ€‹Take care not to let the temperature go over 225ยฐF and burn (if this happens, you can lose potency). Bake for about 35โ€“40 minutes, then remove from the oven and cool before grinding into a coarse powder. โ€‹ The decarboxylated cannabis will keep in an airtight container in a cool, dark place for up to 2 months 2. Heat the butter in a saucepan over medium-low heat. Add the decarboxylated cannabis and cook, taking care not to let the temperature go over 200ยฐF for about 45 minutes. 3. Remove from heat and let sit, undisturbed, for 10 minutes 4. Strain through a fine mesh-sieve set over a bowl. Press carefully with a spoon to extract as much oil as possible โ€‹The milk will keep for up to 6 weeks if covered and refrigerated. This recipe is available for download HERE Original recipe from Vice.com [...] Read more...
January 27, 2026CED Clinic Recipes Cannabis-Infused Spinach Artichoke Dip Cozy, Savory, Crowd-Loving Comfort A bubbling classic, thoughtfully infused. Creamy without being heavy, savory without shouting, and built for portion-by-the-spoon dosing control. โฑ๏ธ Ready: ~25 minutes ๐Ÿฝ๏ธ Servings: 4 ๐Ÿงˆ Infusion: Cannabutter ๐ŸŒพ Gluten-free: Dip itself Ingredients Steps Dosing FAQ Download Recipe Card (PDF) Quick Safety Reminders Friendly reminders that prevent the most common edible mishaps. โœ… Portion first, then enjoy. The spoon is your measuring tool. โœ… Wait at least 90 minutes before reassessing effects. โœ… Label leftovers clearly if others share your fridge. Introduction There is something almost universally reassuring about a bubbling dish of spinach and artichoke dip fresh from the oven. It is creamy without being heavy, savory without shouting, and familiar in the best possible way. This cannabis-infused version keeps everything people love about the classic, while offering a smoke-free, food-forward way to enjoy cannabinoids with more control and predictability. This recipe works especially well for people who want gentle relaxation alongside real food, those who prefer edibles over inhalation, and experienced users who appreciate dosing flexibility by the spoonful instead of the square. TL;DR This is a creamy, oven-baked cannabis-infused spinach artichoke dip that comes together quickly and fits easily into a shared meal or quiet night in. Using infused butter folded into dairy-rich ingredients creates a smooth texture and relatively steady onset. โœ… Ready in about 25 minutes โœ… Approx. 10 to 22 mg THC per serving, depending on portion โœ… Naturally gluten-free and easy to microdose Why You’ll Love This Recipe Most edibles lean sweet, highly processed, or both. This dip goes in the opposite direction. It is savory, protein-rich, and built around familiar ingredients that already belong on a dinner table. The technique is simple, the equipment minimal, and the results feel indulgent without tipping into excess. Because it is portionable by the scoop, this recipe makes it easier to adjust dose without committing to a full edible at once. That makes it particularly appealing for social settings, or for people still learning how their body responds to infused foods. Functional Perks of This Feel-Good Treat Small choices that add up to a smoother experience. โœจ Uses dairy fats to support cannabinoid absorption and consistency. โœจ Easy to scale portions up or down without changing the recipe. โœจ Smoke-free and discreet, suitable for shared meals. โœจ Comfort food that still includes fiber and micronutrients. Pro Tip: Warm, fat-containing dishes like this often feel smoother and longer lasting than sugar-heavy edibles, even at similar milligram levels. Health Benefits: Food That Talks To Your Body Spinach contributes vitamins A, C, and K, along with minerals that support normal immune and vascular function. Artichokes add fiber and compounds that support digestive health, which matters more than many people realize when it comes to edible cannabis absorption. Cannabinoids interact with the endocannabinoid system, a regulatory network involved in mood, pain modulation, appetite, and sleep. When paired with a balanced meal or snack, infused foods like this dip may feel more integrated into the body’s natural rhythms than standalone edibles. As with any infused recipe, this works best as a supportive tool rather than a cure-all. Some people may find it useful for evening relaxation or stress reduction, especially when used thoughtfully and at modest doses. Simple ingredients, big comfort. A flat lay of spinach, artichokes, cheeses, and infused butter ready for mixing. Ingredients & Equipment You’ll Need ๐Ÿฅฌ Ingredients โž• 1 cup fresh spinach, finely chopped ๐Ÿฅฌ โž• ยฝ cup canned or jarred artichoke hearts, drained and chopped ๐ŸŒฟ โž• ยฝ cup cream cheese, softened ๐Ÿง€ โž• ยผ cup sour cream or plain Greek yogurt ๐Ÿฅ› โž• ยผ cup shredded mozzarella cheese ๐Ÿง€ โž• 2 tablespoons cannabis-infused butter, melted ๐Ÿงˆ โž• 1 garlic clove, minced ๐Ÿง„ โž• ยฝ teaspoon salt โž• ยผ teaspoon black pepper ๐Ÿ› ๏ธ Equipment โž• Medium mixing bowl โž• Baking dish or small casserole โž• Silicone spatula or spoon โž• Oven Even mixing helps keep dosing consistent. A bowl of creamy dip mid-mix with visible texture. How To Make Cannabis-Infused Spinach Artichoke Dip (Step-by-Step) Step 1 Preheat and Combine Preheat your oven to 375ยฐF, or about 190ยฐC. In a medium bowl, combine the spinach, artichokes, cream cheese, sour cream, mozzarella, infused butter, garlic, salt, and pepper. Mix until everything looks evenly distributed and creamy, with no large streaks of butter remaining. Pro Tip: Even mixing matters for dosing. Take an extra minute here to avoid concentrated pockets of infused fat. Step 2 Bake Gently Transfer the mixture into your baking dish and spread it into an even layer. Bake uncovered for 15 to 20 minutes, until the surface looks lightly golden and the edges are bubbling. Avoid overbaking, as excessive heat can dry the dip and may degrade cannabinoids. Step 3 Rest and Serve Remove from the oven and let the dip rest for about 5 minutes. This brief cooling period helps the texture set and makes serving safer and more pleasant. Golden, warm, and ready to portion. Freshly baked dip with lightly browned edges. Dosing Guide: Potent, But Predictable Potency Calculation Using the default assumption of 3.5 g cannabis at 20 percent THC: 3.5 g ร— 0.20 ร— 1,000 mg per g โ‰ˆ 700 mg THC in the full batch of infused butter. If that butter is evenly distributed so that 2 tablespoons contain approximately 87.5 mg THC, then this recipe carries about that amount total. Breakdown Per Serving This dip reasonably makes 4 servings. Portion Estimated THC How it looks in real life Full serving โ‰ˆ 21.9 mg THC A generous scoop, better for experienced users Half serving โ‰ˆ 10.9 mg THC A moderate scoop, still meaningful for many Quarter serving โ‰ˆ 5.5 mg THC A small scoop, a reasonable beginner target Suggested Starting Doses Beginner-friendly use often falls in the 2.5 to 5 mg range, which may be closer to a quarter serving or less. Intermediate users may feel comfortable around 5 to 10 mg. Higher doses should be approached cautiously, especially in social settings. If you are newer to edibles, start with the smallest portion, wait at least 90 minutes, and only consider increasing on another day once you understand how that amount feels. Quick Math: DIY Dosing Calculator THC percentage ร— grams of flower ร— 1,000 = estimated total mg THC. Account for roughly 20 to 30 percent loss during decarboxylation and infusion. Divide by the number of servings to estimate mg per serving. โš ๏ธ Dosing Caveat: All dosing numbers are estimates. Actual potency can vary based on flower THC accuracy, decarboxylation temperature and duration, infusion efficiency, storage conditions, and individual metabolism, tolerance, and gut health. Start low, wait at least 90 minutes before reassessing effects, and adjust slowly across different days rather than in a single session. ๐Ÿ’ก Microdose Tip For barely-there effects, start with a teaspoon instead of a scoop. Pair with non-infused food so you can keep eating without escalating dose. How To Make This Non-Euphoric Or Gently Altering For a lower-altering version, substitute CBD-dominant infused butter or use a high-CBD to low-THC ratio such as 10:1. This can emphasize body comfort with minimal intoxication. Some people also experiment with non-decarboxylated preparations rich in acidic cannabinoids, though effects and evidence differ and are typically subtler. True non-euphoric effects depend on individual physiology, not just the label on the infusion. Flavor & Pairing Suggestions For calm evenings, earthy and herb-forward profiles often feel grounding alongside creamy dishes. For light uplift and conversation, subtle citrus-leaning profiles can brighten the richness. For pain-dominated nights, deeper, savory profiles may feel more settling. For creative focus with food, balanced profiles without heavy sedation are often preferred. Pro Tip: Pay attention to how you respond personally rather than relying on strain names alone. Easy to share, easy to scale. Dip served with crisp vegetables. Creative Ways To Use This Dip โž• Spoon over roasted vegetables. โž• Spread on toast or flatbread. โž• Use as a filling for stuffed mushrooms or chicken. โž• Stir a small amount into warm pasta. โž• Serve with carrots, bell peppers, or seeded crackers. โž• Add a dollop to scrambled eggs or an omelet. Pro Tip: For microdosing, try using a single teaspoon at a time rather than a full scoop. Serving Ideas & Mood Pairings This dip fits beautifully into moments that call for comfort without chaos. ๐ŸŒง๏ธ Ideal for quiet evenings with a favorite show. ๐ŸŽง Best enjoyed after a long workday when decision fatigue is real. ๐Ÿงบ Pairs well with soft lighting, warm food, and no urgent plans. Storage Tips & Shelf Life Store leftovers in an airtight container in the refrigerator for up to four days. Reheat gently and stir well to redistribute infused fats before serving. Avoid repeated high-heat reheating, which can affect both texture and potency. Changes in smell, visible mold, or separation that will not remix are signs to discard. Cannabinoid potency may slowly decline over time, so older batches can feel milder. Troubleshooting Common Mistakes Dip feels oily or separated. The mixture may not have been fully blended. Stir thoroughly before baking next time. Texture is too thick. Add a tablespoon of sour cream or yogurt and mix gently. Effects feel stronger than expected. Reduce portion size or dilute with a non-infused batch. Cannabis & Culinary Culture Infused cooking has been quietly moving from novelty toward normalcy. Recipes like this reflect a broader shift away from excess and toward intentional use that fits into real meals and real lives. When food and cannabinoids are combined thoughtfully, they can support a sense of agency rather than mystery. That shift helps reduce stigma and makes cannabis feel less like an event and more like a tool. Final Thoughts This spinach artichoke dip shows how infused cooking can feel normal, nourishing, and grounded. It is not about pushing limits, but about bringing intention into the kitchen. If you make this recipe, consider sharing your variations or how you chose to portion it. Thoughtful food has a way of starting good conversations, both at the table and beyond. FAQ: Cannabis-Infused Spinach Artichoke Dip How do I make cannabis infused spinach artichoke dip at home? You combine a classic spinach artichoke dip base with a measured amount of cannabis-infused butter, then bake gently. The key steps are even mixing and mindful portioning. Can I make this with CBD instead of THC? Yes. Using CBD-dominant infused butter can create a gentler, less intoxicating version that some people prefer. How long does this dip last in the fridge? Generally up to four days when stored airtight and kept cold. What is a good beginner dose for this recipe? Many beginners start around 2.5 to 5 mg THC, which may be a small fraction of a serving. Can I make this without cannabutter? You can make the base dip without infusion, then add infused butter to individual portions for more control. Is this recipe gluten-free? Yes, the dip itself is gluten-free. Pairings may vary. Can this help with stress or sleep? Some people find infused savory foods supportive for evening relaxation, though effects vary. How strong is homemade dip compared to dispensary edibles? Homemade recipes can be less precise unless carefully measured, which is why conservative dosing matters. Can I freeze this dip? Freezing is possible but may alter texture. Potency may also drift over time. Can I use this as a base for other dishes? Yes. It works well as a spread, filling, or sauce with careful portioning. Recipe Card (PDF) Prefer a one-page printable? Download the clinic-formatted recipe card. Download Recipe Card (PDF) Back to top [...] Read more...
June 30, 2025๐Ÿง€ Itโ€™s crispy. Itโ€™s gooey. Itโ€™s golden brown with a secret green. If you thought grilled cheese couldnโ€™t get better, think again. This cannabis-infused grilled cheese sandwich takes everything you love about the classic comfort food and gently lifts it into the clouds. Itโ€™s medicine wrapped in melted cheddar, toasted to perfection. Whether youโ€™re seeking stress relief, deeper sleep, pain support, or just an excuse to make a buttery masterpieceโ€”youโ€™ve just found your new favorite edible. Letโ€™s walk you through every detailโ€”flavor, dosage, prep tips, strain pairings, and yes, even how not to mess it up. ย Why Youโ€™ll Love This Recipe Thereโ€™s a reason grilled cheese has stood the test of timeโ€”itโ€™s the emotional support snack of champions. But add cannabis-infused butter and you get more than nostalgia. You get calm, comfort, and cannabinoids in every bite. ๐ŸŒฟ Soothes nerves and muscles after a long day๐Ÿ”ฅ Hits quickly thanks to fats that aid cannabinoid absorption๐Ÿž Easy to customize with extra ingredients or pairings๐Ÿ˜‹ Delicious enough to forget it’s medicatedโ€”until the relief kicks in ย Health Benefits: Yes, Cheese Can Be Wellness Too ๐Ÿงˆ Cannabis Butter: May ease anxiety, reduce pain, and help with sleepโ€”especially when made with relaxing strains like Granddaddy Purple or Harlequin. ๐Ÿง€ Cheese: A protein- and calcium-rich brain food, ideal for post-workout or winding down. ๐Ÿž Bread: Complex carbs that can boost serotonin production. Yes, this sandwich might actually make you happier. ๐Ÿง˜โ€โ™€๏ธ Combined Effect: Fats help absorb THC and CBD efficientlyโ€”this is a functional edible disguised as a childhood favorite. ๐Ÿ› ๏ธ What Youโ€™ll Need ๐Ÿฅช Ingredients๐Ÿž 2 slices of hearty bread (sourdough, white, multigrainโ€”your mood, your rules)๐Ÿงˆ 2 tbsp cannabis-infused butter (see dosing guide below for potency)๐Ÿง€ 2โ€“3 slices of cheese (classic cheddar, melty provolone, or a smoky gouda mix beautifully) ๐Ÿ‘จโ€๐Ÿณ Equipment๐Ÿ”ฅ A non-stick pan or cast iron skillet๐Ÿ”„ A spatula you trust๐Ÿงผ Optional: a prep cloth to keep things clean (or to cradle the sandwich reverently) ๐Ÿ”ช Step-by-Step Instructions: Making It Melt Just Right ๐Ÿ”ฅ Step 1: Butter & Build ๐Ÿงˆ Slather 1 tbsp of cannabis-infused butter on one side of each slice of bread.๐Ÿง€ Layer the cheese slices between the bread, buttered sides out (crispy magic lives here). ๐Ÿ”ฅ Step 2: Grill to Gold ๐Ÿ”ฅ Heat your pan over medium-low heat. Patience equals flavor.๐Ÿฅช Press the sandwich gently into the pan and grill for 3โ€“4 minutes per side until it turns a deep golden brown and the cheese melts into a soul-soothing pool. ๐Ÿ”ฅ Step 3: Cool & Slice (Or Donโ€™t) ๐Ÿฅต Let it rest for one minute so the molten cheese doesnโ€™t erupt. Or ignore this advice and accept your fate. ๐Ÿ’ก Pro Tip: Want even browning and melty middle? Cover the pan with a lid while grilling. It traps heat and turns your skillet into a mini oven. ๐Ÿ“ Dosing Guide: How Strong Is This Sandwich? Letโ€™s assume your infused butter was made using 3.5 grams of cannabis at 20% THC, yielding approximately 700mg THC per stick (ยฝ cup), or 87.5mg per tablespoon. ๐Ÿฅช If you use 2 tablespoons of cannabis butter (1 tbsp per bread slice): โœจ 1 sandwich = ~175mg THC (for experienced high-dose, seasoned users only!)๐Ÿฅช Half sandwich = ~87.5mg๐Ÿฅช Quarter sandwich = ~43.75mg๐Ÿ‘ถ Eighth sandwich = ~21.9mg โ€” ideal starting point for new users ๐Ÿ’ก Pro Tip: Edibles can take 45โ€“90 minutes to kick in. Avoid the dreaded โ€œI donโ€™t feel anything yetโ€ syndrome. Start low, stay chill, and give it time. โž• Want to Adjust the Dose? ๐Ÿ” Double Strength: Use 2 tbsp of stronger butter or 3 tbsp total (caution: heavy hitter)โž— Half Strength: Use 1 tbsp total across both slicesโž—โž— Quarter Strength: Mix 1 tbsp cannabis butter + 1 tbsp regular butter๐ŸŒฑ Non-Euphoric Version: Use high-CBD butter (or butter infused with CBD-only flower like Charlotteโ€™s Web or Ringoโ€™s Gift) โš ๏ธ Dosing Caveat: Please remember that this dosing guide is only an approximation. The final potency of your cannabis-infused grilled cheese may vary based on the strainโ€™s THC %, your decarboxylation technique, infusion method, how evenly the butter was distributed, and your personal tolerance. Start with a small amount, wait at least 90 minutes, and adjust your next serving accordingly.   ๐Ÿ”„ Want a 10mg Sandwich Instead? If you’re aiming for a milder experienceโ€”around 10mg of THC total per sandwichโ€”you donโ€™t need to change the whole recipe. You just need to use less cannabis butter. ๐Ÿงˆ Hereโ€™s the simple adjustment: โž• Instead of spreading 1 tablespoon of cannabis butter per slice, use just ยฝ tablespoon total for the entire sandwich. Spread it on one side only, and use regular butter or oil for the other slice. ๐ŸŽฏ This adjustment brings your THC dose down from ~87.5mg to around 10mg, assuming your cannabis butter was made with average potency flower (20% THC, about 3.5g used in the infusion). ๐Ÿ˜‹ You’ll still get the flavor, the sizzle, and the crisp golden edgesโ€”but the buzz will be smoother and easier to control. ๐Ÿ’ก Pro Tip: Stir your butter before you measureโ€”it helps keep your dose consistent. And if youโ€™re unsure of the exact strength, test a half sandwich first and wait 90 minutes before deciding on seconds. ย  ๐Ÿ‘ฉโ€๐Ÿณ Expert Cannabis Cooking Tips โœจ Keep your infused butter well-mixed to maintain even dosing๐Ÿ”ฅ Never overheat the panโ€”high heat can degrade THC and ruin the flavor๐Ÿฅ„ Use a pastry brush to spread butter evenly if you’re chasing dosing accuracy๐Ÿ„ Add umami-rich extras like sautรฉed mushrooms or caramelized onions for gourmet vibes ๐Ÿ’ก Pro Tip: Cover the pan while grilling to ensure an even melt and thorough THC activation via fat absorption. ๐Ÿšซ Common Mistakes & How to Avoid Them โ›” Overheating: THC starts degrading around 157ยฐC (315ยฐF). Stick with medium-low heat.โ›” Uneven butter spread: Uneven infusion = unexpected trips. Distribute butter evenly.โ›” Rushing: That impatient flip might lead to under-melted cheese or a burnt crust.โ›” Using weak butter: Infusion not decarbed properly? Your sandwich might taste goodโ€”but do nothing. Make sure your cannabutter is legit. ๐Ÿ‡ Strain Pairings for Flavor & Effect โœจ Relaxation Vibes: Try Granddaddy Purple or Northern Lights๐Ÿ˜‹ Mood Boost: Mimosa or Pineapple Express brighten both flavor and effect๐Ÿง  Focus-Friendly: Harlequin (high CBD) keeps your mind calm and clear๐Ÿ”ฅ Extra Rich: Go savory with Cheesequake or Blue Cheese strains ๐Ÿ’ก Pro Tip: Think of strains as spices. The right one enhances the whole dishโ€”mind and body alike. Also, keep in mind that strain names are like live performances of a band – they’re similar, but rarely the same as you expected. ๐Ÿง‚ Pairing Suggestions for the Perfect Bite ๐Ÿ… Tomato soup (classic for a reason)๐Ÿท A dry red wine (if you’re mixing cannabinoids with alcohol, go slow)๐Ÿฏ Honey mustard or hot honey drizzle๐Ÿฅ’ Spicy pickles for contrast๐Ÿซ– Herbal teas like chamomile or peppermint for a soft landing๐Ÿฅค CBD soda for a balanced experience ๐Ÿงช Creative Ways to Enjoy It Beyond the Basic Bite ๐Ÿ… Dip it in tomato bisque and swirl in sour cream๐ŸŒฟ Chop into cubes and serve atop a cannabis Caesar salad๐Ÿณ Top with a fried egg and a drizzle of hot sauce for brunch bliss๐Ÿฅ’ Pair with infused pickles and a CBD spritzer for a picnic-friendly combo๐Ÿž Use the sandwich as the โ€œbunโ€ for a burger or grilled portobello cap๐Ÿฅช Slice into triangles and serve on a party platter with microdosed sauces๐Ÿฅ„ Crumble into hot chili or baked beans for an infused comfort fusion ๐Ÿ’ก Pro Tip: Leftovers? Reheat low and slow in a pan, not the microwaveโ€”keeps THC stable and that crisp golden crust intact. ๐Ÿง  Final Thoughts: Warm, Witty, and Well-Dosed This isnโ€™t just grilled cheeseโ€”itโ€™s comfort food elevated to a whole new plane of flavor and function. Whether you’re easing into your evening or spicing up lunch, this recipe offers relaxation, nostalgia, and a little edible science all in one golden, gooey bite. Start small, keep it cozy, and share your creations with usโ€”because healing should taste this good. ๐Ÿ“ธ Tag your melts: #InfusedGrilledCheese๐Ÿ’ฌ Comment your favorite add-ons: bacon? tomato? jalapeรฑo?๐Ÿ“Œ Save and share the sandwich that sparks joy (and chill). External Links (Other recipes for CannaButter):ย  Leafly “How to make cannabutter for edibles with our easy recipe“ Epicurious: “Itโ€™s High Time You Knew How to Make Cannabutter“ Bon Appetit: “A Starter Guide to Weed Butter“ ย  Internal Links (Other delicious recipes): Medicated Chocolate Chips Cannabis-Infused Honey Cannabis-Infused Olive Oil ย  Q: How to make cannabis-infused grilled cheese at home? A: Start by making cannabis-infused butter using decarboxylated cannabis. Spread it onto bread, sandwich in cheese, and grill on medium-low heat. Q: How strong is homemade cannabis grilled cheese? A: It depends on your butterโ€™s potency. One tablespoon of 87.5mg THC butter per slice = ~175mg per sandwich. Adjust dosage to suit your needs. Q: Can I make a low-dose grilled cheese with cannabis? A: Yes. Use half regular butter and half cannabutter or opt for CBD-dominant infusions for non-euphoric versions. Q: Whatโ€™s the best cheese for cannabis edibles like grilled cheese? A: Cheddar, mozzarella, Swiss, or provolone melt beautifully and hold up to infused fats. Q: Will grilling degrade the THC in my butter? A: Only if overheated. Stick to medium-low heat and cook slowly to preserve cannabinoids. Q: Is cannabis-infused grilled cheese legal? A: That depends on your jurisdiction. In legal states, yesโ€”just keep it labeled and out of reach of kids. Q: Can I freeze cannabis grilled cheese sandwiches? A: Yes! Wrap tightly and freeze. Reheat on a skillet to retain texture and potency. Q: Can cannabis grilled cheese help with pain or anxiety? A: Anecdotally, yesโ€”especially if made with THC- or CBD-rich strains tailored to your needs. Q: Can I use infused olive oil instead of butter for this recipe? A: You can, but butter provides the best crisping texture. Infused ghee or coconut oil are alternatives. Q: Whatโ€™s the best strain for edible grilled cheese for sleep? A: Try Granddaddy Purple or Bubba Kushโ€”both are in theory supposed to be calming, sedating indica-dominants. But, also – they could be exactly the opposite, because the industry does not yet have standards for consistency… so there aren’t really such things as “strains” in the way we think about medicines have guaranteed, reproducible effects. [...] Read more...
August 3, 2023Servings: 12 Ingredients 1 cup soybean oil ยฝ ounce ganja shake 2 large egg yolks 1 teaspoon fresh lemon juice Pinch of salt 1 teaspoon white vinegar ยฝ teaspoon Dijon mustard โ€‹Directions In a double boiler, combine the oil and ganja. Heat over low until the ganja smell is pronounced but not nutty or burnt. (The oil should have an earthy green tint to it.) Let cool. Remove and strain the herb, squeezing the weed in a metal strainer against the mesh with the back of a spoon to wring out every drop of oil. Make sure that all your ingredients have been brought to room temperature โ€” this is crucial! โ€‹In a small metal bowl, use an immersion blender or whisk to thoroughly blend the egg yolks, lemon juice, salt, vinegar, and mustard. This can also be done in a food processor or blender. โ€‹Using a ยฝ teaspoon measure, very slowly add the infused oil to the small metal bowl, a few drops at a time, while constantly blending on low or whisking until the mayo is thick and starting to form ribbons. (If itโ€™s too thick, you can add room-temperature water in tiny increments.) If your mixture โ€œbreaks,โ€ it can be repaired by whisking some more room-temperature egg yolks in a separate bowl, then slowly whisking those yolks into the โ€œbrokenโ€ mayo mixture. If that doesnโ€™t do it, add a few drops of hot water. โ€‹Cover and chill; itโ€™ll keep in the refrigerator for 4 to 5 days. Original recipe from: Boudreaux, Ashley. The Official High Times Cannabis Cookbook. Red Eyed Deviled Eggs. https://saltonverde.com/wp-content/uploads/2017/09/10-High_Times_Cannabis_Cookbook.pdf [...] Read more...
August 3, 2023This recipe can be used with your favorite vegetables and breakfast meats Ingredients Base: 1 ยฝ cups of mozzarella cheese, shredded 1/2 cup cheddar cheese, shredded 6 eggs 1 cup of milk (canna-milk may be used for a more potent dish) 1 pie-crust, unbaked Filling: 1/2 cup of canna-butter 1 onion, diced 1 cup broccoli, chopped 1 head of garlic โ€‹ Instructions 1. Melt canna-butter in a pan over medium heat โ€‹ 2. Add vegetables to butter and cook on medium heat for about 5โ€“8 minutes (or until veggies are cooked) Do not let the butter or vegetables burn, to maintain potency of the butter 3. Scoop cooked vegetables into empty pie crust and cover with shredded cheeses 4. Beat eggs and milk together and pour into the pie crust 5. Bake for 35โ€“40 minutes at 360ยฐF Allow quiche to cool 10 minutes before serving This recipe is available for download HERE Original recipe from cannabis.wiki [...] Read more...
August 3, 2023Ingredients 2 cups shredded green cabbage 1 Tbsp lime juice 1/2 Tsp salt 3 Tbsp cilantro 1/4 cup canna-oil 1 tomato, diced 1/2 cup salsa 1/2 onion, diced 1 jalapeno, diced 1 avocado, sliced Meat of choice (fish or a ground meat like beef or turkey) 4 corn tortillas Directions 1. Cook choice of meat with fajita seasoning in frying pan, set aside 2. In a large bowl, mix shredded cabbage, line juice, salt and cilantro 3. In a separate bowl, mix canna-oil with tomato, onion, jalapeno and salsa 4. Wrap the tortillas in paper towels and heat in the microwave for 30 seconds, or until warm 5. Fill each tortilla with meat, cabbage mixture, cannabis salsa mixture and diced avocado โ€‹Serve with lime wedge The recipe is available for download HERE Original recipe from Eat Your Cannabis [...] Read more...
August 3, 2023Ingredients 4 eggs 1 cup white sugar ยฝ cup brown sugar, packed 1 ยผ cups grapeseed oil ยผ cup canna-oil 2 tsp vanilla extract 1 ยพ cups pure pumpkin puree 3 cups all-purpose flour 1 tbsp ground cinnamon 1 tbsp pumpkin spice 2 tsp baking powder 2 tsp baking soda 1 tbsp orange zest, optional Directions Preheat the oven to 350ยฐF/175ยฐC. Line a jumbo muffin tin with liners. Place the eggs, white sugar, brown sugar, grapeseed oil & canna-oil into a bowl fitted for a stand mixer or use a whisk to thoroughly beat ingredients together. Blend in the pumpkin & vanilla extract. In a small bowl mix the dry ingredients together. Add to the wet ingredients & mix until just blended. Stir in the orange zest (optional). Divide the batter evenly between 12 muffin cups using a muffin scoop, about 3 ounces each. Sprinkle with pumpkin seeds. Bake for 22โ€“25 minutes or until a toothpick inserted into the middle comes out clean. โ€‹ Allow to cool, remove from the tins & sprinkle with cinnamon. This recipe is available for download HERE Original recipe from myedibleschef.com [...] Read more...
May 8, 2025Cannabis Chocolate Chip Morsels Recipe | Easy 1mg Edibles for Microdosing ๐Ÿซ Cannabis-Infused Semi-Sweet Chocolate Chip Morsels โ€” Tiny Treats, Micro Moments of Calm These little morsels may be small, but they pack a perfectly portioned punch of calm. Each chocolate chip holds just 1mg of THC, making them ideal for microdosing, mellow snacking, or adding to recipes for an infused twist. Whether youโ€™re sprinkling them into cookies, oatmeal, or straight into your mouth (no judgment), these melt-in-your-mouth bites are a discreet and delicious way to medicate. Think of them as edible Legos โ€” build your dose exactly how you like it, 1mg at a time. ๐Ÿซ Why Youโ€™ll Love These These infused chocolate chips are: ๐Ÿฌ Sweet-but-not-too-sweet ๐ŸŒฟ Easy to dose (1mg per chip = flexible freedom) ๐Ÿง  Great for beginners and microdosers ๐Ÿง Versatile โ€” snack on them, bake with them, melt them down ๐Ÿฅฃ Made from pantry staples + your favorite cannabis infusion ๐Ÿง‚ Ingredients & Tools Youโ€™ll Need ๐Ÿ› ๏ธ Equipment: โœจ Double boiler (or glass bowl over a pot of water) โœจ Silicone chocolate chip or dropper mold โœจ Small rubber spatula or spoon โœจ Kitchen scale (for precision) ๐Ÿซ Ingredients: โœจ 1 cup high-quality semi-sweet chocolate chips or chopped bar โœจ 1 tablespoon cannabis-infused MCT oil or coconut oil (at 20% THC = 43.75mg THC):ย  See here for cannabis infused oil recipe ๐Ÿ‘‰ Note: this recipe above is for 1mg THC per morsel. See the section below with the police officer for an easy tweak to make each morsel 5mg or 10mg!ย  โœจ Optional: ยฝ tsp vanilla extract or a pinch of sea salt for flavor ๐Ÿ‘จโ€๐Ÿณ Step-by-Step Instructions Step 1: Melt the Chocolate Using a double boiler over low heat, slowly melt your chocolate chips or chopped chocolate bar. Stir gently with a spatula until smooth and glossy. Avoid overheatingโ€”low and slow preserves both flavor and cannabinoid potency. Step 2: Stir in the Infusion Once fully melted, remove from heat and stir in your cannabis-infused oil. Mix thoroughly to ensure the THC is evenly distributed. Add vanilla or salt if using. Stir again. ๐Ÿง  Pro Tip: If the oil begins to separate, keep stirring and allow it to cool just slightly before pouring. ๐ŸŒ€ Bakerโ€™s Note: To make sure each morsel holds a consistent dose, take your time when mixing. Stir slowly and thoroughly so the cannabis oil is fully incorporated before molding. A well-mixed batch means each bite delivers the calm you intendedโ€”no surprises, just sweet reliability. Step 3: Mold and Chill Using a dropper or spoon, portion the chocolate into your silicone mold. For 1mg-per-chip accuracy, use a mold with roughly 44 cavities (ahem ahem)ย  โ€” this ensures that each morsel contains ~1mg of THC based on 43.75mg infused oil. Place the mold in the fridge for 20โ€“30 minutes until set. Step 4: Pop & Store Once firm, remove from the mold and store in an airtight container in the refrigerator or a cool pantry. Keep away from heat, children, and curious roommates. ๐Ÿงฎ Dosing Guide: Microdose with Confidence With 1 tablespoon of 20% THC oil (~43.75mg THC total) spread across 44 morsels: ๐Ÿซ 1 morsel = ~1mg THC ๐Ÿซ 2 morsels = ~2mg THC ๐Ÿซ 5 morsels = ~5mg THC ๐Ÿซ 10 morsels = ~10mg THC Perfect for microdosing, layering effects, or creating precision edibles. โš ๏ธ Dosing Caveat: Your final THC per morsel may vary depending on how thoroughly the oil is mixed, how precise your mold sizing is, and the exact potency of your cannabis infusion. Always test a single morsel first, wait 60โ€“90 minutes, and adjust as needed. When in doubt, label your batch and start small. ๐Ÿง Creative Ways to Use These Morsels ๐Ÿช Fold them into cookie dough or brownie batter before baking ๐Ÿฅฃ Sprinkle them over yogurt, granola, or oatmeal ๐Ÿ“ Melt and drizzle over strawberries or toast ๐ŸงŠ Drop them into warm milk for quick infused hot chocolate ๐Ÿง Stir into cannabis peanut butter for layered microdosing ๐Ÿซ Mix with CBD chips to balance your buzz ๐Ÿ’ก Pro Tip: Assuming you’ve kept a good and consistently even mixture going while cooking, each morsel ought to be fairly close to 1mg THC, they make it easy to dose baked goods with confidence. Whether youโ€™re making a batch of cookies or brownies, you can scale the potency to match your needsโ€”without complicated math or messy measurements. ๐Ÿƒ Non-Euphoric Alternatives To avoid the high but still get therapeutic benefits, use a CBD-, CBG-, or CBC-infused oil in place of THC. Youโ€™ll still get relaxation and mood support, but without intoxication. A 20:1 CBD to THC blend makes these perfect for daytime use or sensitive consumers. Common Mistakes & How to Avoid Them ๐Ÿšซ๐Ÿค” Mistake #1: Overheating the chocolate. Itโ€™s tempting to rush the melting process, but high heat can cause chocolate to seize or burnโ€”and worse, it can degrade your cannabinoids. Stick to a double boiler on low heat and remove from heat as soon as itโ€™s smooth and glossy. Mistake #2: Not mixing thoroughly. If your cannabis-infused oil isnโ€™t fully incorporated, you risk uneven dosing. Stir slowly but thoroughly for at least a full minute to ensure the oil is emulsified throughout the chocolate. Mistake #3: Using the wrong mold size. This recipe relies on accurate portioning. If your mold is too big or too small, each morsel could pack an unpredictable punch. Use molds with about 44โ€“50 cavities to stay in that sweet 1mg range. Mistake #4: Skipping the test dose. Every batch varies slightly. Try one chip, wait 90 minutes, and gauge the effect before munching down a handful. Cannabis Strain Recommendations for Chocolate Lovers ๐Ÿ€๐Ÿซ When it comes to cannabis and chocolate, flavor and effect both matter. For earthy richness and a relaxing body high, Granddaddy Purple and Northern Lights melt beautifully into cocoa-based recipes. These strains deepen the chocolateโ€™s richness and support winding down. Looking for an energizing, focus-friendly option? Chocolope and Jack Herer add a subtle brightness that pairs beautifully with semi-sweet chocolate and provide creative, social effects without heaviness. Prefer no high at all? ACDC or Charlotteโ€™s Web offer a high-CBD profile that supports calm without couch-lock, perfect for daytime nibbling or when clarity matters most. Expert Cannabis Cooking Tips from Chefs ๐Ÿ‘จโ€๐Ÿณ๐ŸŒฟ Professional edible chefs know: texture is everything when it comes to chocolate. Chef-level tip? Add your infused oil after the chocolate has cooled just slightly off heat. This protects potency and helps your oil blend more evenly without separation. Another pro move: Use emulsifiers like a tiny pinch of lecithin (sunflower or soy) to stabilize your chocolate mixture. This keeps cannabinoids from pooling and enhances bioavailabilityโ€”meaning the effects kick in smoother and more consistently. And donโ€™t forget: chefs use infrared thermometers to keep chocolate at ideal working temp (between 88ยฐF and 91ยฐF for semi-sweet). A little precision goes a long way in making edibles that are as beautiful as they are effective. Perfect Pairings for Morsel Moments ๐Ÿท๐Ÿซ– These morsels may be tiny, but they shine with the right match. For a cozy evening: pair 2โ€“3 morsels with a warm mug of cinnamon chai or peppermint tea. The herbal heat enhances the chocolate while keeping the vibe soft and gentle. For an indulgent twist: a glass of ruby port, dark rum, or a coffee liqueur pairs beautifully with semi-sweet chocolate and rounds out the experience with deeper body relaxation. Feeling social? Try a dark stout or nitro cold brew. The roasted notes pair perfectly with the chocolate, while the caffeine adds balance to low-dose THC. Want a snack? Try pairing the morsels with roasted almonds, orange slices, or a sprinkle of sea salt popcorn for a sweet-salty contrast that enhances absorption and makes microdosing feel gourmet. ๐Ÿคฉย  Want Stronger Morsels? Hereโ€™s How to Make 5mg or 10mg Chips If youโ€™ve tried the 1mg version and feel comfortable adjusting your dose, hereโ€™s how to scale your batch for 5mg or 10mg per morsel โ€” while keeping the same great texture and flavor. ย  ๐Ÿ’ก Reminder: Always decarboxylate your cannabis first, mix thoroughly, and use precise molds for best results. ๐Ÿงฎ To Make 5mg THC per Morsel: โ–ฒ Use the same mold (44 cavities) โ–ฒ Instead of 1 tbsp infused oil (โ‰ˆ 43.75mg THC), use 5 tbsp of cannabis-infused oil โ–ฒ That gives you ~219mg THC total รท 44 pieces = ~5mg per chip ๐Ÿฅ„ Note: 5 tbsp = ยผ cup + 1 tbsp, so adjust your chocolate ratio slightly if needed to maintain smooth consistency ๐Ÿงฎ To Make 10mg THC per Morsel: ๐Ÿ”บ Same mold (44 cavities) ๐Ÿ”บ Use 10 tbsp cannabis-infused oil (โ‰ˆ 437mg THC total) ๐Ÿ”บ This yields ~10mg THC per morsel โš ๏ธ You may need to add ~ยผ cup more chocolate to maintain firmness and snap. Taste and texture can change slightly with high oil ratios, so test a small batch first if unsure. โš–๏ธ How to Make 0.5mg THC Per Morsel: Use the same 44-cavity silicone mold Instead of 1 tbsp of infused oil (~43.75mg THC), use ยฝ tablespoon That gives you ~21.9mg THC รท 44 pieces = ~0.5mg per morsel ๐Ÿ”„ For easy measuring: ยฝ tbsp = 1ยฝ teaspoons ๐Ÿ’ก Pro Tip: Because such a small amount of oil is used, your mixture may feel slightly thicker than the higher-dose batches. Stir gently and thoroughly to ensure the oil is fully integrated, and consider adding a touch of coconut oil or a drop of lecithin to preserve that smooth chocolate texture. ๐Ÿง˜ Why Make a 0.5mg Edible? These ultra-low-dose morsels are great for: โŠ™ Cannabis newcomers who want to avoid overwhelm โŠ™ Daytime users who want the benefits without mental cloudiness โŠ™ Combining with CBD for a therapeutic entourage effect โŠ™ Layering effects over time with full control A 0.5mg morsel lets you add or subtract from your dayโ€™s cannabis experience, one clean, precise step at a time. ๐Ÿฌ Why Would Someone Want 5mg or 10mg? While microdosing is ideal for many, some medical users need more pronounced relief from: โšก๏ธŽ chronic pain โšก๏ธŽ severe anxiety or panic โšก๏ธŽ muscle spasticity โšก๏ธŽ nausea or chemotherapy support Offering precise 5mg or 10mg morsels gives you layered flexibility. One for daytime. Two for bedtime. Three? Make sure youโ€™ve cleared your calendar.   How do I make cannabis chocolate chips at home? Melt chocolate, mix in infused oil, pour into molds, chill, and portion. Thatโ€™s it! Can I use cannabutter instead of oil? Technically yes, but it may not blend as smoothly and could affect consistency. Infused oils (especially MCT or coconut) work best for clean texture and even THC distribution. Do I need a mold? Silicone molds make it easiest, but you can spoon droplets onto parchment paper. Just keep portions consistent. Will heating the chocolate destroy THC? Not if youโ€™re careful. Melt over low heat and stir off the burner. THC begins to degrade at temps over ~300ยฐF (149ยฐC). How long do these morsels last? Stored properly, theyโ€™ll keep for 3 months in a cool, dark place or longer in the fridge. Can I bake with them? Yes! The THC will survive typical baking temps if you donโ€™t overbake. Great for cookies, cakes, or pancakes. Is 1mg strong enough? For beginners or microdosers, yes. You can always layer multiple morsels over time. And dose a chocolate chip cookie with the number of morsels you want, based on the dosage you prefer! What strain should I use for mellow effects? Try Northern Lights or Granddaddy Purple for a chill vibe. For creativity, go with Jack Herer or Lemon Skunk. Keep in mind, though. Anyone can call any plant, by any name. A name may be what you think it is, but perhaps not too. [...] Read more...
August 3, 2023This recipe may be used with heavy cream or whole milk. Materials -Medium Sauce-Pan -โ€‹Thermometer -Mesh-sieve or cheesecloth Ingredients โ€‹6 grams cannabis flower 2 cups whole milk or heavy cream โ€‹ Directions โ€‹ โ€‹1. Decarboxylate the cannabis Heat the oven to 225ยฐF. Spread cannabis buds out into an even layer on a baking sheet and place in the oven. โ€‹Take care not to let the temperature go over 225ยฐF and burn (if this happens, you can lose potency). Bake for about 35โ€“40 minutes, then remove from the oven and cool before grinding into a coarse powder. โ€‹ The decarboxylated cannabis will keep in an airtight container in a cool, dark place for up to 2 months 2. Heat the milk or heavy cream, in a saucepan over medium-low heat. Add the decarboxylated cannabis and cook, taking care not to let the temperature go over 200ยฐF for about 45 minutes. 3. Remove from heat and let sit, undisturbed, for 10 minutes 4. Strain through a fine mesh-sieve set over a bowl. Press carefully with a spoon to extract as much oil as possible โ€‹The milk will keep for up to 6 weeks if covered and refrigerated. This recipe is available for download HERE Original recipe from Vice.com [...] Read more...
March 23, 2025  Cannabis-Infused Olive Oil: The Golden Elixir of Cannabis Cooking Because butter isnโ€™t the only thing that gets you baked. (Simple, Effective, and Delicious)   Why This Recipe Deserves a Spot in Your Kitchen   This isnโ€™t just olive oilโ€”itโ€™s olive oil with benefits. Whether youโ€™re elevating roasted veggies, dressing up a salad, or mellowing out pasta night, cannabis-infused olive oil lets you sneak therapeutic magic into your mealsโ€”without sugar, smoke, or complicated prep.   Olive oil is already a health food darling. Add cannabis, and youโ€™ve got yourself a multifunctional edible thatโ€™s as functional as it is flavorful. Plus, itโ€™s discreet, easy to dose, and ideal for people looking to manage pain, anxiety, inflammation, or sleepโ€”minus the lung irritation.     Health Perks of This Herbal Power Couple     โœ”๏ธ Anti-inflammatory support (great for achy joints and muscles)   โœ”๏ธ Brain benefits (thanks to olive oilโ€™s polyphenols + cannabis neuroprotection)   โœ”๏ธ Gut-friendly (a smoother edible experience for your stomach)   โœ”๏ธ Relaxation without the rollercoaster (ideal for winding down or sleeping soundly)       What Youโ€™ll Need     ๐Ÿ› ๏ธ Materials   Mason jar (for storing your potion)   Cheesecloth or fine mesh strainer   Saucepan or double boiler   Baking sheet   Parchment paper   Oven-safe thermometer (optional but helpful)       ๐Ÿฅฌ Ingredients     3.5 grams decarboxylated cannabis (strain of your choice)   1 cup extra-virgin olive oil (choose one youโ€™d enjoy raw)         Step-by-Step Instructions     ๐Ÿ”ฅ Step 1: Decarboxylate the Cannabis   This is what โ€œactivatesโ€ THC. Without it, youโ€™ve got expensive grass-flavored oil.   Preheat oven to 225ยฐF (105ยฐC)   Break cannabis into small, even pieces   Spread evenly on a parchment-lined baking sheet   Bake for 30โ€“40 minutes, stirring every 10โ€“15 minutes   Your cannabis should look dry and lightly goldenโ€”never dark or charred   ๐Ÿ’ก Fun Fact: THCA (non-psychoactive) becomes THC (psychoactive) via heat. Thatโ€™s why this step is non-negotiable.   Pro tip: If you want a milder effect, decarb for slightly less time, or use a higher CBD strain.     ๐Ÿณ Step 2: Infuse the Oil     Now we bring the fat and cannabinoids together.   Combine decarbed cannabis and olive oil in your saucepan or double boiler   Simmer on low heat for 2โ€“3 hours, keeping it between 200โ€“245ยฐF (93โ€“118ยฐC)   Stir occasionally. Do not let it boilโ€”boiling burns off cannabinoids = sadness   If youโ€™re worried about smell, use a lid or infuse outdoors   Keep it just below a simmerโ€”slow and steady preserves potency.   Tip: If youโ€™re concerned about odor, use a double boiler setup with a lid.       ๐Ÿซ— Step 3: Strain & Store     Let the oil cool slightly   Strain through a cheesecloth or fine mesh into a clean mason jar   Label your jar with the date and strain used   Store in a cool, dark place for up to 2 months   Refrigeration can extend shelf life to a year (but the oil may solidifyโ€”just warm it before use)     How to Use It     Use it as you would any high-quality finishing oil:   Drizzle over roasted veggies or avocado toast ๐Ÿฅ‘   Swirl into hummus, soups, or pasta ๐Ÿ   Add to dressings or sauces (off heat!)   Take a spoonful before your in-laws arrive (kiddingโ€ฆ mostly)     โš ๏ธ Avoid high-heat cooking (above 300ยฐF/150ยฐC) to preserve cannabinoid content.     Dosing Guide: Donโ€™t Wing It, Measure It     ๐Ÿ’ก Dosing is not one-size-fits-allโ€”but hereโ€™s a solid starting point.   Assuming your cannabis is 20% THC:   3.5g = ~700mg THC total   1 cup = 16 tbsp = 48 tsp   1 tbsp = ~43.75mg THC   1 tsp = ~14.6mg THC       ๐Ÿง‚ Recommended Starting Doses:     Beginner: ยผ tsp (~3.6mg THC)   Moderate: ยฝ tsp (~7.3mg THC)   Strong: 1 tsp (~14.6mg THC)   โš ๏ธ Start low and slow. Edibles take 30โ€“120 minutes to kick in, and the effects can last 4โ€“8 hours. Patience prevents panic. ๐Ÿ’ก Pro Tip: Want to be sure about your oilโ€™s potency? Consider having it tested by a local lab for accurate dosing. If youโ€™re an experienced consumer and choose to skip testing, start with a very small amount and increase graduallyโ€”unexpectedly high doses can turn a relaxing experience into an uncomfortable one.     Storage & Safety Tips   Keep away from kids, pets, and unsuspecting guests   Label clearly (no accidental salad surprises)   Cloudiness from refrigeration is normalโ€”just warm it up before use     Why Olive Oil?   Extra-virgin olive oil is rich in healthy fats, antioxidants, and anti-inflammatory compounds. Itโ€™s stable at room temp, delicious raw, and an ideal carrier for cannabinoids. In other words, itโ€™s not just tastyโ€”itโ€™s smart.     Downloadable recipe card for Cannabis-Infused Olive Oil:   ๐Ÿ“ฅย Cannabis_Infused_Olive_Oil_Recipe_Card         [...] Read more...
October 3, 2025Ingredients Cupcakes: 2 cups flour 1 cup sugar 1 Tbsp baking powder 1/4 Tsp salt 1 cup milk 2 eggs 1/4 cup canna-oil (vegetable is best) 1/4 vegetable oil 2 Tsp vanilla extract 1/3 cup rainbow sprinkles Frosting: 1 cup sugar 1 cup egg whites 1lb butter, salted, room temperature 1 Tsp vanilla extract โ€‹ Directions โ€‹Cupcakes: Preheat oven to 350ยฐF. Line a cupcake pan with cupcake liners. Mix all of the dry ingredients together in a medium bowl. Whisk all of the liquid ingredients together until blended. Add the liquid ingredients to the dry ingredients & mix until there are no large lumps. Do not overmix. Gently stir in the rainbow sprinkles until just blended. โ€‹ Use a 2-ounce portion scoop & fill each cupcake liner with one scoop. Bake for 15โ€“18 minutes or until a toothpick inserted in the middle comes out clean. Remove from the oven & allow to cool a bit before removing them from the pan. Frosting: Put 2 inches of water into a medium-size pot, & bring to a boil. Place the sugar & egg whites into a small stainless bowl that will sit on top of the pot of boiling water, or use a double boiler system. DO NOT allow the bowl with the egg white mixture to directly touch the boiling water or the egg whites will cook very quickly. Whisk constantly until temperature reaches 140ยฐF/60ยฐC or until the sugar has completely dissolved & the egg whites are hot to the touch. DO NOT leave unattended or you will have a sweet egg white scramble! Use a hand mixer or pour the egg white mixture into a bowl that is fitted for a stand mixer. Using the whisk attachment, begin to whip until the meringue is thick & glossy, about 10 minutes on medium-high. Place the mixer on low speed, add the cubes of butter, a couple at a time, until incorporated. Continue beating until it has reached a silky smooth texture. If the buttercream curdles simply keep mixing & it will become smooth. If the buttercream is too runny, refrigerate for about 15 minutes before continuing mixing. Add the vanilla & continue to beat on low speed until well combined. Once the cupcakes have completely cooled, place a large star tip into a piping bag & fill with the buttercream. Pipe a rosette onto each cupcake & add the sprinkles on top. Serve immediately, the same day or keep in an airtight container in the fridge for up to 4 days. They can also be frozen for up to 3 months. This recipe is available for download HERE Original recipe from myedibleschef.com ๐Ÿ’ฌ Join the Conversation Have a question about how this applies to your situation? Ask Dr. Caplan โ†’ Want to discuss this topic with other patients and caregivers? Join the forum discussion โ†’ [...] Read more...
April 8, 2025ย  Cannabis-Infused Chocolate Sauce โ€” Decadence That Loves You Back ๐Ÿซ Why Youโ€™ll Love This Cannabis Chocolate Sauce Warm, rich, and silky-smooth, this cannabis-infused chocolate sauce takes indulgence to the next level. Whether youโ€™re spooning it over a scoop of ice cream, dipping fresh strawberries, or swirling it into your coffee, this easy cannabis chocolate recipe for beginners delivers full flavor with gentle effects. For cannabis users, the beauty of this recipe lies in its simplicity and flexibility. Itโ€™s a no-bake, fast-to-make edible that can be dosed by the spoonful and stored for weeks. And thanks to the fat content in cream and chocolate, it also provides a reliable absorption pathway for THC. Benefits of Cannabis-Infused Chocolate Sauce Hereโ€™s what makes this recipe more than just dessert: ๐Ÿซ Dark Chocolate โ€“ Packed with antioxidants and supports heart health. ๐ŸŒฟ Cannabis โ€“ Offers natural stress relief, relaxation, and anti-inflammatory benefits. ๐Ÿง  Mood-Boosting โ€“ Chocolate and THC both increase feel-good neurotransmitters like anandamide and serotonin. ๐Ÿฅ„ Fat-Rich Carrier โ€“ Cream and cannabutter help improve THC absorption. โ„๏ธ Refrigerator Friendly โ€“ Easy to store and dose over time. Pro Tip: This recipe is especially helpful for those managing anxiety, chronic pain, or poor appetite with cannabis. https://cedclinic.com/category/cannabis-recipes/ Ingredients & Equipment Youโ€™ll Need ๐Ÿซ Ingredients: ยฝ cup heavy cream ๐Ÿฅ› 4 oz dark chocolate (70% cacao or higher), chopped ๐Ÿซ 2 tablespoons cannabutter ๐Ÿงˆ 1 tablespoon honey or maple syrup (optional) ๐Ÿฏ ยฝ teaspoon vanilla extract ๐Ÿ› ๏ธ Equipment: Small saucepan Whisk or silicone spatula Mason jar or glass container with lid How to Make Cannabis Chocolate Sauce (Step-by-Step) Step 1: Warm the Cream In a small saucepan over low heat, warm the cream until just steaming. Avoid boilingโ€”too much heat can degrade THC and ruin the chocolateโ€™s texture. Step 2: Melt and Infuse Add chopped dark chocolate and cannabutter to the warm cream. Stir continuously with a whisk or silicone spatula until the mixture is fully melted and glossy. Step 3: Sweeten & Store Stir in your sweetener and vanilla extract. Once smooth, pour into a glass jar. Let it cool before sealing and refrigerating. Pro Tip: This cannabis chocolate sauce thickens as it coolsโ€”reheat gently before serving for best consistency. Dosing Guide: Sweet, But Strong ๐Ÿ’ก Potency Calculation Assuming cannabutter made from 3.5g cannabis at 20% THC = ~700mg total THC 1 tbsp cannabutter โ‰ˆ 87.5mg THC 2 tbsp used in recipe = ~175mg THC total ๐Ÿซ Per Serving (Approx. 6 Servings) 1 tbsp sauce โ‰ˆ 29mg THC ยฝ tbsp sauce โ‰ˆ 14.5mg THC ยผ tbsp (ยพ tsp) โ‰ˆ 7.25mg THC Beginner Dose: Start with ยผโ€“ยฝ tablespoon for ~7โ€“14mg THC Pro Tip: Chocolateโ€™s natural fats help THC absorb more efficiently, meaning it might feel stronger than baked edibles.   Creative Ways to Use Cannabis Chocolate Sauce ๐Ÿ“ Drizzle over fresh fruit like strawberries, bananas, or apples ๐Ÿฆ Pour on top of ice cream, pancakes, or waffles โ˜• Stir into coffee or hot milk for a DIY cannabis mocha ๐Ÿฉ Use as a glaze for donuts or cupcakes ๐Ÿช Dip cookies or pretzels for an instant edible treat ๐Ÿฅฃ Swirl into oatmeal or yogurt for a rich breakfast upgrade Pro Tip: For microdosing, try mixing ยฝ teaspoon of the sauce into your morning coffee or spreading lightly over toast. FAQ: Cannabis Chocolate Sauce โ€” Answers to Common Questions ย  [...] Read more...
August 3, 2023This recipe can be used with your favorite vegetables and breakfast meats Ingredients Base: 4 large eggs salt and pepper (to tasste) 1 tbsp butter (canna-butter may be used to increase potency) 1/2 cup canna-milk Filling: 2 tbsp diced green pepper 2 tbsp diced green onion 2 tbsp ham or meat of your choice 1/4 cup shredded cheese โ€‹ Instructions 1. Beat eggs in a bowl with a whisk. 2. Add canna-milk and season with salt and pepper 3. Add any vegetables and/or meat fillings to the eggs and whisk for a few minutes until egg mixture if foamyโ€Šโ€”โ€Šbeating in air makes the omelette fluffyโ€‹ 4. Melt butter in a small, nonstick skillet over medium-low heat. Pour in egg mixture and twirl skillet so the bottom is evenly covered in egg. 5. Cook until egg starts to set. Lift the edges with a spatula and tilt the skillet so uncooked egg mixture can run towards the bottom of the skillet to set Repeat until no visible liquid egg remains 6. Carefully flip omelette and cook another 30 seconds to 1 minute 7. Sprinkle cheese in one line in the middle of the omelette and fold it in half, cook another 20 seconds them slide the omelette on to the plate This recipe is available for download HERE Original recipe from the Canna School [...] Read more...
August 3, 2023Ingredients 4 quarts popped popcorn 1 cup brown sugar 1/2 cup corn syrup light 1/2 cup cannabis butter 1/2 tsp salt 1/2 tsp pepper 1 tsp vanilla extract 1/2 tsp baking soda Instructions Preheat your oven to 250 degrees Fahrenheit. Spray a large shallow roasting pan with cooking spray and add popcorn. In a separate bowl mix brown sugar, corn syrup, cannabis butter, and salt in a heavy saucepan. Stirring constantly, bring to a boil over medium heat. Boil 5 minutes without stirring. Remove from heat. Stir in baking soda and vanilla; mix well. Pour syrup over warm popcorn, stirring to coat evenly. Bake for 45 minutes, stirring occasionally. โ€‹ Enjoy! Keep refrigerated for extended shelf life. This recipe is available for download HERE Original recipe from thecannaschool.com [...] Read more...